

20240630 20240814 2046988410-Q CHINA PHARMA HOLDINGS, INC. 0001106644 2834 731564807 DE 1231 10-Q 34 001-34471 241207478 2ND FLOOR, NO. 17, JINPAN ROAD HAIKOU HAINAN PROVINCE F4 570216 8689866811730 2ND FLOOR, NO. 17, JINPAN ROAD HAIKOU HAINAN PROVINCE F4 570216 TS ELECTRONICS INC 20030818 SOFTSTONE INC 20030128 SOFTSTONE INC /DE/ 20010808 10-Q 1 ea0210807-10q chinaphar.htm QUARTERLY REPORT Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Â FORM 10-Q Â (Mark One)Â Â QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Â For the quarterly period ended June 30, 2024 Â Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Â For the transition period from _____ to _____ Â Commission File Number 001-34471 Â CHINA PHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Â Nevada Â 75-1564807 (State or other jurisdiction of Â (IRS Employer incorporation or organization) Â Identification No.) Â Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China Â Â 570216 (Address of principal executive offices) Â (Zip Code) Â Â +86-898-6681-1730 (China) (Registrantâs telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading Symbol(s) Â Name of each exchange on which registered Common Stock Â CPHI Â NYSE American Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesÂ Â NoÂ Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YesÂ Â NoÂ Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of âlarge accelerated filer,â âaccelerated filerâ, âsmaller reporting companyâ and âemerging growth companyâ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer Â Accelerated filer Â Non-accelerated filer Â Smaller reporting company Â Â Emerging growth company Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Â Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesÂ Â NoÂ Â Â As of August 12, 2024, there were 17,162,771 shares of common stock, \$0.001 par value per share, issued and outstanding. Â Â Â CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES Â TABLE OF CONTENTS Â Â Page Â Â PART I FINANCIAL INFORMATION 1 Â Â Item 1. Financial Statements 1 Â Â Item 2. Managementâs Discussion and Analysis of Financial Condition and Results of Operations 18 Â Â Item 3. Quantitative and Qualitative Disclosures about Market Risk 28 Â Â Item 4. Controls and Procedures 28 Â Â PART II OTHER INFORMATION 29 Â Â Item 6. Exhibits 29 Â i Â FINANCIAL INFORMATION Â Item 1. Financial Statements Â CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES Â TABLE OF CONTENTS Â Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 (Unaudited) 2 Â Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 (Unaudited) 3 Â Condensed Consolidated Statements of Stockholdersâ Equity for the Six Months Ended June 30, 2024 and 2023 (Unaudited) 4 Â Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 (Unaudited) 5 Â Notes to Condensed Consolidated Financial Statements (Unaudited) 6 Â 1 Â CHINA PHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Â Â June 30,Â Â December 31,Â Â 2024Â Â 2023Â ASSETSÂ Â Â Â Current Assets:Â Â Â Â Cash and cash equivalentsÂ \$739,337Â Â \$1,423,838Â Bankerâs acceptancesÂ Â 15,435Â Â 65,915Â Trade accounts receivable, less allowance for doubtful accounts of \$13,706,077 and \$13,786,074, respectivelyÂ Â 254,850Â Â 504,448Â Other receivables, less allowance for doubtful accounts of \$27,929 and \$27,017, respectivelyÂ Â 28,660Â Â 157,944Â Advances to suppliersÂ Â 161Â Â 2,013Â InventoriesÂ Â 2,818,925Â Â 3,732,517Â Prepaid expensesÂ Â 115,610Â Â 110,258Â Total Current AssetsÂ Â 3,972,978Â Â 5,996,933Â Â Â Â Property, plant and equipment, netÂ Â 5,817,379Â Â Â 7,100,425Â Right-of-use assetsÂ Â 77,259Â Â 116,610Â Intangible assets, netÂ Â 4,393,617Â Â 3,255,232Â TOTAL ASSETSÂ \$14,261,233Â Â \$16,469,200Â Â Â Â Â LIABILITIES AND STOCKHOLDERSâ EQUITYÂ Â Â Â Current Liabilities:Â Â Â Â Trade accounts payableÂ \$141,036Â Â \$966,420Â Accrued expensesÂ Â 208,831Â Â 298,829Â Other payablesÂ Â 1,606,991Â Â 2,282,692Â Advances from customersÂ Â 101,056Â Â 90,507Â Borrowings from related partiesÂ Â 1,140,775Â Â 1,133,809Â Lease liabilitiesÂ Â 78,628Â Â 77,727Â Current portion of lines of creditÂ Â 1,024,303Â Â 1,030,680Â Convertible, redeemable note payable, net of issue discountÂ Â 410,415Â Â 940,000Â Total Current LiabilitiesÂ Â 4,712,035Â Â 6,820,664Â Non-current Liabilities:Â Â Â Â Lines of credit, net of current portionÂ Â 1,403,154Â Â 1,411,891Â Deferred tax liabilityÂ Â 737,522Â Â 742,114Â Lease liabilitiesÂ Â -Â Â 39,910Â Total LiabilitiesÂ Â 6,852,711Â Â 9,014,579Â Commitments and Contingencies (Note 14)Â Â Â Â Stockholdersâ Equity:Â Â Â Â Preferred stock, \$0.001 par value; 5,000,000 shares authorized; no shares issued or outstandingÂ Â -Â Â -Â Common stock, \$0.001 par value; 500,000,000 shares authorized; 17,162,771 shares and 10,625,788 shares issued and outstanding, respectivelyÂ Â 17,162Â Â 10,625Â Additional paid-in capitalÂ Â 37,690,719Â Â 35,282,256Â Accumulated deficitÂ Â (41,684,336)Â Â (39,290,314)Â Accumulated other comprehensive incomeÂ Â 11,384,977Â Â 11,452,054Â Total Stockholdersâ EquityÂ Â 7,408,522Â Â 7,454,621Â TOTAL LIABILITIES AND STOCKHOLDERSâ EQUITYÂ \$14,261,233Â Â \$16,469,200Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â 2 Â CHINA PHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Â Â For the Three Months EndedÂ Â For the Six Months EndedÂ Â June 30,Â Â June 30,Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â RevenueÂ \$924,943Â Â \$1,097,862Â Â \$2,294,782Â Â \$3,058,152Â Cost of revenueÂ Â 1,940,329Â Â 1,244,523Â Â 3,600,192Â Â 3,026,889Â Gross (loss) profitÂ Â (1,015,386)Â Â (146,661)Â Â (1,305,410)Â Â 31,263Â Â 31,263Â Â 31,263Â Operating expenses:Â Â 111,455Â Â 169,820Â Â 219,642Â Â 314,252Â General and administrative expensesÂ Â 91,870Â Â 112,033Â Â 580,326Â Â 530,032Â Research and development expensesÂ Â 164,334Â Â 23,747Â Â 195,785Â Â 46,755Â Bad debt expense (reversal of allowance for doubtful accounts)Â Â 8,476Â Â 4,047Â Â 6,410Â Â (5,989) Total operating expensesÂ Â 376,135Â Â 309,647Â Â 1,002,163Â Â 885,050Â Â Loss from operationsÂ Â (1,391,521)Â Â (456,308)Â Â (2,307,573)Â Â (853,787)Â Â Other income (expense):Â Â 1,438,130Â Â 593,029Â Â Interest incomeÂ Â 1,531Â Â 942Â Â 3,846Â Â 1,890Â Interest expenseÂ Â (48,140)Â Â (137,663)Â Â (90,295)Â Â (217,108) Net other expenseÂ Â (46,609)Â Â (136,721)Â Â (86,449)Â Â (215,218)Â Â Loss before income taxesÂ Â (1,438,130)Â Â (593,029)Â Â (2,394,022)Â Â (1,069,005) Income tax expenseÂ Â -Â Â -Â Â -Â Â -Â Net lossÂ Â (1,438,130)Â Â (593,029)Â Â (2,394,022)Â Â (1,069,005) Other comprehensive loss - foreign currency translation adjustmentÂ Â (45,502)Â Â (523,687)Â Â (67,077)Â Â (318,365) Comprehensive lossÂ \$(1,483,632)Â \$(1,116,716)Â \$(2,461,099)Â \$(1,387,370) Loss per share:Â Â Â Â Â Basic and dilutedÂ \$(0.09)Â \$(0.35)Â \$(0.16)Â \$(0.65) Weighted average shares outstandingÂ Â 16,124,241Â Â 1,689,985Â Â 14,727,410Â Â 1,653,076Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. Â 3 Â CHINA PHARMA HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ EQUITY (Unaudited) Â Â Â Â AccumulatedÂ Â Â Â AdditionalÂ Â Â OtherÂ Â TotalÂ Â Common StockÂ Â Paid-inÂ Â Accumulated

Â (657,884)Â Â (1,684,649)Â Â Â Â Â Â Â Â Â Cash Flows from Investing Activity:Â Â Â Â Â Â Â Â Â Purchases of property and equipmentÂ Â (28,086)Â Â 60,465Â Net Cash (used in) provided by Investing ActivityÂ Â (28,086)Â Â 60,465Â Â Â Â Â Â Â Â Â Cash Flows from Financing Activities:Â Â Â Â Â Â Â Â Â Payments of line of creditÂ Â (492,761)Â Â Â Â Â Â Â Â Â Proceeds from lines of creditÂ Â 492,761Â Â Â 505,114Â Borrowings and interest from related partyÂ Â 13,708Â Â Â 14,057Â Net Cash Provided by Financing ActivitiesÂ Â 13,708Â Â Â 519,171Â Â Â Â Â Â Â Â Â Effect of Exchange Rate Changes on CashÂ Â (12,239)Â Â (23,048) Net Decrease in Cash, Cash Equivalents and Restricted CashÂ Â (684,501)Â Â (1,128,061) Cash and Cash Equivalents at Beginning of PeriodÂ Â 1,423,838Â Â 2,029,971Â Cash, Cash Equivalents and Restricted Cash at End of PeriodÂ Â \$739,337Â Â \$901,910Â Â Â Â Â Â Â Â Â Supplemental Cash Flow Information:Â Â Â Â Â Â Â Â Â Cash paid for income taxesÂ Â \$-Â Â \$-Â Cash paid for interestÂ Â \$43,217Â Â \$39,681Â Â Â Â Â Â Â Â Â Supplemental Noncash Investing and Financing Activities:Â Â Â Â Â Â Â Â Â Accounts receivable collected with bankerâ€™s acceptancesÂ Â \$187,111Â Â \$421,458Â Inventory purchased with bankerâ€™s acceptancesÂ Â 237,336Â Â 351,463Â Conversions of Note Payable to common stockÂ Â 1,050,000Â Â 800,000Â Issuances of stock for intangible assetsÂ Â 1,365,000Â Â Â Â Â Lease liabilities arising from obtaining right-of-use assetsÂ Â -Â Â 158,926Â Â Â The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.Â 5 Â CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED) Â NOTE 1 â€œ ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Â Organization and Nature of Operations â€œÂ China Pharma Holdings, Inc., a Nevada corporation (â€œChina Pharmaâ€), owns 100% of Onny Investment Limited (â€œOnnyâ€), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (â€œHelpsonâ€), a company organized under the laws of the Peopleâ€™s Republic of China (the â€œPRCâ€). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company. Â Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpsonâ€™s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (â€œWFOEâ€) status on June 21, 2005. Â Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the â€œNMPAâ€, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy. Â Liquidity and Going Concern Â As of June 30, 2024, the Company had cash and cash equivalents of \$0.7 million, an accumulated deficit of \$41.7 million and the Companyâ€™s current liabilities exceeded current assets by \$0.7 million. In addition, the Company had incurred net losses of \$2.4 million and had negative cash flows from operating activities of \$0.7 million for the six months ended June 30, 2024. The Companyâ€™s Chairperson, Chief Executive Officer and Interim Chief Financial Officer had advanced an aggregate of \$1,140,775 as of June 30, 2024 to provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Companyâ€™s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Companyâ€™s existing property, plant and equipment can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Â Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entityâ€™s Ability to Continue as a Going Concern management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of managementâ€™s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Companyâ€™s ability to continue as a going concern. The mitigating effect of managementâ€™s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entityâ€™s ability to continue as a going concern within one year after the date that the financial statements are issued. Â Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Companyâ€™s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Companyâ€™s control. Accordingly, substantial doubt is deemed to exist about the Companyâ€™s ability to continue as a going concern within one year after the date these financial statements are issued.Â 6 Â CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED) Â The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Â Reverse Stock Split â€œ Effective March 6, 2024, China Pharma implemented a 1-for -5 reverse stock split as more fully discussed in Note 13. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split. Â Consolidation and Basis of PresentationÂ â€œ The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) and are expressed in United States dollars. The accompanying unaudited interim condensed consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation. Â Helpsonâ€™s functional currency is the Chinese Renminbi. Helpsonâ€™s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpsonâ€™s financial statements are included in accumulated other comprehensive income, which is a component of stockholdersâ€™ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. Â In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the â€œSECâ€) on April 1, 2024 (â€œ2023 Annual Reportâ€). Â Accounting EstimatesÂ â€œÂ The methodology used to prepare the Companyâ€™s financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.Â The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Â Loss Per Share â€œ Basic loss per share is calculated by dividing loss available to common stockholders by the weighted-average number of shares of common stock outstanding, excluding unvested stock. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common shares, including unvested stock, had been issued and if the additional common shares were dilutive.Â The potentially dilutive common shares related to the convertible, redeemable note payable of 2,003,001 and 2,155,964 at June 30, 2024 and December 31, 2023 as discussed in Note 9, respectively, and the option to purchase 13,300 shares of common stock at June 30, 2024 and December 31, 2023 are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company. Â Recent Accounting Pronouncements Â In December 2023, the FASB issued guidance to enhance transparency of income tax disclosures. On an annual basis, the new guidance requires a public entity to disclose: (1) specific categories in the rate reconciliation, (2) additional information for reconciling items that are equal to or greater than 5% of the amount computed by multiplying income (or loss) from continuing operations before income tax expense (or benefit) by the applicable statutory income tax rate, (3) income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes, with foreign taxes disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5% of total income taxes paid, (4) income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and (5) income tax expense (or benefit) from continuing operations disaggregated between federal (national), state and foreign. The guidance is effective for fiscal year 2025 annual reporting, with early adoption permitted, to be applied on a prospective basis, with retrospective application permitted. We do not expect the adoption of this accounting standard to have an impact on our Consolidated Financial Statements but will require certain additional disclosures. Â From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of

ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

7 CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED)

NOTE 2

ACCOUNTS RECEIVABLE, NET

Accounts receivable, net, consist of the following:

	June 30, 2024	December 31, 2023
Trade accounts receivable	\$13,960,927	\$14,290,522
Less: allowance for doubtful accounts	\$(13,706,077)	\$(13,786,074)
Trade accounts receivable, net	\$254,850	\$504,448

We recognize bad debt expenses per actual write-offs as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is lower than that of the previous period, we recognize a bad debt credit for the difference. The allowance for doubtful account balances were \$13.71 million and \$13.79 million as of June 30, 2024 and December 31, 2023, respectively. The changes in the allowances for doubtful accounts during the three and six months ended June 30, 2024 and 2023 were as follows:

	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024	Three Months Ended June 30, 2023	Six Months Ended June 30, 2023
Beginning of Period	\$13,759,993	\$16,955,959	\$13,786,074	\$16,739,527
Bad debt expense (reversal of allowance for doubtful accounts)	\$8,476	\$4,047	\$6,410	\$(5,989)
Foreign currency translation adjustment	\$(62,392)	\$(834,751)	\$(86,407)	\$(608,283)
Balance, End of Period	\$13,706,077	\$16,125,255	\$13,706,077	\$16,125,255

NOTE 3

INVENTORIES

Inventories consisted of the following:

	June 30, 2024	December 31, 2023
Raw materials	\$1,194,063	\$1,849,213
Work in process	\$87,308	\$413,597
Finished goods	\$1,537,554	\$1,469,707
Total Inventories	\$2,818,925	\$3,732,517

NOTE 4

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

	June 30, 2024	December 31, 2023
Permit of land use	\$395,223	\$397,684
Building	\$9,177,692	\$9,234,836
Plant, machinery and equipment	\$27,029,997	\$27,170,123
Motor vehicle	\$301,818	\$303,697
Office equipment	\$386,334	\$388,740
Total	\$37,291,064	\$37,495,080

Less: accumulated depreciation

	June 30, 2024	December 31, 2023
	\$(31,473,685)	\$(30,394,655)

Property, plant and equipment, net

	June 30, 2024	December 31, 2023
	\$5,817,379	\$7,100,425

8 CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED)

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

Asset	Life
Permit of land use	40
Building	20
Plant, machinery and equipment	5
Motor vehicle	5
Office equipment	3-5

Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was \$636,721 and \$640,979 for the three months ended June 30, 2024 and 2023, respectively and \$1,270,981 and \$1,265,700 for the six months ended June 30, 2024, respectively.

NOTE 5

INTANGIBLE ASSETS

Intangible assets represent the cost of medical formulas approved for production by the NMPA, the intellectual property acquired (the "Bonier Agreement") from Chengdu Bonier Medical Technology Development Co., Ltd. (the "Bonier"), the Technology Transfer Agreement with Tao Liu, and the Technology Transfer Agreement with Lihua Li, both are discussed below. No costs were reclassified from advances to intangible assets during the six months ended June 30, 2024 and 2023, respectively. Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was \$104,922 and \$55,161 for the three months ended June 30, 2024 and \$202,069 and \$109,024 for the six months ended June 30, 2024 and 2023, respectively, which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.

On February 2, 2024, Helpson entered into a Technology Transfer Agreement (the "Lihua Li Agreement") with Lihua Li (the "Transferor Li"). Transferor Li owns an invention patent of a pharmaceutical composition for treatment of psoriasis (the "Li Invention Patent"). Pursuant to the Lihua Li Agreement, Transferor Li will transfer the ownership of the Li Invention Patent to Helpson. Transferor Li or his designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application. The aggregate transfer price as contemplated by the Agreement is \$1.365 million which was paid to the Transferor and his two designees upon the issuance of 3,000,000 shares of common stock of the Company at \$0.455 per share based on the closing market price of the Company's common stock as of the closing date. The Company recorded the amount as intangible assets on the accompanying balance sheet as of the closing date. The value of the intangible asset will be amortized over its remaining useful life of approximately 20 years. During the ten years after the product launches to the market, if and only if the product generates profit, Helpson shall pay 10% of the net profit of the sales in cash on an annual basis to Transferor Li.

On December 15, 2023, the Company entered into a Technology Transfer Agreement (the "Tao Liu Agreement") with Tao Liu (the "Transferor Liu"). Transferor Liu owns an invention patent of a drug combination for the treatment of chronic obstructive pulmonary disease (the "Liu Invention Patent"). Pursuant to the Tao Liu Agreement, Transferor Liu will transfer the ownership of the Liu Invention Patent to Helpson. Transferor Liu or his designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services.

During the ten years after the product launches to the market, if and only if the product generates profit, Helpson shall pay 15% of the net profit of the sales in cash on an annual basis to Transferor Liu.

On November 28, 2022, the Company entered into a Technology Transfer Contract with Bonier. Bonier owns the know-how of a technical invention and creation of an ophthalmic oxygen enriched atomization therapeutic instrument, which has obtained a utility model patent (the "Utility Model Patent") and applied for an invention patent (the "Bonier Invention Patent") at the same time. Pursuant to the Bonier Agreement, Bonier will transfer the ownership of the Utility Model Patent of the technical invention and the Bonier Invention Patent application right of the invention to Helpson. Bonier or its designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services, with a term of ten years.

9 CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED)

The Company will pay a service fee of 15% of the net profit of the corresponding product sales revenue, which will be paid in cash annually after it launches to the market, contingent on the successful authorization of the above mentioned Bonier Invention Patent. There were no service fees or profit payments paid related to the above three agreements for the three and six months ended June 30, 2024 and 2023, respectively.

The Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement. The Company's evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data for the related drug and the Company's estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the three and six months ended June 30, 2024 and 2023.

Intangible assets consisted of NMPA approved medical formulas, a Utility Model Patent and two Invention Patents as follows:

	June 30, 2024	December 31, 2023
NMPA approved medical formulas	\$4,736,859	\$4,766,353
Technology from Bonier	\$1,715,813	\$1,726,497
Invention Patents	\$3,002,782	\$1,653,028
	\$9,455,454	\$8,145,878
Accumulated amortization	\$(5,061,837)	\$(4,890,646)
Net carrying amount	\$4,393,617	\$3,255,232

NOTE 6

OTHER PAYABLES

Other Payables consisted of the following:

	June 30, 2024	December 31, 2023
Compensation payable to officer	\$1,251,506	\$1,243,506
Compensation and interest to related parties	\$20,000	\$12,000
Business taxes and other	\$335,485	\$1,027,186
Total Other Payables	\$1,606,991	\$2,282,692

NOTE 7

RELATED PARTY TRANSACTIONS

The Company had previously received advances from its Chairperson Li. Total amounts owed were \$1,140,775 and \$1,133,809 and are recorded as "Borrowings from related parties" on the accompanying condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively.

On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB 4,770,000 (\$738,379) with its Chairperson Li. The loan bears interest at a rate of 4.35% and was payable within one year of the loan agreement. The due date of the loan agreement has been extended annually on identical terms, and is due July 9, 2024. Total interest expense related to the loan for the three months ended June 30, 2024 and 2023 was \$6,852 and \$6,945, respectively and \$13,708 and \$14,057 for the six months ended June 30, 2024 and 2023, respectively. Compensation payable to the Chairperson Li is included in "Other payables" in the accompanying condensed consolidated balance sheet totaling \$1,251,506 and \$1,243,506 as of June 30, 2024 and December 31, 2023, respectively.

10 CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED)

NOTE 8

LINES OF CREDIT

On December 21, 2022 the Company entered into a new line of credit for an aggregate amount of RMB 7,300,000 (approximately \$1.0 million) with interest payable monthly at a rate of 3.9% with Bank of Communications. The Company received an advance on the line of credit in the amount of RMB 3,800,000 (approximately \$0.56 million) on December 30, 2022.

On February 24, 2023 the Company received an advance on the line in the amount of RMB 3,500,000 (approximately \$0.51 million). The Company has no further availability on this line of credit. The line of credit was paid in full on December 15, 2023, five days before the due date of December 20, 2023.

On December 20, 2023, the Company received a new line of credit in the amount of RMB 3,800,000 and an interest rate of 3.9% and is due December 15, 2024. In addition, the Company's Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest expense under this facility for the three months ended June 30, 2024 and 2023 was \$10,237 and \$5,465, respectively and \$19,302 and \$10,568.

On February 2, 2024 the Company repaid RMB 3,500,000 under this line of credit.

On February 22, 2024 the Company entered into a new agreement on identical terms and received an advance on the line in the amount of RMB 3,500,000 which is due of February 20, 2025.

On September 30, 2022 the Company received a line of credit for RMB 10,000,000 (approximately \$1.54 million) with Bank of China. The loan bears interest at the rate of 3.45% and was due September 28, 2023.

On September 22, 2023 the Company repaid this note in full.

On September 25, 2023 the Company entered into a three-year revolving loan and received proceeds of RMB 10,000,000 (approximately \$1.4 million). The interest rate for the loan is 3.35% for the first twelve months of the loan

and adjusts based on the latest one-year loan market quotation rate less 10 basis points as published by the China National Interbank Funding Center on the working day prior to each twelve month anniversary of the loan. The loan is due on September 24, 2026. The loan is collateralized by the Company's new production facility and the included production line equipment and machinery. In addition, the Company's Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. Total interest paid on this loan was \$11,993 and \$12,724 for the three months ended June 30, 2024 and 2023, respectively and \$23,915 and \$25,320 for the six months ended June 30, 2024 and 2023, respectively. A Principal payments required for the remaining terms of the loan facility and lines of credit as of June 30, 2024 are as follows: A Year A Lines of Credit 2025 A 1,024,303 A 2026 A 1,403,154 A A \$2,427,457 A Fair Value of Lines of Credit " Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the lines of credit outstanding as of June 30, 2024 and December 31, 2023 approximated their fair values because the underlying instruments bear an interest rate that approximates current market rates. A NOTE 9 " CONVERTIBLE NOTE PAYABLE A On November 17, 2021, China Pharma entered into a Securities Purchase Agreement (the "Agreement") pursuant to which the Company issued an unsecured convertible promissory note (the "Note") to an institutional accredited investor Streeterville Capital, LLC (the "Investor"). The transaction contemplated under the Agreement was closed on November 19, 2021. The Note matured on February 17, 2023. On April 13, 2023 China Pharma entered into an Amendment (the "Amendment") with the Investor which extended the maturity date of the Convertible Note Payable to May 19, 2024. As consideration for the extension, China Pharma agreed to an extension fee of \$65,639, representing 2.0% of the balance of the Note and accrued interest on the date of the Amendment. The amount was satisfied by increasing the Note balance by the amount of the extension fee. The Company recorded this as additional interest expense during the second quarter of 2023. In addition, China Pharma decreased the price at which the Investor can convert the balance from 85% to 82% of the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, and assumed an additional obligation to redeem a portion of the outstanding balance of the Note monthly or be subject to additional penalty fees. A 11 A CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED) A On May 23, 2024, the Company entered into an Amendment No. 2 (the "Second Amendment"), to the Note by which the parties have agreed to extend the maturity date of the Note to August 19, 2025. In consideration of the extension, the Company has agreed to pay to the Investor an extension fee equal to two percent (2%) of the outstanding balance of the Note (the "Extension Fee") totaling \$10,934, and lower the minimum monthly redemption amount from the outstanding balance of the Note that the Company is obligated to redeem from \$150,000 to \$37,182.33. The Second Amendment also includes customary representations and warranties by the Company. The Company recognized the Extension Fee as interest expense for the year ending December 31, 2024. A The Note was originally convertible into 70,000 shares of China Pharma's common stock at a price of \$75.00 per share through April 19, 2022. Thereafter, the Note was convertible into 35,000 shares at a price of \$150.00 per share. As of June 30, 2024 the Note is convertible into 2,736 shares of common stock. A Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default. A Pursuant to the terms of the Agreement and the Note, the Company must obtain Investor's consent for certain fundamental transactions such as consolidation, merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change of control, reorganization or recapitalization. Any occurrence of a fundamental transaction without Investor's prior written consent will be deemed an Event of Default. A Investor may redeem all or any part the outstanding balance of the Note, subject to \$500,000 per calendar month, at any time after one hundred twenty-one (121) days from the Purchase Price Date, as defined in the Note, upon three trading days' notice, in cash or converting into shares of China Pharma's common stock, at a price equal to 82% multiplied by the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding balance of the Note with the Investor's consent. At inception, the Note was redeemable into 176,229 shares based on the lowest volume weighted average price of \$29.79085 on the inception date of November 19, 2021. As of June 30, 2024, the Note was redeemable into 2,003,001 shares of common stock based on 82% of the lowest volume weighted average price of \$0.2049 on that date. A Total interest expense for the three months ended June 30, 2024 and 2023 was \$19,058 and \$105,545, respectively, and \$33,370 and \$151,563 for the six months ended June 30, 2024 and 2023, respectively. A On January 11, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3945, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 380,228 shares of common stock to the Investor on January 16, 2024. A On February 1, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3725, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 402,685 shares of common stock to the Investor on February 5, 2024. A On February 16, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3675, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 408,164 shares of common stock to the Investor on February 21, 2024. A On April 2, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2927, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 512,470 shares of common stock to the Investor on April 3, 2024. A On April 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2774, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 540,735 shares of common stock to the Investor on April 19, 2024. A On May 20, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2539, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 590,783 shares of common stock to the Investor on May 21, 2024. A 12 A CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED) A On June 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2137, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 701,918 shares of common stock to the Investor on June 17, 2024. A NOTE 10 " LEASES A The Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right of use assets when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company's incremental borrowing rate at the initial measurement date. For the three months ended June 30, 2024 and 2023, operating lease cost was \$19,228 and \$17,848, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was \$19,947 and \$18,744, respectively. A For the six months ended June 30, 2024 and 2023, operating lease cost was \$38,629 and \$37,635, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was \$40,074 and \$39,525, respectively. As of June 30, 2024 and December 31, 2023, the Company reported right of use assets of \$77,259 and \$116,610, respectively and lease liabilities of \$78,628 and \$117,637, respectively. As of June 30, 2024, its operating leases had a weighted average remaining lease term of 1.0 years and a weighted average discount rate of 3.55%. A Minimum lease payments for the Company's operating lease liabilities were as follows for the twelve month period ended June 30: A 2025 A \$80,148 A Total undiscounted cash flows A 80,148 A Less: Imputed interest A (1,520) A A 78,628 A Less: Lease liabilities, current portion A (78,628) A Lease liabilities, net of current portion A \$- A The Company has leases with terms less than one year for certain provincial sales offices that are not material. A NOTE 11 " INCOME TAXES A Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. A Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the "more-likely-than-not" threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2023, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2019 through December 31, 2023 and the Chinese income tax return for the year ended December 31, 2023 are open for possible examination. A Under the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%. A There was no provision for income taxes for the three and six months ended June 30, 2024 and 2023, respectively due to continued net losses of the Company. A 13 A CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED) A As of June 30, 2024, Helpson had net operating loss carryforwards for PRC tax purposes of approximately \$22.6 million which are available to offset any future taxable income through 2029. Approximately \$2.7 million of these carryforwards will expire in December 2024. The Company also has net operating losses for United States federal income tax purposes of approximately \$10.3 million of which \$5.1 million is available to offset future taxable income, if any, through 2040, and \$5.2 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year. A U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the "U.S. Tax Reform"), was signed into law on December 22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code

by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of June 30, 2024 and December 31, 2023. Therefore, the Company provided for a valuation allowance against its deferred tax assets of \$21,992,061 and \$21,531,017 as of June 30, 2024 and December 31, 2023, respectively. The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

NOTE 12 – FAIR VALUE MEASUREMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data; and Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Company uses fair value to measure the value of the banker’s acceptance notes it holds at June 30, 2024 and December 31, 2023. The banker’s acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value:

	Fair Value Measurements at Reporting Date Using	Description	June 30, 2024	Level 1	Level 2	Level 3
Banker’s acceptance notes	\$15,435	\$15,435	\$15,435	\$15,435		
Fair Value Measurements at Reporting Date Using	Description	December 31, 2023	Level 1	Level 2	Level 3	Banker’s acceptance notes
\$65,915	\$65,915	\$65,915	\$65,915	\$65,915		

14 CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED)

NOTE 13 – STOCKHOLDERS’ EQUITY China Pharma is authorized to issue 500,000,000 shares of common stock, \$0.001 par value, and 5,000,000 shares of preferred stock, \$0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Board of China Pharma. According to relevant PRC laws, companies registered in the PRC, including China Pharma’s PRC subsidiary, Helpson, are required to allocate at least 10% of their after tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach 50% of the company’s registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferable to the parent company in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is \$8,145,000 at June 30, 2024 and December 31, 2023. Effective March 6, 2024, the Company implemented a 1-for-5 reverse split of its common stock. The reverse stock split was approved by the Company’s Board of Directors through unanimous written consent and the Company’s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2022, which was held on December 17, 2023. Upon the effectiveness of the reverse stock split, every 5 shares of the Company’s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder’s percentage interest in the Company’s outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts have been retroactively restated for all periods presented in the accompanying unaudited condensed consolidated financial statements. Effective March 6, 2023 China Pharma implemented a 1-for-10 reverse split of its common stock. The reverse stock split was approved by the Company’s Board of Directors through unanimous written consent and China Pharma’s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of China Pharma’s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder’s percentage interest in China Pharma’s outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts have been retroactively restated for all periods presented in the accompanying unaudited condensed consolidated financial statements.

2024 Share Issuances On January 11, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3945, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 380,228 shares of common stock to the Investor on January 16, 2024. On February 1, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3725, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 402,685 shares of common stock to the Investor on February 5, 2024.

15 CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED) On February 16, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3675, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 408,164 shares of common stock to the Investor on February 21, 2024. On April 2, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2927, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 512,470 shares of common stock to the Investor on April 3, 2024. On April 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2774, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 540,735 shares of common stock to the Investor on April 19, 2024. On May 20, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2539, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 590,783 shares of common stock to the Investor on May 21, 2024. On June 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2137, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 701,918 shares of common stock to the Investor on June 17, 2024.

2010 Incentive Plan On November 12, 2010, the Company’s Board adopted the Company’s 2010 Incentive Plan (the “Plan”), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the “Amendment”), pursuant to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December 19, 2019. On October 25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to the Plan to increase the number of shares of the Common Stock, that are reserved thereunder by 100,000 shares from 80,000 shares to 180,000 shares. On October 27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares of common stock that are reserved thereunder by an additional 100,000 shares from 180,000 to 280,000. On December 17, 2023 the stockholders approved Amendment No. 1 to the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares from 280,000 to 580,000. The Plan gives the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 580,000 shares of common stock. Through June 30, 2024, there were 84,700 shares of stock and stock options granted and outstanding under the Plan. A total of 13,300 options were outstanding as of June 30, 2024 under the Plan. As such, there are 482,000 additional units available for issuance under the Plan.

16 CHINA PHARMA HOLDINGS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED JUNE 30, 2024 AND 2023 (UNAUDITED) There were no issuances of securities from the Plan for the six months ended June 30, 2024 and as such, no compensation expense was recognized for the period. As of June 30, 2024, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.

NOTE 14 – COMMITMENTS AND CONTINGENCIES Current vulnerability due to certain concentrations. For the six months ended June 30, 2024, no customer accounted for greater than 10.0% of sales and two customers accounted for 63.6% and 13.7% of accounts receivable. Three suppliers accounted for 23.5%, 23.4% and 17.6% of raw material purchases, and three different products accounted for 35.2%, 22.7% and 10.2% of revenue. For the six months ended June 30, 2023, no customer accounted for greater than 10.0% of sales and three customers accounted for 53.4%, 11.5%

and 10.5% of accounts receivable. Two suppliers accounted for 19.5% and 18.0% of raw material purchases, and five different products accounted for 22.4%, 19.8%, 11.8%, 10.9% and 10.0% of revenue. A Nature of Operations A Economic environment -A Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company's operations. A In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government. A NOTE 15 - SUBSEQUENT EVENTS A The Company evaluated all events and transactions that occurred after June 30, 2024 up through the date the Company filed these unaudited condensed consolidated financial statements. No events require adjustment to or disclosure in the unaudited condensed consolidated financial statements. A 17 A Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. A The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology, such as "anticipate," "believe," "expect," "plan," "intend," "seek," "estimate," "project," "could," or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the readers that any such forward-looking statements contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report and some of which are discussed in our other filings with the Securities and Exchange Commission (the "SEC"). These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events. A These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward-looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation. A Business Overview & Recent Developments A China Pharma Holding Inc. ("China Pharma") is not a Chinese operating company but a Nevada holding company. All of our operations are conducted in the PRC through Hainan Helpson Medical & Biotechnology Co., Ltd ("Helpson"), our wholly owned subsidiary incorporated under the laws of the People's Republic of China (the "PRC"), where the manufacturing facilities are located. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. It manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all of them have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the "NMPA", formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy. A China's consistency evaluation of generic drugs continues to proceed in 2024. Helpson has always taken the task of promoting the consistency evaluation as a top priority, and worked on them actively. However, for each drug's consistency evaluation, due to the continuous dynamic changes of the detailed consistency evaluation policies, market trends, expected investments, and expected returns of investment ("ROI"), the whole industry, including Helpson, has been making slow progresses in terms of the consistency evaluation. One of the flagship products, Candesartan tablets, a hypertension product, has passed generic-drug-consistency-evaluation in early August 2023. A 18 A Helpson has taken a more cautious and flexible attitude towards initiating and progressing any project for existing products' consistency evaluation to cope with the changing macro environment of drug sales in China. In 2018, relevant Chinese authorities decided to implement trial Centralized Procurement ("CP") activities in 11 selected pilot cities (including 4 municipalities and 7 other cities), since then, nine rounds of CP activities have been carried out as of August 6, 2024, which significantly reduced the price of the drugs that won the bids. In addition, the consistency evaluation has been adopted as one of the qualification standards for participating in the CP activities. As a result, Helpson needs to balance between the market access brought by CP, the investment of financial resources and time to obtain the qualification of CP, and the sharp decline in the price of drugs included in CP before making decisions regarding CP for any products. A In addition, Helpson continues to explore the field of comprehensive healthcare. Comprehensive healthcare is a general concept proposed by the Chinese government according to the development of the times, social needs and changes in disease spectrum. According to the Outline of "Healthy China 2030" issued by Chinese government in October 2016, the total size of China's health service industry is expected to reach RMB 16 trillion (approximately \$2.5 trillion) by 2030. This industry focuses on people's daily life, aging and diseases, pays attention to all kinds of risk factors and misunderstandings affecting health, calls for self-health management, and advocates the comprehensive care throughout the entire process of life. It covers all kinds of health-related information, products, and services, as well as actions taken by various organizations to meet the health needs. In response to this trend, Helpson launched Noni enzyme, a natural, Xeronine-rich antioxidant food supplement at the end of 2018. It also launched wash-free sanitizers and masks, in 2020, to address the market needs caused by COVID-19 in China. As Chinese government officially terminated its zero-case policy, now the responsibility to protect people from the impact of COVID-19 falls more to the citizens themselves, and masks and sanitizers have been popular since COVID-19. Helpson has sufficient production capacity for medical masks, surgical masks, KN95 masks, and N95 masks, which also meets the personal needs for protection against other respiratory infectious disease. Helpson's N95 medical protective mask has received registration certificate at the end of 2022 and right now has been selling in the mainland China nationwide. A Helpson will continue to optimize its product structure and actively respond to the current health needs of human beings. A Results of Operations for the three months ended June 30, 2024 A Revenue A Revenue decreased by 16.4% to \$0.9 million for the three months ended June 30, 2024, as compared to \$1.1 million for the three months ended June 30, 2023. This decline was mainly due to an increasing number of drugs from other medicine providers being included in national CP, while Helpson's peer products have not passed consistency evaluation. As a result, they are not qualified to participate in CP, the resulting sales has decreased. A Set forth below are our revenues by product category in millions (USD) for the three months ended June 30, 2024 and 2023: A A Three Months Ended June 30, A Net A A Product Category A 2024 A 2023 A Change A % Change A CNS Cerebral & Cardio Vascular A 0.37 A 0.35 A 0.02 A 6% Anti-Viral/ Infection & Respiratory A 0.48 A 0.47 A 0.01 A 2% Digestive Diseases A 0.04 A 0.17 A -0.13 A -76% Other A 0.03 A 0.11 A -0.08 A -73% A The most significant revenue decrease in terms of dollar amount was in our "Digestive" product category, which generated \$0.04 million in sales revenue in the three months ended June 30, 2024 compared to \$0.17 million for the same period a year ago, a decrease of \$0.13 million. This decrease was mainly due to the decrease in sales of Omeprazole because of the implementation of CP. A Our "Other" product category sales decreased by \$0.08 million to \$0.03 million in the three months ended June 30, 2024 from \$0.11 million for the same period in 2023, which was mainly due to the decrease in sales of Vitamin B6 for Injection that was caused by the implementation of CP. A 19 A Sales under "CNS Cerebral & Cardio Vascular" product category generated \$0.37 million in sales revenue in the three months ended June 30, 2024 compared to \$0.35 million for the same period a year ago, which is an increase of \$0.02 million. This slight change in sales was caused by market volatility. A Our "Anti-Viral/ Infection & Respiratory" product category generated \$0.48 million of sales in the three months ended June 30, 2024, compared to \$0.47 million in the same period in 2023. This slight change in sales was caused by market volatility. A A Three Months Ended June 30, A Product Category A 2024 A 2023 A CNS Cerebral & Cardio Vascular A 41% A 32% Anti-Viral/ Infection & Respiratory A 52% A 43% Digestive Diseases A 4% A 15% Other A 3% A 10% A For the three months ended June 30, 2024, revenue breakdown by product category showed certain changes to that of the same period in 2023. Sales of the "Anti-Viral/Infection & Respiratory" products category represented 52% and 43% of total sales in the three months ended June 30, 2024 and 2023, respectively. The "CNS Cerebral & Cardio Vascular" product category represented 41% and 32% of total revenue in the three months ended June 30, 2024 and 2023, respectively. The "Other" product category represented 3% and 10% of revenues in the three months ended June 30, 2024 and 2023, respectively. The "Digestive Diseases" product category represented 4% and 15% of total revenue in the three months ended June 30, 2024 and 2023, respectively. A Cost of Revenue A For the three months ended June 30, 2024, our cost of revenue was \$1.9 million, or 209.8% of total revenue, while cost of revenue was \$1.2 million, or 113.4% of total revenue, for the same period in 2023. The increase in cost in this quarter was mainly because the increase in idle equipment costs due to reduced production, as well as the increased inventory impairments. A Gross Loss and Gross Margin A Gross loss for the three months ended June 30, 2024 was \$1.01 million, as compared to \$0.15 million during the same period in 2023. For the three months ended June 30, 2024, we had a gross loss margin of 109.8% as compared to a gross loss margin of 13.4% during the same period in 2023. The increase in gross loss is triggered by the decrease in the revenue and increase in the cost of revenue as described above. A Selling Expenses A Our selling expenses for the three months ended June 30, 2024 and 2023 were \$0.11 million and \$0.17 million, respectively. A Selling expenses accounted for 12.0% of the total revenue for the three months ended June 30, 2024, as compared to 15.5% during the same period in 2023. As a result of the adjustment of many policies of healthcare reformation, we had reduced the number of personnel and expenses to efficiently support our sales and the collection of accounts receivable. A General and Administrative Expenses A Our general and administrative expenses were \$0.09 million and \$0.11 million for the three months ended June 30, 2024 and 2023, respectively. It accounted for 9.9% and 10.2% of our total revenues in the three months ended June 30, 2024 and 2023, respectively. A

Research and Development Expenses – Our research and development expenses for the three months ended June 30, 2024 and 2023 were \$0.16 and \$0.02 million, respectively. Research and development expenses accounted for 17.8% and 2.2% of our total revenues for the three months ended June 30, 2024 and 2023, respectively. The increase in research and development expenses were mainly due to our increased efforts in drug consistency evaluation.

20 – Bad Debt Expenses – Our bad debt expense for the three months ended June 30, 2024 were \$8,476, as compared to \$4,047 for the same period in 2023.

In general, our normal customer credit or payment terms are 180 days. This has not changed in recent years. Such relatively long credit term is due to the peculiar environment affecting the Chinese pharmaceutical market, as deferred payments by state-owned hospitals to local drug distributors are common, and their deferred payments will indirectly delay the payments from our customers to us. Due to the timeliness requirements of the NMPA for logistics of drug sales, Helpson, like most other pharmaceutical companies in China, sells substantially all the drugs to local drug distributors, certified by GSP (Good Supply Practice), the standard of products supply, which is a standard protocol to control the quality of the products during circulation. These GSP certified distributors then sell the drugs to state-owned hospitals. The GSP certified distributors’ payments to us are usually delayed as they will pay us after they receive payment from the state-owned hospitals. Therefore, as most of our customers are GSP certified distributors, we adopt a unified policy for bad debt allowance reserves for GMP’s customers who are typically GSP certified distributors. As is typical in the Chinese pharmaceutical market, there are no written contracts between the Company and any of its GSP certified distributors requesting the distributors to pay the Company’s account receivable upon their receipt of funds from the distributors’ customers, or state-owned hospitals. Nevertheless, the Company’s customers typically process the payment of the account receivable to the Company upon their receipt of payment from their customers, i.e., the state-owned hospitals, as a matter of implied consensus or industry standard. In the event the length of collection term is deviated from any of the past pattern of any particular customer, the Company will adjust its credit term.

The amount of accounts receivable that was past due (or the amount of accounts receivable that was more than 180 days old) was \$0.06 million and \$0.02 million as of June 30, 2024 and December 31, 2023, respectively.

The following table illustrates our accounts receivable aging distribution in terms of percentage of total accounts receivable, respective gross accounts receivables as well as the allocated allowance for doubtful accounts as of June 30, 2024 and December 31, 2023:

	June 30, 2024	December 31, 2023
1 - 180 Days	1.36%	3.45%
180 - 365 Days	0.50%	0.06%
365 - 720 Days	0.05%	0.09%
> 720 Days	98.09%	96.40%
Total	100.00%	100.00%

21 – Gross Accounts Receivable Amount – Allocated Allowance for Doubtful Accounts – 30-Jun-24 – 31-Dec-23 – 30-Jun-24 – 31-Dec-23

	1-180 Days	180-365 Days	365-720 Days	Over 720 Days	Total
June 30, 2024	\$189,315	\$495,366	\$70,668	\$13,826	\$13,960,926
December 31, 2023	\$495,366	\$70,668	\$13,826	\$14,363,431	\$13,960,926

Our allowance for doubtful accounts as a percentage of accounts receivable was 98.2% and 96.5% as of June 30, 2024 and December 31, 2023, respectively.

We conduct analysis and review on accounts receivables for customers on a specific, per-customer basis in the fourth fiscal quarter of each fiscal year. For customers (i) whose business license has been cancelled or expired; (ii) whose key business certificates such as GSP (Good Supply Practice) license have been invalid or revoked; (iii) who have no ability to continue operations, or (iv) who are encountering other issues that lead to accounts receivable unrecoverable, the receivable will be written-off as per the resolution of our Board of Directors.

Our bad debt allowance estimate practice is that we consider accounts receivable balances aged within 180 days current, except for any individual uncollectible account assessed by management. We account for the following respective percentage as bad debt allowance based on age of the accounts receivables: 10% of accounts receivable that is between 180 days and 365 days old, 70% of accounts receivable that is between 365 days and 720 days old, and 100% of accounts receivable that is greater than 720 days old.

We recognize bad debt expenses per actual write-offs as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is lower than that of the previous period, we recognize a bad debt credit for the difference. The allowance for doubtful account balances were \$13.7 million and \$13.8 million as of June 30, 2024 and December 31, 2023, respectively. The changes in the allowances for doubtful accounts during the three months ended June 30, 2024 and 2023 were as follows:

	June 30, 2024	June 30, 2023
For the Three Months Ended	\$13,759,993	\$16,955,959
Bad debt expense	\$8,476	\$4,047
Foreign currency translation adjustment	(62,392)	(834,751)
Balance, End of Period	\$13,706,077	\$16,125,255

Our operating loss for the three months ended June 30, 2024 was \$1.4 million, compared to an operating loss of \$0.5 million during the same period in 2023. The increase in loss from operation is triggered by the decrease in the revenue and increase in the cost of revenue as described above.

Net Interest Expense – Net interest expense for the three months ended June 30, 2024 was \$0.05 million, as compared to \$0.14 million for the same period in 2023.

Net Loss – Net Loss for the three months ended June 30, 2024 was \$1.4 million, as compared to a net loss of \$0.6 million for the same period a year ago. The increase in net loss was mainly the result of increased cost in this period.

Loss per basic and diluted common share were \$0.09 for the three months ended June 30, 2024 and \$0.35 for the same period in 2023.

The number of basic and diluted weighted-average outstanding shares used to calculate loss per share were 16,124,241 and 1,689,985 for the three months ended June 30, 2024 and 2023.

Results of operations for the six months ended June 30, 2024 – Revenue – Revenue decreased by 25.0% to \$2.3 million for the six months ended June 30, 2024, as compared to \$3.1 million for the six months ended June 30, 2023. This decline was mainly due to an increasing number of drugs from other medicine providers being included in national CP, while Helpson’s peer products have not passed consistency evaluation. As a result, they are not qualified to participate in CP, the resulting sales has decreased.

Set forth below are our revenues by product category in millions (USD) for the six months ended June 30, 2024 and 2023, respectively:

	2024	2023
Six Months Ended June 30	\$1.40	\$1.47
Product Category	2024	2023
CNS Cerebral & Cardio Vascular	0.70	0.75
Anti-Viral/ Infection & Respiratory	1.40	1.47
Digestive Diseases	0.08	0.37
Others	0.29	0.78

Other – The most significant revenue decrease in terms of dollar amount was our “Other” product category, which generated \$0.11 million in sales revenue in the six months ended June 30, 2024 compared to \$0.47 million in the same period a year ago, represented a decrease of \$0.36 million that was mainly caused by the decrease in sales of Vitamin B6 for Injection as our such product is not yet eligible to participate in CP.

Sales of our “Digestive Diseases” was \$0.08 million in sales revenue in the six months ended June 30, 2024, compared to \$0.37 million in the same period a year ago, which represented a decrease of \$0.29 million. This decrease was mainly due to sales decrease of Helpson’s Omeprazole products due to ineligibility to participate in CP.

Sales of “CNS Cerebral & Cardio Vascular” product category generated \$0.70 million in sales revenue in the six months ended June 30, 2024, compared to \$0.75 million in the same period a year ago, which represented a decrease of \$0.05 million. This change was mainly due to market volatility.

23 – Sales of our “Anti-Viral/ Infection & Respiratory” product category generated \$1.40 million in the six months ended June 30, 2024, and \$1.47 million in the six months ended June 30, 2023. This change was mainly due to market volatility.

Six Months Ended June 30, 2024 – Product Category – 2024 – 2023

	2024	2023
CNS Cerebral & Cardio Vascular	30%	25%
Anti-Viral/ Infection & Respiratory	61%	48%
Digestive Diseases	4%	12%
Others	5%	15%

For the six months ended June 30, 2024, revenue breakdown by product category remained similar to that of the same period in 2023. The “Anti-Viral/Infection & Respiratory” products category represented 61% and 48% of total revenues in the six months ended June 30, 2024 and 2023. The “CNS Cerebral & Cardio Vascular” category represented 30% and 25% of total revenue in the six months ended June 30, 2024 and 2023, respectively. The “Others” category represented 5% and 15% of revenues in the six months ended June 30, 2024 and 2023, respectively. And the “Digestive Diseases” category represented 4% and 12% of total revenue in the six months ended June 30, 2024 and 2023, respectively.

Cost of Revenue – For the six months ended June 30, 2024, our cost of revenue was \$3.6 million, or 156.9% of total revenue, comparing to \$3.0 million, or 99.0% of total revenue, in the same period in 2023. The increase in the proportion of cost to revenue in this quarter was mainly due to the increase in idle equipment costs due to reduced production, as well as the increased inventory impairments.

Gross Profit (Loss) and Gross Margin – Gross loss for the six months ended June 30, 2024 was \$1.31 million, compared to gross profit of \$0.03 million in the same period in 2023. Our gross loss margin in the six months ended June 30, 2024 was 56.9% compared to a gross profit margin of 1.0% in the same period in 2023. The deterioration of gross margin in this period was mainly due to the increased cost.

Selling Expenses – Our selling expenses for the six months ended June 30, 2024 and 2023 were \$0.22 million and \$0.31 million, respectively. Selling expenses accounted for 9.6% of the total revenue in the six months ended June 30, 2024 compared to 10.3% in the same period in 2023.

General and Administrative Expenses – Our general and administrative expenses for the six months ended June 30, 2024 were \$0.58 million, as compared to \$0.53 million in the same period in 2023. Our general and administrative expenses accounted for 25.3% and 17.3% of our total revenues in the six months ended June 30, 2024 and 2023, respectively.

24 – Research and Development Expenses – Our research and development expenses for the six months ended June 30, 2024 and 2023 were \$0.20 million and \$0.05 million, respectively. The increase in research and development costs is mainly due to drug consistency evaluation.

Bad Debt Expense (Reversal of Allowance for Doubtful Accounts) – Our bad debt expense was \$6,410 for the six months ended June 30, 2024, as compared to reversal of allowance for doubtful accounts \$5,989 for the six months ended June 30, 2023. The changes in the allowances for doubtful accounts during the six months ended June 30, 2024 and 2023 were as follows:

	June 30, 2024	June 30, 2023
For the Six Months Ended	\$13,786,074	\$16,739,527
Bad debt expense	\$6,410	(5,989)
Foreign currency translation adjustment	(86,407)	(608,283)
Balance, End of Period	\$13,706,077	\$16,125,255

Our operating loss for the six months ended June 30, 2024 was \$2.31 million, compared to \$0.85 million in the same period in 2023. The increase in loss from operation is triggered by the decrease in the revenue and increase in the cost of revenue as described above.

Net Interest Expense – Net interest expense for the six months ended June 30, 2024 was \$0.09 million, compared to \$0.22 million for the same period in 2023.

Net Loss – Net loss for the six months ended June 30, 2024 was \$2.40 million, as compared to net loss of \$1.07 million for the six months ended June 30, 2023. The increase of net loss was mainly a result of increased cost and expenses in this period.

For the six months ended June 30, 2024, loss per basic and diluted common share was \$0.16, compared to loss per basic and diluted common share of \$0.65 for the six months ended June 30, 2023.

The number of basic and diluted weighted-average outstanding shares used to calculate loss per share was 14,727,410 for the six months ended June 30, 2024, and 1,653,076

for the six months ended June 30, 2023. 25 Liquidity and Capital Resources Our principal source of liquidity is cash generated from operations and bank lines of credit. Currently the Company has not witnessed or expected to encounter any difficulties to refinance those lines of credit this year. As of June 30, 2024, the aggregated advance from our CEO was \$1,140,775 for use in operations. Our cash and cash equivalents were \$0.74 million, representing 5.2% of our total assets, as of June 30, 2024, as compared to \$1.42 million, representing 8.6% of our total assets as of December 31, 2023. All of the \$0.74 million of cash and cash equivalents as of June 30, 2024 are considered to be reinvested indefinitely in the Company's Chinese subsidiary, Helpson and are not expected to be available for payment of dividends or for other payments to its parent company or to its shareholders. The Company obtained various lines of credit in details described under Note 8 to its unaudited condensed consolidated financial statements contained in this report which is incorporated by reference herein. China Pharma issued a convertible note to an institutional accredited investor as disclosed in Note 9 to the unaudited condensed consolidated financial statements contained in this report which is incorporated by reference herein. Although the Company obtained additional lines of credit in three and six months ended June 30, 2023, there can be no assurance that the Company will be able to achieve its future strategic goals, including the launch of new products. This raises substantial doubt about the Company's ability to continue as a going concern. Although our Chairperson and Chief Executive Officer had advanced funds for working capital in 2023, there can be no assurances that this will continue in the future. We may seek additional debt or equity financing as necessary when we believe the market conditions are the most advantageous to us and/or require us to reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives. There can be no assurance that any additional financing will be available on acceptable terms, if at all. Operating Activities Net cash used by operating activities was \$0.66 million for the six months ended June 30, 2024, compared to \$1.68 million in the same period in 2023. As of June 30, 2024, our net accounts receivable was \$0.25 million, compared to \$0.50 million as of December 31, 2023. Total inventory was \$2.82 million and \$3.73 million as of June 30, 2024 and December 31, 2023, respectively. Investing Activities There was \$28,086 used in investing activities during the six months ended June 30, 2024, compared to \$60,465 provided by investing activities for the same period in 2023. 26 Financing Activities Net cash provided by financing activities was \$0.01 million in the six months ended June 30, 2024; compared to net cash used in financing activities of \$0.52 million for the same period in 2023. According to relevant PRC laws, companies registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach fifty percent (50%) of the companies' registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. As of June 30, 2024 and December 31, 2023, Helpson's net assets totaled \$(4,375,345) and \$(2,289,000), respectively. Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson's net assets that was designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends, was 50% of Helpson's registered capital, which was both \$8,145,000 as of June 30, 2024 and December 31, 2023, respectively. The amount that Helpson must set aside for the statutory surplus fund accounts exceeds its total net assets at June 30, 2024 and December 31, 2023. There were no allocations to the statutory surplus reserve accounts during the six months ended June 30, 2024. The Chinese government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of China. Our businesses and assets are primarily denominated in RMB. All foreign exchange transactions take place either through the People's Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People's Bank of China. Approval of foreign currency payments by the People's Bank of China or other regulatory institutions requires the submission of a payment application form together with certain invoices and executed contracts. The currency exchange control procedures imposed by Chinese government authorities may restrict Helpson, our Chinese subsidiary, from transferring its net assets to our parent company through loans, advances or cash dividends. Off-Balance Sheet Arrangements As of June 30, 2024, we did not have any off-balance sheet arrangements. Critical Accounting Policies Management's discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Our financial statements reflect the selection and application of accounting policies which require management to make significant estimates and judgments. Please refer to Note 1 to our unaudited condensed consolidated financial statements, "Organization and Significant Accounting Policies" for the discussion of our critical accounting policies. 27 Item 3. Quantitative and Qualitative Disclosures about Market Risk As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item. Item 4. Controls and Procedures Evaluation of Disclosure Controls and Procedures Our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness of our "disclosure controls and procedures" (as defined in the Securities Exchange Act of 1934 (the "Exchange Act")) Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and (b) is accumulated and communicated to management, including our Chief Executive Officer and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as described above. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of June 30, 2024 to satisfy the objectives for which they are intended. This was due to the material weakness in our internal control over financial reporting, with respect to our lack of accounting financial reporting personnel who were knowledgeable in U.S. GAAP, as disclosed in our annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024. Notwithstanding the aforementioned material weakness, management has concluded that our condensed consolidated financial statements included in this report are fairly stated in all material respects in accordance with U.S. GAAP for each period presented herein. Changes in Internal Controls over Financial Reporting There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 28 PART II OTHER INFORMATION Item 6. Exhibits The exhibits required by this item are set forth in the Exhibit Index attached hereto. 29 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. A CHINA PHARMA HOLDINGS, INC. A Date: August 14, 2024 By: /s/ Zhilin Li A Name: Zhilin Li A Title: President and Chief Executive Officer A (principal executive officer) A Date: August 14 2024 By: /s/ Zhilin Li A Name: Zhilin Li A Title: Interim Chief Financial Officer A (principal financial officer and principal accounting officer) 30 EXHIBIT INDEX No. Description 10.1 - Amendment #2 to Convertible Promissory Note dated May 23, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on May 30, 2024). A A 31.1 - Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A A 31.2 - Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A A 101.INS - Inline XBRL Instance Document A A 101.SCH - Inline XBRL Taxonomy Extension Schema Document A A 101.CAL - Inline XBRL Taxonomy Extension Calculation Linkbase Document A A 101.DEF - Inline XBRL Taxonomy Extension Definition Linkbase Document A A 101.LAB - Inline XBRL Taxonomy Extension Label Linkbase Document A A 101.PRE - Inline XBRL Taxonomy Extension Presentation Linkbase Document A A 104 - Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) A 31 A +86 898-6681-1730 0.09 0.16 0.35 0.65 false --12-31 Q2 0001106644 0001106644 2024-01-01 2024-06-30 0001106644 2024-08-12 0001106644 2024-06-30 0001106644 2023-12-31 0001106644 us-gaap:RelatedPartyMember 2024-06-30 0001106644 us-gaap:RelatedPartyMember 2023-12-31 0001106644 2024-04-01 2024-06-30 0001106644 2023-04-01 2023-06-30 0001106644 2023-01-01 2023-06-30 0001106644 us-gaap:CommonStockMember 2022-12-31 0001106644 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001106644 us-gaap:RetainedEarningsMember 2022-12-31 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001106644 2022-12-31 0001106644 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001106644 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001106644 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001106644 2023-01-01 2023-03-31 0001106644 us-gaap:CommonStockMember 2023-03-31 0001106644 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001106644 us-gaap:RetainedEarningsMember 2023-03-31 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001106644 2023-03-31 0001106644 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001106644 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001106644 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001106644 2023-06-30 0001106644 us-gaap:CommonStockMember 2023-12-31 0001106644 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001106644 us-gaap:RetainedEarningsMember 2023-12-31 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001106644 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001106644 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001106644 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001106644 2024-01-01 2024-03-31 0001106644 us-gaap:CommonStockMember 2024-03-31 0001106644 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001106644 us-gaap:RetainedEarningsMember 2024-03-31 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001106644 2024-03-31 0001106644 us-gaap:CommonStockMember 2024-04-01

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002: I, Zhilin Li, certify that:
 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.;
 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of

the end of the period covered by this report based on such evaluation; and

Â d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

Â 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

Â a)all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Â b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Â Date: August 14, 2024

Â /s/ Zhilin Li

Â Name:Â Zhilin Li

Â Title: Chief Executive Officer

Â (principal executive officer)

Â EX-31.2 3 ea021080701ex31-2_china.htm

CERTIFICATION Exhibit 31.2Â

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Â I, Zhilin Li, certify that:

Â 1.I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.;

Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

Â 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Â a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Â b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Â c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

Â d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

Â 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

Â a)all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Â b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Â Date: August 14, 2024

Â /s/ Zhilin Li

Â Name:Â Zhilin Li

Â Title: Interim Chief Financial Officer

Â (principal financial officer and principal accounting officer)

Â EX-32.1 4 ea021080701ex32-1_china.htm

CERTIFICATION Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Â The undersigned hereby certifies, in her capacity as Chief Executive Officer and interim Chief Financial Officer of China Pharma Holdings, Inc. (the "Company"), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:

Â (1)The Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

Â (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Â Dated: August 14, 2024

Â /s/ Zhilin Li

Â Name:Â Zhilin Li

Â President and Chief Executive Officer

Â (principal executive officer)

Â /s/ Zhilin Li

Â Name:Â Zhilin Li

Â Title: Interim Chief Financial Officer

Â (principal financial officer and principal accounting officer)

Â This certification accompanies each Report pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Â§18 of the Securities Exchange Act of 1934, as amended.

Â A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Â EX-101.SCH 5 cphi-20240630.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Accounts Receivable, Net link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Property, Plant and Equipment link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Other Payables link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Lines of Credit link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Convertible Note Payable link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Accounts Receivable, Net (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Other Payables (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Lines of Credit (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Organization and Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Accounts Receivable, Net (Details) link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Accounts Receivable, Net (Details) link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Changes in the Allowances for Doubtful Accounts link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Inventories (Details) - Schedule of Inventories link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Property, Plant and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of the Assets link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Other Payables (Details) - Schedule of Other Payables link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Lines of Credit (Details) link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Lines of Credit (Details) - Schedule of Principal Payments link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Convertible Note Payable (Details) link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Leases (Details) link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Leases (Details) - Schedule of Operating Lease Liabilities link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 996029 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 cphi-20240630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 cphi-20240630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 cphi-20240630_lab.xml XBRL LABEL FILE Total Current Assets TOTAL ASSETS Related and Nonrelated Parties [Axis] Total Current Liabilities Total Liabilities Total Stockholders' Equity Balance Balance TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Gross (loss) profit Total operating expenses Loss from operations Net other expense Loss before income taxes Net loss Net loss for the period Net loss Net losses Comprehensive loss Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net Cash Used in Operating Activities Cash flows from operating activities Net Cash (used in) provided by Investing Activity Net Cash Provided By Financing Activities Net Decrease in Cash, Cash

Equivalents and Restricted Cash Cash and Cash Equivalents at Beginning of Period Cash, Cash Equivalents and Restricted Cash at End of Period Cash and cash equivalents Organization and Significant Accounting Policies [Abstract] Accounts Receivable, Net [Abstract] Schedule of Accounts Receivable, Net [Abstract] Trade accounts receivable, net Trade accounts receivable, less allowance for doubtful accounts of \$13,706,077 and \$13,786,074, respectively Balance, Beginning of Period Balance, End of Period Trade accounts receivable, less allowance for doubtful accounts (in Dollars) Inventories [Abstract] Schedule of Inventories [Abstract] Total Inventories Inventories Property, Plant and Equipment [Abstract] Long-Lived Tangible Asset [Axis] Property, plant and equipment, net Property, plant and equipment, net Statistical Measurement [Axis] Intangible Assets [Abstract] Finite-Lived Intangible Assets by Major Class [Axis] Net carrying amount Other Payables [Abstract] Schedule of Other Payables [Abstract] Total Other Payables Related Party Transactions [Abstract] Lines of Credit [Abstract] Schedule of Principal Payments [Abstract] Total Credit Facility [Axis] Convertible Note Payable [Abstract] Leases [Abstract] Schedule of Operating Lease Liabilities [Abstract] Total undiscounted cash flows Total Operating liability Income Taxes [Abstract] Fair Value Measurements [Abstract] Financial Instrument [Axis] Fair Value Hierarchy and NAV [Axis] Stockholders Equity [Abstract] Commitments And Contingencies [Abstract] Subsequent Events [Abstract] Document Type Document Quarterly Report Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Entity Central Index Key ASSETS Current Assets: Bankerâ€™s acceptances Total Other receivables, less allowance for doubtful accounts of \$27,929 and \$27,017, respectively Other receivables, allowance for doubtful accounts (in Dollars) Advances to suppliers Prepaid expenses Right-of-use assets Operating lease right of use assets Intangible assets, net LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Current Liabilities: Trade accounts payable Accrued expenses Other payables Advances from customers Borrowings from related parties Borrowing from related party Lease liabilities Less: Lease liabilities, current portion Current portion of lines of credit Convertible, redeemable note payable, net of issue discount Non-current Liabilities: Lines of credit, net of current portion Deferred tax liability Lease liabilities Lease liabilities, net of current portion Commitments and Contingencies (Note 14) Stockholdersâ€™ Equity: Preferred stock, \$0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, \$0.001 par value; 500,000,000 shares authorized; 17,162,771 shares and 10,625,788 shares issued and outstanding, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock shares issued Common stock, shares outstanding Common stock shares outstanding Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Revenue Cost of revenue Operating expenses: Selling expenses General and administrative expenses Research and development expenses Bad debt expense (reversal of allowance for doubtful accounts) Bad debt expense (reversal of allowance for doubtful accounts) Other income (expense): Interest income Income tax expense Other comprehensive loss - foreign currency translation adjustment Loss per share: Basic (in Dollars per share) Diluted Weighted average shares outstanding (in Shares) Conversions of Note Payable to common stock Conversions of Note Payable to common stock (in Shares) Foreign currency translation adjustment Issuance of common stock for intangible assets Issuance of common stock for intangible assets (in Shares) Cash Flows from Operating Activities: Depreciation and amortization Inventory write off Changes in assets and liabilities: Trade accounts payable Other payables and accrued expenses Advances from customers Cash Flows from Investing Activity: Cash Flows from Financing Activities: Proceeds from lines of credit Line of credit received in advance Borrowings and interest from related party Interest expense Effect of Exchange Rate Changes on Cash Supplemental Cash Flow Information: Cash paid for income taxes Cash paid for interest Supplemental Noncash Investing and Financing Activities: Accounts receivable collected with bankerâ€™s acceptances Inventory purchased with bankerâ€™s acceptances Conversions of Note Payable to common stock Issuances of stock for intangible assets Lease liabilities arising from obtaining right-of-use assets Interest expense Trade accounts and other receivables Advances to suppliers Inventories Prepaid expenses Purchases of property and equipment Payments of line of credit Related Party Chief Executive Officer and Interim Chief Financial Officer [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES ACCOUNTS RECEIVABLE, NET Schedule of Accounts Receivable, Net Trade accounts receivable Schedule of Changes in the Allowances for Doubtful Accounts Foreign currency translation adjustment INVENTORIES Schedule of Inventories Raw materials Work in process Finished goods PROPERTY, PLANT AND EQUIPMENT Schedule of Property, Plant and Equipment Total Schedule of Estimated Useful Lives of the Assets Estimated useful lives INTANGIBLE ASSETS Schedule of Intangible Assets Gross carrying amount OTHER PAYABLES Schedule of Other Payables Compensation payable to officer Compensation and interest to related parties Business taxes and other RELATED PARTY TRANSACTIONS LINES OF CREDIT Schedule of Principal Payments 2025 2026 CONVERTIBLE NOTE PAYABLE LEASES Schedule of Operating Lease Liabilities 2025 INCOME TAXES FAIR VALUE MEASUREMENTS Schedule of Assets and Liabilities Recorded at Fair Value STOCKHOLDERS' EQUITY COMMITMENTS AND CONTINGENCIES SUBSEQUENT EVENTS Less: allowance for doubtful accounts Allowance for doubtful account Less: accumulated depreciation Accumulated amortization Less: Imputed interest Permit of land use [Member] Building [Member] Plant, machinery and equipment [Member] Motor vehicles [Member] Motor vehicle [Member] Office equipment [Member] Plant, machinery and equipment [Member] Minimum [Member] Maximum [Member] NMPA approved medical formulas [Member] Technology from Bonier [Member] Invention Patents [Member] Lines of Credit [Member] Banker's Acceptance Notes [Member] Level 1 [Member] Level 2 [Member] Level 3 [Member] Ownership [Axis] Antidilutive Securities [Axis] Related Party Transaction [Axis] Title and Position [Axis] Debt Instrument [Axis] Lender Name [Axis] Tax Period [Axis] Income Tax Authority, Name [Axis] Class of Stock [Axis] Plan Name [Axis] Customer [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Type [Axis] Supplier [Axis] Product and Service [Axis] Ownership percentage Cash and cash equivalents Accumulated deficit Working capital deficit Reverse stock split Reverse stock split, description Potentially dilutive common shares (in Shares) Depreciation expense Amortization intangible by useful life, descriptions Amortization expense relating to intangible assets Transfer price Issuance of common stock (in Shares) Price per share (in Dollars per share) Intangible asset useful life term Net profit sales rate Percentage of net profit Loan payment Interest rate Term of loan agreement Other payables Line of credit facility amount Interest rate of line of credit Due date of line of credit Interest expenses Repayments of line of credit (in Yuan Renminbi) Line of credit facility borrowing amount Received proceeds from loan Interest paid Debt extension fee (in Dollars) Note and accrued interest Debt redemptions weighted average price Number of trading days Extension fee Outstanding balance of extension fee (in Dollars) Redemption amount (in Dollars) Note converted into common stock Conversion price (in Dollars per share) Description of interest accrued Redeem of outstanding note (in Dollars) Debt instrument redemption price percentage Lowest volume weighted average price Note redeemable into shares (in Shares) Weighted average price (in Dollars per share) Interest expense (in Dollars) Debt redemption amount (in Dollars) Redemption amount (in Dollars) Stock issued during period shares (in Shares) Issued shares Operating lease cost Operating lease payments Operating lease weighted average lease term Operating lease weighted average discount rate Enterprise income tax rate Operating loss carryforwards Operating loss carryforwards available for future taxable income Operating loss carryforwards limitations, descriptions U.S. federal corporate income tax rate Valuation allowance on deferred tax assets After tax income, percentage Reserve account balances, percentage General and statutory capital reserves amount (in Dollars) Converted share issued and outstanding Common stock reserved shares Common stock issued Total option outstanding Additional shares available for issuance Issuance of securities (in Dollars) Compensation expense (in Dollars) Unrecognized compensation expense (in Dollars) Concentration risk percentage Organization and Nature of Operations Liquidity and Going Concern Reverse Stock Split Consolidation and Basis of Presentation Accounting Estimates Loss Per Share Recent Accounting Pronouncements Onny Investment Limited [Member] Hainan Helpson Medical & Biotechnology Co., Ltd [Member] Convertible, Redeemable Note Payable [Member] Options [Member] Helpson [Member] Chairperson [Member] Loan Payable [Member] Bank of Communications [Member] Bank of China [Member] Revolving Credit Facility [Member] Convertible Notes [Member] China Pharma [Member] China Pharmaâ€™s [Member] Tax Year 2023 [Member] Domestic Tax Jurisdiction [Member] China Pharmaâ€™s Common Stock [Member] 2010 Incentive Plan [Member] Two Thousand Ten Incentive Plan [Member] Customer One [Member] Accounts Receivable [Member] Customer Concentration Risk [Member] Customer Two [Member] Accounts Payable [Member] Supplier Concentration Risk [Member] Suppliers One [Member] Suppliers Two [Member] Suppliers Three [Member] Product One [Member] Revenue Benchmark [Member] Product Concentration Risk [Member] Product Two [Member] Product Three [Member] Customer Three [Member] Raw Material Purchases [Member] Revenue, Product and Service Benchmark [Member] Product Four [Member] Product Five [Member] Related and Nonrelated Parties [Domain] Statement [Table] Statement [Line Items] Equity Component [Domain] Accounts Receivable, Net (Details) - Schedule of Changes in the Allowances for Doubtful Accounts [Table] Schedule of Changes in the Allowances for Doubtful Accounts [Abstract] Long-Lived Tangible Asset [Domain] Property, Plant and Equipment [Table] Schedule of Property, Plant and Equipment [Line Items] Statistical Measurement [Domain] Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of the Assets [Table] Schedule of Estimated Useful Lives of the Assets [Line Items] Finite-Lived Intangible Assets, Major Class Name [Domain] Intangible Assets (Details) - Schedule of Intangible Assets [Table] Schedule of Intangible Assets [Line Items] Credit Facility [Domain] Line of Credit Facility [Table] Line of Credit Facility [Line Items] Financial Instruments [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value [Table] Schedule of Assets and Liabilities Recorded at Fair Value [Line Items] Antidilutive Securities, Name [Domain] Ownership [Domain] Accounting Standards Update and Change in Accounting Principle [Table] Organization and Significant Accounting Policies [Line Items] Related Party Transaction [Domain] Intangible Assets (Details) [Table] Intangible Assets [Line Items] Title and Position [Domain] Debt Instrument, Name [Domain] Related Party Transactions (Details) [Table] Related Party Transactions [Line Items] Line of Credit Facility, Lender [Domain] Lines of Credit (Details) [Table] Line of Credit [Line Items] Convertible Note Payable (Details) [Table] Convertible Note Payable [line Items] Tax Period [Domain] Income Tax Authority, Name [Domain] Income Tax, Examination [Table] Income Taxes [Line Items] Class of Stock [Domain] Plan Name [Domain] Stock, Class of Stock [Table] Stockholders Equity [Line Items] Customer [Domain] Supplier [Domain]

Product and Service [Domain] Concentration Risk Type [Domain] Concentration Risk Benchmark [Domain] Commitments and Contingencies (Details) [Table] Commitments And Contingencies [Line Items] Accounts receivable collected with banker's acceptances. Number of additional shares available for issuance. Advances to suppliers. After tax net income percentage. A banker's acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank. Conversion of related party note and interest to common stock. Deferred Tax Assets Valuation Allowance. Percentage of extension fee. Description of interest accrues on Note. The amount of inventory purchased with banker's acceptances. Represents the amount of issuance of securities. Liquidity and Going Concern. Net profit sales rate. Number of shares redeemable by Notes. Number of trading days. Other receivables, less allowance for doubtful accounts. Percentage of balance note and accrued interest. Percentage of net profit. Amount of redeem of outstanding note. The redemption amount for outstanding balance. Reserve account balances percentage. Disclosure of accounting policy reverse stock split. Right-of-use assets. Total option outstanding. The amount of transfer price. Represents the amount of unrecognized compensation expense. Useful live of Assets table text block. The weighted average price per share. Represent the amount of working capital deficit. Customer one. Customer two. Two thousand ten incentive plan. Convertible Notes Payable, Current Stockholders' Equity, Reverse Stock Split Assets [Abstract] Entity Small Business Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Earnings Per Share, Diluted Liabilities, Noncurrent [Abstract] Operating Loss Carryforwards Retained Earnings [Member] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Weighted Average Number of Shares Outstanding, Basic Finite-Lived Intangible Assets, Net Other Receivables Less Allowance For Doubtful Accounts Local Phone Number Debt Instrument, Redemption Price, Percentage Building [Member] Stock Issued During Period, Shares, New Issues Entity Common Stock, Shares Outstanding Product Concentration Risk [Member] Investment Income, Interest Title of 12(b) Security Additional Paid in Capital Operating Expenses [Abstract] Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax Accounts Receivable Collected With Bankers Acceptances Board of Directors Chairman [Member] Supplemental Cash Flow Information [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] Increase (Decrease) in Accounts Payable, Trade Redemption Amount For Outstanding Balance Accounts Payable, Trade, Current Equity, Attributable to Parent [Abstract] Preferred Stock, Shares Issued Property, Plant and Equipment [Member] China Pharmas Common Stock Member Prepaid Expense, Current Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Security Exchange Name Minimum [Member] Common Stock, Shares, Outstanding Increase (Decrease) in Prepaid Expenses, Other Retained Earnings (Accumulated Deficit) Schedule of Line of Credit Facilities [Table Text Block] Depreciation Net Cash Provided by (Used in) Investing Activities Payments for Other Fees Inventory, Finished Goods, Gross Preferred Stock, Shares Authorized Interest Paid, Excluding Capitalized Interest, Operating Activities Inventory Disclosure [Text Block] Preferred Stock, Shares Outstanding Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Net Proceeds from Long-Term Lines of Credit Bankers Acceptances Increase (Decrease) in Accrued Liabilities Maximum [Member] Entity Address, Address Line One Common Stock, Shares Authorized Entity Incorporation, State or Country Code Entity Address, Address Line Two Operating Lease, Liability, Noncurrent Onny Investment Limited Member Operating Lease, Weighted Average Discount Rate, Percent Helpson Member Share-Based Payment Arrangement, Expense Increase (Decrease) in Operating Capital [Abstract] Net Cash Provided by (Used in) Financing Activities [Abstract] Additional Paid-in Capital [Member] Accrued Salaries, Current Accounts Payable, Other Share-Based Payment Arrangement, Option [Member] Net Cash Provided by (Used in) Investing Activities [Abstract] Inventory Purchased With Bankers Acceptance Note Suppliers Two Member Intangible Assets Disclosure [Text Block] Customer One Member Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Liquidity And Going Concern Policy Text Block Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Aftertax Net Income Percentage Unlabeled Abstract3 Unlabeled Abstract2 Vehicles [Member] Unlabeled Abstract5 Unlabeled Abstract4 AOCI Attributable to Parent [Member] Unlabeled Abstract1 Unlabeled Abstract0 Property, Plant and Equipment, Useful Life Unlabeled Abstract7 Allowance for Doubtful Accounts, Premiums and Other Receivables Unlabeled Abstract6 Proceeds from Related Party Debt Common Stock, Capital Shares Reserved for Future Issuance Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unlabeled Abstract9 Unlabeled Abstract8 Fair Value, Inputs, Level 3 [Member] Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Related Party Transactions Disclosure [Text Block] Accounts Receivable, Allowance for Credit Loss [Table Text Block] Extension Fee Net Cash Provided by (Used in) Operating Activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Working Capital Deficit Line of Credit, Current Office Equipment [Member] Suppliers One Member Fair Value, Inputs, Level 1 [Member] Finite-Lived Intangible Assets, Gross Equity, Attributable to Parent Advance To Supplies Accumulated Other Comprehensive Income (Loss), Net of Tax Line of Credit [Member] Payments for (Proceeds from) Productive Assets Raw Material Purchases Member Land [Member] Technology From Bonier Member Long-Term Debt Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unlabeled Abstract Current Fiscal Year End Date Line of Credit Facility, Maximum Borrowing Capacity Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Address, Postal Zip Code Inventory Write-down Hainan Helpson Medical Biotechnology Co Ltd Member Revenue Benchmark [Member] Document Fiscal Period Focus Redeem Of Outstanding Note Property, Plant and Equipment Disclosure [Text Block] Schedule Of Intangible Assets Abstract Schedule Of Assets And Liabilities Recorded At Fair Value Abstract Convertible Debt Securities [Member] Accounts Payable, Other, Current Lessee, Operating Lease, Liability, to be Paid Product One Member Equity [Text Block] Repayments of Long-Term Lines of Credit Property, Plant and Equipment [Table Text Block] Short-Term Debt [Text Block] Reserve Account Balances Percentage Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Operating Expenses Statement of Financial Position [Abstract] Line of Credit Facility, Interest Rate During Period Short-Term Debt Supplier Concentration Risk [Member] Shares Issued, Price Per Share Entity File Number Entity Tax Identification Number Number Of Trading Days Lessee, Operating Lease, Liability, to be Paid, Year One Document Type Stock Issued During Period, Shares, Conversion of Convertible Securities Schedule Of Estimated Useful Lives Of The Assets Abstract Document Period End Date Entity Interactive Data Current Revenue, Product and Service Benchmark [Member] Bankers Acceptance Notes Member Line of Credit Facility, Expiration Date Long-Term Debt, Maturity, Year Two Lessee, Operating Lease, Liability, Undiscounted Excess Amount Weighted Average Price Trading Symbol Finite-Lived Intangible Assets, Amortization Method Inventory, Net Entity Address, City or Town Use of Estimates, Policy [Policy Text Block] Commitments and Contingencies Nonoperating Income (Expense) [Abstract] Income Taxes Paid, Net Common Stock, Value, Issued Revolving Credit Facility [Member] City Area Code Debt Instrument, Convertible, Conversion Price Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Operating Lease, Payments Product Three Member Percentage Of Balance Note And Accrued Interest Selling Expense China Pharma Member Stock Issued During Period, Value, New Issues Loan Payable Member Statement of Stockholders' Equity [Abstract] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Income Tax Expense (Benefit) Amortization of Intangible Assets Income Statement [Abstract] Lessee, Operating Leases [Text Block] Customer Two Member New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Statutory Accounting Practices, Statutory Capital and Surplus Required Suppliers Three Member Schedule Of Property Plant And Equipment Abstract Inventory, Raw Materials, Gross Earnings Per Share, Basic Accounts Receivable, before Allowance for Credit Loss, Current Assets Liabilities Research and Development Expense Accounts Receivable [Member] Long-Term Line of Credit, Noncurrent Unrecognized Compensation Expense Entity Shell Company Subsequent Events [Text Block] Debt Instrument, Fee Amount Stock Issued Increase (Decrease) in Inventories Finite-Lived Intangible Asset, Useful Life Accounts Receivable, Allowance for Credit Loss, Current Gain (Loss), Foreign Currency Transaction, before Tax Additional Shares Available For Issuance Product Four Member Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Proceeds from Lines of Credit Product Two Member Conversion of Stock, Shares Converted Tax Year 2023 [Member] Net Cash Provided by (Used in) Financing Activities Convertible Notes Member Invention Patent Member Property, Plant and Equipment, Gross Subsidiary, Ownership Percentage, Parent Interest Expense, Nonoperating Bank Of Communications Member Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Amendment Flag Entity Address, Country Accounts Receivable, Credit Loss Expense (Reversal) Stock Issued During Period, Shares, Purchase of Assets Deferred Income Tax Liabilities, Net Effective Income Tax Rate Reconciliation, Tax Credit, Percent Entity Central Index Key Operating Income (Loss) Operating Lease, Liability Loan, Held-for-Sale, Term Debt Instrument, Interest Rate, Stated Percentage Taxes Payable, Current Transfer Price Common Stock [Member] Entity Registrant Name Other Cash Equivalents, at Carrying Value Repayments of Lines of Credit Statement of Cash Flows [Abstract] Operating Lease, Liability, Current Income Tax Disclosure [Text Block] Customer Three Member Interest Accrues On Note Description Payments for Loans Increase (Decrease) in Prepaid Supplies Common Stock Dividends, Shares Issuance Of Securities Long-Term Debt, Maturity, Year One Net Profit Sales Rate Reverse Stock Splits Policy Text Block Liabilities, Current [Abstract] Domestic Tax Jurisdiction [Member] Accounts and Nontrade Receivable [Text Block] NMPAApproved Medical Formulas Member Other Employee-related Liabilities, Current Operating Lease, Weighted Average Remaining Lease Term Deferred Tax Asset Valuation Allowance Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Inventory, Current [Table Text Block] Nature of Operations [Text Block] Long-Term Line of Credit Revenues Stock Issued During Period, Value, Conversion of Convertible Securities Accounts Payable and Accrued Liabilities, Current Accounts Payable [Member] Increase (Decrease) in Contract with Customer, Liability Rightofuse Assets Operating Lease, Cost Other Receivables, Net, Current General and Administrative Expense Concentration Risk, Percentage Earnings Per Share [Abstract] Depreciation, Depletion and Amortization Line of Credit Facility, Periodic Payment, Principal Contract with Customer, Liability, Current Document Fiscal Year Focus Common Stock, Par or Stated Value Per Share Useful Live Of Assets Table Text Block Earnings Per Share, Policy [Policy Text Block] Entity Current Reporting Status Common Stock, Shares, Issued Entity Emerging Growth Company Interest Expense, Other Short-Term Borrowings Gross Profit Retained Earnings, Appropriated Operating Loss Carryforwards, Valuation Allowance Stock Issued During Period, Shares, Employee Benefit Plan Total Option Outstanding Bank Of China Member Two Thousand Ten Incentive Plan Member Intangible Assets, Net (Excluding Goodwill) Accounts Receivable, after Allowance for Credit Loss, Current Finite-Lived Intangible Assets, Accumulated Amortization Document Transition Report Related Party [Member] Inventory, Work in Process, Gross Net Income (Loss) Attributable to Parent Long-Term Debt [Text Block] Debt Instrument, Convertible, Number of Equity Instruments Product Five Member Increase (Decrease) in Accounts and Other Receivables Schedule Of Changes In The Allowances For Doubtful Accounts Abstract Assets, Current [Abstract] Document Quarterly Report Liabilities,

Current Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Accrued Liabilities, Current Consolidation, Policy [Policy Text Block] Liabilities and Equity [Abstract] Shares, Outstanding Commitments and
Contingencies Disclosure [Text Block] Customer Concentration Risk [Member] Interest Expense, Debt Debt Instrument, Repurchase Amount Cost of
Revenue Operating Loss Carryforwards, Limitations on Use Entity Filer Category Fair Value Measurement and Measurement Inputs, Recurring and
Nonrecurring [Text Block] Conversion Of Related Party Note And Interest To Common Stock Property, Plant and Equipment, Other Types [Member]
Preferred Stock, Value, Issued Liabilities and Equity Note Redeemable Into Shares Nonoperating Income (Expense) Percentage Of Net Profit Preferred
Stock, Par or Stated Value Per Share Operating Lease, Right-of-Use Asset Assets, Current EX-101.PRE 9 cphi-20240630_pre.xml XBRL
PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Document And Entity Information - shares 6 Months Ended Jun. 30, 2024
Aug. 12, 2024 Document Information Line Items $\bar{A}$ Entity Registrant Name CHINA PHARMA HOLDINGS, INC. $\bar{A}$ Trading Symbol CPHI $\bar{A}$
Document Type 10-Q $\bar{A}$ Current Fiscal Year End Date --12-31 $\bar{A}$ Entity Common Stock, Shares Outstanding $\bar{A}$ 17,162,771 Amendment Flag false $\bar{A}$
Entity Central Index Key 0001106644 $\bar{A}$ Entity Current Reporting Status Yes $\bar{A}$ Entity Filer Category Non-accelerated Filer $\bar{A}$ Document Period End
Date Jun. 30, 2024 $\bar{A}$ Document Fiscal Year Focus 2024 $\bar{A}$ Document Fiscal Period Focus Q2 $\bar{A}$ Entity Small Business true $\bar{A}$ Entity Emerging Growth
Company false $\bar{A}$ Entity Shell Company false $\bar{A}$ Document Quarterly Report true $\bar{A}$ Document Transition Report false $\bar{A}$ Entity File Number 001-34471
 $\bar{A}$ Entity Incorporation, State or Country Code NV $\bar{A}$ Entity Tax Identification Number 75-1564807 $\bar{A}$ Entity Address, Address Line One Second Floor,
No. 17, Jinpan Road $\bar{A}$ Entity Address, Address Line Two Haikou $\bar{A}$ Entity Address, City or Town Hainan Province $\bar{A}$ Entity Address, Country CN $\bar{A}$
Entity Address, Postal Zip Code 570216 $\bar{A}$ City Area Code +86 $\bar{A}$ Local Phone Number 898-6681-1730 $\bar{A}$ Title of 12(b) Security Common Stock $\bar{A}$
Security Exchange Name NYSE $\bar{A}$ Entity Interactive Data Current Yes $\bar{A}$ X - DefinitionBoolean flag that is true when the XBRL content amends
previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type:
xbrl:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name:
dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrl:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of
current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix:
dei_ Data Type: xbrl:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd
and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. +
ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType
Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which
may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo
definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrl:gYearItemType Balance Type: na Period
Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name:
dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionFor
the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-
1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo
definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrl:dateItemType Balance Type: na Period
Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1:
<http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name:
dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrl:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean
flag that is true only for a form used as a transition report. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -
Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data
Type: xbrl:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS,
etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available.
+ Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X -
DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name:
dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrl:normalizedStringItemType Balance Type: na Period Type: duration X -
DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2
Namespace Prefix: dei_ Data Type: xbrl:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town +
ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrl:normalizedStringItemType
Balance Type: na Period Type: duration X - DefinitionISO 3166-1 alpha-2 country code. + ReferencesNo definition available. + Details Name:
dei_EntityAddressCountry Namespace Prefix: dei_ Data Type: dei:countryCodeItemType Balance Type: na Period Type: duration X - DefinitionCode for
the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type:
xbrl:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have
filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher
SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type:
dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of
registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes
or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership
Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name:
dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrl:sharesItemType Balance Type: na Period Type: instant X -
DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to
such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related
disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type:
dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. +
ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrl:booleanItemType Balance Type: na Period Type:
duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may
contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. +
Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X -
DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these
categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing
the related disclosure. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -
Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na
Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available.
+ Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na
Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to
submit such files). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-T -Number 232 -
Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type:
duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. +
ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrl:normalizedStringItemType Balance Type: na Period Type: duration
X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1:
<http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name:
dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrl:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that
the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name
Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type:
xbrl:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer
Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -
Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix:
dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo
definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrl:normalizedStringItemType Balance Type: na
Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -
Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type:
dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. +
ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1

+ Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Unaudited) - USD (\$) Jun. 30, 2024 Dec. 31, 2023 Current Assets: $\text{\$}$ 1,423,838 Banker's acceptances 15,435 65,915 Trade accounts receivable, less allowance for doubtful accounts of $\text{\$}$ 13,706,077 and $\text{\$}$ 13,786,074, respectively 254,850 504,448 Other receivables, less allowance for doubtful accounts of $\text{\$}$ 27,929 and $\text{\$}$ 27,017, respectively 28,660 157,944 Advances to suppliers 161 2,013 Inventories 2,818,925 3,732,517 Prepaid expenses 115,610 110,258 Total Current Assets 3,972,978 5,996,933 Property, plant and equipment, net 5,817,379 7,100,425 Right-of-use assets 77,259 116,610 Intangible assets, net 4,393,617 3,255,232 TOTAL ASSETS 14,261,233 16,469,200 Current Liabilities: $\text{\$}$ 14 Trade accounts payable 141,036 966,420 Accrued expenses 208,831 298,829 Other payables 1,606,991 2,282,692 Advances from customers 101,056 90,507 Lease liabilities 78,628 77,727 Current portion of lines of credit 1,024,303 1,030,680 Convertible, redeemable note payable, net of issue discount 410,415 940,000 Total Current Liabilities 4,712,035 6,820,664 Non-current Liabilities: $\text{\$}$ 4 Lines of credit, net of current portion 1,403,154 1,411,891 Deferred tax liability 737,522 742,114 Lease liabilities 39,910 Total Liabilities 6,852,711 9,014,579 Commitments and Contingencies (Note 14) Stockholders' Equity: $\text{\$}$ 4 Preferred stock, $\text{\$}$ 0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding Common stock, $\text{\$}$ 0.001 par value; 500,000,000 shares authorized; 17,162,771 shares and 10,625,788 shares issued and outstanding, respectively 17,162 10,625 Additional paid-in capital 37,690,719 35,282,256 Accumulated deficit (41,684,336) (39,290,314) Accumulated other comprehensive income 11,384,977 11,452,054 Total Stockholders' Equity 7,408,522 7,454,621 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 14,261,233 16,469,200 Related Party $\text{\$}$ 4 Current Liabilities: $\text{\$}$ 4 Borrowings from related parties $\text{\$}$ 1,140,775 $\text{\$}$ 1,133,809 X - DefinitionAdvances to suppliers. + ReferencesNo definition available. + Details Name: cphi_AdvanceToSupplies Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionA banker's acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank. + ReferencesNo definition available. + Details Name: cphi_BankersAcceptances Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_AccountsPayableOtherCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-8> + Details Name: us-gaap_AccountsPayableTradeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-11>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14> + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 17:

[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18):
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19):
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21):
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22):
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23):
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24):
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25):
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26):
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27):
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28):
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29):
[http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30):

stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. +

ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(22\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(22))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2> + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_ConvertibleNotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(15\)\(b\)\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(15)(b)(2))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482525/740-10-45-4>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482525/740-10-45-6> + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482686/350-30-45-1> + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(6\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(6))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(22))) -SubTopic 10-Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(24\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(19\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(19))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(25\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(25))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(26\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(26))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(23\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(23))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(21\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(21))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 15: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(14\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(14))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))) -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 27: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 29: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30> + Details Name: us-gaap Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 8: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-5>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 21: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap LinesOfCreditCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 45 -Paragraph 13 -Publisher FASB -URI

13Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481573/470-10-45-14> + Details Name: us-gaap_LongTermLineOfCredit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherReceivablesNetCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1> + Details Name: us-gaap_PrepaidExpenseCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A)Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(17\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(13\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 ->

Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference> 13: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference) 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquityNamespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Å Å Trade accounts receivable, less allowance for doubtful accounts (in Dollars) $ 13,706,077 $ 13,786,074 Other receivables, allowance for doubtful accounts (in Dollars) $ 27,929 $ 27,017 Preferred stock, par value (in Dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized 5,000,000 5,000,000 Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value (in Dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized 500,000,000 500,000,000 Common stock, shares issued 17,162,771 10,625,788 Common stock, shares outstanding 17,162,771 10,625,788 X - DefinitionOther receivables, less allowance for doubtful accounts. + ReferencesNo definition available. + Details Name: cphi_OtherReceivablesLessAllowanceForDoubtfulAccounts Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: <a href=) 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference) 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference) 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference) 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference) 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: <a href=) 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtl-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <a href=) 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: <a href=) 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: <a href=) 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference) 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference) 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference) 5:

(0.35) \$ (0.16) \$ (0.65) Weighted average shares outstanding (in Shares) 16,124,241 1,689,985 14,727,410 1,653,076 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(24\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(24))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(26\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(26))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(22\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(22))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5): [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6): [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(20\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(20))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7>: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 45-Paragraph 5-Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X-DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 45-Paragraph 5-Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5+Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X-DefinitionThe aggregate cost of goods produced and sold and services rendered during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2): [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(2\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(2))-Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3): [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5): [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 7): [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\(A\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(ii)(A))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15): [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B + Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X-ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X-DefinitionThe amount of net income \(loss\) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B+Details Name: us-gaap_CostOfRevenue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X-ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X-DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2): <http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4): [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5): <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8): [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9): [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10): [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11): [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12): <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14): <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16): <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18): [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19): [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20): [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X-DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(4\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7+Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X-DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(4))-Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2): [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(2\)\(a\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(2)(a))-Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1+Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_)

Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 9: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 23: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(11\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 9: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-05\(b\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1)Reference 11: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(10\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 12: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(15\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.I.7\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph \(a\) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph>

(SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1> + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32> + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type:

xbrl: stringItemType Balance Type: na Period Type: duration X - Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + References No definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: duration X - References No definition available. + Details Name: us-gaap_OperatingExpenses Abstract Namespace Prefix: us-gaap_ Data Type: xbrli: stringItemType Balance Type: na Period Type: duration X - Definition The net result for the period of deducting operating expenses from operating revenues. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30) Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1) Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph \(a\)-SubTopic 10-Topic 220-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph (a)-SubTopic 10-Topic 220-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1) + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: credit Period Type: duration X - Definition Amount of expense (reversal of expense) for expected credit loss on accounts receivable. + References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479319/326-20-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479319/326-20-50-13) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2) + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 730-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1> Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 912-SubTopic 730-Name Accounting Standards Codification-Section 25-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1> + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli: monetaryItemType Balance Type: debit Period Type: duration X - Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28) Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A) Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B) Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30) Reference 21: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 42-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42> Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22) Reference 23: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40> Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22) Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-05\(b\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-05(b)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1) Reference 26:

[http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExpenses recognized in the period that are directly related to the selling and distribution of products or services. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingExpense](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingExpense) Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - \$ / shares 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Statement [Abstract] Å Å Å Diluted \$ (0.09) \$ (0.35) \$ (0.16) \$ (0.65) X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD (\$) Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total Balance at Dec. 31, 2022 \$ 1,498,289,931 \$ (36,211,496) \$ 11,573,065 \$ 4,289,998 Balance (in Shares) at Dec. 31, 2022 1,498,179 Å Å Å Conversions of Note Payable to common stock \$ 595,799,405 650,000 Conversions of Note Payable to common stock (in Shares) 191,806 Å Å Å Net loss for the period (475,976) (475,976) Foreign currency translation adjustment 205,322 205,322 Balance at Mar. 31, 2023 \$ 1,690,295,739 (36,687,472) 11,778,387 4,669,344 Balance (in Shares) at Mar. 31, 2023 1,689,985 Å Å Å Balance at Dec. 31, 2022 \$ 1,498,289,931 (36,211,496) 11,573,065 4,289,998 Balance (in Shares) at Dec. 31, 2022 1,498,179 Å Å Å Å Net loss for the period Å Å Å (1,069,005) Balance at Jun. 30, 2023 \$ 2,285,30,376,144 (36,280,501) 11,254,700 4,352,628 Balance (in Shares) at Jun. 30, 2023 2,284,927 Å Å Å Balance at Mar. 31, 2023 \$ 1,690,295,739 (36,687,472) 11,778,387 4,669,344 Balance (in Shares) at Mar. 31, 2023 1,689,985 Å Å Å Conversions of Note Payable to common stock \$ 595,799,405 800,000 Conversions of Note Payable to common stock (in Shares) 594,941 Å Å Å Å Net loss for the period (593,029) (593,029) Foreign currency translation adjustment (45,502) (45,502) Balance at Jun. 30, 2023 \$ 2,285,30,376,144 (36,280,501) 11,254,700 4,352,628 Balance (in Shares) at Jun. 30, 2023 2,284,927 Å Å Å Å Balance at Dec. 31, 2023 \$ 10,625,35,282,256 (39,290,314) 11,452,054 7,454,621 Balance (in Shares) at Dec. 31, 2023 10,625,788 Å Å Å Å Conversions of Note Payable to common stock \$ 1,191,448,809,450,000 Conversions of Note Payable to common stock (in Shares) 1,191,077 Å Å Å Issuance of common stock for intangible assets \$ 3,000,1,362,000 Å 1,365,000 Issuance of common stock for intangible assets (in Shares) 3,000,000 Å Å Å Å Net loss for the period (955,892) (955,892) Foreign currency translation adjustment (21,575) (21,575) Balance at Mar. 31, 2024 \$ 14,816,37,093,065 (40,246,206) 11,430,479 8,292,154 Balance (in Shares) at Mar. 31, 2024 14,816,865 Å Å Å Å Balance at Dec. 31, 2023 \$ 10,625,35,282,256 (39,290,314) 11,452,054 7,454,621 Balance (in Shares) at Dec. 31, 2023 10,625,788 Å Å Å Å Net loss for the period Å Å Å Å (2,394,022) Balance at Jun. 30, 2024 \$ 17,162,37,690,719 (41,684,336) 11,384,977 7,408,522 Balance (in Shares) at Jun. 30, 2024 17,162,771 Å Å Å Å Balance at Mar. 31, 2024 \$ 14,816,37,093,065 (40,246,206) 11,430,479 8,292,154 Balance (in Shares) at Mar. 31, 2024 14,816,865 Å Å Å Å Conversions of Note Payable to common stock \$ 2,346,597,654 600,000 Conversions of Note Payable to common stock (in Shares) 2,345,906 Å Å Å Å Net loss for the period (1,438,130) (1,438,130) Foreign currency translation adjustment (45,502) (45,502) Balance at Jun. 30, 2024 \$ 17,162,37,690,719 \$ (41,684,336) \$ 11,384,977 \$ 7,408,522 Balance (in Shares) at Jun. 30, 2024 17,162,771 Å Å Å Å X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD (\$) Common Stock Additional Paid-in Capital Accumulated Deficit Accumulated Other Comprehensive Income Total Balance at Dec. 31, 2022 \$ 1,498,289,931 \$ (36,211,496) \$ 11,573,065 \$ 4,289,998 Balance (in Shares) at Dec. 31, 2022 1,498,179 Å Å Å Conversions of Note Payable to common stock \$ 595,799,405 650,000 Conversions of Note Payable to common stock (in Shares) 191,806 Å Å Å Net loss for the period (475,976) (475,976) Foreign currency translation adjustment 205,322 205,322 Balance at Mar. 31, 2023 \$ 1,690,295,739 (36,687,472) 11,778,387 4,669,344 Balance (in Shares) at Mar. 31, 2023 1,

Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_ StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 4.E\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2) + Details Name: us-gaap_ StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$) 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash Flows from Operating Activities: $\hat{A}$ $\hat{A}$ Net loss \$ (2,394,022) \$ (1,069,005) Depreciation and amortization 1,473,050 1,374,724 Bad debt expense (reversal of allowance for doubtful accounts) 6,410 (5,989) Inventory write off 411,431 24,259 Changes in assets and liabilities: $\hat{A}$ $\hat{A}$ Trade accounts and other receivables 182,533 (344,449) Advances to suppliers 1,845 294,625 Inventories 719,121 (791,042) Trade accounts payable (821,907) (238,684) Other payables and accrued expenses (241,434) (425,153) Advances from customers 11,142 (458,999) Prepaid expenses (6,053) (44,936) Net Cash Used in Operating Activities (657,884) (1,684,649) Cash Flows from Investing Activity: $\hat{A}$ $\hat{A}$ Purchases of property and equipment (28,086) 60,465 Net Cash (used in) provided by Investing Activity (28,086) 60,465 Cash Flows from Financing Activities: $\hat{A}$ $\hat{A}$ Payments of line of credit (492,761) Proceeds from lines of credit 492,761 505,114 Borrowings and interest from related party 13,708 14,057 Net Cash Provided by Financing Activities 13,708 519,171 Effect of Exchange Rate Changes on Cash (12,239) (23,048) Net Decrease in Cash, Cash Equivalents and Restricted Cash (684,501) (1,128,061) Cash and Cash Equivalents at Beginning of Period 1,423,838 2,029,971 Cash, Cash Equivalents and Restricted Cash at End of Period 739,337 901,910 Supplemental Cash Flow Information: $\hat{A}$ $\hat{A}$ Cash paid for income taxes Cash paid for interest 43,217 39,681 Supplemental Noncash Investing and Financing Activities: $\hat{A}$ $\hat{A}$ Accounts receivable collected with banker's acceptances 187,111 421,458 Inventory purchased with banker's acceptances 237,336 351,463 Conversions of Note Payable to common stock 1,050,000 800,000 Issuances of stock for intangible assets 1,365,000 Lease liabilities arising from obtaining right-of-use assets \$ 158,926 X - DefinitionAccounts receivable collected with banker's acceptances. + ReferencesNo definition available. + Details Name: cphi_ AccountsReceivableCollectedWithBankersAcceptances Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionConversion of related party note and interest to common stock. + ReferencesNo definition available. + Details Name: cphi_ ConversionOfRelatedPartyNoteAndInterestToCommonStock Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of inventory purchased with banker's acceptances. + ReferencesNo definition available. + Details Name: cphi_ InventoryPurchasedWithBankersAcceptanceNote Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionRight-of-use assets. + ReferencesNo definition available. + Details Name: cphi_ RightofuseAssets Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_ CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_ CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)

Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>

Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference> 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference> 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference> 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference> 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference> 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference> 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference> 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference> 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference> 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference> 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference> 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference> 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference> 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference> 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference> 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference> 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference> 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles. + ReferencesNo definition available. + Details Name: us-gaap_PaymentsForProceedsFromProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap_ProceedsFromRelatedPartyDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference> 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference> 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1> + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification

-Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Organization and Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Organization and Significant Accounting Policies [Abstract] Â ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES NOTE 1 â€” ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Â Organization and Nature of Operations â€”A China Pharma Holdings, Inc., a Nevada corporation (â€œChina Pharmaâ€), owns 100% of Onny Investment Limited (â€œOnnyâ€), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (â€œHelpsonâ€), a company organized under the laws of the Peopleâ€™s Republic of China (the â€œPRCâ€). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company. Â Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpsonâ€™s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (â€œWFOEâ€) status on June 21, 2005. Â Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the â€œNMPAâ€, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy. Â Liquidity and Going Concern Â As of June 30, 2024, the Company had cash and cash equivalents of \$0.7 million, an accumulated deficit of \$41.7 million and the Companyâ€™s current liabilities exceeded current assets by \$0.7 million. In addition, the Company had incurred net losses of \$2.4 million and had negative cash flows from operating activities of \$0.7 million for the six months ended June 30, 2024. The Companyâ€™s Chairperson, Chief Executive Officer and Interim Chief Financial Officer had advanced an aggregate of \$1,140,775 as of June 30, 2024 to provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Companyâ€™s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Companyâ€™s existing property, plant and equipment can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Â Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entityâ€™s Ability to Continue as a Going Concern management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Companyâ€™s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of managementâ€™s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Companyâ€™s ability to continue as a going concern. The mitigating effect of managementâ€™s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entityâ€™s ability to continue as a going concern within one year after the date that the financial statements are issued. Â Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Companyâ€™s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Companyâ€™s control. Accordingly, substantial doubt is deemed to exist about the Companyâ€™s ability to continue as a going concern within one year after the date these financial statements are issued.Â The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Â Reverse Stock Split â€” Effective March 6, 2024, China Pharma implemented a 1-for -5 reverse stock split as more fully discussed in Note 13. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split. Â Consolidation and Basis of PresentationÂ â€” The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) and are expressed in United States dollars. The accompanying unaudited interim condensed consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation. Â Helpsonâ€™s functional currency is the Chinese Renminbi. Helpsonâ€™s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpsonâ€™s financial statements are included in accumulated other comprehensive income, which is a component of stockholdersâ€™ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. Â In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Companyâ€™s audited consolidated financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the â€œSECâ€) on April 1, 2024 (â€œ2023 Annual Reportâ€). Â Accounting EstimatesÂ â€”Â The methodology used to prepare the Companyâ€™s financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.Â The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Â Loss Per Share â€” Basic loss per share is calculated by dividing loss available to common stockholders by the weighted-average number of shares of common stock outstanding, excluding unvested stock. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common shares, including unvested stock, had been issued and if the additional common shares were dilutive.Â The potentially dilutive common shares related to the convertible, redeemable note payable of 2,003,001 and 2,155,964 at June 30, 2024 and December 31, 2023 as discussed in Note 9, respectively, and the option to purchase 13,300 shares of common stock at June 30, 2024 and December 31, 2023 are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company. Â Recent Accounting Pronouncements Â In December 2023, the FASB issued guidance to enhance transparency of income tax disclosures. On an annual basis, the new guidance requires a public entity to disclose: (1) specific categories in the rate reconciliation, (2) additional information for reconciling items that are equal to or greater than 5% of the amount computed by multiplying income (or loss) from continuing operations before income tax expense (or benefit) by the applicable statutory income tax rate, (3) income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes, with foreign taxes disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5% of total income taxes paid, (4) income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and (5) income tax expense (or benefit) from continuing operations disaggregated between federal (national), state and foreign. The guidance is effective for fiscal year 2025 annual reporting, with early adoption permitted, to be applied on a prospective basis, with retrospective application permitted. We do not expect the adoption of this accounting standard to have an impact on our Consolidated Financial Statements but will require certain additional disclosures. Â From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts

such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference> 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference> 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference> 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent> + Details Name: us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounts Receivable, Net 6 Months Ended Jun. 30, 2024 Accounts Receivable, Net [Abstract] $\hat{A}$ ACCOUNTS RECEIVABLE, NET NOTE 2 $\hat{A}$ "ACCOUNTS RECEIVABLE, NET $\hat{A}$ Accounts receivable, net, consist of the following: $\hat{A}$ $\hat{A}$ June 30, $\hat{A}$ $\hat{A}$ December $\hat{A}$ 31, $\hat{A}$ $\hat{A}$ 2024 $\hat{A}$ $\hat{A}$ 2023 $\hat{A}$ Trade accounts receivable $\hat{A}$ $\hat{A}$ 13,960,927 $\hat{A}$ $\hat{A}$ 14,290,522 $\hat{A}$ Less: allowance for doubtful accounts $\hat{A}$ $\hat{A}$ (13,706,077) $\hat{A}$ $\hat{A}$ (13,786,074) Trade accounts receivable, net $\hat{A}$ $\hat{A}$ \$254,850 $\hat{A}$ $\hat{A}$ \$504,448 $\hat{A}$ $\hat{A}$ We recognize bad debt expenses per actual write-offs as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is lower than that of the previous period, we recognize a bad debt credit for the difference. The allowance for doubtful account balances were \$13.71 million and \$13.79 million as of June 30, 2024 and December 31, 2023, respectively. The changes in the allowances for doubtful accounts during the three and six months ended June 30, 2024 and 2023 were as follows: $\hat{A}$ $\hat{A}$ $\hat{A}$ For the Three Months Ended $\hat{A}$ $\hat{A}$ For the Six Months Ended $\hat{A}$ $\hat{A}$ $\hat{A}$ June 30, $\hat{A}$ $\hat{A}$ June 30, $\hat{A}$ $\hat{A}$ 2024 $\hat{A}$ $\hat{A}$ 2023 $\hat{A}$ $\hat{A}$ 2024 $\hat{A}$ $\hat{A}$ 2023 $\hat{A}$ Balance, Beginning of Period $\hat{A}$ $\hat{A}$ 13,759,993 $\hat{A}$ $\hat{A}$ 16,955,959 $\hat{A}$ $\hat{A}$ 13,786,074 $\hat{A}$ $\hat{A}$ 16,739,527 $\hat{A}$ Bad debt expense (reversal of allowance for doubtful accounts) $\hat{A}$ $\hat{A}$ 8,476 $\hat{A}$ $\hat{A}$ 4,047 $\hat{A}$ $\hat{A}$ 6,410 $\hat{A}$ $\hat{A}$ (5,989) Foreign currency translation adjustment $\hat{A}$ $\hat{A}$ (62,392) $\hat{A}$ $\hat{A}$ (834,751) $\hat{A}$ $\hat{A}$ (86,407) $\hat{A}$ $\hat{A}$ (608,283) Balance, End of Period $\hat{A}$ $\hat{A}$ 13,706,077 $\hat{A}$ $\hat{A}$ 16,125,255 $\hat{A}$ $\hat{A}$ 13,706,077 $\hat{A}$ $\hat{A}$ 16,125,255 $\hat{A}$ X - DefinitionThe entire disclosure for accounts receivable, contract receivable, receivable held-for-sale, and nontrade receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 310 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310/tableOfContentReference> 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/326/tableOfContent> + Details Name: us-gaap_AccountsAndNontradeReceivableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountsReceivableNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventories 6 Months Ended Jun. 30, 2024 Inventories [Abstract] $\hat{A}$ INVENTORIES NOTE 3 $\hat{A}$ "INVENTORIES $\hat{A}$ Inventories consisted of the following: $\hat{A}$ $\hat{A}$ June 30, $\hat{A}$ $\hat{A}$ December 31, $\hat{A}$ $\hat{A}$ 2024 $\hat{A}$ $\hat{A}$ 2023 $\hat{A}$ Raw materials $\hat{A}$ $\hat{A}$ 1,194,063 $\hat{A}$ $\hat{A}$ 1,849,213 $\hat{A}$ Work in process $\hat{A}$ $\hat{A}$ 87,308 $\hat{A}$ $\hat{A}$ 413,597 $\hat{A}$ Finished goods $\hat{A}$ $\hat{A}$ 1,537,554 $\hat{A}$ $\hat{A}$ 1,469,707 $\hat{A}$ Total Inventories $\hat{A}$ $\hat{A}$ \$2,818,925 $\hat{A}$ $\hat{A}$ \$3,732,517 $\hat{A}$ X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/330/tableOfContent> + Details Name: us-gaap_InventoryDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, Plant and Equipment 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] $\hat{A}$ PROPERTY, PLANT AND EQUIPMENT NOTE 4 $\hat{A}$ "PROPERTY, PLANT AND EQUIPMENT $\hat{A}$ Property, plant and equipment consisted of the following: $\hat{A}$ $\hat{A}$ June 30, $\hat{A}$ $\hat{A}$ December $\hat{A}$ 31, $\hat{A}$ $\hat{A}$ 2024 $\hat{A}$ $\hat{A}$ 2023 $\hat{A}$ Permit of land use $\hat{A}$ $\hat{A}$ \$395,223 $\hat{A}$ $\hat{A}$ \$397,684 Building $\hat{A}$ $\hat{A}$ 9,177,692 $\hat{A}$ $\hat{A}$ 9,234,836 $\hat{A}$ Plant, machinery and equipment $\hat{A}$ $\hat{A}$ 27,029,997 $\hat{A}$ $\hat{A}$ 27,170,123 $\hat{A}$ Motor vehicle $\hat{A}$ $\hat{A}$ 301,818 $\hat{A}$ $\hat{A}$ 303,697 $\hat{A}$ Office equipment $\hat{A}$ $\hat{A}$ 386,334 $\hat{A}$ $\hat{A}$ 388,740 $\hat{A}$ Total $\hat{A}$ $\hat{A}$ 37,291,064 $\hat{A}$ $\hat{A}$ 37,495,080 $\hat{A}$ Less: accumulated depreciation $\hat{A}$ $\hat{A}$ (31,473,685) $\hat{A}$ $\hat{A}$ (30,394,655) Property, plant and equipment, net $\hat{A}$ $\hat{A}$ \$5,817,379 $\hat{A}$ $\hat{A}$ \$7,100,425 $\hat{A}$ $\hat{A}$ Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: $\hat{A}$ Asset $\hat{A}$ Life $\hat{A}$ years Permit of land use $\hat{A}$ 40 $\hat{A}$ " 70 Building $\hat{A}$ 20 $\hat{A}$ " 49 Plant, machinery and equipment $\hat{A}$ 5 $\hat{A}$ " 10 Motor vehicle $\hat{A}$ 5 $\hat{A}$ " 10 Office equipment $\hat{A}$ 3-5 $\hat{A}$ Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was \$636,721 and \$640,979 for the three months ended June 30, 2024 and 2023, respectively and \$1,270,981 and \$1,265,700 for the six months ended June 30, 2024, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference)

future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the three and six months ended June 30, 2024 and 2023. Â Intangible assets consisted of NMPA approved medical formulas, a Utility Model Patent and two Invention Patents as follows: Â Â Â June 30,Â Â DecemberÂ 31,Â Â Â 2024Â Â 2023Â NMPA approved medical formulasÂ \$4,736,859Â Â \$4,766,353Â Technology from BonierÂ Â 1,715,813Â Â 1,726,497Â Invention PatentsÂ Â 3,002,782Â Â 1,653,028Â Â Â 9,455,454Â Â 8,145,878Â Accumulated amortizationÂ Â (5,061,837)Â Â (4,890,646) Net carrying amountÂ \$4,393,617Â Â \$3,255,232Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1:

into a Securities Purchase Agreement (the “Agreement”) pursuant to which the Company issued an unsecured convertible promissory note (the “Note”) to an institutional accredited investor StreeterVivory Capital, LLC (the “Investor”). The transaction contemplated under the Agreement was closed on November 19, 2021. The Note matured on February 17, 2023. On April 13, 2023 China Pharma entered into an Amendment (the “Amendment”) with the Investor which extended the maturity date of the Convertible Note Payable to May 19, 2024. As consideration for the extension, China Pharma agreed to an extension fee of \$65,639, representing 2.0% of the balance of the Note and accrued interest on the date of the Amendment. The amount was satisfied by increasing the Note balance by the amount of the extension fee. The Company recorded this as additional interest expense during the second quarter of 2023. In addition, China Pharma decreased the price at which the Investor can convert the balance from 85% to 82% of the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, and assumed an additional obligation to redeem a portion of the outstanding balance of the Note monthly or be subject to additional penalty fees. On May 23, 2024, the Company entered into an Amendment No. 2 (the “Second Amendment”), to the Note by which the parties have agreed to extend the maturity date of the Note to August 19, 2025. In consideration of the extension, the Company has agreed to pay to the Investor an extension fee equal to two percent (2%) of the outstanding balance of the Note (the “Extension Fee”) totaling \$10,934, and lower the minimum monthly redemption amount from the outstanding balance of the Note that the Company is obligated to redeem from \$150,000 to \$37,182.33. The Second Amendment also includes customary representations and warranties by the Company. The Company recognized the Extension Fee as interest expense for the year ending December 31, 2024. The Note was originally convertible into 70,000 shares of China Pharma’s common stock at a price of \$75.00 per share through April 19, 2022. Thereafter, the Note was convertible into 35,000 shares at a price of \$150.00 per share. As of June 30, 2024 the Note is convertible into 2,736 shares of common stock. A Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default. A Pursuant to the terms of the Agreement and the Note, the Company must obtain Investor’s consent for certain fundamental transactions such as consolidation, merger with or into another entity (except for a reincorporation merger), disposition of substantial assets, change of control, reorganization or recapitalization. Any occurrence of a fundamental transaction without Investor’s prior written consent will be deemed an Event of Default. A Investor may redeem all or any part the outstanding balance of the Note, subject to \$500,000 per calendar month, at any time after one hundred twenty-one (121) days from the Purchase Price Date, as defined in the Note, upon three trading days’ notice, in cash or converting into shares of China Pharma’s common stock, at a price equal to 82% multiplied by the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding balance of the Note with the Investor’s consent. At inception, the Note was redeemable into 176,229 shares based on the lowest volume weighted average price of \$29.79085 on the inception date of November 19, 2021. As of June 30, 2024, the Note was redeemable into 2,003,001 shares of common stock based on 82% of the lowest volume weighted average price of \$0.2049 on that date. A Total interest expense for the three months ended June 30, 2024 and 2023 was \$19,058 and \$105,545, respectively, and \$33,370 and \$151,563 for the six months ended June 30, 2024 and 2023, respectively. A On January 11, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3945, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 380,228 shares of common stock to the Investor on January 16, 2024. A On February 1, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3725, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 402,685 shares of common stock to the Investor on February 5, 2024. A On February 16, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3675, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 408,164 shares of common stock to the Investor on February 21, 2024. A On April 2, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2927, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 512,470 shares of common stock to the Investor on April 3, 2024. A On April 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2774, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 540,735 shares of common stock to the Investor on April 19, 2024. A On May 20, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2539, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 590,783 shares of common stock to the Investor on May 21, 2024. A On June 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2137, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 701,918 shares of common stock to the Investor on June 17, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_ShortTermBorrowingsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for short-term debt. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContent> + Details Name: us-gaap_ShortTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases 6 Months Ended Jun. 30, 2024 Leases [Abstract] A LEASES NOTE 10 “ LEASES A The Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right of use assets when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company’s incremental borrowing rate at the initial measurement date. For the three months ended June 30, 2024 and 2023, operating lease cost was \$19,228 and \$17,848, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was \$19,947 and \$18,744, respectively. A For the six months ended June 30, 2024 and 2023, operating lease cost was \$38,629 and \$37,635, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was \$40,074 and \$39,525, respectively. As of June 30, 2024 and December 31, 2023, the Company reported right of use assets of \$77,259 and \$116,610, respectively and lease liabilities of \$78,628 and \$117,637, respectively. As of June 30, 2024, its operating leases had a weighted average remaining lease term of 1.0 years and a weighted average discount rate of 3.55%. A Minimum lease payments for the Company’s operating lease liabilities were as follows for the twelve month period ended June 30: A 2025 \$80,148 A Total undiscounted cash flows A \$80,148 Less: Imputed interest A (1,520) A \$78,628 Less: Lease liabilities, current portion A (78,628) Lease liabilities, net of current portion \$- A The Company has leases with terms less than one year for certain provincial sales offices that are not material. X - ReferencesNo definition available. + Details Name: us-gaap_LesseeOperatingLeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent> + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes 6 Months Ended Jun. 30, 2024 Income Taxes [Abstract] A INCOME TAXES NOTE 11 “ INCOME TAXES A Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. A Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the “more-likely-than-not” threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2023, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2019 through December 31, 2023 and the Chinese income tax return for the year ended December 31, 2023 are open for possible examination. A Under the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%. A There was no provision for income taxes for the three and six months ended June 30, 2024 and 2023, respectively due to continued net losses of the Company. A As of June 30, 2024, Helpson had net operating loss carryforwards for PRC tax purposes of approximately \$22.6 million which are available to offset any future taxable income through 2029. Approximately \$2.7 million of these carryforwards will expire in December 2024. The Company also has net operating losses for United States federal income tax purposes of approximately \$10.3 million of which \$5.1 million is available to offset future taxable income, if any, through 2040, and \$5.2 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year. A U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the “U.S. Tax Reform”), was signed into law on December 22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory

deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings. Â In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.Â Â The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.Â Â Management considers projected future taxable income and tax planning strategies in making this assessment.Â Â Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of June 30, 2024 and December 31, 2023.Â Â Therefore, the Company provided for a valuation allowance against its deferred tax assets of \$21,992,061 and \$21,531,017 as of June 30, 2024 and December 31, 2023, respectively. Â The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 6.I.5.Q1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 11.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2) + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Measurements [Abstract] Â FAIR VALUE MEASUREMENTS NOTE 12 Â€œ FAIR VALUE MEASUREMENTS Â Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 Â€œ Quoted prices in active markets for identical assets or liabilities; Level 2 Â€œ Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data; and Level 3 Â€œ Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. Â The Company uses fair value to measure the value of the bankerâ€™s acceptance notes it holds at June 30, 2024 and December 31, 2023.Â The bankerâ€™s acceptance notes are recorded at cost which approximates fair value.Â Â The Company held the following assets and liabilities recorded at fair value: Â Â Â Â Â Fair Value Measurements atÂ Â Â Â Â Reporting Date UsingÂ DescriptionÂ June 30, 2024Â Â Level 1Â Â Level 2Â Â Level 3Â Bankerâ€™s acceptance notesÂ \$15,435Â Â \$Â Â Â Â Â \$15,435Â Â \$Â Â Â Â TotalÂ \$15,435Â Â \$-Â Â \$15,435Â Â \$-Â Â Â Â Â Â Â Â Fair Value Measurements atÂ Â Â Â Â Reporting Date UsingÂ DescriptionÂ December 31, 2023Â Â Level 1Â Â Level 2Â Â Level 3Â Bankerâ€™s acceptance notesÂ \$65,915Â Â \$Â Â Â Â Â \$65,915Â Â \$Â Â Â Â Â TotalÂ \$65,915Â Â \$-Â Â \$65,915Â Â \$-Â Â X - DefinitionThe entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 820 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/820/tableOfContent> + Details Name: us-gaap_FairValueMeasurementInputsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity 6 Months Ended Jun. 30, 2024 Stockholders Equity [Abstract] Â STOCKHOLDERS' EQUITY NOTE 13 Â€œ STOCKHOLDERSÂ€™ EQUITY Â China Pharma is authorized to issue 500,000,000 shares of common stock, \$0.001 par value, and 5,000,000 shares of preferred stock, \$0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Board of China Pharma. Â According to relevant PRC laws, companies registered in the PRC, including China Pharmaâ€™s PRC subsidiary, Helpson, are required to allocate at least 10% of their after tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach 50% of the companyâ€™s registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is \$8,145,000 at June 30, 2024 and December 31, 2023. Â Effective March 6, 2024, the Company implemented a 1-for-5 reverse split of its common stock. The reverse stock split was approved by the Companyâ€™s Board of Directors through unanimous written consent and the Companyâ€™s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2022, which was held on December 17, 2023. Upon the effectiveness of the reverse stock split, every 5 shares of the Companyâ€™s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholderâ€™s percentage interest in the Companyâ€™s outstanding common stock, except for adjustments that may result from the treatment of fractional shares.Â All share and per share amounts have been retroactively restated for all periods presented in the accompanying unaudited condensed consolidated financial statements. Â Effective March 6, 2023 China Pharma implemented a 1-for-10 reverse split of its common stock. The reverse stock split was approved by the Companyâ€™s Board of Directors through unanimous written consent and China Pharmaâ€™s stockholders at its Annual Meeting for the fiscal year ended on December 31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of China Pharmaâ€™s issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholderâ€™s percentage interest in China Pharmaâ€™s outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts have been retroactively restated for all periods presented in the accompanying unaudited condensed consolidated financial statements. Â 2024 Share Issuances Â On January 11, 2024Â the Investor delivered its notice of redemption for \$150,000Â of the Note and related interest at the conversion price of \$0.3945, which wasÂ 82% of the lowest volume weighted average priceÂ during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total ofÂ 380,228Â shares of common stock to the Investor on January 16, 2024. Â On February 1, 2024Â the Investor delivered its notice of redemption for \$150,000Â of the Note and related interest at the conversion price of \$0.3725, which wasÂ 82% of the lowest volume weighted average priceÂ during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total ofÂ 402,685Â shares of common stock to the Investor on February 5, 2024.Â On February 16, 2024Â the Investor delivered its notice of redemption for \$150,000Â of the Note and related interest at the conversion price of \$0.3675, which wasÂ 82% of the lowest volume weighted average priceÂ during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total ofÂ 408,164Â shares of common stock to the Investor on February 21, 2024. Â On April 2, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000Â of the Note and related interest at the conversion price of \$0.2927, which was 82% of the lowest volume weighted

average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 512,470 shares of common stock to the Investor on April 3, 2024. On April 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2774, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 540,735 shares of common stock to the Investor on April 19, 2024. On May 20, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2539, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 590,783 shares of common stock to the Investor on May 21, 2024. On June 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2137, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 701,918 shares of common stock to the Investor on June 17, 2024. 2010 Incentive Plan On November 12, 2010, the Company's Board adopted the Company's 2010 Incentive Plan (the "Plan"), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the "Amendment"), pursuant to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December 19, 2019. On October 25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to the Plan to increase the number of shares of the Common Stock, that are reserved thereunder by 100,000 shares from 80,000 shares to 180,000 shares. On October 27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares of common stock that are reserved thereunder by an additional 100,000 shares from 180,000 to 280,000. On December 17, 2023 the stockholders approved Amendment No. 1 to the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares from 280,000 to 580,000. The Plan gives the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 580,000 shares of common stock. Through June 30, 2024, there were 84,700 shares of stock and stock options granted and outstanding under the Plan. A total of 13,300 options were outstanding as of June 30, 2024 under the Plan. As such, there are 482,000 additional units available for issuance under the Plan. There were no issuances of securities from the Plan for the six months ended June 30, 2024 and as such, no compensation expense was recognized for the period. As of June 30, 2024, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants. X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityNoteAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(e\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18) + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments And Contingencies [Abstract] COMMITMENTS AND CONTINGENCIES NOTE 14 " COMMITMENTS AND CONTINGENCIES Current vulnerability due to certain concentrations For the six months ended June 30, 2024, no customer accounted for greater than 10.0% of sales and two customers accounted for 63.6% and 13.7% of accounts receivable. Three suppliers accounted for 23.5%, 23.4% and 17.6% of raw material purchases, and three different products accounted for 35.2%, 22.7% and 10.2% of revenue. For the six months ended June 30, 2023, no customer accounted for greater than 10.0% of sales and three customers accounted for 53.4%, 11.5% and 10.5% of accounts receivable. Two suppliers accounted for 19.5% and 18.0% of raw material purchases, and five different products accounted for 22.4%, 19.8%, 11.8%, 10.9% and 10.0% of revenue. Nature of Operations Economic environment Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company's operations. In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContent>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContent>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent> + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events 6 Months Ended Jun. 30, 2024 Subsequent Events [Abstract] SUBSEQUENT EVENTS NOTE 15 " SUBSEQUENT EVENTS The Company evaluated all events and transactions that occurred after

June 30, 2024 up through the date the Company filed these unaudited condensed consolidated financial statements. No events require adjustment to or disclosure in the unaudited condensed consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounting Policies, by Policy (Policies) 6 Months Ended Jun. 30, 2024 Organization and Significant Accounting Policies [Abstract] A Organization and Nature of Operations Organization and Nature of Operations

“A China Pharma Holdings, Inc., a Nevada corporation (the “China Pharma”), owns 100% of Onny Investment Limited (the “Onny”), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (the “Helpson”), a company organized under the laws of the People’s Republic of China (the “PRC”). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company. Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (the “WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy. Liquidity and Going Concern Liquidity and Going Concern As of June 30, 2024, the Company had cash and cash equivalents of \$0.7 million, an accumulated deficit of \$41.7 million and the Company’s current liabilities exceeded current assets by \$0.7 million. In addition, the Company had incurred net losses of \$2.4 million and had negative cash flows from operating activities of \$0.7 million for the six months ended June 30, 2024. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer had advanced an aggregate of \$1,140,775 as of June 30, 2024 to provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing property, plant and equipment can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Reverse Stock Split Reverse Stock Split “Effective March 6, 2024, China Pharma implemented a 1-for -5 reverse stock split as more fully discussed in Note 13. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split. Consolidation and Basis of Presentation Consolidation and Basis of Presentation “The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) and are expressed in United States dollars. The accompanying unaudited interim condensed consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation. Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024 (the “2023 Annual Report”). Accounting Estimates Accounting Estimates “The methodology used to prepare the Company’s financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates. The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Loss Per Share Loss Per Share “Basic loss per share is calculated by dividing loss available to common stockholders by the weighted-average number of shares of common stock outstanding, excluding unvested stock. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common shares, including unvested stock, had been issued and if the additional common shares were dilutive. The potentially dilutive common shares related to the convertible, redeemable note payable of 2,003,001 and 2,155,964 at June 30, 2024 and December 31, 2023 as discussed in Note 9, respectively, and the option to purchase 13,300 shares of common stock at June 30, 2024 and December 31, 2023 are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company. Recent Accounting Pronouncements Recent Accounting Pronouncements In December 2023, the FASB issued guidance to enhance transparency of income tax disclosures. On an annual basis, the new guidance requires a public entity to disclose: (1) specific categories in the rate reconciliation, (2) additional information for reconciling items that are equal to or greater than 5% of the amount computed by multiplying income (or loss) from continuing operations before income tax expense (or benefit) by the applicable statutory income tax rate, (3) income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes, with foreign taxes disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5% of total income taxes paid, (4) income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and (5) income tax expense (or benefit) from continuing operations disaggregated between federal (national), state and foreign. The guidance is effective for fiscal year 2025 annual reporting, with early adoption permitted, to be applied on a prospective basis, with retrospective application permitted. We do not expect the adoption of this accounting standard to have an impact on our Consolidated Financial Statements but will require certain additional disclosures. From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption. X - Definition Liquidity and Going Concern. + ReferencesNo

definition available. + Details Name: cphi_LiquidityAndGoingConcernPolicyTextBlock Namespace Prefix: cphi_Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy reverse stock split. + ReferencesNo definition available. + Details Name: cphi_ReverseStockSplitsPolicyTextBlock Namespace Prefix: cphi_Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1> + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2> + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1) + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8> + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounts Receivable, Net (Tables) 6 Months Ended Jun. 30, 2024 Accounts Receivable, Net [Abstract] Â Schedule of Accounts Receivable, Net Accounts receivable, net, consist of the following: Â June 30,Â DecemberÂ 31,Â Â Â 2024Â 2023Â Trade accounts receivableÂ Â 13,960,927Â Â 14,290,522Â Less: allowance for doubtful accountsÂ Â (13,706,077)Â Â (13,786,074) Trade accounts receivable, netÂ \$254,850Â Â \$504,448Â Schedule of Changes in the Allowances for Doubtful Accounts The changes in the allowances for doubtful accounts during the three and six months ended June 30, 2024 and 2023 were as follows: Â For the Three Months EndedÂ Â For the Six Months EndedÂ Â Â June 30,Â Â June 30,Â Â Â 2024Â 2023Â 2024Â 2023Â Balance, Beginning of PeriodÂ Â 13,759,993Â Â 16,955,959Â Â 13,786,074Â Â 16,739,527Â Bad debt expense (reversal of allowance for doubtful accounts)Â Â 8,476Â Â 4,047Â Â 6,410Â Â (5,989) Foreign currency translation adjustmentÂ Â (62,392)Â Â (834,751)Â Â (86,407)Â Â (608,283) Balance, End of PeriodÂ Â 13,706,077Â Â 16,125,255Â Â 13,706,077Â Â 16,125,255Â X - DefinitionTabular disclosure of allowance for credit loss on accounts receivable. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13> + Details Name: us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountsReceivableNetAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventories (Tables) 6 Months Ended Jun. 30, 2024 Inventories [Abstract] Â Schedule of Inventories Inventories consisted of the following: Â June 30,Â December 31,Â Â Â 2024Â 2023Â Raw materialsÂ Â 1,194,063Â Â 1,849,213Â Work in processÂ Â 87,308Â Â 413,597Â Finished goodsÂ Â 1,537,554Â Â 1,469,707Â Total InventoriesÂ \$2,818,925Â Â \$3,732,517Â X - ReferencesNo definition available. + Details Name: us-gaap_InventoryDisclosureAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(c\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1> + Details Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, Plant and Equipment (Tables) 6 Months Ended Jun. 30, 2024 Property, Plant and Equipment [Abstract] Â Schedule of Property, Plant and Equipment Property, plant and equipment consisted of the following: Â June 30,Â DecemberÂ 31,Â Â Â 2024Â 2023Â Permit of land useÂ \$395,223Â Â \$397,684Â BuildingÂ Â 9,177,692Â Â 9,234,836Â Plant, machinery and equipmentÂ Â 27,029,997Â Â 27,170,123Â Motor vehicleÂ Â 301,818Â Â 303,697Â Office equipmentÂ Â 386,334Â Â 388,740Â TotalÂ Â 37,291,064Â Â 37,495,080Â Less: accumulated depreciationÂ Â (31,473,685)Â Â (30,394,655) Property, plant and equipment, netÂ \$5,817,379Â Â \$7,100,425Â Â Schedule of Estimated Useful Lives of the Assets Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: AssetÂ Life â€ years Permit of land useÂ 40 â€ 70 BuildingÂ 20 â€ 49 Plant, machinery and equipmentÂ 5 â€ 10 Motor vehicleÂ 5 â€ 10 Office equipmentÂ 3-5 X - DefinitionUseful live of Assets table text block. + ReferencesNo definition available. + Details Name: cphi_UsefulLiveOfAssetsTableTextBlock Namespace Prefix: cphi_Data Type: dtr:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal

of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets \(Tables\) 6 Months Ended Jun. 30, 2024 Intangible Assets \[Abstract\]](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Tables) 6 Months Ended Jun. 30, 2024 Intangible Assets [Abstract]) Schedule of Intangible Assets Intangible assets consisted of NMPA approved medical formulas, a Utility Model Patent and two Invention Patents as follows:

	June 30, 2024	December 31, 2023
NMPA approved medical formulas	\$4,736,859	\$4,766,353
Technology from Bonier	\$1,715,813	\$1,726,497
Invention Patents	\$3,002,782	\$1,653,028
Accumulated amortization	\$9,455,454	\$8,145,878
Net carrying amount	\$4,393,617	\$3,255,232

 + ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Other Payables \(Tables\) 6 Months Ended Jun. 30, 2024 Other Payables \[Abstract\]](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Other Payables (Tables) 6 Months Ended Jun. 30, 2024 Other Payables [Abstract]) Schedule of Other Payables Other Payables consisted of the following:

	June 30, 2024	December 31, 2023
Compensation payable to officer	\$1,251,506	\$1,243,506
Compensation and interest to related parties	\$20,000	\$12,000
Business taxes and other	\$335,485	\$1,027,186
Total Other Payables	\$1,606,991	\$2,282,692

 X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Lines of Credit (Tables) 6 Months Ended Jun. 30, 2024 Lines of Credit [Abstract]">http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Lines of Credit (Tables) 6 Months Ended Jun. 30, 2024 Lines of Credit [Abstract] Schedule of Principal Payments Principal payments required for the remaining terms of the loan facility and lines of credit as of June 30, 2024 are as follows:

Year	Lines of Credit	2025	2026
2025	\$1,403,154	\$2,427,457	

 X - ReferencesNo definition available. + Details Name: us-gaap_LongtermLineOfCreditCurrentAndNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\) \(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases \(Tables\) 6 Months Ended Jun. 30, 2024 Leases \[Abstract\]](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22) (b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Tables) 6 Months Ended Jun. 30, 2024 Leases [Abstract]) Schedule of Operating Lease Liabilities Minimum lease payments for the Company's operating lease liabilities were as follows for the twelve month period ended June 30:

	2025	2024
Total undiscounted cash flows	\$80,148	\$80,148
Less: Imputed interest	(1,520)	(78,628)
Less: Lease liabilities, current portion	(78,628)	
Lease liabilities, net of current portion	\$	\$

 X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements \(Tables\) 6 Months Ended Jun. 30, 2024 Fair Value Measurements \[Abstract\]](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Measurements [Abstract]) Schedule of Assets and Liabilities Recorded at Fair Value The Company uses fair value to measure the value of the banker's acceptance notes it holds at June 30, 2024 and December 31, 2023. The banker's acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value:

	June 30, 2024	December 31, 2023
Fair Value Measurements at Level 1	\$15,435	\$15,435
Fair Value Measurements at Level 2	\$	\$
Fair Value Measurements at Level 3	\$	\$
Banker's acceptance notes	\$15,435	\$15,435
Total	\$15,435	\$15,435

 X - ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1:

Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details
Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na
Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. +
ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Reference 11: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\(b\\)\\(2\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1\)Reference 12: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \\(f\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1\)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11\)Reference 15: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11\)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.7-04\\(18\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1\)Reference 20: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.6-07\\(9\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1\)Reference 21: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \\(SX 210.6-09\\(1\\)\\(d\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3\)Reference 22: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(i\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A\)Reference 23: \[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(ii\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A\]\(http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A\)Reference 24: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(iii\\)\\(A\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A\)Reference 25: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(iv\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A\)Reference 26: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \\(SX 210.13-01\\(a\\)\\(5\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A\)Reference 27: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(i\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B\)Reference 28: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(iii\\)\\(A\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B\)Reference 29: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(iii\\)\\(B\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B\)Reference 30: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(iv\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B\)Reference 31: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(5\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B\)Reference 32: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B\)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A\)Reference 36: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B\)Reference 37: \[http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\(SX 210.9-04\\(22\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1\]\(http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1\) + Details
Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. +
ReferencesReference 1: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \\(b\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1\)Reference 2: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1\)Reference 3: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \\(b\\)\\(4\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1\)Reference 4: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph \\(d\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9\)Reference 5: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph \\(c\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9\)Reference 6: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9\)Reference 7: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph \\(a\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7\)Reference 8: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \\(g\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1\)Reference 9: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \\(d\\)\\(1\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1\)Reference 10: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \\(d\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1\)Reference 11: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \\(d\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1\]\(http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1\)Reference 11:](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)

[illegible]

Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 59: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 60: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 61: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(f\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 62: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(f\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 63: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 64: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 65: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(iii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 66: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(2\)\(iv\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 67: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 68: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(h\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 69: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph \(SAB Topic 11.M.Q2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5)Reference 70: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4)Reference 71: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4)Reference 72: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4)Reference 73: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph \(d\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8)Reference 74: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph \(d\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8)Reference 75: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4)Reference 76: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph \(e\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4)Reference 77: [http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4)Reference 78: [http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2)Reference 79: [http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2)Reference 80: [http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2)Reference 81: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 82: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 83: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 84: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 85: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 86: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6>Reference 87: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 88: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 89: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 90: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(b\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 91: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 92: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 93: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 94: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 95: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 96: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 97: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 98: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3>Reference 99: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1)Reference 100: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1) + Details Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_OtherCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit) not available for dividend distribution. Includes, but is not limited to, retained earnings appropriated for specific business purpose. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\(ii\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(e\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)

<https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name> Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481142/505-10-45-3>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Name> Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481142/505-10-45-4> + Details Name: us-gaap_RetainedEarningsAppropriated Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\) \(a\)\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19) (a)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(13\)\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(1\)\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph \(SAB Topic 4.C\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480008/505-10-S99-4> + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=cphi_OnnyInvestmentLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=cphi_HainanHelpsonMedicalBiotechnologyCoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounts Receivable, Net (Details) - USD (\$) Jun. 30, 2024 Dec. 31, 2023 Accounts Receivable, Net [Abstract] Â Â Allowance for doubtful account \$ 13,706,077 \$ 13,786,074 X - ReferencesNo definition available. + Details Name: us-gaap_AccountsReceivableNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481962/310-10-50-4> + Details Name: us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net - USD (\$) Jun. 30, 2024 Dec. 31, 2023 Schedule of Accounts Receivable, Net [Abstract] Â Â Trade accounts receivable \$ 13,960,927 \$ 14,290,522 Less: allowance for doubtful accounts (13,706,077) (13,786,074) Trade accounts receivable, net \$ 254,850 \$ 504,448 X - ReferencesNo definition available. + Details Name: cphi_ScheduleOfAccountsReceivableNetAbstract Namespace Prefix: cphi_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481990/310-10-45-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(3\)\(a\)\(1\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(1)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/exampleRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483467/210-10-45-1> + Details Name: us-gaap_AccountsReceivableGrossCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481990/310-10-45-2> + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481962/310-10-50-4> + Details Name: us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Accounts Receivable, Net (Details) - Schedule of Changes in the Allowances for Doubtful Accounts - USD (\$) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Schedule of Changes in the Allowances for Doubtful Accounts [Abstract] Â Â Â Â Balance, Beginning of Period \$ 13,759,993 \$ 16,955,959 \$ 13,786,074 \$ 16,739,527 Bad debt expense (reversal of allowance for doubtful accounts) 8,476 4,047 6,410 (5,989) Foreign currency translation adjustment (62,392) (834,751) (86,407) (608,283) Balance, End of Period \$ 13,706,077 \$ 16,125,255 \$ 13,706,077 \$ 16,125,255 X - ReferencesNo definition available. + Details Name: cphi_AccountsReceivableNetDetailsScheduleofChangesintheAllowancesforDoubtfulAccountsLineItems Namespace Prefix: cphi_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(4\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481962/310-10-50-4> + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name> Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-10A>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name> Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-12>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481956/830-20-45-5>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481694/830-30-45-21> + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147479319/326-20-50-13>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(5\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Inventories (Details) - Schedule of Inventories - USD (\$) Jun. 30, 2024 Dec. 31, 2023 Schedule of Inventories [Abstract] Â Â Raw materials \$ 1,194,063 \$ 1,849,213 Work in process 87,308 413,597 Finished goods 1,537,554 1,469,707 Total Inventories \$ 2,818,925 \$ 3,732,517 X - ReferencesNo definition available. + Details Name: cphi_ScheduleOfInventoriesAbstract Namespace Prefix: cphi_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(6\)\(a\)\(1\)\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_InventoryFinishedGoods Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/exampleRef->

Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_InventoryRawMaterials Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_InventoryWorkInProcess Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, Plant and Equipment (Details) - USD (\$) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Property, Plant and Equipment [Abstract] Á Á Á Depreciation expense \$ 636,721 \$ 640,979 \$ 1,270,981 \$ 1,265,700 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment - USD (\$) Jun. 30, 2024 Dec. 31, 2023 Schedule of Property, Plant and Equipment [Line Items] Á Á Total \$ 37,291,064 \$ 37,495,080 Less: accumulated depreciation (31,473,685) (30,394,655) Property, plant and equipment, net 5,817,379 7,100,425 Permit of land use [Member] Á Á Schedule of Property, Plant and Equipment [Line Items] Á Á Total 395,223 397,684 Building [Member] Á Á Schedule of Property, Plant and Equipment [Line Items] Á Á Total 9,177,692 9,234,836 Plant, machinery and equipment [Member] Á Á Schedule of Property, Plant and Equipment [Line Items] Á Á Total 27,029,997 27,170,123 Motor vehicles [Member] Á Á Schedule of Property, Plant and Equipment [Line Items] Á Á Total 301,818 303,697 Office equipment [Member] Á Á Schedule of Property, Plant and Equipment [Line Items] Á Á Total \$ 386,334 \$ 388,740 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-7A> + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-7A>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478451/942-360-50-1> + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of the Assets Jun. 30, 2024 Minimum [Member] | Permit of land use [Member] Á Schedule of Estimated Useful Lives of the Assets [Line Items] Á Estimated useful lives 40 years Minimum [Member] | Building [Member] Á Schedule of Estimated Useful Lives of the Assets [Line Items] Á Estimated useful lives 20 years Minimum [Member] | Plant, machinery and equipment [Member] Á Schedule of Estimated Useful Lives of the Assets [Line Items] Á Estimated useful lives 5 years Minimum [Member] | Motor vehicle [Member] Á Schedule of Estimated Useful Lives of the Assets [Line Items] Á Estimated useful lives 5 years Minimum [Member] | Office equipment [Member] Á Schedule of Estimated Useful Lives of the Assets [Line Items] Á Estimated useful lives 3 years Maximum [Member] | Permit of land use [Member] Á Schedule of Estimated Useful Lives of the Assets [Line Items] Á Estimated useful lives 70 years Maximum [Member] | Building [Member] Á Schedule of Estimated Useful Lives of the Assets [Line Items] Á Estimated useful lives 49 years Maximum [Member] | Plant, machinery and equipment [Member] Á Schedule of Estimated Useful Lives of the Assets [Line Items] Á Estimated useful lives 10 years Maximum [Member] | Motor vehicle [Member] Á Schedule of Estimated Useful Lives of the Assets [Line Items] Á Estimated useful lives 10 years Maximum [Member] | Office equipment [Member] Á Schedule of Estimated Useful Lives of the Assets [Line Items] Á Estimated useful lives 5 years X - ReferencesNo definition available. + Details Name: cphi_PropertyPlantAndEquipmentDetailsScheduleofEstimatedUsefulLivesoftheAssetsLineItems Namespace Prefix: cphi_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML

50 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Details) - USD (\$) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Intangible Assets [Line Items] $\hat{A}$ $\hat{A}$ $\hat{A}$ Amortization intangible by useful life, descriptions $\hat{A}$ $\hat{A}$ Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. $\hat{A}$ Amortization expense relating to intangible assets \$ 104,922 \$ 55,161 \$ 202,069 \$ 109,024 Transfer price $\hat{A}$ $\hat{A}$ \$ 1,365,000 $\hat{A}$ Issuance of common stock (in Shares) $\hat{A}$ $\hat{A}$ 3,000,000 $\hat{A}$ Price per share (in Dollars per share) $\hat{A}$ 0.455 $\hat{A}$ 0.455 $\hat{A}$ Intangible asset useful life term 20 years $\hat{A}$ 20 years $\hat{A}$ Net profit sales rate 10.00% $\hat{A}$ 10.00% $\hat{A}$ Percentage of net profit $\hat{A}$ $\hat{A}$ 15.00% $\hat{A}$ Helpson [Member] $\hat{A}$ $\hat{A}$ $\hat{A}$ Intangible Assets [Line Items] $\hat{A}$ $\hat{A}$ $\hat{A}$ $\hat{A}$ Percentage of net profit $\hat{A}$ $\hat{A}$ 15.00% $\hat{A}$ X - DefinitionNet profit sales rate. + ReferencesNo definition available. + Details Name: cphi_NetProfitSalesRate Namespace Prefix: cphi_Data Type: dtr:percentItemType Balance Type: na Period Type: instant X - DefinitionPercentage of net profit. + ReferencesNo definition available. + Details Name: cphi_PercentageOfNetProfit Namespace Prefix: cphi_Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of transfer price. + ReferencesNo definition available. + Details Name: cphi_TransferPrice Namespace Prefix: cphi_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482686/350-30-45-2> + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares of common stock issued as dividends during the period. Excludes stock splits. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2> + Details Name: us-gaap_CommonStockDividendsShares Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionThe amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483426/235-10-50-4>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org/350-30/tableOfContent> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482686/350-30-45-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483154/926-20-50-5> + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_Data Type: dtr:types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionAxis=cphi_HelpsonMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Details) - Schedule of Intangible Assets - USD (\$) Jun. 30, 2024 Dec. 31, 2023 Schedule of Intangible Assets [Line Items] $\hat{A}$ $\hat{A}$ Gross carrying amount \$ 9,455,454 \$ 8,145,878 Accumulated amortization (5,061,837) (4,890,646) Net carrying amount 4,393,617 3,255,232 NMPA approved medical formulas [Member] $\hat{A}$ $\hat{A}$ Schedule of Intangible Assets [Line Items] $\hat{A}$ $\hat{A}$ Gross carrying amount 4,736,859 4,766,353 Technology from Bonier [Member] $\hat{A}$ $\hat{A}$ Schedule of Intangible Assets [Line Items] $\hat{A}$ $\hat{A}$ Gross carrying amount 1,715,813 1,726,497 Invention Patents [Member] $\hat{A}$ $\hat{A}$ Schedule of Intangible Assets [Line Items] $\hat{A}$ $\hat{A}$ Gross carrying amount \$ 3,002,782 \$ 1,653,028 X - ReferencesNo definition available. + Details Name: cphi_ScheduleOfIntangibleAssetsLineItems Namespace Prefix: cphi_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section 545 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480265/350-10-545-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480265/350-10-545-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478859/928-340-50-1> + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482665/350-30-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483154/926-20-50-5> + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_NMPAApprovedMedicalFormulasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_TechnologyFromBonierMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cphi_InventionPatentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Other Payables (Details) - Schedule of Other Payables - USD (\$) Jun. 30, 2024 Dec. 31, 2023 Schedule of Other Payables [Abstract] $\hat{A}$ $\hat{A}$ Compensation payable to officer \$ 1,251,506 \$ 1,243,506 Compensation and interest to related parties 20,000 12,000 Business taxes and other 335,485 1,027,186 Total Other Payables \$ 1,606,991 \$ 2,282,692 X - ReferencesNo definition available. + Details Name: cphi_ScheduleOfOtherPayablesAbstract Namespace Prefix: cphi_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses,

payroll taxes and fringe benefits. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8](http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8) + Details Name: us-gaap_AccruedSalariesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_OtherEmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Related Party Transactions (Details) 3 Months Ended 6 Months Ended Jul. 08, 2019 USD (\$) Jul. 08, 2019 CNY (¥) Jun. 30, 2024 USD (\$) Jun. 30, 2023 USD (\$) Jun. 30, 2024 USD (\$) Jun. 30, 2023 USD (\$) Dec. 31, 2023 USD (\$) Related Party Transactions [Line Items] Á Á Á Á Á Á Loan payment Á 738,379 ¥ 4,770,000 Á Á Á Á Term of loan agreement Á 1 year Á 1 year Á Á Interest expense Á Á \$ 6,852 \$ 6,945 \$ 13,708 \$ 14,057 Á Chairperson [Member] Á Á Á Á Á Á Related Party Transactions [Line Items] Á Á Á Á Á Á Borrowings from related parties Á Á 1,140,775 Á 1,140,775 Á \$ 1,133,809 Other payables Á Á \$ 1,251,506 Á \$ 1,251,506 Á \$ 1,243,506 Loan Payable [Member] Á Á Á Á Á Á Related Party Transactions [Line Items] Á Á Á Á Á Á Interest rate 4.35% 4.35% Á Á Á Á Á X - DefinitionAmount of obligations incurred and payable classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(15\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1) + Details Name: us-gaap_AccountsPayableOtherCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B) + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPeriod between issuance and maturity of loan held for sale, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap_LoansHeldForSaleTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionCash payments for and related to principal collection on loans related to operating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(g\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25) + Details Name: us-gaap_PaymentsForLoans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromRelatedPartyDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(c\)\(2\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(c\)\(2\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(g\)\(3\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1) + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(13\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 3: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=cphi_LoanPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Lines of Credit (Details) 3 Months Ended 6 Months Ended Feb. 22, 2024 USD (\$) Feb. 02, 2024 CNY (¥) Dec. 20, 2023 CNY (¥) Feb. 24, 2023 USD (\$) Feb. 24, 2023 CNY (¥) Dec. 30, 2022 USD (\$) Dec. 30, 2022 CNY (¥) Dec. 21, 2022 USD (\$) Sep. 30, 2022 USD (\$) Sep. 25, 2022 USD (\$) Sep. 25, 2022 CNY (¥) Jun. 30, 2024 USD (\$) Jun. 30, 2023 USD (\$) Jun. 30, 2024 USD (\$) Jun. 30, 2023 USD (\$) Dec. 21, 2022 CNY (¥) Sep. 30, 2022 CNY (¥) Bank of Communications [Member] Á Á Á Á Á Á Á Á Á Á Á Á Line of Credit [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Line of credit facility amount Á Á Á Á Á Á Á Á \$ 1,000,000 Á Á Á Á Á Á Á ¥ 7,300,000 Á Interest rate of line of credit Á Á 3.90% Á Á Á Á 3.90% Á Á Á Á Á Á Á Á Line of credit received in advance \$ 3,500,000 Á ¥ 3,800,000 \$ 510,000 Á ¥ 3,500,000 \$ 560,000 Á ¥ 3,800,000 Á Á Á Á Á Á Á Á Due date of line of credit Feb. 20, 2025 Á Dec. 15, 2024 Á Á Á Á Á Á Á Á Á Á Interest expenses Á Á Á Á Á Á Á Á Á Á \$ 10,237 \$ 5,465 \$ 19,302 \$ 10,568 Á Á Repayments of line of credit (in Yuan Renminbi) | Á ¥ Á ¥ 3,500,000 Á Á Á Á Á Á Á Á Á Á Á Á Bank of China [Member] Á Á Á Á Á Á Á Á Á Á Á Á Line of Credit [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Line of credit facility amount | Á ¥ Á Á Á Á Á Á Á Á Á Á Á Á Á ¥ 10,000,000 Interest rate of line of credit Á Á Á Á Á Á Á Á 3.45% 3.35% 3.35% Á Á Á Á Due date of line of credit Á Á Á Á Á Á Á Á Sep. 28, 2023 Sep. 24, 2026 Sep. 24, 2026 Á Á Á Á Á Á Line of credit facility borrowing amount Á Á Á Á Á Á Á \$ 1,540,000 Á Á Á Á Á Á Á Á Interest paid Á Á Á Á Á Á Á Á Á Á \$ 11,993 \$ 12,724 \$ 23,915 \$ 25,320 Á Á Bank of China [Member] | Revolving Credit Facility [Member] Á Á Á Á Á Á Á Á Á Á Á Á Line of Credit [Line Items] Á Á Á Á Á Á Á Á Á Á Á Á Received proceeds from loan Á Á Á Á Á Á Á \$ 1,400,000 Á ¥ 10,000,000 Á Á Á Á Á X - DefinitionInterest expense incurred during the reporting period on other short-term borrowings. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1) + Details Name: us-

gaap_InterestExpenseOtherShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(16\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1) + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDate the credit facility terminates, in YYYY-MM-DD format. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_LineOfCreditFacilityExpirationDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionThe effective interest rate during the reporting period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_LineOfCreditFacilityInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of the required periodic payment applied to principal. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14) + Details Name: us-gaap_ProceedsFromLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15) + Details Name: us-gaap_RepaymentsOfLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_LineOfCreditFacilityAxis=cphi_BankOfCommunicationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LineOfCreditFacilityAxis=cphi_BankOfChinaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Lines of Credit (Details) - Schedule of Principal Payments - Lines of Credit [Member] Jun. 30, 2024 USD (\$) Line of Credit Facility [Line Items] Å 2025 \$ 1,024,303 2026 1,403,154 Total \$ 2,427,457 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(f\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(16\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B>Reference 5: <http://www.xbrl.org/2003/role/exampleRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(b\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4) + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type:

instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-04\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1> + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.12-04\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1> + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Convertible Note Payable (Details) 3 Months Ended 6 Months Ended Jun. 17, 2024 USD (\$) \$ / shares shares May 23, 2024 USD (\$) May 21, 2024 shares May 20, 2024 USD (\$) \$ / shares Apr. 19, 2024 shares Apr. 17, 2024 USD (\$) \$ / shares Apr. 03, 2024 shares Apr. 02, 2024 USD (\$) \$ / shares Feb. 21, 2024 shares Feb. 16, 2024 USD (\$) \$ / shares Feb. 05, 2024 shares Feb. 01, 2024 USD (\$) \$ / shares Jan. 16, 2024 shares Jan. 11, 2024 USD (\$) \$ / shares Apr. 13, 2023 USD (\$) Apr. 19, 2022 \$ / shares Nov. 19, 2021 \$ / shares Jun. 30, 2024 USD (\$) \$ / shares Jun. 30, 2023 USD (\$) Jun. 30, 2024 USD (\$) \$ / shares shares Jun. 30, 2023 USD (\$) Convertible Note Payable [line Items]

Debt extension fee (in Dollars)	\$ 65,639
Note and accrued interest	
Debt redemptions weighted average price	
Number of trading days 10 days	10 days
Extension fee 2.00%	
Description of interest accrued	Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default.
Redeem of outstanding note (in Dollars)	\$ 500,000
Debt instrument redemption price percentage 82.00%	82.00%
Weighted average price (in Dollars per share)	\$ 2,003.001
Debt redemption amount (in Dollars)	\$ 150,000
Stock issued during period shares (in Shares)	701,918
Convertible Notes [Member]	
Note converted into common stock	
Conversion price (in Dollars per share)	\$ 0.2137
Debt instrument redemption price percentage	
Interest expense (in Dollars)	\$ 19,058
Debt redemption amount (in Dollars)	\$ 150,000
Convertible Notes [Member]	
Note converted into common stock	
Convertible Note Payable [line Items]	
Minimum [Member]	
Debt redemptions weighted average price	85.00%
Redemption amount (in Dollars)	\$ 150,000
Maximum [Member]	
Convertible Note Payable [line Items]	
Debt redemptions weighted average price	
Common Stock [Member]	
Convertible Note Payable [line Items]	
Conversion price (in Dollars per share)	\$ 75

 + ReferencesNo definition available. + Details Name: cphi_ExtensionFee Namespace Prefix: cphi_ Data Type: dtr:percentItemType Balance Type: na Period Type: duration X - DefinitionDescription of interest accrues on Note. + ReferencesNo definition available. + Details Name: cphi_InterestAccruesOnNoteDescription Namespace Prefix: cphi_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares redeemable by Notes. + ReferencesNo definition available. + Details Name: cphi_NoteRedeemableIntoShares Namespace Prefix: cphi_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of trading days. + ReferencesNo definition available. + Details Name: cphi_NumberOfTradingDays Namespace Prefix: cphi_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPercentage of balance note and accrued interest. + ReferencesNo definition available. + Details Name: cphi_PercentageOfBalanceNoteAndAccruedInterest Namespace Prefix: cphi_ Data Type: dtr:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of redeem of outstanding note. + ReferencesNo definition available. + Details Name: cphi_RedeemOfOutstandingNote Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe redemption amount for outstanding balance. + ReferencesNo definition available. + Details Name: cphi_RedeemptionAmountForOutstandingBalance Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe weighted average price per share. + ReferencesNo definition available. + Details Name: cphi_WeightedAveragePrice Namespace Prefix: cphi_ Data Type: dtr:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5) + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3)

+ Details Name: us-gaap_DebtInstrumentRepurchaseAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(8\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F](http://www.xbrl.org/2003/role/exampleRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6) + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for fees classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(g\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25) + Details Name: us-gaap_PaymentsForFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=cphi_ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=cphi_ChinaPharmaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Details) - USD (\$) 3 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Dec. 31, 2023 Leases [Abstract] Å Å Å Å Operating lease cost \$ 19,228 \$ 17,848 \$ 38,629 \$ 37,635 Å Operating lease payments 19,947 \$ 18,744 40,074 \$ 39,525 Å Operating lease right of use assets 77,259 Å 77,259 Å \$ 116,610 Operating liability \$ 78,628 Å \$ 78,628 Å \$ 117,637 Operating lease weighted average lease term 1 year Å 1 year Å Operating lease weighted average discount rate 3.55% Å 3.55% Å Å X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5) + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4) + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Leases (Details) - Schedule of Operating Lease Liabilities - USD (\$) Jun. 30, 2024 Dec. 31, 2023 Schedule of Operating Lease Liabilities [Abstract] Å Å 2025 \$ 80,148 Å Total undiscounted cash flows 80,148 Å Less: Imputed interest (1,520) Å Total 78,628 \$ 117,637 Less: Lease liabilities, current portion (78,628) (77,727) Lease liabilities, net of current portion \$ 39,910 X - ReferencesNo definition available. + Details Name: us-gaap_LeasesOperatingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1) + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Income Taxes (Details) - USD (\$) 6 Months Ended Dec. 31, 2017 Jun. 30, 2024 Dec. 31, 2023 Income Taxes [Line Items]

Enterprise income tax rate	25.00%	Operating loss carryforwards	\$ 22,600,000	Operating loss carryforwards limitations, descriptions	A through 2040, and \$5.2 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year
Valuation allowance on deferred tax assets	\$ 21,992,061		\$ 21,531,017	Maximum	[Member]
U.S. federal corporate income tax rate	35.00%	Minimum	[Member]	Income Taxes [Line Items]	U.S. federal corporate income tax rate
Domestic Tax Jurisdiction	[Member]	Income Taxes [Line Items]	Operating loss carryforwards	10,300,000	Operating loss carryforwards available for future taxable income
			5,100,000	Tax Year 2023	[Member]
Operating loss carryforwards	\$ 2,700,000	X - DefinitionDeferred Tax Assets Valuation Allowance.			

 + ReferencesNo definition available. + Details Name: cphi_DeferredTaxAssetValuationAllowance Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit). + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 231-Publisher FASB-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12A-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12A-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(h\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(h)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12A-Subparagraph \(b\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12A-Subparagraph (b)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12A-Subparagraph \(a\)\(5\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12A-Subparagraph (a)(5)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(h\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(h)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1) + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 15-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 15-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15) + Details Name: us-gaap_IncomeTaxExaminationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-3) + Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionA description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income. + ReferencesNo definition available. + Details Name: us-gaap_OperatingLossCarryforwardsLimitationsOnUse Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2) + Details Name: us-gaap_OperatingLossCarryforwardsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TaxPeriodAxis=us-gaap_TaxYear2023Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value - USD (\$) Jun. 30, 2024 Dec. 31, 2023 Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]

Total	\$ 15,435	\$ 65,915	Level 1	[Member]	Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]	Total	\$ 15,435	\$ 65,915	Level 3	[Member]	Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]	Total	Banker's Acceptance Notes	[Member]	Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]	Total	15,435	65,915	Banker's Acceptance Notes	[Member]	Level 1	[Member]	Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]	Total	Banker's Acceptance Notes	[Member]	Level 2	[Member]	Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]	Total	15,435	65,915	Banker's Acceptance Notes	[Member]	Level 3	[Member]	Schedule of Assets and Liabilities Recorded at Fair Value [Line Items]	Total	X - DefinitionA banker's acceptance, or BA, is a promised future payment, or time draft, which is accepted and guaranteed by a bank and drawn on a deposit at the bank. + ReferencesNo definition available. + Details Name: cphi_BankersAcceptances Namespace Prefix: cphi_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-30 Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-31 Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-32 + Details Name: us-gaap_FairValueOptionQuantitativeDisclosuresLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=cphi_BankersAcceptanceNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Stockholders' Equity (Details) - USD (\$) 6 Months Ended Jun. 17, 2024 May 21, 2024 May 20, 2024 Apr. 19, 2024 Apr. 03, 2024 Apr. 02, 2024 Feb. 21, 2024 Feb. 16, 2024 Feb. 05, 2024 Feb. 01, 2024 Jan. 16, 2024 Jan. 11, 2024 Jun. 30, 2024 Dec. 31, 2023 Dec. 17, 2023 Apr. 13, 2023 Dec. 27, 2022 Dec. 27, 2021 Nov. 19, 2021 Stockholders Equity [Line Items] <table><tr><td>Common stock, shares authorized</td><td>500,000,000</td><td>500,000,000</td><td>Common stock, par value (in Dollars per share)</td><td>\$ 0.001</td><td>\$ 0.001</td><td>Preferred stock, shares authorized</td><td>5,000,000</td><td>5,000,000</td><td>Preferred stock, par value (in Dollars per share)</td><td>\$ 0.001</td><td>\$ 0.001</td><td>After tax income, percentage</td><td>10.00%</td><td>Reserve account balances, percentage</td><td>50.00%</td><td>General and statutory capital reserves amount (in Dollars)</td><td>\$ 8,145,000</td><td>Common stock shares issued</td><td>17,162,771</td><td>10,625,788</td><td>Reverse stock split, description</td><td>1-for -5 reverse stock</td><td>Redemption amount (in Dollars)</td><td>\$ 150,000</td><td>\$ 150,000</td><td>\$ 150,000</td><td>\$ 150,000</td></tr></table>	Common stock, shares authorized	500,000,000	500,000,000	Common stock, par value (in Dollars per share)	\$ 0.001	\$ 0.001	Preferred stock, shares authorized	5,000,000	5,000,000	Preferred stock, par value (in Dollars per share)	\$ 0.001	\$ 0.001	After tax income, percentage	10.00%	Reserve account balances, percentage	50.00%	General and statutory capital reserves amount (in Dollars)	\$ 8,145,000	Common stock shares issued	17,162,771	10,625,788	Reverse stock split, description	1-for -5 reverse stock	Redemption amount (in Dollars)	\$ 150,000	\$ 150,000	\$ 150,000	\$ 150,000
Common stock, shares authorized	500,000,000	500,000,000	Common stock, par value (in Dollars per share)	\$ 0.001	\$ 0.001	Preferred stock, shares authorized	5,000,000	5,000,000	Preferred stock, par value (in Dollars per share)	\$ 0.001	\$ 0.001	After tax income, percentage	10.00%	Reserve account balances, percentage	50.00%	General and statutory capital reserves amount (in Dollars)	\$ 8,145,000	Common stock shares issued	17,162,771	10,625,788	Reverse stock split, description	1-for -5 reverse stock	Redemption amount (in Dollars)	\$ 150,000	\$ 150,000	\$ 150,000	\$ 150,000																																								

[illegible]

+ Details Name: us-gaap_DebtInstrumentRepurchaseAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EquityClassOfTreasuryStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap_PREFERREDStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1) + Details Name: us-gaap_PREFERREDStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 944 -SubTopic 505 -Section 50 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 944 -SubTopic 505 -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477908/944-505-50-1) + Details Name: us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph \(SAB Topic 4.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4) + Details Name: us-gaap_StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=cphi_ConvertibleNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=cphi_ChinaPharmasCommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=cphi_TwoThousandTenIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details) 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Customer Concentration Risk [Member] | Customer One [Member] | Accounts Receivable [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage 63.60% 53.40% Customer Concentration Risk [Member] | Customer Two [Member] | Accounts Receivable [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage 13.70% 11.50% Customer Concentration Risk [Member] | Customer Three [Member] | Accounts Receivable [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage Á 10.50% Supplier Concentration Risk [Member] | Accounts Payable [Member] | Suppliers One [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage 23.50% Á Supplier Concentration Risk [Member] | Accounts Payable [Member] | Suppliers Two [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage 23.40% Á Supplier Concentration Risk [Member] | Accounts Payable [Member] | Suppliers Three [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage 17.60% Á Supplier Concentration Risk [Member] | Raw Material Purchases [Member] | Suppliers One [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage Á 19.50% Supplier Concentration Risk [Member] | Raw Material Purchases [Member] | Suppliers Two [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage Á 18.00% Product Concentration Risk [Member] | Revenue Benchmark [Member] | Product One [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage 35.20% Á Product Concentration Risk [Member] | Revenue Benchmark [Member] | Product Two [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage 22.70% 19.80% Product Concentration Risk [Member] | Revenue Benchmark [Member] | Product Three [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage 10.20% 11.80% Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Product One [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage Á 22.40% Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Product Four [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage Á 10.90% Product Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member] | Product Five [Member] Á Á Commitments And Contingencies [Line Items] Á Á Concentration risk percentage Á 10.00% X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20> + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9](http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 450 -SubTopic 20 ->

Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=cphi_CustomerOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=cphi_CustomerTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=cphi_CustomerThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=cphi_SuppliersThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=cphi_RawMaterialPurchasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=cphi_ProductOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=cphi_ProductTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=cphi_ProductThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=cphi_ProductFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=cphi_ProductFiveMember Namespace Prefix: Data Type: na Balance Type: Period Type: XCELCEL 63 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial Report.xlsx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~? IUE!K9;O=05SP6.XYB1^QL4\$UFG2&98T1G^=D 4. #?# MT4Q0C?!)MHK@PI+27)#6SRFU4H(FLB!J4>")(<7K;YH] M5Z%82=J\$^!!&N^<<<9ST6S[!Z5&T?950-RCEU+5 9<8WS2J-2S%UGB5@M MG#P=\$Q+<E L&08:7)"82J3E^34@3 BNEVOZKR2.FJW"\$2M"/F(9 M-AIRM1!MG&IA&I!;\$L1>[\$2M!^6:PUDSY@R.S-D77.UI\$.\$9)>T^(^8LZ+ MDI&_H8X2IKMHG%8!V/>7L-)P>B"RV;I^N^Z&U3-L+((W1!)072N0)/J<_Z3(T M!Z:.60F)A%9JGZJ^_ZH^C(!?&Y^C[E>G+T^Y;&O^M^N@GL!_J':^K^<(+ M.7N?<^E[IGT/:'2MSAD6R4)RU3393>~\$ M\$YI^&V[14 5^E=? EK[DHN^Q;Y.FOH70^+ ,Y% GM,T+T.WF)&M^M^M-D&G^#>G!>KB.=D\$N785VWGV^1^<?4I^?&J]A&F, # M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_\$L%!.D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C\$7H<.>77% CT9+CVZ9EM6ZO*7<9;2).<I)FI- GJ^K>9;'151W/55OR ML+YJ;053L ^6:W(GPP13A8+&DACEI>F2J)+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X\$G.V#P(RN;LYJ7IE,6>F/MM# DL6XA9N^)-7>W5YNT2402(JP# 4A M^Y+W+C[^^3-G>_U_HL@6V\$5\$)DU1?^XG!/3-R0JA4)?.NVB8+A=OB5,V[&KXF M8\$O#>FZ==>? _VUI4/;074;SHYG@'K'.M4YA,LOZ1^P7^WBH 1JV^*NJ]j^26<.[1]8\$@F S6VZ3VW+,-?2K6J\$2^Q\$ M2P=^Y(8&XQJ!#1? CQ1BK:~QK<:,0QY@%CS#*%F.^'19H;.j6+K#F.'F!] MU4#E/!04#6CV#30,9FV;J/D3@H\W/[O#;#^"Q([A[8N_5!+ P04 M" "J@ Y9;G7Z3?4% #4'P & ^'AL+W=X^O"2=-9PXZJ!J8R3;\$B*)^DG^R;? M*);QAI12B<0^87K0V2FW?>=[O2V](RC.^ M9;&^L^<(BHDJ?BG57;@6C? BJ*PBYQG\$SWHD'<&I^G^UQB9Z,X3%08Q6P@DDBRB MX062A7QWT<*M_87(8+U1YD)W7+ZE; [9DZN_M0NBS;N'B!Q&+9N:P3I\$U\#MI,'Q|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|Q\$DF M\BJ1.2K% ^FQV3MY?_J7\$SP\$QP^+ "[F^G7>RT<=>F M8J_+4N0^G5<5!/G>%, _ 3<[T%OL? 56\$D3B;PIZJ+L+D5L^7//Q\$?7S1!JTK_ M#FJE7.S.YGUY&58;.8QB02%^*M.MF\$*P5>FJ^>NW.:5K@;I<=<"QKS3Q78 MCK\$9X93Y5_ L#J#R#BJWOKT(W^B /DGGQ+O0P4;/1*%TJO1B7GR]D^X7#F M^#". K5PG(X9J.-!:=Q [VHP^AJ?K&14-0B 5F]34P.)>>U|Q. <^< K>S^AU4AF^*7IE"=T9148?][A\$! M/JC9S.;=8I;+<GC7&OQGM1^E7LS5^X^FWCR@P2Y@N;,\$.ZLP[6=]UAK&K MXG@!Y^9802Y6SQKK>;QMUA]2\$OBN^*)E,;,%Z(T?Y[I(Q+\$-Q829 ?H=0-^* M\#K?PEZ696+>([XA=0/Z""7C.V8QZA#/#.ZH\$;76^-EJ((DQB)[X6F&B/\$ M8)PYXKAD,+F,TB=5.;<,"V+Z5I0I\$>@([G1^XQ0Q^@T?P#48.@_@0M5 M= +J^F&3[!D\$#5>JISD]@*5LXMTY7] 7P^DYRH4R B=C^JQF!<,@8/- /8Q MIQ/Q%DO1L2ZP\$MVPDXHE->[QMT0E]OJL9 M1(KHD5.7T+UUV&T(T6+K<=; 2F #9TR1R?DAGW23

(4FDC|P. Y2J)?%V MW^1A#X |W8" @ 02/= \$3@+ |A, ^U\$#6 Z+D6SAGJ "YW6L;O\$S9AA4C)+5%6 M&JGLQF7?H3?O+!UBUM4V3QL-[6'PA|(Z =H|LXE. YW8T;"O! ^!\$54Y. ?4W "DWYOZ?87E4J]?#D:7K\$GDML!>[;8J;\$#8)15P/N5E&9W ML <;'1 _!5!+ P04 " ^J| @ Y9R8H&7CH) #V2& 'AL+W=O:D6"%+X142QJ)*^J.Y"P+[R%=Q7EUUVHK M1&W|OO]N 6R6F %>JG>%GN1R| <^~^4Nj>7;|F%9[4J1;-I&NVQ) M;=M=[I(T7)Q>M| [-6-Y>%XBZQXNEF0Q3 ^ ^j0^.;OF M%|O;ZWWR.(Y\$ 7G L93OEB>53;H3>946N56*^YO\$S^1=S)Vf06OQ9R|>|K/7 M5G,17XKB; /ZP^9F83<>B4RLZT8BD3|>Q4ID6;.D 2BK\$UV<^FP;GK ^1SUN M+UY>S>D\$JLB^V^Zj;?R|= (X;\$#;2@-8'J-* >B,-6-> J0W&7.)= ZXT8,6: M\$<KX\$R|J|K<X+>Q/P;K\$728U;GM=5D1665S+<+6:VGVZVM8RP&G>C*R|N1I M366[^G95Y|LY3L3&Dj ^j(DLW22W?W-7RAQQ =645|)=L?ZZ+;*.*L?7OF4 M>#j9T5 ^M/YFO?Z<X)=*MNL:ZLSW>A?K?;ZZ7M72MZ6"Y|MQX?W2#CKJQ MVIEQUG8\$M%Z96 ^|D1|(<9IDUL\$%K03|L#E&A;5#< M1^NT|D2BZ2* UUM1 DM>H+SSM|TX2 2BL# FZV E -S;K _E%HU[24"3]JEG9ZR M3EL=|J+S/LF2?"VL|);7N'YK;?C16U*H<O=E=Q6|9FG'F|) # SKY>Y?G0C MZ@;?4=1|9&H;XM155*9&2|IM R OHECL=LUQD:QKHAENY?9SX.8L1.,6*3801: MCJ|;[:5**ZLVd?|U5'25>Q N4DIE|;Q4=J4 ^68N;A1PWE2@?Q>+VAU?#M7 ^" MQC2F6(0I%B.)#5+ (3RGDQA3**>U13EER9FBGL=^*6L@|)XEOR)1-675CKXZ13 MC4PZ|[DVL]Q &7PKKF7;"P)N*V:AT4|X"A:4&B2=6'?;=6S5#[YEG%.|':QX MG|J64.P= 2X*B&|KD|3*Z, NM0@|J|=7QF0?>^4 <8'5E" LRP(YE^5@68|) '[E]HAU UE M|>3Z'O>4*X|T2T|S(V> ^IX1(-^2NK-LXAV,4G& (4/*=ZNAB00?/?E=6F8S MSR5G2V0W1\$9TQX \$G M.A.; 'W^I3#5(E2U&\$MMF-N>V8D9VN>4OL|@4W|G'4LH|K6P943,|L&ZC*\$ MU&;|HO*D90O ^PXV=6GI\$8+*#02RBBP)8 =QQ;W?6|;#.=2P Y=!KD M3ZF2.ZD+<\$%U _|^!|"|R#"X TQ&X "R<-\$'/C|>|(|%RZHCH8P7)C|G|LH MH^1Q|Y&HQEMHPDSU1T\$?;Z;16=|VVK)|50;|012.|2GU"540A=4 #FQ&N MCGH(J;E#;8>KHUZW|+C#7411GV/U/192'TY;CI2MW'S?V@!213HZI%J&HQ MEMHPE3U34[1GV6!& _;F2;?9VSA")Q9#GAA,\$M =T:@9T M1+Z@ +/+~B~MI:@.CNJ6H2J|F#1#9|;,SLU, N'JC|T\$Z3,|["3#7'D>9WD M#VF3Z2J1%V!.=6QG=EJ7;.B.OT262QIAJ'9WSDWUC.\$#&D _ ?&;Z|>WZD9 MW^=EX.(=IA,|LX?;#%U"4!\$>52U"58NQU(;Y|1>HB&|66D.*6(A/ 6.G <M/U!WDK%ZC"?T.P#|VB,|^VX(|U:>D1@LH1!+*&(FE/B>J# ^LMVP|3T"|F M(SYGC|'IZ C/.\$ ^4<|@,H#A/3OOCQ^\$@.45EYVW+E4D|JP"82IIA-E=X=NX^6I 5F8'9A ^1H5X5+482VVH8K.S|'@0 MSZ9|I)L,18#E&,@IB,0#U@:(9|U\$; ^4#12SR1|O=F#VL\$%>%2U&\$MMF,H> MXIDMUF=40V;EN6=Y4-5+5+4(52UFP/- R@)|NCYVR9?U6)OVK%(9-X;7">? MM#SB407.T|<\$F.<&MD?4#1? |HK+~8PSIJW5T#X#|WF@:C3\$@*7';=19C55/MULQ,UA/VV^&X :39Q,WSU+TJLP.SAS2F6H2J%F.1#5/9(S|UO\$R.'W ^7*M1 M1 4X?;1\$18Z8CY6HT!ESN\$35+?,1T14U)|FJ&H1|EJ, MI3;|Y%X/S-P,S" _JL)Y^ IPRKMX(7.? *YO,Y:G49FGV=|X\$J)*\$8|PU'.CA M/1\$S,Q\$C;KAS'45E#IQ ^|B>V:6Y-Q6J6H2J.F1#9;|(SQ'.|QN5|JQZX0E M%+HF#AG/F*|G*#U64|IP/0F9|+ M=L.TG'U?|K3MR3F6.ZD+&8C4 &8#D&5#&;&0 ED;|X@U.|VGS\$; ^!<@. M?L.0879@|JL^RLVH:C&6VC&5R|-O&F^#4@6P ^I7- S<2_E|;>>[*T]? LG. M4U=[-LOA?E2U'6Q:U|N1;|(196,@ WY?R#j@>|)|S|SIJXYN PJ02P,\$% M @JH .68*6C163|P TA|!@ !X;|JW;W)K|B% ^&XZ>(6? FF1E>|CUO=EPKM'CMJR;RJE&Z I|F R#>=^R MYH.L>06_K*?;.@T?U?V|15GA5VT+>|Y'=??ZJ6"3 -2R&VO&|&\$K)#B MZ|O9%3Z _H8E98"7^+?A# <0>+5-64GXW'SX7E|/ (.ES|5P>|ESV|X611.MH..O@|J)|T|RSV|C|L 9/UG@P9L4;?B/+_XA";YACZ0P5?;UVI?X| _|.P#9Y M1E|NR|; ^1P^M!;+4,+4YKM-P _>@. "K:C.5 9XV(BC|;# 'O8 <#>I&A@G1B 3TL MH.;0%|DU9Z3;|&AY -21AJTF3=V; ^QJL\$94YACOM()?:S3BQM9%7 HO\$P M KI&E#B&#W<:7N"*= (D&MVP9H, ^P8DWZ-VWBNT* 3+OT1GZ=O<1O?O; ^XNY M!BA&X3P _/;Z?2R9>&R, I'5WC3H%AY?G*Z?@PF=>39CF0B5?B/7?4!T> W M1 (2.O#SY; /H+CH/773: D;?3#0B|'0A|VA=? (65FLE< M1K8K|02Y)G|XH50+ P(N9COCPOP").(@SH|@Z@1/P\$4=N,@+|B, 'BW|VDQ2 #68AM|=+BO 8+&%)6770\$|(<#)#@ -@A1Y,P,2|IPAMW>+& OWFM60\$Y;~?C0? M;Q.MZ)WB>ZX:5IKP9"4X&|JMRCB|MHT+N5G|J)*R%#YG(\$>P,SW@-\$- [QT]JQ MT%F4I9G;EJ2S)?;|KG:0UZI|Z@D|*,@C8,#:13 9/30\$.*1X '\$L1D(234|, M.XB|/WHWK+KG#1+@#\$W#(0D:'RD%6XER.G33MPS=-U)V8G|6F9JY3^A2BA6| M?#2Y^\$41(-S;>%A| _P\$9Y@_ M7=|A=Y9D. C)|\$#2 R2O<8'>9DS=V(E8PPIP5F0#;BZ|E-XW0B, ^*;;&7 MQA9 M6<|8R&|J%9"K'50QAVSIWF7J !|A@F'R|V'DR;LJ1">0|PR| _139^:LM M\$=IB;|JCP|'0CH<|J5#|'R, TBR;B|J>+&?;9>*UTS|8\$O|'<6|!\$P EUB M#|TTL#8DR3VLZ0I.6SAJE;# MD;LJ11,DFFL3T|P25ZR?2WKO)6VTSWH:1= [-6VQW*E| SV9,3|J|;VJTD|V MHOE?U&;?L2Y|ZDCE-,@C8>G-Y: +@S">RN<|J76(7W9^J|V7.MY| WXOH+~! MJR?'23J-<."BTXBQG,<(Tl,G"5|E? Y\$|Q2WPIU|50+G7N8K>),2N7&C27-MZ36|GHTY?#9I< ^PR&7!1 EP80| M/=F3S,N3=Z:QM*150: #42#Y=JON9.5F26|V|6J6?"-M|I/-OE:@_D;|FFW; M 3-P\$E4.'002|&=UOS*7D1 ^AW'F Z_HU."^+*#^LF!H<M\$3F|)4%("1ZZ MIT.,9G\$Z6VTIWM*7NZ=7V25^&^! 6JB|L6%"? 56J? ^>1; ^1MM..9K^"ZNM'J|^=A1C #0KDL\$6T2J|H3>H#QO?W7Z2PK'|MC&B|UK9|>=^Z.HX)|\$VC* MAR<|@L|AJ9|XJC|4H/Z2XU^CEH?VJ;? LV-<31":4#KL.QQR-,JA/#\$#H7W5 M0?U5QXVLS"@;|\$>M3+|J#B6|33'#/(@MVR|&BTS+|V|3M&|D\$4P. 0@+%@ M&|S(G1K0EQ|47W|;I|=.,W;? =Q?2508X=>^~SV -Z">5>370; <0>X34|U|J.1K4|E|2! 57N|W'|0LK9W|NIM=S.MQO.'JZ, /R^EN^VAP F M= TU_N _4L\$#!|0 (*#EGZ70|)4F 8 >@PO=VJR;W-H M965T&ULM5|;<INX?|7GK|XMQU|1|SEV4Y-Y-<9Q;3MQO; M#|7-3M|@ ^A#8(8D("7 "TK/WU ROOJU|. #UVZ4J5T0U,IC3<+8TOI|=4N#UUEEE MS/7>FU?|J-^>65J7^1:75OAZK*4=O-6%6;|>F^|USSXE'|7GAXR-B2!4J|41|XL ^M.E5%083 QF^1YEY|&WL2FZHG|LD&4NG3HUQ9<|ZO7 M>S MB4PM9%WX3V;|045Y3HA>;@K' XMU6/M|M?2VGE3QLW@H,QU ^"OOHAXZ M&WYZ;,,D;|@PW^\$@YO%=|/+~V06PM|J4*|/+~KO|G.Y|J|,O,7;|O|FRN| ME#K 7085Y4S,|J7.5%WDJ|M1?3-#6U|JKE>BFM3Y&FNW*M#CU- |V\$;3W@;3|D)3M|PG^K=9<#<3#B,EH0M ^O7G|V7|J|JYO+&S MQ>5|<7WUZ|7IQ=EL% |JGW|Y|J,E,C,5?; AI,AZ _%_M@>*!LB^EKZ29B&N M*F7YN=N2UWJ#P/VMSJW*Q'@T^@LM|]"NL7VMEW2J01*%|U54SN@)\$#) *C9B< MD&^|V|Y|Y3VRI+Y0'0X M#*%|H1 6NI6T:F6*#&|/%ZBDV|5%7L%/6X239|U. M1B^ G% ^|=^BP \$V3U2FX)OVM:FP5-40"V=1H M'1,JTZ*6VES!</,5JH&O*3> &R">LOXS_NQG(965 M1 D1Z25%.'LPK+@,C\$6ISE3U"QEB*92?L6|H&0ZS?>2"ILS(E;R5HFY4KH-3#;UJ** ?1 E6H M^<IDM,'BL ^".&2RH|/8 MR9? |%5Q|C.;|KB99DC.,4\$YF?5D/H@<O<|72^?2(F8T;? MV7J9|D|,1+&Z|7W|>":(Q|U|PX:C^HD@H8E2|I5L%8^) H4 M^RGM _U?H @I M"N904DV5UF5=.#|HA9 >&7A ^|Y0%\$S^USC\$MLJ;UM10!12|GC;N|JNU0IE GM M2^D20:\$5;|M8@|Z@Z1 M2"|^JH'H^*HJD2\$'H+PKV\$0*<3@C? JH07L7A.=;'2B0?=\$\$H(DE<M:#H5-8C+9HF/C|PZ8G,-468LD|G<: IL0\$E=&B8V2|)6%5T\$K&1G?KP|S M^|8L&H A/*N"G0A"<^=JY 7QV118(|&3;3UNFC : M&0IYEX1|AAQF*| #SCZ"Y"TT4:5Q68D&DVK W262|RR@9|U+9G9Y|&EVF;917 MRK|JG\$S|UJZR&EL_Z@-7T|T^&KHI<, <%HM@E6C#|JZ@JYU|<X.EI%| M.+^H=7: 7(EU@U9W\$&.M^C 2D)|&U3+4,&|)QC@2%PKVTTM?1)ESB?B54 WI \$NB=P|%=6U=32J.2|AKPF28|<[G.&L3-K);D!H;D&4!8O,M="C"+#<|-G>+1"X1*C;FC!@7? _=;LTRVOISU> M^JG|J1E-IAM:PSA|=NMHKDC,BJ0##&#;5C8|*-.22C-C(95+XW)QMPP&Q7783 M M838#.(+1+ |6L|9F4&&U\$&|'JW|]"9X3W6QWCM&R5XZD|N5L\$;Y31R,1|QJ21HT@B=|F^*VA5'A;T+>;Z;-U#EXQ;I#E%VQS< M#L4GH'F|9.9-^DW,*M G+ (D6;2KDM|Q->|(UE5E-?V?D2 -I#&?A&A/.8NR M&Z|J|VRKYI#2*HWD^?+ 9G;|B9Z8L=E>1;P5GY-**1X=G.CV0%GGGTCH|QF MG8C@((|JU XFS76K,\$ZD38MO"?%\$|59<# N^+M|J5BAH*3;M6M?T|;7PO); M#M' RPN F52Y,C<6X53 ^>@8HR<2DM8,9|J#FFL MW539,@X- =CA\$JSW|;9^3Q+;.=O.H^?XP+;FO@J!N|G@VQ+;@X)** '|J1TB M9E?#6(L-/5AUXJV0UCN _J@45DCQ0Z (P1&0P198COB&H'0V0':.+") MH5%O.D<@Q), '-ZYY9%\$#TY|ZTQ|NL9I(ZO1M5RSA "9|D6N,Z7F16E3EW5- M1G:=(RX)R:4Q@1=Z8T.B.|15)Q _FF|A|+BV>S;A!+M39:7<, (9NA9^K=JAR MJT*&U4CKCD|9BEF/6-(AYE:F+C^B0=-,<3KW;-|8& _MS)C;C/4= Y.2P&W(M.%91Z|KWO.0^|6E@_ A'/RF2KHC>|/3L|ZWY.V&8<[.?:& <(T'>+Y.O; MU%6WK,(>R|6@9>S|GEH>HRP=NO6, 04)2JMP^O74R /V6V^550 2A#|N2>C/X_.U&*^XBW0A+|/C4|CG>QB@/(L30(1R3?V-J;? 0D11|FTT|U M2S;<0^GT^M.L;+!|@2@.K8|?H M=|15P8-1 TC2T@?21>@ |ZC|XX^41493VU2GD|H=(1 8|;-9# ^.1G|J8 M4E-|L|SP? N)5U**JR="U)?\$OF?Z417-?7NH*V>39B?|F;Q)VK\$%X2|Y7,QZ(3D++^Z?CT45YJ|=2%08A\$<.N?UEF|L."FC M5 4"P5M\$FP=6DS4+SZOBDVXBV.5 M|,B25 -O>4K+(HB"MY P|F24>71(U=Y4 MF0: V|:7B*#FV+Y)H@ WZ0W%|5T|J2F-/8J\$<\$<> 2"6S1S<21%G'!VHTD(ML" _EB@4=;<:2A X? MQ4)|HL1@|DWGMPRP|E(3647.GJH=LXX3Z,<2GDY=24M M.#(ZC9;9EB&?HQYG9N, 8M@E1&P6W/T4DH;JHLC ?_ECO-OL)%:5G6FB (M94R|J706G2=9#')!|=JC,S3|NI=MTV9|Y\$S6DX:5(|T,P.#PQK);)J0 M#07B ^>:U4>7PZ:H50P|<(-2;?2H,K,DB&VU@H\$@>|J5.GQ+V+C\$<-|X4..' ^)|N8 4\$L#!|0 (*J M#EFWWJ0)2P0 !D*8 >@PO=VJR;W-H965T&ULE59; M;|I|('G5QRY595(WN K8 I|(-7:KMHT2FC|L-J'P3|&WMHS=&8(R? |Z/3& M0U|U'PW.YWOG.=&6V\$ *X*1 T|=<75V'FT7@V|79466Y-;U\$;:(2<7LF.; MIG+952N)+~"==4/* 7K5G)G(? ZR^I&TJS;HF1EC5R5|H/\$?Q<^<L9;|J/ +W*B#M,1A+&|Y;V/=CQ#|D;L_-4&@='G'J^P|@POT?BQQ7|E4;P<+Q#?V|J|M)UL6 M3.&5|+Z5F2|&SL"!#'.VKO2MV|R)6WMB@Y>*2ME V#1GPHYX\$Z5II46^%B4%=M|N;+^K9^!.8>,|(!N!P|)N%#F6|YAFDY\$4Y#F- *\$9@3752A.YDIN@W&E) MNR7)Z87\$'HN!%X0G< +6U#BQ?^|JGP|'5".4GY<|Q MJQO0Z#BH|9FA6K\$4QPX5A4)YC| [DS2N_Y|TJ03EJ*4>GT">75U?>OUS| ^!V M=C7|V5R^G%&E&?S8SQ|(AWG>?UY/H, WKP:|+!| _%I3|JWGY('H&74D'E Mj32("2D(N*JKSDRV&'HHN) (IEZ@A-I.W.R.4J)IY49Y9AE24OR*#|I) MSW.3H J^Y :Y|Y|T/F|2S|U+7S&4Z-*0B;6"YVOJ\$W,&0GW09|K|?MPWLP& M9A;|^?;K2WP&H(X<@>Q1Z/8B|PH&L W-?#DI? (15 1O6^T|/U|!(5*EB1 M590V:T95*TN-?X@|5QVF8\$=-|NB;%HPOZ2"YYP7F%S 7UH7XH)|K&C+RZEI2 M#Y#2+>QD>:F@H Y\$C\$B46 G.-BH4V/M2K"W'Z4F0NT3LPB_UBF-5@|+;RSY&T MD|J)L+2FL=G7:.(?&> ;: OF33SW=4G5H>+@?+I=?7*C|K1|Y#6:GW8-P51F M4W6(|,K|/SH^|J*|K>"D3>+B7|)1N-G|MRIICAXEL<|@EMFJ|EZI^ALN MNXB7C3M.;NH)MTX;M@Q. ZD(B6DVJ?("Z;-9HFN1,D8 6|8V|:=G>;;STT MMU" 1A6VW>\$?;BQ+J3=8% ^DL "7->:J\$Z|X+&#DWG,E)-S9PIF+|<> (F20A^ MSTWBF'X)'02K?;#A,JX3T _=L990%*137TCI7%6MN ^Q?NDDQKDIYGO<-D|#TAT\$8\$7?#>@G- MLTVCYPW<8! 28FLT>>HG<|<|A@SS@|@-XOB9U6.70?@|NJY1+NVCA|);&Y MN=O5|J MUSV5SW^~^H^D3DQ0.117F).I=J&,9/0.29;K.SEOQ(:GA)V6-#; M#W;4Y0/NY\$ HW,0K:U^#D?U!+ P04 " ^J@ Y9\$Wf9(9@=" ^I0 &0 M ^AL+W=OOLD|4 M|^5Z53\$ZM0JEZ|@*R*|B|H+7R3.FHN**T5T?6 DG>@|KJ25UWZ2\$S,BN= MM&N/(IWPK2HIPT59^X4EW13*+*CII"8;?\$+UO7X4>N;T M+&FMD\$G*0A<3ZTK;SP+37Z;|(-B(P|B,|6L.'UDT4^M5PC"\$O,E&\$@>GC# M:RQ+0Z1E _YQ6OV1|G@8|JEOV|J|U+2LB|9J7+S17Q=1**AQ3;E60+F*^|J MBQO?QDO9?J|PAUG|J P9SGF' &.%M*K|? =J9OY)PF|)=@&!:X/O^N\$O|O+FCY@O?J M!S^!O5E()0M^>2HTXPf|OAGC&5;IQ; ^NI+&|JH|>=GWM'J*\$R|J%6&|JC3 MQ?V|^?WSPW(Q? SHF|23XN+3|A^=PD|!#A+VFX-I=4F|?@RH0 MUKS4|J5L,Q|H5F%BAO.L|A|A@."S|Z8OICG;8\$D:20|5"DI**9|MC4+;|0CZ M2L*1|70!X\$7;2B#60 ,180DM@,W@= +|&@4#VXIH_K>YK#A#<41#;413J M*!R;|B-|!|&PO=VJR;W-H965T JYY^E6 M|F^Z|C^#DH1&MGOFU,90);*3+&A|F3^460RRD|I=|J=(;|.QR3HT8140 MCAK&6W|^=7M+~9_*S@C>PE(IW34-4X_G.(1VYH?^T|8-7)? &;HSFTPU;PQ

_P.X|8XM72J'|=+|JGV|M@E+&#MM9+~SQG7#VWYD#|L|[#GDP01_Z,YWEI1OAB%7SGZF?E2H;|/*%R%*PU MA+4567S0^ 83;Z8C@R&LX:C^H^0VL O>N)W M^AT@;+5K3TD<4!|(47\$|&Q.&SN| ^/~PIOR|Z&C|C)863|>B9Z MPTJ8?@|~|A^|.=OWX1|X|(V3@G1Q|GR|OKI>+F|JL_D??V=4M.;OZ2!; M??V|O%GQSNZOIV1+RJT?>A>|>=>K%2|A#R3.4QK"8XY59+ NY6& M'1)G."I" &|?2)G29C.|@#|P#K3Q?|*P*TGf^U*~NF\$|SF10!%\$5GK@S|A|E|H3RC|G/ MN IH7^0T">/*YIH2EJLT2=DC%0S&F<%SO% 04"3.(P)WHO!~K2;#HG'E8^ M8B^U+4_O|>VP50PMY#W*8?4";7ACB7J8_U4GB,

ZJ9 49%#343CL=-43[|QN MD0N^@N\$"/03^I"<23#89,&SD-'S=E+LEX3CP38,7BGWXM_ 970W*C\$*4I\$; MWTAD^JDU(I)JQ%)JJEQT%]]|VB"GZ1)0 L4"NPT|T3 M H T?:4%6VG|);+JH%1#*4WX#?Z-Z\$M((('T&1A,R'=,L" 9TS1]V MV-XI [%>0IX=JVVBO'S6@UJ|KVC09M:903Z6;UOCG|)0UP.|K*&ULO5EI;|PX\$OVN7T'T9 <)&H&WW;3N' >>8B1>QQYAD=C|L|@-.8K>(& M2**&I-SN^? 7|JBAUJR|GBJE=P(<.LEC7>U6D7J'_.>HRI;QX+/-+2O=>EEWENLDJF*G(ST:#P>RLD+KL7;WF9 ?VZK6I M?:Y+=6^%JXM'VO5;E9O5FJZPUS[X52]S3P_ KEY7_|.[KY].Z'Q'/#06J2U'5'UGK_U:P^ MJL:>*75:VM6PM)H2*+ -I5G0SE=4E ^>XNW&O\AU4W19;G4|UR);:>4=Z /M;32R|.D\$%SVBI8=##\$3MZ;TF1_?RE2EN //H;Y&U&KTJ01DP+ 5I=,I|\$ M8C0839Z0-]J8.&9YX^&IU4? SS>NZ\14;|ZYBY0=KDN#1"R4M7R42]Z0\$&3MD' MU;OZ\8?A;/#]"5TG&UTG3TF NGK[?/[YV];@DR*.*WCW MRY6\$6HE"13F0>\$1_4N71" M5I4U'RH5?%)PF=8I;_ US[N|O(^.^4J'7'N^&+FN9T|*6;|&+^'OM<7TYZ3; M;/#J|K2FULN|Z:94'^CT_ KYZ(1,6%.)=ILIE6HLP*KH-VH@O*L'DYO6E7Q7 M*Z'.BJ:*=Z8?BT| ^[>];V4&Q3J30UA9ND5W>>#19^*+-.3KF,AR 34G&AO MSB=>U1_ 8S\$WN)56B50[8-K|VCG185 <+7;L\$RKN'U08E'&C3'TWN')-E^B#+ M1#GA#?EO+T|J|,76Y9'V M\$+_Q?20TD86Q70_ 1*H-UHE3Z&-F|IBBG3|S#[_'.BR-\$Y;J)OJ|YTBV/E: MZ:11N@5V2M%?._ IAM=,+>IY\$HB|U&*G'DA>"TJ_?^1"C|[:RF2C(7IDEUT9-D'>18Y36V)"8 M.H.S=I25+;5D()|;"5+>+Y+&*BL(KWZN8G2]P2<#G(0-H#>=8+=M(RS|!9*!|Y1@1UE1XX%|.CN1"MH'*SX6 27XY&O:.SZ30>SH8;7R&[&QR M1)'S'D6>XB@>SRW S'%S&#*85L4VR4P*BPR1K TL'ZC+);.YK8;R&2F5A;.TF M4Y0W3;1.|UJKX8S; *6N3 "F=A1HK UKQO@>!*? PS_//O%LU%&)&DF82>+F,F>KPWYHLYPX6"YBBFE? M[PL/:3_O%E NC|J|]'MHJ|D;|.16/T4CUJY H%9AL-VG+W?EOD?5L\$A5P@J3@+ MVL3,95UBQ^;:6? GQD(O.-.F|'H)&(&ZQ MT?P*|YA,?HO8W'Z+2R*8UB,CF.Q9C#> M@9@8C*+!N/H/P:C.Y0FVDH'E(7J5; Y'JH5\$OBU*~N 9M@+,VRVOMW"BCR3 M\$&KHAD;A;Y6AD|)|+@|C[&BZ'/B@6F4K1W)FB|>,H7+&BI@?R'&)'G Z9;*'S M/Y\$'HW*-'!U,J0(6RUWH =8,N.4N|J' +C2J2Z)CO'B6&KK#&#;+>+|HJ>UL\$%7*);.N[8%L U&+NX31YD H M?7|HHC^3,OVIXDB#EB0\$>15R4?;W6NW5^\$0\$K)E.U4L%#<#@'IT\$NIH<&B# M9;#|AO*MF8\$+_ .PKZ|UNNFU\$N MLR2'0 C@H,)<^W3Q0VXDUX*RH:9=MAXJ&^E&2E&_ Q_2L)&72B6,3.A43&E.T MY=K? P|L/3>^@G7,3"18J^9@DI!1WFJW)ELI#.(%CWL'F=V9?(VBS0?2)J|@3T M>=>Z3^U%^'TTSW5A!84!|V/3D(+.V4A)AU34-N.&CT7?D'-I&+,MPJ|M7H3U+= M=M'DNPITES|"46D2D=C'G4L=1(A\$%S\$Z;FM'1K?B<^1Q7GL|J06G#U|J&|S>#P=IYW^A<^?&G8:QN?8BUP, MQW0UFL63R /H4# :!X BXL11LVFN!M=1)#B|C|;+Z#1|J-E* M+1SWO1|A&|JFP AB?Y>B.>3^.)R\$;|F_ \$BNN/0-&G5;%I)[_ 'E.IX-SW\$] MCD=8:#0>B6,7&\$SW*VT2S11 M(E<+3|WTSZ>J4.O;+V|J_ IPT-QX|&%JF2H():#>+XSQ|0TML/F^>/5O4\$L# M!|0 (*_J #EED*OY|K@(_P% 9 >@PO=VJR;W-H965TJ^>F|G^O_ *@@H89QD8+HJ|P 55EB5#&GRVGUUI|@;OV" M' MESOFLFO+>F3U@^>FG/A#<10L'5E;N7F'K;Y#<'Q?BOMOF33QM+&J(E;+UEO MP:B@YJ)=V=V'78 P_ =-T'J/-=7N147C+&TK&2&Z)L- +)9PZ7JT'B."UN4 M.Z/0RQ>GTAM3@B(+JLR6%>AQ8)#3>H|LBY^U>/H./B'74IA2D[G((7^#U!+ M)XB^")K1@X2?U^*%Q*%|;\$C[!_CB+L'8|<7_E2#Y- 5UJH_!?'^+TOUY;JOY *_M|J=(-RR#B8<-H\$%)@I<>'T5)>'Y +:13VC_IGM(<7UOR6+Z^M\$PZ+U+PZJWZ5H929CXPV<1VM2G0^HG9Y3LJV6PTV\$UJ)6;(_% MUL*TS=:=J- JVG;H0_!VSETS#|)"DPH*A(8GIP_/J'9M|LC&J]>O2VFP^YU9 MXK@%690/07TAI7C;V@FZ IW|4\$|L#|!0 (*_J #EDDR_L#"00 !() 9 M >@PO=VJR;W- H965T4I29=)VCW(3\$O,V?.F1F2 MFNRE^J(+1 //52GTU"N,J2^"0<=<%5DSW98V"=C925Y+4+2[XMC%T(9I...?;\$1 MS2_U@Z@Z#P'DO\$*AN12@<#%/UYM%&(K7VSN!7CGO)8@Q6R5K\$+W;R'9JZH26\$ M)6;(&C#Z><(K+&L+1#3^_F)Z74CK^'+&Z*J3?V(,(<- MVY5F*? <X5?P.)JELM3N^*P.VX2_LYTVLCHZ\$X."B^?/1_S|A;+|A\$|]= M8L>|'^>187C/#9A,EJZ"L:~9@9J|O(D<%|8HCT;1+<B<_ UMBROSFL^4.>| (.PK560?;#6#5;|!M80;J4PA88;D6^VC|@7AVYN"6WB-|'_ DG M^I'\$/L1AG+Z#EW1B\$X>7^&Q^|=|K8VBV9^G=#>PZ6E8>VXN=,TRG'IT,#2J M) 1F'S|S\$P_#R'=|J1S|JWVVO/DI7|U|A:O7| N|Q%-/W ML>|N5SN-SID!^4,Z23FP_(F) M##5LE*QZW&BX*AA7-2I-Y^TS|I_.*E8"J^1.T*|<%<9Y\$=I|Z(J& V B M=|,D|9/TMF|; M#816V^U|V)=,=L%MUN\$%\$0"JN8'J_ 74E)O)Z5?C;TQX.X;ZA?YX.7I?T MV)6)/PK'QW|JAX-1%TWSY_12Z]^~8IN"E#! |Y_3|_ 5O"ZHS0L76;G+7>^T M9^">+5%;N+;E[?XWM3R%ICR3=8|.8#R(\$X\$; IDG"-J|L/Q-F;+WCQ3E6H MMXUUD20KH? FR>I6NP= _WKQS_Y@W7PNW3&TYW=LE;L@U|(|&JCF|6XF1M;N MU5M+OV^H&Q;TT8+*#M#^1DK33FR [C-H]C=02P,\$% @ JH .62D&ULK5=M;JLV\$;ZN M7T&X.;|GJT'7RT|ZQ\$#&C)EB&M@F2K,[P_|MT1872E1)*H|WZW='RK+D.FXW M|((LM4;SCCS7F9>,3H4YZS07|9\$L<5Y|UUP>C""^>7;9|Y6 MNO5;)*YE|X|JWP\$K1+1#^J@V?99DP(= 0POM0^>|V2:-A^WGB LK%# M+;J4V8*WWA|JO|/><8^D;.\$8K\$>|DZF=6QQ.COT0?;7_)RLT|JSV25-K(O#8& M!#DOW#|J|KO|O,CCV7S:(X/OXG8+693Q);'3.R571.%L|(8/- E1K#>|X@46Y M-PJ^_|VK8.R_/8|TU"='?(<^7#|Z?*>W%R1V=WE M^&N'?.._AT|W)CLF;5|=A\$+PE_ |(34^>LX3E@J7P.OE+GF@ H1^+RV7BBV1883FLBH,SKC|>\$\$F 9?T.+1EE'F>57PA)&JZP%Y: 6@(#Q#H1B3|J)HD8'3PLX M\$PAWHUWX?JX+WSOR!_X\$RU^V4IDS=1P@.FJ8G- 5@...<1<+1'HTYZOXN|4S0 MRYB'IE,W?CGS|D42EP"15|HES0.1?T LETU+;N|6<;9@EP^LZ3""87< M+|8P|DOW#N<*>T|!"4162DBDM"RJ@>Y; #0J0("C|OB%M_6WSV%;Q6KR4) K!D<)|@PSF*3R M?@@"|W)MT?Z7UO2V<%<93|(-I^#K%|!+9HQ9N&>EZ6K&2WS');VNZ&)Z KO8 M" (:CW;TM='+C|>T.F_@ "O0H57I+%;5|;1+%MD%L_|2@JF|X\$6JCA<=|6|6VA M7JVS5;45+*1A&PG9M8WWW.X4T|+UIS7 !L82|?#BZ4+I5,YR\$<^G:4W8G P M6Z,=X>P*1;NWL*K1(|I?QVWX HFFA433TW_U|W?H*+I7W|VT_#F#9,M: M*+BB<^/A*P(9^|O%72P/;=:(|)I#2@|/:Q2L|G!;"LYH+##-2_UYFN7,ZPN M^61-@='7&,<<W%+&82JFME|B#>#E'10:TA81PCDH11(|&|_@BA@|PJC11N MA=9B\$?7 DD)UBNDUOW)G6TBS^~1B@|[LKJK9+H49IY0|KC5IA,HTM4"*JU)6Y MGN39SF1?*E|:UL.I.80"HVK|;1TG_Y>.>U_K^>");NAV7DQ,TY4@_|J253K M9=B?@&|J;WG>|J,P>A+\$|7\$|J9V4W0**C9'|LVN9U|V@;_Y L87|T|ZYTJ?>|J|@Q_V=Y M\$TIKT(?YLJ\$^#&|&UY\$?J8-XY|WH?C_?A_U|!"%76_ /5#A|GCK<6? W8>M+M. ME3.UM#=#9'-L_YZU8PVE|J|DZVG>YNMA^I6O("ZLX68.H|)G/&#';=;"|_MEO:&-I<[GOV,8,+E,X,XO)AH(+-%?VZ3J02P,\$% @ JH 61!S MJE(X"@ EB(|D IX;|W;W)K&ULU5G|JLX M#OVN7T%6XTD\$+!T|C);%)II@|&C:SBP6B_U 6XS-&_U*4G&A|OWI|J2E9 M3IPTW=T|V@|M(HF|KW|ON9>*CM>5^E.OA##LILA+?3)8&5_ /SS4BY4HN|Y6 MM2CQY*12|3>X5,M#72O|,[NIR ^3*)H<%ER6@]- C>^J2G1Y7C3*QJ IXDUV,H(C()&+A2\$)^#^NQ;G(0|)%J902|Y|N.B^<^'FT MYG#A);UTDI |J)\$W8NZHT*|TNRDQDN L/855G6M*;CJY4_?O33ED:12R|S|& M#|A+_U=3'R |JE79| FVBCBDQ_V>=>V\$CO8+I9IYKFN^\$"<#%(46ZE8,3G_ ^ M*9Y\$+QXP>=29/'I(^NGYA_>7WS|_..EVPOV_L/G"W9Y|H|S7.RS|V%)=O>_ M_?S341+^UA/<- 7S#Z4B,VU*9'L7AJ8Q^P? E*EIQ=KCCJ@|G2""4R|DM3_M_QV_>_J1NF&8QDD MK5=RL6*T_+PJ:EYNF-2Z@|Y>LJ;4I\$5DP:('8J|V FLJM6\$EX=G710|W:LC. M\$O9J(TU@9;!ST,)*S|J2QCEP+%)IB""CJ|'C!'+/2T-ST/V|NWCYNP?GTK M?QA|QD-4*FYXQI8:411YYS-Z@_91W;AF7- 5ODE<;CJA_F8OXD)\$%FZQ@ M'G*|OUC='75OOGR-@22<4U>:Y4>+4! M'IO5B|WQPTGN|U^>1:50718L,N,UM0G@GI%>H1'8T?D+@&'5/ M6N_0|2Z7+O-@-6T7!>BL MKI2|YUW_*.A)#&?0E44,^#70C.'+%OYG|@W+_ YNM4\$B'AN-@\$@UK9D]1"2 MU!5"2+*%O3["_9J-63)3ME^|;FRMH;L M+&6H".O.FB4FZK&Q\$S;G=FOX=EF'.X2^HBSNM;(@K>T2!|^95.lF\$>YW;9 M&CN\$6ECR2IX|>RQ 3WVT+K|>=RWZG0\$;3UL/XBBR.X0A;+*QJ'=JVEL8M7Z=MC:BS4G0&LKS\$A;M|D_=>YK,!11S| MC&6GF.D+&B %D&%P>/>G4I;W|\$7|8#H>0@!2Q@F|=|JE|JNV7|H<3JQ)8+|&M^!&|,IF >^902<=^F6^H V(X^V^#P_.LZ*;8,3;(/?3<)I.O'AJ6GWQJ-9| MR%V_TKY- !5_+_|@8B|>-%DV!4FM|J9V<4O,0_9|[3M>M<^"01827@%|N|N: M5|URY7QJ|OSCR8+8DBNITA|U#^"EKC?>G|FOFO?A)*^\$3Y;<)"A|F**R 9"/VF, MZZ0|9L_Y<K=|L88,IC2|;5^XPR8@LP|U#"T=J^<^"JWJ|B=(=U)Q3CC?7&;_ MQHYH-E1R|S7,X.7X2!IFH?4X;)=VI&M|NNW<D;_H M;BIV#5<N5NIUBMC,D=Y3MC>TS2T|L7*D^&|YJ;QQA(|^W M|C4^>JF;.00-1 FS4-D.-KL^FRP=KP=?Y?6PS|3=+J|H\$X2J|"8XS#|IQL MW|_9_- |&SAY;:77Q|_14)&6=Z|'5NL3JE.Q9+L%XOCOK6BPD'22"7JQ|'1.G MW6M)'9X**I=?&J|&2^<%(O-(E"MX3MQ"VD\$&L- 6*.6%SRE+)|@2E)>MZEZZ M|8P|ED 1_#NI|6+&N7-L0\$TZ*SI#7"J|TPV'7;JU-<*&=AA|V&2S;J&..?^ MM-P#^F&(J2TGL^%T%AV-VXV=|F|_W/XWM.YM|8&^VQ-4)I_L6J|B65G..FL MOWL|^KH3T3")1C/G C?6!9\$|W|^X^OA7L7B|?+& MR;9L'V=SLAWW_P1&X=8|C&_IJC[#\$X6|+&P.G;./J)W.G?&B(8IO.D?W M)>|M4U? 50V#2CNH2?^B^<E_?WQ< MCLJ;O|O<GBT#N';EL00FVH\$B-@|EVDY0_P16P+M/KK@0|N#YDET| M;X3 M_ :J|N!8M| U#A.PM\$T^@:."3NY7@?)|A* 3M\$;3H= >@HC:)PFGX+S770 M9+8PV7>DT?<*TIC^TO|C@S0#2\$?I-X|D\$8E|\$-GQ|OLM|C|T>EN&L7A+&ZF M,TIC3NLX'N;O?199G|UF"VWQ|8ZKI<3Q M,1=7V|H-I^&|4^XK""=AJM|^>3"OC'D*^&M*\$PH6H^G5Q6P1J>DH/L4Y?0_ M4\$|L#!|0 (*_J #EECM^#@0 |)*9>+&PO=VJR;W-H965TVW^>VGVW;4F;V^V^1+L_==*CN-2N?J_M|U|YB54W'9U#01W%M|4W_2'+&NV-L +&ZID+TV2TU|%A8IF\$ _NSLPFNG%2 M*+@SS#95Q8= GN5/W/'9Q.@U,V2- MWNC!^K12\$XH.I0'9W!7(|.-@!3LI.>0U_TII>WN,N 2|_IG;);K5QIV;4J MH'B-[R&^+9%T0^OR/>KPUT9UV2""69J|DV1@_ @VUB ^JO<#0QJ M?%W#J#9_W MH1R#B^RP""^J^+A^..3J M..ZWKX_7K)@PCQ_&_ F04 |+\$=\$6KFJ|MG5G+&9.@?VY;E8|RV|);+AT;=>Y."SS>4,8D|>T|J1X_&39\$R.(M9@)/"&P3F G M(QXC&U X- !|Q|OWF2+8J)HUX|JBX9*MMN&+1MNN('_J;=%63=(1FZ8M0GC M'O\$%&=>Y/G@UPR0*U"(1XVK6EMD|J^I6 A;|[B=%|E=H!0*HT*+11#;A|I MX5#>J\$.I+11?0J|/="Y|OIAOG-ML)+1,E#ASB.\$PHBX M&Q@%-0O<[S(2@,+L\$_.DWFG0(_+\$_.UW@IP?KT.CJ3?UN^9UEHY;? M.|YEV6M^+UE:| <2J/_F|A_#N04TMSHTM|P?^?C\$^X%VQ|B,X|T/+O_C+&3 MP?|_ \$J|SMD#^BA9\$B>CK.5W%@_3X;X8MU@-55/M;V=|JBZ|J78-VU;SG" MRL"KJ">'6(% <01&:(%|IX+>?@Y'3YD)VR""TPV#%V%) (CE;TWT&EZ-T(MKM7|HJ,\$M_-9CN*)^V|V?;V=1\$N'2_FX>IVR|U2**| M0&C2'0VC,8BVZ=K? P69:X<7&OJ8X@T2#|G@_D)KMUEO@_V=+=804\$|L#!0 M |*_J #EFS^G7;8P@_P4 9>+&PO=VJR;W-H965T+(M) 7:4AWV4Y5G2KR2.?2MU 21757S9<3,H8FS?S> MA;_NM;_ 2Y7;74R6D [&]|,M(|^87YXW>DLW%+|T\$VNYGLMA:G|N.LK2Y MF\$PMW|P|X?>RX|^&=F'P6W\$D:>^>| <7|XF#R8(>HHCRR|HU MW1-5<6*X,9 M.YV3Q4D6'|N|M?>8D>[= M3GD^#6W0|T5:3AG+?"E)GH|-9^+E^X|H|FI2G 4=A?YA\$^&^|Z;=>O4# MZ1? J@(|Q_#J+=|&X;E_#D|T|JZ=MLZG%?6VID27DS5_K\$Z>4+?J38I8' M3 M_ ^\$! YJM0|1HP|^,Q9I4G0RKHA|XTUH=\$X7Q1_1'(J+D|N?'?U^6)P|X>.) MWLV3I|1?OO_J^HV|J3GJW^JNQGS|6GIW_X_\$XME^KGGUZMELLS=2F?J\$-_M>4^%,@F*J.^4#H#B4-H6J|C)Z;2H3#?#1GK*:=&CY>|N,W2JR@ M7+_.5UQ^&P_Z-M:RC=B! MSC6AUW-WB^=%YD_?%&-%Q4Q|AD:"7|Z5VRBM&E+;;(%YRJ|"PK'DY-H|Z*/_M^XF 31!;6VO^%(>^>=^0-PX*2ATS)*G: C+|0%|,T55P_Q_?T01\$4A@Z# MKBP4%UB-1'G5S&A<_|,O|X""24W|@.W|!#0;8>1W%9(#5* M9PBW<98IA44'DUZPL8\$")|Z|=ENBDG.JUWATO-|_.JZC^>|>O9>9=E=\$\$4I MH_-L#&M_&O&|1|YP5E5)HJ8_#_+OLQN9F|8HF=05.U- 57(*A77|)%26;_.5(RC^JCL\$TQML4|3\$M95#T-@6 M4A9E7P\$-VI=K%|M,7PRU|J|R[?T]G-UI7R2O M@5FJG=8#J|60&S.? =G70?2JV6LU>8#I78>>V(ZS1E|UJ808X;);\$!^4L; M%EFGQZS9%&F-U_#JT<69B_W|E*8R,FAKY)M(V|JGHH|X|T6>?=%T%IE IE M^&'/(L? |Q1HT<77844XWA+("PQJX DPEHOJ)=#7A,>ST|ER?>X&@;2;45RF MZP=DP.M|A|ZT6|)@FUP>4K09*Q*G'(XO|M|C@&N&XX&17YS+&.!J)\$Z6#V-U7 MB^>^&|&%RH"4CS5,.P7;_HMF8+GIH|,JH:T(EBJ8HT|K%#5_&'&T3<4SK-#ZPC MKZKM|M)O;AW4#7SYRX""13>|_>=>I-HP6YL(V\$EONV&R5T)'>U/" M'ZG|6|+4F&L;X5GMBL23L3_ZGOL=3(SMX3N0L44I;_7B,8;4?&3RV#=#R M19MSX;|1EYLH|-T|E=YZ?^AP22";7&^J|=7SZG'.P6CY|/_&|GIAV#3RM M90-Z[^X^J|R79REUP8A|J;"50OUG|)AMU_+[R*40 M8 1CSWG3|33.IT^Q4E MRU<@?9W@&S;R?Z9JZ9X#^BYJ65K4|@PG7@EEQ0+3PQ'RL@-)_6%J@TIXOU#1 MO^&A;F7XRUO'|UB3=|T?W5CX;QK5|XDX770?>=NIGAS4Y8K7>ZS^68%L,E MUO @@@|JMTVU4*1^JW#CO%ZWOP4D;YW|G+D&RV7!7E,22N7;.E+>J(?II?8C M@2FQC:8+Z<8J,CJU[2\$CGJ7R?+&"A" IU(O|A71F21NUOI;R5@H.V@R=J

(BH0C&0%PMQ>6JY(2ZPG7?>R<;&53>:.(+|M'.'.#G'O';SSD;#M5PK7>'UBUL 6=&770E)U:V1_LU@D1YUY?LE
M1=KMNp6vP6XQZ;9T&AJS.Y=OZM;7;6IY.'""VVVF4C=);M?&@A3>..@\$/Jv6 MTJ>O5J;/%BV6:K;@^A6WP/!(JS\$96|N&R-K)U(&.M&+|%LX
^Y")3*#5|P#> M-IELT'G>5\$(>Q)|QR1".M)%D8+@6ZU?(X%&PO=VJR:W-H965TR=RQ\$J|):%>D>JW/MJ?S|P68ZE<%NF
MODUOYL:6PM/2+@:NLBAD.%06@.%PN#LHA=#JZ6'8N|'#30U/[0FFL.#JLA3V MZ00+LSSJC7KMQJ5:Y)XW|M/#2BSP'OU=-6%I-
>A0I'1I.V4T6P)?J8Y'&R?;M';!;A4N#W=HS<"2I,7>|'^2/D;4A 5FGA\$%_3S@&'18%Q-&^P:SU|GD@^O/M+?I9B|UB2H874U|A|J3/CW|/9
X%W7A+|WR95VBV6&|S|0N.(5EM)WL|'B"3?|Z?M:W\$NE")I4.-#.(.@&Y[Z]J|:Z'>#|;|EQUITX;'JOLO3+QP?3 U.:^52V06
!ED#=#!QAN=N'<M:)|[F&F]|OGY 9JF(U;9B?C-P% J?463(9J&_VV_@3;I)(P%O|N|BA=~/M4^./UX*.F-NO8W+|'+M*9'C4HY9P!^P-
WW_<K0|'B#17;'>|LMJ.G9 M|:=+N#W^?#.#J|GQUL M#A.JERO#Q@!0>M#:#.M|LP|S+43P3D"JVP6?X\$.24I96!T7J2%HBZ5L.Q5EE-J
M|FM%I6!A,G|! 4UZI4?V%P63L\$,P>3?|!>9 M6K/33+@9 M,XF8WZB|S@O4J'OT(8?#C@JF=8>8(XT;4/4#
MAD:DVFUHUC40R0IM/JGT922S2V3!,2:=+A|N6'+)1W295568G5T:VMY&K\$;1 MW) #CW| ^&R171M/VMW| O.0?E:K TY]=Z? TZBEMEITU#>|
MAJAPZP= M/FV|GL:.%-U6X\$J;&TP4S;9THT?+|O1^;BC 9L\$.NO|11G|'#4\$L#|!0 (M *J #EGH)K/^40H !E 9>>PO=VJR:W-H965T?5P|1X?++VO M?
CX|=-,52K/=@.FDIHO|D:N^<|>MW9ZQ"HK>|IDZK=1AGJ9'ARLN|<^|H_#LC3UJ M9&JOI90+/'U:L7MS1.AS/KQ07;0/G@K%TM/#PY/'U51(2Z)?
U>JL:|/["24 M'P'R0DD" B"<3?|Z?M:W\$NE")I4.-#.(.@&Y[Z]J|:Z'>#|;|EQUITX;'JOLO3+QP?3 U.:^52V06
M+T1CSX3D%4:Y|)^M8|L11BQJY|VJZ8S[E=3QEWF|L<.AUF*9W=;B;#GG0.PX4 MM'S*/3J|9,V:66H:7013 VJH9S41,JEMW@KT<^?7GI3O%|.50KK?
L^>?.BE MOWETJ;&9WA|6C90G44I^AYOC|J)HOW3LF2Y%N=W.\$!IU:N6M6D R>P7^4NLA M&Z4#EJ?Y^'IYYH|,49
W^@PS&R09W|JFSENXQ3_V1SEC?+HU#YV56J|(V|M \$M.V&M;Q<>=MN/[I]J>7KT^_].+U|/^??;V\$J3|^=W%U= V
MZ7B E%>OKYZQ;1 ^ ^&:9J#E#UI<:GAT_&S2I274G+U9|X47V- 8%9Q36I; ML9_.PJ.M|*M|DSJ0M5|0%|PPYD+DEP|<[*4R*#J]D*HRAD-L*V
2'BWC<1Q M|OS,\$HQ|I@1WGF7|I|PA|C"0MXW,,S3S 2.:%;'EDIZQ-8+9|JTX+*JU)XT MHBYAM@O4PH|!-.4CU+<#@A';MC;V|KK92-5D;
J65YAB|5*3S|MDQ4A4GTO"" M@|1I)W8#WWD'T'Q@9'5O *M'F0+D\$B5(AF6@V5/8DC&7-8|9)KWPJ\$QJ L(A7L MB|U=IY1+R-
+8K^";&:V'["\$8.8V):9*X23DQJ'V"H<2)"0V1HXQE2C';DQ'RF M1".|DMB#F*S0=|_?6FE6E!"9N:)|PEOT\$K7Z:8.1K|%)!M|O;\$X\$MX0#J|
M1*.Z9B>8^,U@!!7E377L+@|O?;=PBQ2&*?POL+V PBE|;4BR7<#-#&K%RR MM% H3&L=H0 6;E/F.M/%|"&5#W&HF"O<1,2W% 4
?I?"OP^\$8@<0F: >? MMY#+|VRJ|E,"+<#M%D*A:31:Y0=M _"J'TST!_'BK(5SK;?N@6; Z-D-F 12ZSZ# M8L(|L+UOPS#B*O|/ULCB"CS&ZQUD
T5O!PX03QYEM3P|J|,">,\$@O*W*T T ME6%SF(16 "IT3S,U'8'O@D>8A%UCYE#=#J\$1Y+RD">5FCTB !\$M1#(6!-L@ MJG\$?&@ ^N\$-B|JS&M?B(=V
9ES41,4SNZ""44+=|H7.2|U@A90\$0ZE@2H4 MU@Q19B55>ZT|,BIA"W@Q?UKP\$Y1#8FXSP YOR5W(@O>A|A#>: L@(|W@5<M P3-
D@VF'10>F32T'4EP%|"0 >.T'BR|B@W3,N0R*7*@%'%:LVNCXC#I|CKJ9F<1V 0@PH'6G;|B-\$T>3YE^S>;=AT)L> |TR M,T'QQ-UJ 2|?
9"IM1J|"+T?WS|OV|X=C?|= M7O^L1|P9+%(LWY'2;\$C|D|J|V+J;3 7|)ABCV=8E*\$E'Y'2U*'=HEB S6BDOU\$ ML2|@+I+E@_ %Q^@&\$514I&@V2'I&8C^
VR='P| MY9J|>#XJ|&7I+&F&D>32^Q M",K3;Y6DR>CD>R?I!"1-UJ 4F DZU\$4REC?;B!EH^|JW1VGV>D Z)E7\$-J M0U*#>8A-YH6F/0H7\$-
XIK(NX5=MJQ'|;FJBS=4F1|SYWPTE2\$SKX6^~3 @_112 MBSQJ' "9?;PCWNT\$10;O?FWMF);^A&PV\$#O5J|CX|^IXB#%=(;X&MDL#G6AZ
M_UQ:D'V&+4@9BC(-) 2O>NP;.'J+6U? (1T9CH';&4?)=0,A@;U^A(0, =M0L)|K,9N% SUD ;UIAQR\$SX@!4!0A(|L|4YOM M^<%&UU=FF,.HL-
P+U@M(AEBZP6|7&. ^S-PX: MAK\$B'H,OJ;R:=H5ML73_B.B)-MZLHU(4X|Y|/<4@<^N\$U#Y'D T?J|JMN M7U2 I7Y|W|W|.S@-
H.JT|@Q#B5YB|90R6|C8AU@+\$.XV4 Z59U?^M+3Y; MS=-9Z?Q?P Z@=#J3'7\$&|(AKT'%)-#0P?>246'SNBRL'0<&.S\$57-0
M27;?KS?'(C&I?F2C*&0XFFI,+MB2O@B@TZU:DUS\$ZF.V1W96Z\$<(.DWB2 MCI606GF,C>% "3= 'R/4264,JQ6:"C@|I[W=F=W7<.&>CU(032Z-VQI!3-
(15A MDA2UI?;NJF,IS';NS'DB'L/S=3A-A.Q8.YM,|=|^*=PNVL<*Z=5XUB&X7:W'3
M|>!X\$X\$7812E|JNH1R;V%|DWI^Y^D6;|S>R7C08C6@8T\$|X_.X|;\$RZ)=U9 MVBWU+AQ5MSI3|(RG>3R'V1*9)5?T
MRJ\$S42YUM|4LFX6FPWXJ|VW'9^N^AMXB=BVZ\$|Y'Y' 9>|MM(Z1NN.ICB,/> M5RHK81?A6QP|QJ?;QPJ6NJ?
=YSYG|2N73?XK=|+;A<2&B@Q1]=T>#PYB,'1 MWGA3A6|>9L9|LPJ72|&|&37 ^|G|JZYH0&ZCZ!_ P502P,\$% @ JH . M68JF#C#U P &PD !D
!X;|JW;W)K&ULE59= M<^(V%WG5JSQ3G;.&>HO(")\$!-8VF9G!(E^VX=.'X1|P9J|U|D0 +O|JTHV MWB3#T08%6^+>HW.|H=!'ZF^Z
S1P.'1"SWV.F/FR#0288T|J|XL4= _6ZD* M9FBI=H\$N#;+4.15Y\$?(A95 P+KS|R T|JLE(5B;G A|5Z*HFF'J98B/8R R MCALK|N,W0@FHY+M| G-
^6CHE70HJ2|O*&Y%*P.|. |NHIMW|JH|@S|Y'O2K M*P|["1;*3|8A?WZ=+>+2',,3\$6@=%CCS|LRLU*G'|JZ|Q4MDKMT0&K&|IV85-K|HG&F=<%%
M_63/C0Z0|;A#QSBQB%VO.N#',M/S#+#2,D#*&M-:/;#A>|J|B1P7|E^>C*) M.?F9R4P6|3>DLM' 1 HS*0P7.Q0|1ST*#|UA#8.D@906-SP)^KH0/O; +
<1CWS^#UUGVA|J| W'^>?Q|O_ VWT491 M|OQS*00:N7|V5;/C2Y9@F/RD.CVJ,W^?@AN@QOS_#NM|S|Y| GLX?%XGZ| MF" 73W"W_2SA^7Z?OG;?
M|F|GS^=(GL>|.OPFGD/4AX|AG\$4W<|9>)>A52I\$B ML*JR@8IM>|.J"Z05@I&0H#Y4_|!|D9"18K;.-#%-@,D0-^&HLX)M#D!|=*/8
MWF@7A&S2'%6)8FLA"\$CZC:PHR9CT*(P 5'HAQ<@MZ|9CG6JFL-W5|JYXW09
MR|OG%74VZ^<8V,@J94DR=LDZ,ZTPA<:S*,N>=\$|HY|W;| %UWJZ#=@5Q:6 MP|0|4|42.YR**N59-09=+?FY3|3OMVB4ZU4,JT2|YYB;^#'%CPF?
AT"M*& M |<|BHK8-1V5FK8>Z.A \$!-=<3G'L|& WH4H(AF@H3@X(R9=2"OE.R+1 M=8LQK%ETSFFX|5;|JQ2=H|?
M3^L:.'I'Z^>W-,W@BZ9J11V.NA&G.FSBES M9=<3GT;EJ12V. <O<\$C(TVYM2M%>.6Z|;|3|3|RF9>+&5G'E@>@1K\$5!|[[&|:0UI_OA.O M0>M|>
(NZ/6FX49*E9/>UXL2"E70|>J8*1.?#3M*A3DG 5|,+7@TLRKN=&|LD MD+W; >G:UN^WDOZL'WG?S^K-AP=2.TRWFN"77T+|>.*#J45POC"S=^
M(0TGN M7C/Z>D%E#>C K93FN+|'M-|#DV|02P,\$% @JH .63ZV"(B= @Y@4 M !D IX;|JW;W)K&ULG51+3JM \$+|S*T9&XE3%
MCA,HA<02H.G:2E|*@|ZJ'C;V-.ZRWCV2|J2?>?W= N*D:JH7|SR_ ^6;7,Z.5 MTH^F0K3P7
MIQE@E;7,6QR:OL&:FIQJY'F5KIDE52|BTVD41B|J19PFR4E< M,RZC;|1L-SH.*6<%EWBCP;BZ9OIE@D*MQE\$ VAAN^:*RWA!GHX8M<(;VOKG1
ML4=2L\$KE(8K"1K+<731,Y|,?7P|>."X,ELR^\$|F2CUZV5,QCA)" 7FUB,P.M.I9XB4X(*+QM,;NI(^<5O>H^|O5.OHC
MKOLY|GBY\$B9|8=7&IN|BR|JQJEXG\$X.R 9DS^M[V\$HX35Y2<.->#=%@HL MWS+LI%6*|^FM|"\$H-V42.2 |H,ZO)RRG/9C,W-
CD4|J8+NEK1KE6.=? MS7\$J(5\$X\$X@2LE:65@*^LL LR5B4|^*=UPFJ|J_3|V8-|@;2|)WNPM1T M/OX"WN!>?X3O#W-C?T1|W:UVZ(-
=Z/Y*3DS#J&R1?)1..62R "4%:N#0F"Z!+DX:%@3(MF(65)X|K7UD:5\$#O1UV M;P>N 5MIY185G0@%009A4Z?D@C+>8A)"<9*
[O@F:NZ\$>2I|E,\$KP(5\$HNFY4;.1CM0 _JP:[WC;=F MKT:]^|O&\$J|3MAW#SMHML8MV=G^MQOPBND%EP8\$E|2:J-X>1Z#;K=(J5C5A MDN?
*TEX(8D6+&+4/('IE-THOD'WVK-?4\$L#;!0 (*J #EDU^|>?REO| M *PI 9>>PO=VJR:W-H965TE*E=(-3.4I?TWBR,+7' M5|L|=955,N-
-97\$Z&8T>G18RUTG#ZIGDEEVJ;?JVN+>4LERTNE76ZTL&KQXF@Z?O|J|^*-.MO.)N5J|S=IHLR-414?P>E'(V(U6HU!),B3|WZE(5!5\$")|BT-/V3-K8
M_ =Q0?V"OYBY=.K2%) SS*>?#T^#IE:R+KP|WZK8H"71"JU!2. Q?KL;A MZ\$BDM?FC)O!09GK|?>1D5T-
CR^&|D;|@PW^<@Y0^U|+E>?T7SEQ3.5J?>?@LV6U2P#ZZO)08)_K_50G(T&8C*: MG!@=|;*.2L;TSNZA|)\$NI((X>.405%+>W_Z8?QP|,R
?>M*;>J_.'*|E|ZVBIa M%)N|2P = N8 @O(B|)^>#P9CY^>#UIO&\$?;ZMRJ3(Q'H| 10K _^K56UJWR
M2N1:0%5%YBQ,0/*=W(C)|1ET=.%NI|17EG2>_V|PHK@^-;|1OUJ|JW4);9,5U: M|8 *G'B5PTMYN#1,X?#|H06&&M6TFK5J;
(#D&BMSG4|8>+)"2HPG@7%63&0\$0)4J MP\$P6R"GKV9|JVS*IX\$V^!-7SLMYD:L5"X.W5R1Z97.G7.*R 76 *5K|HF^4 M|
[P,VB,ZUQ|OB0OZZ&2I1"8WPUT.H#(1)U\$.F.2;.3T;|;SY<19ND\$R|J\$B@05|72|>@J(TB-2PU?>040>55#!@B9'I/718@*); MZA1F<.5;.G@6:6!P='P,|L?<
0.,Q:0HB#R|T6R# 2|6|H5F2L'XCU2N\$= M+=1*38+64PXV'^!H3QY5|1F-Z(R-W@ ^WGR!N!K
MA.Q%CGC^*L_XK|>'5%:NYD>DAU3AK,*XRH#+Q%B^"DDFL M^W@CJ; U(X^1I\$R7VKQB:R&APEGH.'B*6,D);>9*Z38PV=32BP+V091H|48\$ M#*=
(6BLK|@OBD,F" F,DO^>OX.)=-.UP|T70QK-"<>9@V-;|W|_OK;?3R M0001N. E"O&\$#9, K:ULND3V0@P-7EF|?3\$ZX0,E%7H)R|)\$S1\$CQQ&|R
M|*!|S\$H"JU>2+B/=O@/_B0*U&+8|XRP1|.J&""@AFJ2|+Z|(N6#VHHY|B M&0= _!|JO\$S*USCMT*>UM12012|G3?2HVU0IE|KM2^D<^|O
O7OX\$|@J9|." M>U<(| 5MSX1+30S_1XK6Y|A>8|K6|J054E5&21P,H,0%_#E3-H !7+9R?PE M=Y3 OLT8RM_ "I|E44E0J|>4<8NVN_)*)A"
KE5:4RBB_)0(26|7 012 M-(4I@)5K;Q(7&)|#58.C:T*6GOUH2RF_ \$K"Z^"5C(ROE|!=?M630>PVE?!3L1HN?;
MU4A3XE=#V/V(FSK+H+1L9FD>=@H^:M8B^JFD<6=H|E2PBBMRFF*\$X\$V; M\$21OH8D*G|N|J|SCQI8(E)?
GK6;&3F%Z31HMI&>86L=;JB,W7M+;NQ|_ ^M<4=Z>J|J43C&;46G7\$1\$?;C-E?DOJ(A#KL<0OIK|E%V&= ""^/;#45=7 M*5|RP">S|J7^FE!
@K7J|J|JH_H&TRR!MB1@R'OW<&|1:VSN|J53+&.TNH48 M:U6 D8",K&4JK<#@^'L,@7MMHZFE3|K\$^4RLXL|F';|/(0%3,.[O,PCY*MOK
M3P=8\$KUS*YKZV|2<42""=EDQ|^>8,9V729BZY%GH+&+VFR_/M\$|JU)"R9. _J7I-UOS3|=|GK9X|6?W3J|J1A1Q6GL8A|)^ M'?\$JH=J)M"&'9-
1&9J|,"I^;LRW8.1\$B/B^IT\$LEU>|_>@V MBO>E^>|+V_J04*G?(T|NB|I.%|10B9VC/=1^PL5A:Y&55|/9ACL\$<37"MD(ZED)":16B&P@%5
ASBH5\$Q25HBE5\$=3Z: T\$F7L|,BDT#OGLEAIFL*8,L M'C; #_05B=-8K;1,522 (C|AS|+W\$|0;Y7#7^2;@B&X|@A1UZR
MM2O7@R'UXJ%R;A.W5D\$BW#VI=HI!"FU@6|QW8Z"+F7|. M8"\$[E#2G|!FT>CX4JRQL[6&QUF?K'KIDW+^*=KFX/90X_*P;5P>'NPU|/@/M
2D:DS;J*O8E:|PWT-RT\$B^V=|>RB+ PP_.AE^=)|#ARJ9AFP;@%?>N4@_UG1WA M8Y|O?PGAG5\$7TF<|W| R92K#P|_?7F|2CXJ|C;RG@JW-ELHB4&
LO|M13\$9 M@|G9*YI^>|@V|_<4QE5I-;)|+J2|>I|J?"T84/7,8TU36R>FZR83+>= M1EW7>>^<%DGV286F@YJC= P(-\$=PK5_)*\$#?E<(BU?
O#J2|L6WA_ 0%\$; M18^JW^#0#A|E6K+A.XH;7(F:|F\$Q|B|>H:|IGB;C'/>#)76M2V,;<| M:HHL2QL*CRWK 9LH^+2|%->ZD@>VDUW(N/L9X|#M-
KS#^/4 S2HWF?Z|JP0|_*TJ6>|B|[SF5!-4A_ \$7>F-#HCO TC4C>FC5! MUN!|;?>LPH7)7I65HB(PIT MV|>'K% ^BBX4IZ|JY*8YIO|O-
@4A*X#9G:*FKY^YZ7W*4|J3T_.P 9-(UK69^0J\$8O RU6#/'0)@JF&0XF M<3@XN|IL)^!X-:UL7HAQG(0T|/H;/'L?0?<
9NZ@4CDB|@VNM1@'0'744MP|L9^&T;#Q M="K=3;W& 67 O|ZBOT#MGO2VN|X>=\$J|KYUA%82|H3LIM#%0*&@EL:UGLE-TU_QF,1F?X-V;+
M3 ;CBXO!DX?GE*3|T>B.|\$FG0)&%;V+NC|/9%_0B>ZJNF8!FW 9<)>5 T3 M:XL81.TV|ANBJ.QR>="(X2 M=D*7:DMC">V;PH8J3&JM-
V3XT7|>2D. ^J@A3Y0|N<+<4^5;EMR@*4P*.R M)?*F;VJSB 8;'|J27#1.#M|@>GSJMB\$;VJ6R7\$L9\$^"T|&G;J\$MQ?|7-'P
MNJO%6;S|KG2|J|DV8Z|NRCNT02E'U_>>F,W26Q^>|J|O|IN;PM8F 40A:=%QSK>OIT, A3^46N|96;B@P#|I5D2#MRA M2-7+39Z19K|@63O4,NV@,-
=-.PPC+>|JG^>9M|G=^H1+CIY| AQ7NB#7JFC- MACV.BK|NF%#<?<7J|^E>8^K_ZH\$LHCMX"UDT@>991X=4K4WPF|)"^T|AXB@*R^2:((J^D- MQ6?
5C%Q(36EL3)N#.? (F|=HYN*LE3CAM\$|C/D|RRB6EJ:VX|!85|8U9Z(\$9 M-I-Y|<0.0*1B-2+G3T4.T-IQ^:45(FSJEM;\$&3ZHQX|!=%,@=\$P,Z|SDS%
M\$;PR G+L1X|#16G@MS+|,E31=|(|.S|JPU_Q"Q"X_*:M MP9AFY|K M=%G*T@|US|X^<+8M_0?E?4\$L#|!0 (*J #EFJ&N\$|H0)_J(T(9 M
>@PO=VJR:W-H965T,TJ|K:E-Q_MRI>@+&L+MFJ|K>Z|J6N|JOVH>J#209;J3PVUGU.N|+4%FC|ACYLPGYK&_MZ5ZJFW+.. "MKH2>5MC=A/?
U_D6:Z|OY X%|:REJ|KFA|=KX>J>0%|ZIKOPP M""* YJ7PYE.W|JCF4|JF8|A3XJ\$ W=JLD!\$X|!^IM>'M(ZGXP|J>Z>=M*RXQGM9_5H69COSQAX4 MN.9-
99|D_@<|Z'\$;\$;2#|H\$;|J|N0=EK0G=&I4Y7WD2F&3|FP4|9:D9^:~+|>.,J>.,?R ME:|J9"|JBN^FQ8|U|=0W%8;^D|SS'L M."|J|X_->(|.HH|!&
(3Q%|;RHUQPYO.C_0YML%)&4:|^DYU|QY?![679Z)W M^>9|1= #HWI|; [-5;T^8*Y;BG^%|GS_392R:"D&NXI+|^%3^<C)_|D|QT%_\$.6C*
(O.UFP5DH(PJ.Z.5>&< W:FX.X4;A*RK*POX+V5W'6,6CU*61")&7Q;C;B; MJ.Q?((4?102^W4BCR+T#B= 5;SM0|0<JZ-31Z'5-0Q9EH2W;
<103|Z\$;SEK@ M:CD-QBP<1X38BZ:3^IO<0^F3L&&8L#|+|JR>*VS_I&74J#N,6IP\$MONT: V MO7?

1MIRC?=<NX/W?)Z=<I0X9I<@|L1E:UJFV[;7+G&M?*F&IG;KBE P^HK`M MKZ4TW<0Z/>^1SA`4\$L#!0! (*J #EF!NGRND ('H% 9>&PO M=VJR:W-H965T[?OIGJ-SKW2TV&KUK&L OUX; M+O3ZJ8UIYYZGBGQJ;LJJD`P`7JD.;G`H-IYN%?=<?R!S<?<?WU`C64`2=>?]`W`M`E (SG FX\$X1W34-5;J7P`M`V5O3.?? N*>;6IC)[QIT=<(-/`#YUMXI`DC2ID: M\$)I01142^<|F*|BFJ|G?>=<PU09/7W=|. !D`AN`< (<|JW#1KW*2VIHOE!R M2Y3-1C8;]*7V: !3`A#V4!Z-PE2`.Y#? B!821BH\$F`Q`IFH/^`M/`.,MMUKJBJQ MK`6! V6\*;F5PM2?:?|SEE/ B/50TR@<KWLE;A2<\*OG3@CD>^2T` C\$WS16&;4`M!7T`4>:/` [4V`J` #SV.%#CSQ<1YKD;EN:0%+|SV@<|V DWJX`TS|RS=4QJ`M`!|I`H`6*S`L`1%;D0\$QF2?)CLL|[\$\$AT5;:0&FW,C622G+T)Q.;^01[#WWO M+Z& 9@V*1(\$|L0=A3R:~W;MWD`#BE&N2> &LJCUIOQ&63QSPR=?;\$\*1^`L`D`M5; (K4F6N1&?D3B(W&263JZ88`AC2?1LK0,290221J)%\$G;NJGDT=!\*#`L`M` 7E/OC<+;G<6)AA^;AJ%;A*DY%<C;OO_`\*VO>MMT9TP@S7&V?%A.1`|J#=#|M>]5NJ=HPHOF`J`^69HX1`U`P9&MKV[UM*@_5`NPQL<1E\$W`J4I^LQ_8# <;G`M-O!#4\$L#!0! ( \*J`#ED.O4B`0, #L( 9>&PO=VJR:W-H965T`M>ZB6PTAJUW MJ]?^:UK`G;>1J|O(- MFPXPVDJBA;9E|7, 7^Z4;N,>#CIVNUN; 6RUZMH-[T]`C<2=>Z&430N=:D1`M`0%#1+|SJ8KQ.C;Q5^>V`O`5F31B(MD*^<5L?BN7KF|(8`=<P2&RP;|L!T)Y?` &|0%0^HOJ|B8|=8MD\$|6|`.:S!+=|W|J254;.#Z|HJC`"H=X+;`%`<&5`MR7|4C7.7%(2HCT8(X.VZ<=5?3ODX<0@|WJ|B\$|X,0LM[|=<19WC#-5@LJ|D0: M;40S@<@W56B.YTC.%N#<=2OS9HIU<;B?65^1&2#6>=|JPKR>W7H>DQ|9|\_`2V`M`-2KA.?1E|`PB@<N>L0-?X(|(W>BT|4BMUTY?`?V`G`-`"OS/ZW2\$EOFKW.SICBQ>61SC>|J9P4L7;PG`N0#`MN`L`7SX9`^`8`|WCSB\$?`7)WCM2P`#D14Y&(<YXA?A#Y/`\_E/`F`\*4^%P.NI`M`-2)<CJZ|5+<C/6^ZW=S`ABH&MW`T4T`Y|DBB<CBF?J6`D`;\$`VC3;.<W(|`LAC`M\$N4`B(B#);9#B41ZB?B\$8Q\$`98`F`/`?`&\*`&H.1CS`0`U/J`MASG-|J2|0(>K3`!W?`2TD>8`Z*`AA&-`LR`"-`\$#QU/E154|`2)3-!3%N&8T`MC7WGD|`),DRBE81Y0?Q8;4-?N8|[T&I.8Z:8F@<SDQ>2L|<=%@VS,^@E9B!` MT4^6D%>X|VF4QW26X,ZYF&A*.AS0STF`5%;.J3G\*%`#OTSAR(6V2J;V2OYS`M6|TJW:26`<%`U<#>)>QR\$,>@4EU`MKN=B?J))`:=N`Y^`X`S?^BR9=/_`A`J`M`->^MUISMT^GT,EZ/#*3^OBLWC&Y:SI%`.%1HZE^E6`4Y/E7C1HO>)/@|H?&QLE*`MKSM(HX#?\*`R`T<6<3/175C|`#4\$L#!0! (*J`#EDZ`8|9`0`(\$T`&`9`M>PO=VJR:W-H965T`-P|PCG`MWXYS2P(D|84YU915|KJT>ACTH`I`|`Q25/DB^|`)?6C|`3+T`#380V\*2(C7C|)%\$UZ` M=M#FL|JTC.OC22F7GX=ZY|C&*`+W`EML`W`&BDZTV+7>DFEUD.X.|&8);&:5Q`M7\$8M%RI`-!X3>!!WLA@<ZJ|DH`5GK|QKYF`L`-`\$`MVG\$3H!7? (<2>B`B|=<1,SRG|&7@<GJYZ%VJF7#`+`+|H621N|TK\$|H<`M|`MZ3|HPR|JK*?2>+66=OB`P`B;Q24Q76Z|083@<U`H!5;|OAB9O0|C|@<L`MW`WDI`G|6>0(W`WM`J`1%K`6`EW!`JX4D|Y?>PDV|JP`6|1+1`S`Y` (3N55Z\$`#7`M7CU`%C`-XS2`@9>=B|T&O`Q`%`O`U|C@<A+M`J`|@`7C`=1:QHW`MZ|`#Q`=|`K9? N|H|\$%S^TV(B`R|O`@EYRR`D0`#`JR>D<`4`JP8EK+E#Y8`K!MQ!`M\$`<L74OWHC0>6DL`62|JH`|JC@<@WN+OV|=88|M!`UG`"M|HW^TLN|H<3LGA>|C9`M)`M954Q`N2Q95F3|1ZSW2DNJ>X6MT2VLM!*\$G;|)4K`JR;R4EBR?3H\*O^64L`MCE,VJ5+R*@O2TBJ8LKPZH)=#Q9*<`"95L\$`SKW`M|P|!|;9SXFJ]` =P6+RX15`MV03NX2YGU31F95|`"??>|FO`C7D5`N=C>KHHSSN;9JQ;|B1G+&5\$;9;`M;M25RW%`%`L^+|MHG;C9`69`XI`=#X85*\$8;E-2I` M=V`V`&A`ZV<0|J3OT7`M`-M|J|4Z`3W`#^@BS^5!+`P04`"^(`@`Y9UW|W`MH`."`#10`0` `AL+W=O|;16#|)0R.DF0>5M>UY%)F|@H.;\$|6`Q`)-2Z89;=4Z`JT&`M7GA0(R)&:1HUO)9!O`[2YW`5&=%+6&IB>F.ANO`!0BUF0=QL`NXXM>5=1M1`M`FOY&F|`2F`<7&KUH08`G|J|2IE20`RGE`P\$9|OQB|>|`RH86^V;`R62EUUYPO`MQ3R@<3A`R`?UCX+CA7`N|J6\$|JURCGIN4YS`/L`M!` /Z`H+L&S:LX|>^/!T0L?V^+;`+`RB\$T|429Z\$`J3T`#`-AI<|`E`?88L9`MX2|`%U|J@<U`R`-?Y`|(L`O`@<?`(-FA;`D#D>N|JXL>A2-3@>#/<=UO.;Q`ID`M`N|PLTC`2|Z2699+I2H9>1TGO|XO19B&;MLC`|8+10Y;.*|QF|K`WX<`"62=OWV+|3B`P+OC`A`?C|8KK=2T`\$5`BEZ<M`3@<B^Y`1`U`UODU7RF+3>|/!"00!>|YJ93=>Z`86YG?P%02P,\$%`@`M|JH`6>|166!W`@`&UL`MC53O|;P\$|W>O^<(4\$`\*16M(D|;21EH`"!"3JHT?0H@<|G)HK`#EV9COK^M|S`M=M|JLH*|B2^<WOGL`=<|S;`*TG.D0+<3S60H4Y6C;3;0YI76S)R|H`B7ME\$K7`MS!+4Z|`T&EGABVH1QE\$T`60&99#`?&R|LYE|K>2EQ6L6|;`QC|H`MX|;O`<L`839K9V`H0T7YKEH0V+;4O\$9IN`|@<L9P`EZ|H`G7Y`N`G\$|QXTY6|(K`M9?74G0?BGD0.\$H+;+>.@`=<G`J0`\$`\$`NYWG`%`I`L1?`\_G`>J9<5,WBE`MK`>V`H>7`108,E.86`4YB/N^AD|OEP|XW|AT^4F`+>+&|JOJ73`AFLONRQY`W`M`8AW|;7W1WD5,YCFE4SK3@<73.QN85O5U>3."`|=-Q.3;N`V5K02`|J0\$K0+`"2`=-TZ)CB|H`AFL`UDK8R|`%X66/Q`=-Y\$`M7E|H|E|.(3Q)^N49)`\$0XBA.3`E2.N)YTO`<LJ52ERM`C`2TM2AJKMN`*CW`Y`MJTQ`PW`GM`|=HK34`Q9|`=DO.(5Z,0N`9TKOC`MZ)K|9<+&|)94|V`E=CP|0G<4|8R7C|;52EDSJEQ6|B|A`=NV72MD|>?T|VSV`M!U!+`P04`"J@`Y98YZ5A;\$`#K|O`0`AL+W=O`ON`H(@`=-21`V`@`FTDRC;J6|<(V/8P|<`M`A`AMKGIW9#H`C`OVNG`11T?8F`|GD^>J?W3FNE`Y`W`FG.16V+|D041ZB|&A<07NE`<|`MM^R?O7?R|F0&KY7XR3.;SX)Q`!FN6`7LO`J`X.;/T`&E2AC`A`J`40|H)6Q`M|MB`24`!93.RY|U`V`&WP|\$&T`L=3<7>94?F67)5*L`M(LF`C?Q5CV`Q`I`MDT@`<9URPMED@63P`P.DC6PH79|J0\$|J|`M`P`PAB`!A`&MDC8W|\$EFFV|`M`#TE`JRC>`*K`!PF`5O(<^E\$`7XB@>`."`KMPH|G|J`+&OJZ6QFA!`|F7O>`&XK`M`@<I7&|3LAIG`U|@`H`@<3D|J>`+|`+|`+0`!X`28PD`6H|JG`R`#Q?MFW7`*B`D`X`J`44(59`U3>8`\$`%643+Z<`<WC`MWL6E`=-4*`@`#B55`G|H`W`%690;|JRV|K`%Z`T`A+W@<4OGJ;T`T`+H`PB?7;2H`P`M`MX1C&4;E64`\*!E|QDZ1`6H|L`FG+`M>`>DL`0<`S.D;HW8!`+=Y2RFX7|H`\*VOR?`%|+`P04`"J@`Y9J7|@`(#`M`!`P`&0`AL+W=OO`M`\*53M4D`=@`2`C`04D`%`=-M4RM5E`8/TQY`A`J\$@`\$F|UF`"+`F`Z9HE`#K4`=-`@LSODJM6PC`M`P`PYRM|`|M?7ZKR0|9E(1G`*`U`7`C0N|1&D`9|AVG;JW>`."`C`MS<`<H62CTZXVLR`M`EJ`\$`J`K4`@`#SA|0KA@<(G&KPHS|J%.ZP`WY|OW`\*`R`>7`*`V`55<4@<XS+9>`<M`+9MEXJ`4`M;F`#?2Q4GTTD>?2`+6P|LY6P`T`X`A:12S`XPKQ&F)&+V|V|X+``,`D`Q`|FF`T`MH3B`#@)`^`V03`JT3B`1|JP|>IY;<17B`OY3|8|[(P5`M`O|G`?Z1`SNQ`379V!`MR5F`HX#NAD`JA`X`^`C`=-YT?8`RM&75,OD!A`N2,C2>?FM@|JRL(EAR`M`Q>|)S.63#ZB|CXZB|JG|Y0YCG&W3,8(4EF`X192)1+C2`18W`W`7M`XEQ|@M`M4\$`G|5<|39@?`FV4H(R8Z)UJQ.186\*`<13H`EN5;G.YR|;D6^>)N!`8H\$|L`^`Mj02U+`Y7P`+8U`SLUWAG2V\*`(&F`J8.0VPUQ|ZS`IMB+<@`&YHV+M`#FN>`>2J5E`MN,8CG`-`"NQ|@<XW|VYKZ`M|J|DVZG1Y|KXS&7%\$DF`N\$`#`U79`7OU`N|JDT`M`#6;6M45`QZ`VW`%PIREFJ`>^J|O`0|H`Y8K|;ORZ1L|J|EOWAFFZ87K%I0&|`M2PIM`4|J`>BRW9>&5;EOL0MEJ6|`4HO)&KG0/M+10(KPR6HW|JSQ;U!+`P04`M`"J@`Y9`FH2#2H`^`@0@&0`AL+W=OX|;O0#%4I0;^I.S`5VP&R`<KJY\$N`=:24&8|`M86G`HLY3D`|`>^ZB2AH95`JH6`W`V|V7^PLD`W7;K`L|HD2SLY|6MDC%K`E`@`J`M`JRQ`8OCDB3|`..|JC8Q2^<N|B`>JW9>|LPM+`=@TB|`QF5B>J|T8`F`SNH|`%`ME`P`&8,T`#4I>E,5%J3^YK|O`XQZ|UH7|DD8|>Y#PM/Y+?`S4`L2.OG&Z|T0B`M`28`U`C`|L1..A`JL16(<`\*!HU@<L`Z`M`X\$X`H|J`>K`K`Y`F`19VE,W`+`#`RF?|XBF@<GR,HFR`="IXNR`46|XB5&KQUP`+|OXB)^3KC4>`M`OG765`-(G|2)?M1\$O`BC&L\$`\$`D`^MMU`2|VJ|;B@`?3F\$`MFW\$T`L`QPE`2`UZG|XF|QO2`&9E@`=-9J|Y9`2S0`X>`KU+|OW>`MOON`\_`U`\_E`+7=8I.Q|`^`*`@|Q|C4`JW@<@`Y`N9|BN\$`4A8@<(2`M`%C`Y+|Y;`YY`*|G28EGY.RH7V|UOZ`Q2T71Y>`\$`95>H,ONZFPFRU|M`J9`V|7`MG\$|A9>`"0ML|;Q|@W@`?7OLE`MO`Z`M`=-5%\$S16>`<|`M2`=QE&|Y9X2)B`+A`F`G8;C|D|82\$(UG+<`..ZH`>|UGYD`M`<584K`R`GQZ3NN6`.=+?`L`GUQQ3L`#P6ALM`LY>`T&8U;SQNUV;D<|S@8`M`#`<UV.Z`C@<X8YMC1C+|{`#?`=0U>UREY+L`<5P`7MD0;#6D1UMCNSHY?Q|F?W`M!9GG64`R`A218RX7CC00`2A`=<87>?S%G788T`I3E0`MF@NE>5`"#Z44%|(HK6`O`/7G`=>JXQ`J3CD30`2G.A`J`Z`T`H+4;2V`MXXV`MXP3E`<1Y53>K|E7-6|Y9T5P!`!K>`+|Z`J`E#8`={`Q`3`=-RCO8J`D`MN5`"=-B0^`"P06`=8TQQI>QEUB`K`=MBV`*`KGY5`KM+T068`=-ZP0`9`Z?>=>M`|BRD0|6|F|TAPH8S72`C`A|`\*!U\$T`JFWEH|E`-N5\$8P2D`6\$`13E0F@NE`M>5`"#Z444%|(HK4`O2T`Z`KBT`5J`F`<FEWQ`%5BR`Y\$1`%ZS3R#5FO`M9VD|`MH`4A`*V`TKR7|`!`@R@M!!%`UMN6Q;2U76A@<)9%TC`XE4A|E+|I/S`TS>`MT&3U@<5SP3+|HF69QMGC@`T`S0`J`O|H5(L`474RC`@`=<`V`TGP|H`8`#20A2M`M`2AM14H?OG|6@<S|3`\$T|TISH30/2O.AM`I`S`U`TMN.WE3|`=7H|`\*L8O9Q5`M`S`M0`14H+I7D0`X8|`#1A`..&R`VT?76MMNKF;1W2`Y8+&ANS`=<O`F`S&64`E`M;L|LD@<5S3AVI`%FIM`ZW!0F@<EN5`|;Z7Y4`H`I84H6OLK`N`G`&K`J;FY@0(M`Q`M`H`L`E0F@>E`^5!`.\*6%`%K|;`=MBC\*\$L24RNY`PM/4WC`<|>`%R7H|L2>0)`M4`Q|7KXPPU`R4RUV0BBC`#G`TQ`5`RC`A`=\*AK|Y3`#`TTQ`VTSH&`&`KK`Z`M8`#`VJ|Y`%`+`MHVYK9D9ZIK9U`J.57Z8RH#4|*`V|TEPHS8/2?`@M@`)"`%`WM`^`W`SE|62|`Y|+1(M`Z4Y4`H+I7D`??K|OED`<4H\$&`&PX`&J`*`U`2`L|XLG+`%|4|S50D&HVK5J`MW6S`=-)S`Q`HE`KWM`|J|W`L`13O`ZQ@BV`<NV\$2YHON`CG`8;7H,3W0|GG`M`5U/6`R%;5N`^JWF1.94BT&9VQO&P@<Y|G|@<H5LH`FQ`%F/P4\$`L#!0`M`(\*J`#EG`M`5X)P(P`%`9>&PO=VJR:W-H965T).?`-MO|J)`=DP*`ME@7RR`=-`1G|QW2;`THSD`6/4`FGFP<`?Zi92DQ`^@9&`D`*I`X`MLU`Z9|9`O>`FTL`%`RH%O<|P2D0&99`F2FVMT7355G`|`TU`799`|X`H9IY`M`Y`"QN`<UBW0`D8C08@<GVHUAHCVK`40`1HN)`\$PVX>+`WR|CE`X1O`IS`M`B`=-2;4HPONBWD0NH)`O&X`=VA`\$`L0PA%A&|ZSJ`_T@<YR?VCUX|`LF8`M`<42WWEA`#`\_/@`B`%`|`@<M|8UGZ`#3<`<WX`0`=<|L0`P|`W1MC(O`41L2Q`M&J)`=K`YB|;CT8U7+|J`MN`+4`=SGB;+K`C`0`^`^`=<`CD@<7|SHC`8#1`7K|I7D`"]`|>P<3E`%G+S;JQ4>+`Y7`ML3|6F\$;G|3/(8TMZ628U`GLUE0LAWF`/C`*`@CQ`D|HJ;I`^`<`<7`B>R9`KC7`M`|`&GBX\$F|;`C`GQ2JSNRN`%F@E?`RU`#TEN`<J>`=>S>`&8CN`9`UGLX0>SV4`M`MY@XJ|`<S`NF9V`5J8D03`^Y`3`#J`A`C`TJWWV|`JRC`?3D|DT@<Y|>L`%V`M`=-FXOU`Y`G@<+GB+X|H|G|4\$`L`#10`(\*J`#EDJ|LM.A`(<4&`9`M>PO=VJR:W-H965T|NJ|E8R`B1HJW`F%+&G|5JR|H;@<LJN>M3.G)>5E!`M`MNU`Y`G\$HM&Y`|`+M64|9`-+H&+W`%FV`|J6;|3>`\*`K6\$)^`K`<ECAS`M>Y`L`\*\*%2A.B(A`SF7`C3>63J|<W`G9J;TR.DY40`<R`9LYU`@`#J|DV#`P?`M6Y@`#YX8(9?SN`JW^2/<`S`P?`|`#>T>`#`@`=P`M8`@`P36`\*O`MVEHPS9)8BAV1IAK9S;I8J`H|HJ`Q|C4\$G<+<Q.GD(DU`4VE%;B`%8LM6`\$|{(M5W`Q|A@<6<5`3DE2UQWLH8`#3DY`#`@EM`L`7H|+L`L`A1E2`<U\$7+8B`-B`M`C75&0GH`?&|P|YR`#`Y`BW+|PX`#`B`+X`?|`%`8&P`M|JG`T`OU;TB>D`CTD.CJ6HA`%`DX@<42R+|`)\*A&\$`Z`R`7WFHAI`X`<87>5(AQRM`M`\$S`+|(MBFV\$RUJ|VU`=60F.7LL`2D`F@+`\$X+9>&PO=VJR:W-H965TNVDF@>0TJF>M|7NR6M`#`9%3O|9)5%565+Y`M`=09;`,`P`EN/16;K38|F2THQMX|OUY|RAQY78L>5\$`5X7@1.)Z|P`#`IO\$`MV`<&QO5P4`?QO`2R\$N`+62RCMVA@<J84TKH`X2`=HXND;TR.8JG`JH;TU`E`M`2MHNH16;9<&?`K2ZG`0|X|P&V!`?A|O@<(\$6D|PK8>P`833>HA.O`|VZV`1>`M`|`@<FDY&44R`<.(9AYJ|6LTZE5P4R?6N+|`G%Z`LTR47&MR!`D4.SIBL\$M`M`<17K|V8|FA9;?2|WY|F\$;Z|8\$&`\$FJRWE`U`DX\$1O@<4P95AKE>`>Y@T9`%J`9`Z`M732`=-Z1S|+Y(MWXGL|/`"IO`"2^<R3&67F2&|`#`#9%XP72F&`-!`%D(VX&RZL`C;82|)SPZ6`OC2R\$|ZPS)`HDZ`M`Z`|DR+&CK`#21%VRZ`LB`A`U(19F1@AY`+M`^|@`%C|M`U@<ZVW6>`<M.(AV&2`=P3`MZ+51Z3)3YS71G\$X`K|O`#`ZB|A).E3.FGCSZ@W|J86`#7`M`>ET2\$|I0+|W7|XT\$ELA>UC(O4CG`%L`XX\$`=<%4ROY9Q>05CD|Q|B`4`#`?2U`M9`9(7ONSP<18`E2`+`#8S;`TC>3YB\$`JN|K6UYMK`=IOQH&`=<M`+1`M660`2V(QYYSO);>7<7%LJ|P`"124`9GSE16`E|`TES47`M5;Z`S`N`+7@W)`(*Z@>`>E|@%|LQ)I|W;L7J13OE.4`+@72.Z`\*`HO?`T|Y`7|MYW7@<@6RVR@RXZ;3\$&UB">BSOA>ZYK4I."F"2<(&\$K&?.M3^9)P9O`=>|5`+3`M1B;|)BO`GT|G+9XYG`#`&3|D`%K`%|F`E1DC;^5H.FU)0`<RV7|5O;`=984E`MS`E|K`G.SIR|@<W8XQU5#|SZ\$#V>V.AEG\$K|1%6`C34XVTC`%BX`L`12\$U6`\_1`MTLQ`A`^!|)PA|O`PC`<E1`VA`<H9W96`NL`<H5O`#`+H`+6`=-BYL`RE`AC`S`H`Y`V`\*`MZ`\$|U1ZQ`%`!<5`+18@`\$`SRDMTA992N>0|`HBO41`=SA1Z7W3Q`G`J`F`EW>`MB+A94`JF+A6<`5E|QP8H|`#ZBP`NB`OKV`T|F;|EAZ`^L`Z`=|L|);`5BH`MH7F|H9NS8)`Z`CCR\$CW`W`^VZ|(MPH&@`?`7J|P`M?U`K`+SKK|TGO?D08`*`7/0/8ZK`7B3N71;1&I`Z.49\$?QN`AO|VXM1>?M7`=+`M&`&|+D<`SO`>`=-173|A.W\$`<?2CKP4|>B`=-JBT|L.S|K|QAE6EW8`>Y3|(`M73`R1`|`@<O|X`N`81`A|Q`=<SD`D`+H&O6&P|D|DXC`6C`|P5`#`7|76G<4+^W9`MM`|`GW2V`N`=5W\$0@`#T`_G`>B`O`?CCGNV`MLM`0`02P,\$%`@`JH`6`=<|.WR0`M`@`S@<`<D`IX`|JW`&K&ULK55M3|LP\$&K`M5C9`(#`RVHIV:23`%&V3D`H0VX`=I`JSDVE@<D`K`="`O|J|;"2`^@L58OW2V`=[MGO`SOMY`6|O10X@T6`94#&Q84`N.C&W|XXC5LB`4%AR|NBPQ?`YI`P`83R|5VAANRSJ4VV`#4`MX3?<@<KRK`%ESM|(XE(R50014`%83ZJ|`=<SP`M`QQ`<`B`O`Q3722L`W>O`MVQB`M`2|`4`J`J`0`6GPW`H`@TD;K&O|M|`2\$U`<^`J8|ARVI66|18P8|5DLE|8EU8`M`*`5K@<MYP|9?H`4ST`P|X3Y1`O`&`=<18`\*\*V`9&4+5CF&R;|J`M`TX3J.KF57|T2A9Q|JN2X`+1#`"T`K3`7?`\$`SAYI4ABD`DE`8E`4`09W`=TF`ME2.3C;61+&5;`|J;0`6U`>`*`\$|`\$UHS?`\$XSR`KPR6%|>`!O`[F`=9F`G>`>H`=M)|Q>TW/D.V?(<|R@YSZSM|/CG`%WW`^|NC/DN`W!>`_/O|=!?`K`L`Y|J\$0`=<`\*J|&2)<`<U`E|+69#`*EK`\*`R`=7.V@V?2J`S7|BG`M|GCF|J@3`R`V?

*70IETUYBO"16H@)4*Y9P/52_DS?1H1)5ICTNF53_UBQS_M7"-1.P=UOF).[C8Z0#?"XS]02P,% @_JH_6?*:ZSY_P]I,_ID_M
!X;_J]W;K&ULO0A)=;JLVY%/TKA8+;+9!\$G6Z5_MV0*69;,Z<C1K_M#LO=&NK;#2])>4G;S]T?*"BCYLF8@++>+2^V^_US=;FE\$77%_MV8ZRKW<(-
*W(B_YW%@+L;DV39ZLH2#|BFZ@E%>6E!5\$R"%;F7S#@*0UJ;A_MV[|LR!9;<2S^MR^"03_-B3PK8<\$0KXJ^L\$*;<R.EN;F#C^<2G;+46ZH09SS9D
M!0!@F163(!EB7_"BAY1DO\$8#DW2L77M!_E_7\$WQGL>+!8J50>*?V]N_3_MN6\$!19!#(A0#D7);N(4!5TQ2Q!>+&U&CQJ8#|XV^VW^OD93%A,,MS?
_J4K>+M&Z&4EB2A>?Z.X!+!R%#|!@#L_MG@#8#;,!#3\$5+G50UWZ&RVRR4DWC@V#R.B9Q_M(EXPZO@FCB|0(B>E0*1,T6_-?
JFPGH]@MW<+<E2)S^<2/4<+154.B^Z1^G6)M/C_?J/KQ^CG6!;,MV1^W^O@+=;J*!;@S_Ma)NR,&UU!+8Z=LGWG;!
[>B^@X/^!_V_CSM^_6L7O_26!NR(>1_M|N^\$?_!\$_-M7;.*!^9H^1.6Q)''QO[107]QS+P\$=H0M7|C_MMJ]^+!-/!NTVL"!K=5YFJ5?
0#_K^6ZD%1%E1_!J7R<90&2C*%@9TSGRL_K_M*ETL!LX?N@=-!Z+M\$S(J3UO7+37BO:THCM7;517P;.K+!E_!8DRX=R3^!W^@_M!&|_..X
%N6;Y0G!>B?;UH8\$4FU\$.1?T5!_3E^H!8*>UY*=Z_V)R_9Y_M|VW>P2LM\!&4)9F(!;"2L_U)~&+/+07AD/2?R;+4J#QPZ%#A;XH3MNT^A56E5
MW519GF;E2FM!++<6YN5C-G<.*?J3,4V+!NOM\$ _9LXU@F!=-MA/!
C^P#>XX%VHX;.OZX07^766#M6SfN)^="MG+!6EYA3!;57VMP|UK6U38N9Y=E(K9A6;I>|NN;F=/6/6Y%[;"RHR@*#KT|^HD#"_<6
MX;&ZKFQ^!JEG@K^T!;669#^UYM5R3VVK\$S\$ _LR|ZWNP_U|FQ;0|FHIM6);N_M+<+!%D_CUN#XJ6|A\$(>5AV+<R>I8?
*NNX\$ZJN3CMEEL!+UU4MUJES.A;M;_N+!+1.UEUTD9!K;AJWS?=-G.EN.T5!O&PO=V]R_M.W_H965TDX@38CQ!Z(<+<
>65OG%#D7=PW.OCGE(>K11^JM9_M5CRE,O"C*.5M>N;.#;S%>3<7*HU%*YGH73.K6OJ96S6&GA6!>4R9DDRb;N_MBF@RjN|_J&2D2BM%-3
-3)GG7#_=@E2;<42CYQL?Q7E_8UX.EKS)=R!_>2>M;=>*Y1,Y%_8H0JB93&.7M&;V|0*)|X+&|C|JZ3^5>J;.^!<3X;1XEG!!+F_MUD_P|_4_KT%*C^1X?<
N!1O68G#_@_AGJCR|YE|P|_!R;_J9E?CZ^HB&2QX_M*=>U_M7D^NX3^F^N!D^R6;W;!*1>6FLRG?|CD\$NBNTW?JP58B_!JEX(8+L
M=>#E2Q?;MCGRTVA#MGW9H_j^M8R|V\$3AW|_U;_Y7N^@F6GWA#K5|NB_S_MR0M+>)&_1M|J|L7.5M^27
V^YD.97|ANY^P*R"MCP)H;|T/_TH|WW&YW7)A+W#YLRPN29|<\$).PWO?AL4NKSHW5_MN;*\$K_<"WE04(B)S|F4^<3WH?AB_9
8Z%|83E3|3TD#=>X@OBN|_#=#FS>"

0Iz_X_0ZM>4^DW5<5L*F8EBB6H"16U9QD'>7!>_M30PZ2&98)SA09K<=AQ35S5E*X.SQA^6KQP4^Y|Y1[63]4,"74.B2D%':ME_M<_K3*
[JY3K#I#A27^Y=IY0A0_ZA6Z)YU7T9JF2J_K^F_E9A+W%IP|+8%_M#=-9(V7GU0;OP2AK;DJ+VU40@-)_@FF1W&W.B"00Q8+;8<3Q)
#>6S)AK!<+<C&@DF2^WFO+!_!E(O=H6J5@F?3JS^K|PC=I_M,\$Z*6ED3E>!P^K/A8.D.&=<4_F)ZU6<=<B6Q63!(AD|KSA8%([_])G:4^);R_M='\$<
>I=Q';.#&=>|A;..3|LA4?K&V)@VFRW0EDTX6+LBN^B^#_J|C_#;D!|MF\$^<%%S+D_U.O@-;_DIUPO16&-(MA(6#2BZ;H+2VVN;.<J=76T?
^L57EU0N0>@?8/N/Z%4O:YX4^KZS!_)O!_M4\$!#!0(<*_J^EF[F^W^H00/6.9>+PO=V]R;W_H965T;HED8FV[|L.@#
M+8UL(I2H)6D|Z=>W*^FRY2A;+!L|Q|0UYP5G<#>2|C+>=^JH5!>9H<+4Q%EI_MG5^YKH16D%)U+G+(!\$TB9\$HUL|J|EJW|)"Y^7<#SQNZ*669,QT7?
7;Y8NU_MYBR#N21JG;94M!%N|XSL0_9_K4@>UPO_W^_EL1!_SH_IN!>Q7HU<2X\$>D<"UUQ^\$ML/4_4T^!_R1_MKX^X3|E|_#GD&BMM\$@K;
(X@95GY2Y|)(?8_R;..""I<CHOP^H58#>=>#2_M>P|0KP^J8ST;_D_1NEO&7@>@74DVG8RFV1!IK9#_.00T^C7JQS^3*^Y;XEB%.M3^|R3;,E6W
@UTJ|5N0L\$T95^<(+<3S0TC_?GHW=C6Z;@_WJFA02MK@#=#H>_MN1>97BDRRV^6_!A_W|8@?\$&_93RWQ|_!M;+V^<^S|_>*\$^73WJOX.L=>E?_D
3&=L@EC1V3J&;_BQ>M4Z?78LATRQAU(@+2C<=^!H?2VQ;(5D3@%4/F#C&B!=\$QJP/8S4*G.VU+(!MDP%#K4^30X/H7@/3<3^G_UY|B1+<
<_IYWH%REIPV|_VH|;WHU|>_J37^B(B9%!(M4PZW+!\$C^2,9>1AA=^M.MT|^+*J|K_LK_D&^RIWO.*OP/5+3EMJ^Y9JW|9_MJ?
K<#)#/;_V5D;@0.Q2<8T7;_|J7O>|>\$7GG?<^@X/N|/J8(>Y7)FR65#_MSE\$MYZ@|B0J|XOY*^5?IFU*=E,&7KE_M\$5K)_4=;|&#_+PV@H|GN|OX?7
M;.*#.#_NV0G31%\$.^!=-W5J?^Y1(W;UIC;F>G;GJ.RYDMETWJ|@YM?G<)_M!GA+@9|J_T9K6.K1|V4IU;..VRA17;@=-^U<&6SZ;8P4|LH%L#!|SA4O;
MEWM^54R|;ST?=>+!);MM,HVL76G(S=R=6W?73UK9Y=K;.*%5MEFMMB;4[!_!MO_K=!
[B3BI+54Zi5MK|B^>U1)LGK0=<=N%#0R^<+!J5.&F>IWHZEG|JVO9Z^+!_M2!F#_AO_ZM9OZ0=-6YQ8|BC+^&^"
[ZE6)NB\$8QFW3X_<T#^+US91B=1(RF|VZTM^BN^*#B2_!L46_M17L.SSVZ(B^<G.R&_J0V_1M^+G^N9L|&Z0^!<E6V@H.IN_M\$B7090TJY1*HJ^"BH?KB
7NYF#G<+>7J|AZ_MH^<T_YV6=WWH+<6R9_5PQ0!^E8SYQ?7?_N|QOCLU_XULJ|MAA|F|?+F>_919!#IBT^?_H|N(8|MTQ&QW|MF=^
_8|UX_L?J3FV605;&_UMR|JF2|V9.8F#EK^B5_Z_B_T;.!+5!F>?M^?F_81L|J|@OPGL@+8#4B3;^ZK1N|J^!5(H=DC;L+V|VIL;)|AW+H^&M>RW
4V9P.KWEFO(U6^2+I4^K=#;.&|J^4Y>H=-D|W|J6E7DF5N@T|@QJO;|_M;|_!^|F|K.2+&\$;M9.>J5_Z_JDVH|5/T?^<^PWYGA_TP^<X3>0&3BNX>00|AH#
M.A?|S@6_YB_X1O.|Y|J|AS=-.BC4OWV1.MQ|?J#B|J23.8.>9#4R^WX*2_M_H|G|>^Q\$|H|+*#W+^WM&|KUBL+2E(3HS%
M=FC7?N_M^QRG8EF>_G\$G;PP23HXKM#?2C8!+WERQ^>C3PX_9N^JTM+!J|G9M_MB^OAI768|6OZ35Z^_S47&#RFA4[V+JW(J1V_ZM>_!7!'
#_!R^#4XZ^>|Y^M|SXXQO5|&HBCD^<=OE|IT5|!\$MCLHUXPKL#|J|SPV12<_L^T|ST0MLCPI+MHR+I3|J#1#U!+P04^_!J^Y90%;9Z8^_M_L|P^&0
^AL+W=ON@MC.EN?%JG2RB8OI05E/AF+E7!#;\$5PM>5_I8|_M4B%|&@2)7S!>>NG_K4U4.I.K(W@)\$T7T|JBB8>KD#(3=#+1>%Q|X8FGL@!_M*K;
*9C^!J|PYC_(HV)33*3|LE.ON1#_M+|^&\$0\$!FK+>#QQ|&|(050AM_MY|>LZ4EML>OZ|)=LPR8QI&4OSBN5D.O_Y^M4FBX^A
>UUT\$>GZ6|(D|XZ>K1+J\$S%ZDYV^<G3BX|HGOCY^W.F.MC<)>S|J72X_!>Y=^>|NS|);*-<45;I2)1Z_M.I(%M@3-
W^*VJZ0#\$2^S(G<+>@NK+7@HD3M&UBG88T^N;.@&?CK=JPN7^J|XW8<M|JQK^O<@|9F5>+&D^V.L;06#<
<@QB3(<=)?J6CUNY<*>%P1|Y@J|!6VC=J\$^MC?7^XI/6|E<85K8EASWC\$K^EI3UV^TS?C_0!3%07Z|Y_0%@;T^NP?*7+2.\$U_M.OTA#1-
|5Z+>97+X^R=!!&ULM9EK;JLV%<_!"J\$^0P8;TSC_AUBBSOOP^Q|4N1X5_MNCV7L0&0Y^E+5
EZ4H2TM^LOIF1|/R#*^GXRU=PSW(3|H;KN|,AK).LA#PG+^934Q_MWMN7C0+01GQ5P|<71_BJ8|_!EN+E>3@RKR_A26;@0=7/(P@30N2RN_K
M#36;.@OA|74+/2P;KQKS0_7,6|WLI2;B3\$PR|)6=)!*!_!H6Z05_6+!7E_M7!^O8GN6018|((5E6BU4&69)7O_2!^A%_L^YAL^!K6@=ZK_MJP7>j8)^+>B?
0IK@7^<j8%+!F705MU1|JF5_J9V..=L37D0K6G%1&J)4JRY_ML|J^*KIXG2R>D=I%3^DMQ2+!_1)TYS04M7^7(1@*1)*GX=FU+55,2;BYH:
M5%3G&U27W+!<@>29YTM8=NA#O;ZOT9NJA4TSG9=F7CE.X.^|])8@J^<8JE#_MAND^!(<=<=
J5K=^YFJL<_Y.^7G_N^JZ|S^7V/E512UR18Z<3TOQT^O!A#C9_M1#C9Q^T_N%L768E@WU
H=3J04_5)=+#!T>|X|U+4%1)X\$E|ZPCH|^!6<#Z;.&%_!_!TX_MV!|JX3GMPPFW<\$#7M>_RA|&V2|OC5H1T4=43W+|JM1,5(36_WI_WI_!MSMJ\$)
MWP(7Z|O|PUD^!|JURI_RKE|JB(D+&_&S3%B(8LP83\$2K.6X0>_XP8|;_!P_M38|)"S|A<+&|_JH^"FM9Z+XYG>U_E0-Q|PU/K39^K3;N
MK+!G^?>=L^1QJ7|<_HVAH\$YV60GG_V\$3B|2IMCDH+46D1^BW&HK6JQ9R|MY_RH95%_QG(C)BU_HH_3);_28%MSLBG93?C9;3J;@C^!7D_(Y+#!#Q^?<
|G+#!.9J^SS2+S3>=>^FQ;_I_MJVS#B,99F,1<2A_N|)^22Y^2E16|J\$K^<^J|5\$|SU7=N4^2,Z6#|3M|616MHCN_MZ^8OB;#X|D+OZ^Y72D4|_FG02;O|LN+;
|P^Z7^6<Z,QJD&|9>=N,V?KB<7_M\$VY+X+G7>XGKRIM.K0H04VRRZK_N=>Z|^!VX3;69Y\$3>6B|5\$8UU^#;|W|M>%.!YS^HP#
<5^\$5\$A;_+3^0^DP^UIAT518#^*VP;"HLAU98_1560RM<_!4N_MAE98_Q760RN0V6^D9H.KM(|>+3)8;C)X\$FAP\$G@T><(<=#|YS!Q)X>!)X-
'GAR&GE1CZU'_0;08S@<_YENK^GETK|X9725&00U2J^M?<_XS^?O>5K|^"SJY3+3FCGD@?N+J7;..<@B30/PEWVTJ4T+_BRT^334%9_M1J0
F^@Z|^!J1?UITJ^T?>C;+<|97K_F>^YGE^QL^Y_MW|Z(W?*_J77K;@_S.S^W|J_G>O+&^M|HX|ACG3)&5
JX2Z>SRC2>H8YDR3M^%G)QM|DLYFOM#JH|X9_QA^<98QQS;G_M#1#%MO3GN.T9Z|?>LZPGHT.IC4NIC7>F^?>F/>L/CWD&?6QUHDYH8URHVD'
M^<T0?ZU2|(FBYSC04JGK5N0T|Y)RG|?7^Z7^6YX64X>V3T;_M(1V)&4.C.1&6\$K.1F(|?7^3F\$3?A^5^ZJ(|J0MF2|G/L.^J5C6_7|PK?_MN?|(JT7?
61RS_MCO.M.Q|HTX|J@;_<^|W\$4V1D9B^A)3D9B&Q^0QD9B_Q\$XE9_M2.Q&8@X2E\$|S^B|A^SUCVOR?+!JGNH|&66LR7BVXALX=^S_<6K|MM%#B
M>=>\$MY2|^Z(.P3J;161M|Y;46|J5|N@<^1S3.L|S1NY3<8|Y|W;O=CT;|3SEYXB=+|25).AF@+55*BF034=JAE0S81J\$E2S_MH9H#U5RHYD\$U^Z5U8_C-
3^S^C^%V#N=3&_Z_J9ML;3(C41JDE0389)^E13_MH9H&U72H9DU_U\$Zi94,V&@Y4>5#_M!3_RZ/!
A.7CZZ^Y^#VN^_H^6(6UW#IXBRQ^%QB|J\$J^9!_1FJ\$5!_A6H_M5_!2LZZOS=<S|&I6P6=>P7_H04M.\$=LJ.9_1>J>5#_1VG=B#RN|/"LI4?G
M9ENQL="^%UX|_4DJ^9#_06J|5!<@VKZF2=O_1\$B%_6_J^W^;(^*!9>|!MYW|+!@_!L.&_J5^8ORJ7|S3F?;4XP7UN3="QIN7|&#P+|N^5!>^JC_MM&
{&1+=&?_BHOX|G_H)G2JDMU+>6K93_0#R>=S%E9R&4.=U!_A&H25).A.MF@+55*BF034=JAE0S81J%E2SH9H#U5RHYD\$U^Z5UT_JX|
(JLH;RH_NPH)H(MU22HD)_U!Ji4\$V#;C14_Z;="4LJ9#^0_JN5#<^VH^2NM^<LOYQ\$N!_L8M_|D^<S394+K_N(A)PZ1;\$MM&#;_J5?
3KJ6=;|JYME|BE3^Jv^<12|=MND\$S;|M%+NV^|QOZY=|L_MQV6=<=H^H@DZ9|>236\$S^Q0E1M%|5TNI^?F_MHM7^92B_A&\$XC);A2|GDC-
DY1EH4KJW^"Q\$8BT24TA;.)\$VB6DDH.806(=M\$NN2F\$EB%HG9).:LL=N#+%2|K\$F%)\$1&=\$G;((^B?DD_H^P7!))0X_T)
M412.PNDBNR@%EY6I^W3;|0AU^P|106T7@8EJ6D2OC^%M&M&+!+8MY=-ZE/|MJL+_.^&4^JR1_B_W1^!<K;JN\$F+|(>#>V7SB?5\$S">Q_83EL-
9VZ6G;(U|B_5V=BLKRT02!>X5_63;J|1_ZC60J4U514.Z;_AFHJZ|AFHUD+U+J|J9_M|&A;AFHU|J^KU4_U%0_5^JCFQY;|PRB(4T1R|X2_S|CE-
^M1Z.4Z0/5_M^"(LP\$H+U;#D5A0H|8K|E18^HV|>_T4_6;.#;#X3*PHT0S_3E.9PEV>W6_M>EF_\$>39^O^T9JG5.KL8GW;9Z1=MY^#HV;.3(|7YW(DZ;
3|VCU|?3X,9ZF_M=Z;@|6CZF|2<9)<=>+X^P6(Q&0J7_XHFP#))_M|V8A4A&R_H|QXS^!|@_MN^F99T&RC^;#5_R^R|?%)=0|+?
<YY&^5M%CYWG^#41A.LTX>OGZ\$|.WUWFRY_M6C|[PFM15^>U=JHJ|&CFH&JG50K8M|J|H9J&CFH-
J51S4BW|K^W^M^!4UGZND?;Z2WIE#R9|GHZ3;#G_N<X^L;U8S9YXQA_M^D3P0?34XT.OOC|FH|H;9^RB,6_MVT5G&RjX.UN_BK|WA-
C^*_5(G+3BQ(G|H^*)1VR=&U="H^HE1_M#31JY2H732J>6)4^XUJGQC50;V4_U%0_5^JCFHJ|TO+^!TA|&ZDH.7
M\$(-="N.XSDH)C991=H8^G72.YZ.SOS|KO_EU_6OBK743^RC11M^HM9O;^T_M_!J50;J95&O.TVYGH_!J_J95%#Z;I9.\$SH.%2C).IU49L%#8;=<
^HW=*H_M4N.F|J;_?^T4Y.DPGO81J_ZJ_9#_125%3KHJY|@_*RQ_6|4JQO.HE_M0,52V^P;S;^"B24UM>NQL|^Z@BMDXJ^JJJ-
9&_0W5=5%0\$4^V#_EU4_U_MOC4_U1Q4ZZ&BVH>J051S4>U_7EDJ@WH.X7M6+_UZB\$%."0+46|BFH|J|.M&J4T5_1S4_U^H|U4.C61S4?
U0;4ELJG^S(28C4=MB54.&ZZ3VKIP|SQ;5S7_5@<E7;5IC^T;@2JM5!_0345U=JHJ|&CFH&JG50_MK8M|J|H9J&CFH-JO8V6_Y|_S;D|MV0SL=F0I(Y;

—M7I-5)))D)IRHW@6 M F=4?Y#VU1@DZA6^ZUE2O% ^IL\KQS9ABE<=>B*S< <GNC G)A%44X[LI+WX M&RHJ&K9])&RS63A)HJ%AJ2-
A-Z?D)IEHV\$Y6G+G1+))RRFOF[>UXADU+J IX6F\$% \$9JM?>2*2\$5,C M87- F%VJ7LS<%Q<(5NOC?HY*M1-j*:.BFHEH;U314TU-0+4 JG51S40U"j5L
M5^0K8=>+JJIYJ-9^>CO?>3"%3,?+2)MFJ>CG[KNQ/^&^,1SN+W"ZY4>V?G M)W4A.ZHHJ*:.B6AO5-%334;HEVPGRW+ONLY!&5<7ZXWJM:
[Y+;%2?B]5+Y X\$*:.07L MG(&N\$E\$JQ51 MS4>U-7E)H<^P7QZU U3^657 0Q <QZ>QK <?Z*:.K\I\WVDMCK?JIY^I@ M9ZJCFHHJ'.GU4U%M0&GY?
+O. "i55QCXR27U>39J0RM.(IJ)JI MJ 9&-0W5=-0S4*V#.#U4U-0C4.U1O4ZZ&:BVH>J051S9=**FK4WU. IX+F
M<I2^704771.J6ORA4^74A6B0UJ5HHJ'.BFIM5-034P@7>32FEBVH>J051S4>U-7E.16I+HP@50Q>=<.<^8+X+>=1.JJFHHJ%. 'j5i5M06CYU2?04)?
V<I\UHR6LD"U5JHHJ'.BFIM M5-034i5K5i=D9#ZVR@FHHJ)*JU44U# 1W5#%3KH%H7U4O4LU# 1C5GHU57K>NA
M.5U4U"MCVHJ@TH+9^IJE4VTIOP>.U^i.P&M=9NM#MZJIVK M9.B5JY.O18KB<-7WY8;0HM\$57=B-.3&U12 1445% 1K8UJ&JKH&.@6@25
MNJAFHHJ%.C.J-.C60S47U3O4ZZ..CVH#2LLGOWU#.#GODI Z H74U4*V%:@JF MJ.C61C4
U714.U"M@V1=5# 1S4U&J4<5.NAFHMMJJKU4=P7P16CU M^2N1I2 I^H+H@W6 M"Y/P6QJ=ME.9Y=1=G^(IDX R7WRY\$%^\$QWF2S*>KFTJA.JC:
(T^6 S=i*X MN9.%>)E?>ZYYV [4\$ L#H0 (<?J #ED>^& GBP. "<0.9>&PO M=VJR.W H965T)CIGVQV7\$V8TK \$6GHJ J1^I M&)D=2Y:74+&
<5C"9F" 900#D@N" E"N M&.#X.L 2BD(2B67VWV;C%0\$GEZ L"<5*V8+&".J^.. RMJ]>\$%^CT"<%.V MIQV VP+<Q6iNM=>J^"W"/J:0 "
N5I8Y9R>H4YCN:4^i55T8) 7JAR*OP M* DOQKB5 S .l8Y^T&4A.W\$< X+I\I^/ZK1" [WVY[S>YX]=19MRI3+<MSG>X7?2i5^TA#ETFFY?<CI=3M^IY+
[QT9GNCEZ?Q\$KR<^&W2@QW1811X+Y2.%\$*CM.F.IPM>9OPMK P M/8(COKAT2Q"=R3GV;Q#CM>2=U^S8@.?>4M+ F OFYZ[OP9FUI*/O\7*
M\T%+9YNK&HDD93O?2B2ER).G<^"O(A#B?>*#F0U\CEF1I+P=C"/2V1Q4I4XXQ5D.?>WL=TXB =.Z0^X2I)5G#D.002*U!H% 6IB& M+.*AY-
Z)>Z8V(Y^Y^4O).^<<61(URSIC:9R IG55.KLY F M2@>.Z#>RIX%>QR IS<0.1 ZNC 1ZU=O9KY4H^B^2M(HH7M>X3.*8W3+<KD1
MZ^V10MJUJ7LVBFI3U.I"JV".20#%.&W* SPI&^=O.5.^ VT>#GO.XO>/ M'D86.Z(6>&3THI<— R+NHIN).3BSYZI7=52PWXIO21E:26Q
MLXYS+COH.6&LVJ4H8004*UDI&CJ]i#@5 DARTSVY(#(5BW=9)D4MYTW%1) MHCA(+.B\$[%E^<5?NDBR1 Y^A>Q%.H(OM_*J.3A<2N4.(G&1
DC\$ZW M^CABT.FCD .3JOP4I&LJGT@F7J/(44"2#64S1 YI<=1 B007?1JGWN79S1 M.P+P=iH&8WP2
7T=1Q\$V&6LP^>B974Q97%+JG2ODZ4.XFUJGDH1Z ^>%.NU+IPCEZ13U6U9+V7I)JESCW27.J%KM2Z<^(+ M# "A=P...+GBZ%
(M=J76Y7@H2+ #U92W Q&S4ISJ.3V6>=>^2JT+ZU\Z8^OM M\$2LF0M)\$\W.H0Z6^D)367S"L4>RT">^&%KM2ZP(JU"MX Y*%*G98K3M5B5VI=
MCH>JIGJ6=>+TFGOUTJB CE8" \$LH9^K<.N8#J4"MM<^UNJO6T\$M*EEQ.*F& M>E\$Z+2\$;M6.4(IQ+TM&P79*0@<^PVJ\ZAJD^S8YIYI=
IER45JGFL TA RK86M* M%G M OSXVFR2*=>95V+UL05EK M:JLVY(TKA#9L+>1&HF0YCID^D#1#DD1)&OWH=>@6KJ.B4BB1JYI^S^CY14
MR41EQG(Y^C(NM) AQ>=>=>@>249.XLU@ 2/2UR\$LOH192+BJVZ0+^(@X84LH MU9LYXP6I Z18 ^6+)@605J.CI C&2D%HD263ZMD13R9LJ7-
PCU^8E44A/IS M13G.3#WL?7OP0)64C PDIF2?C\$R\$ +>ZIN J8EHP64@K(2<9A/O4M<1V.M.*19G"1FQ=
(YW*C+%G2?AFWJIC@AR2*6F\IO#=>0YYDQ?%W0^JUOK0= OJ#Ji\$Z 4 2\$)S1J M18^J)I)5#HG-
T:40H%Z3.D.WE.OH3B4%>1X@93R#.#I)MBC?WD^>^C5SZIG MOE3ZBGIM GLJ@XLM^?IZOR\$?7I&Q0&X.@?2FV^WT^JX+B^1R<5Q*U.H6M
M3F"%%^W@.UR#+>=>"GV04(B ^F2HYQWUSZM7I858DA2FGEJF O@>0.27G X M^U/%\$=DAD11*U%D8T ^8)+D2I G6L\$%TIO^L.O*
(HG GHILJ^C> SW(TR M8AJU.8VL="W"&G*\$T9<^*#>PM@91A:=\$D1K)QFVQI\Z 74KDB.R0: Q*M #ZL1ZVP JI07W(SE/D==KF=.FCX?
6/K#R.F(S)>@&I\$=.04XJ6ZNV\$R9.O>&K<^L@KB03.MGF&V M7.NS3 CNF5I8/0OVLE=HV<^97"U*.8JG>?"I=iJ=.S16^*5 GU;#5YEB: M^@!
IU+^U SB1F5IOX#=#9 U8^9G:JIG<+4 L9GG)WJ" X CG90XM8.NV\$R9 M.FL86CV5IH71X%L[I7N&6Z/<N8Y#102P.\$% M@JH.6>#G.X"V\$@ \$S\$H!
ID IX: "JW.WK&ULK=U.4IM8NL:OKZ)BIF.W5^7IDFT/0E5W=Y.)UF7W3A6(\$NJV:%F0 M9&I ^&VIG9
MRQ+UFXMNCI)= =Q^I2I&2WZ7/WI\$5 JFA."C^5BM2YR=E4 M#I^>GZIGI^DR67 *M+5YDINLWR9%)MA[OSI4>)C?@Y+<
I(KOGIY\$H7PCF= =^<87SZV\MR5T.ID7J.TWGYV *C?S9J.L\$F.5D2>W7Y^U^W^O\RP/L YZGWJ=O(A.*M^5.EOU92F+ B"+>+O>KKIAL:E-
IL6Z^="J)? MCKVX.I^FC^LB6VX^V.PG^J> IOIVY%O\D@CHX.D+8#I/T^PR.#AML^PZX# M1ML\HZY3&F^C+L.N@.N@Z8+
(=.DZX^(IX+I+K@*OM@*NN 13I\LP.@JY M=F=S\X JWBP2D^F1WPL6# WYTR.Z4B OG7#KVOR+ N3KK8^R+N\N=N=CIO
MKE\$BYW/O+@H6+GO+NLO=3IITN12R1+SLA.S R\$F17". ML^J^7AZ HY <=>66^*A24L @W?SK?C"N NPR*. 7F?+6J2?T @O+7 MXISX?>
PBI74R7ZS *7P4XE 62OGI\$S^2%YIMY9CSV5.V7F3IB^PA.FINJA+ MRNHFO.E/IJ G6TFIZIOTNMH/FX^B2D^P^<^?YVCI<27X^DGATM.OA
M1.#H.*5J]V^6J5T>JUV&^..M0I#^I.CP 4NPZ6CPXWVX6KZJ5/7IS9 M8:AX<72XU6^X8^OTN UE^/).R=>9) 5Z^3=+L/5 S MS?>7ZL.&X7Z^X=L?>
VJ.A09>2>^4X6&ZM)+=E4>1JN @P^X2I2F9^K ^ MBRU+W IUEI^X>1.J 1ND?#WADP&\$6Z7^G88- OXBC9K^V2W7I4.R2I^<M.7X17Z?>
Y4WIV 8^ B1>#?S4MK20FDYA(8B)?2FDYA(8B)?621FDYA(8BZ) M>20V3&?O (2"TDL(K\$8PFHO.WJ F5&?OTU6RZSE: NT^>#L+Y/B6\$Y+&X
MS+Y2= AWD)F5.P\0F\$QB^HFI)*F\$YB\HF9)&1F\$UB^HFY).J8- G
MK+O^<W0I^FS ^7S^I#9^A IDQ.,2"PDL8C\$8@BKJ"G^T6R>5R4.ORI^TR6CWUOIOG%I8C*)*22FDIA&8CJ)&21FDIA%
M8C:1.23FDICW@DW>A.#@TV @ID5%IZ+1A2ID6DOT3L2DTE.(3&5O#02 MTTC.(#&3Q^P2LTC.(3&?Q+O)IO<2FHJIR8D%)>26\$1B.835DN+R-
2DN6YB MMJMB\$P%IAD.DK7Y.0UO4L(I717=H4J)U.WU @.9G\$%)324PC.9W\$#I(S M2N&B18M12K&RVHJ).@FHHJFHHJ:
M@6HFJEFH9J.:@VHNJGEI(>) SER*H ^S8ZN! KH J4"U\$M0K68TNIAJ. M3NSIUG= ?Y>OW8?"^>L=%JOFHYJ'.BJJ^BFHYJ'.B.J6:AFHYJ#.BZJ
M>5OMI^UO<2>2)I) K6MIB.^%JIX F=>JILX 4I 134\$U%=4T5 1S4 U\$J4L5+ 1S4\$U%J6I MK=8E.OI^I(9Y P#5 M1+4^UF +JF5^UB(NM08^70?
J4YNMT^QH/BWG00.A) MUI^ E!N7M08&FB7.*KJ)*@FHHJ&KJHJ:@FHEJ%JK9J:@FHMJWHF1/OX MF^7^OJ&0OUU1&J LBT?
U04"U\$M0K68TNJY4S6 EYMI^>.3.H>D>K^1 MD ^O4YQ2C\J M4T0G2>?^E15I5A50ZQJ^L:.*%6S8U4 I6GIWKJ@5=V. M53VTZA35?
%0+4"U\$M0C58DJK+I[A5%L8WH9M9] 3=2\$J98O^92A?IXS +T1 MDDU8)W>A)#/9XUO.MJR13<I7\$K\BR:5MVIH+65#05U"->J>:!EK3I%33
M0FO.G6H2:YVW4TTPK3E^1 5 E0+42U"M9C2Z@MMU<>AOGI^&CHJ^=WS. IYF.^> MAX7.PW1W\QT^NZIY^<I>^>04 0YI5
O> 5VY?P#B5(LIK.Y15WV&8GNCGL^I M IKM^=&57MR<5MDA.M^OO.OI7XD\COM?#2.7P IOE^OJ@Z&DR&>VJ3 M5M&j6E-54I1 JE7ZFA5HZJ^!
I7HSJ54VTJM585.IXW.LMM&3JD5X>=5 MDQ9^ZERTHJ=J4U3542U.M1#5(E2+*V^OE.=N6J>VIM32K; JW+>=J2BVHR
MJBHFHJ^AFHJZAFH9J^A6HYJCFHYJ^AVI35/1+4"U<^Q05WZJ5>(<AZGA<M3.VN^A95OZJ8WJ\$;96775/9RG #46QG1-
EQ4DU0 0345U314TU"0#43U2O4 MLU^0347U.RM5EOAL(3BFBT+125 E0+42U"M9C2ZD)JWISI?>W IN.N9E MDPFB9>YZ%.R7R3?
QJ0OGEF^TJ WOH2I>VNF^ZHI).@JHJ.BFH9J.:@J.FE:AFH9J.^ZIN.E0:7.M.Y+Z. 1%ZWJHUIJ .B&Ji.@64UHJ7JH7.FJ6I28
MOD=YZW>=>SAIS3=AL.N.4^OK.U=I@K.MHJ'.BJJ^BFHYJ'.B.J6:AFHYJ# M.BZJ>> 1A*9K6^BT?
%0+4"U\$M0C58DJK1X141<^JSM^<+5.GJ^3I3 *C/J3 MP8^V J^&C#HJFHHJ&CFH&JFH9J&C6H.JKFHYDF".T^KV.(@CZJi:@6
MHEJ\$C&EU2.E.@R6VOOYXE6>3K^I52GD^6VKGO\VX11348U!=545 -034J 7CS8?M+EM53 MFA?SIN+FO7I6OC#2P=/6C.*HJHJ.BFH9J
M.JH9J&BFH5J.IH9Y.9NM9J.:Z%5IZCFHUIJ.B&JL@64UH5\$J&U=JF82WE M0MIZ#)7G39QZ/ JI^Y=.T%87.SJXK^RUAO@H7>P=%
<=>CRIVMOA"2VK^BDI MF>SUBVMH6?UVV2MIJR 90.N.S66%Y.J/G4+ +6L?3N1JLHZ.%GW2 FKT7A M 9XT+>3J RC0IG54"U M1+4(U>+=.1V^5?
2U:2)U>#>7@OU\I0I^N1#? MNQM> IOJW&T&QW5%1344U# 1W5#%0S4RH MLJ.@FHHJFHHJ:@6HFJEFH9J:@VHNJGFH D4U^I4"5 M1+4^UF
+JX5 U MNPI^QZ6ZMI=N^YKG?PH^WNJ^@FHHJ&KJHJ:@FHEJ%JK9J:@FHMJHJ M4F18.V17Z%=5D5% 0344U#>5T5# 0S40U^J5L5^0S44U
M.WCXP^IOH>K>BG6HJ\I%J!936CUJE188\PF ^Y.ZC?MO?MO^WHF^=N&C MFHJ)*JHJ^CFH%JH9J&CFH
J+JY2P9G6NIG^MJ#CVHJH6H%I%3&GU M1^EZI(2M?C=>I&R2TVX>^O7+OY\$%.IU% 0345U314TU"0#43U2O4LU"
M0347U3O4FZ^CVHJH6HJ%J%3&FUC^H5K?LCOG5 A+NHJ).@JHJ.BFH9J. M:@JF.AFH9J.^ZIN.CF=H4U7O4"U M1+4(U6^JX=U.H ZM&Z?
+>3306 M.W.OOGU44U^ 134 U714.U# 1#4+U6O4Q02WHHUIJ.B&J M1.@64UH2Z2J0I2TX>@KIO9MVL7>@H\H\HJ'.BJJ^BFHYJ'.B.J6:AFHYJ#
M.BZJ>./#^?I. K.Y(IJ .J%J:A6DOH4"IFOQ^0^>CJYG0G2?XW 2)\$ MZ4HP5K T5.@V134^U0)4"U\$M0K68TNHA5^7L\$S\^<T/A 1G5%1344U# 1W5
M#%0S40<4 M0#49U1144U#0S4=U0Q4U-0C4.U1O4 4& M.&P^F=I6C.ZHJHJ^BFH9J.JH9J&BFH5J.JHYJ.BFH=J4U3S M42U
M1#5(E2+*V>4^<K NX^VOF&C^J^BFHJ&CJH&AFHHJ%.C.J M.:CFHHJ.E4U#M0+40U2)4BRFM^CJCO W KU 5^5(M0+T?J)H(."^13\UK01I4
U4)4BU MIK1ZKE1 M>^VOX@W<3^M V14GE8S(LPDVZGN7SAV>KIH3I6WF1S49U1144U#0S4= MU0Q4U-0C4.U1O4 X>T5="(
(^J@6HJ^D:A&HQI:TD MS?GZ^DT+ 2F2ZL+ +I+OZ+Q5J898^K#5I>*OJH"GMVLD\$G J33H\WXRL M#K ^)#Z3LL#W+ / S>7K7 PI02P.\$% @JH
654P7RD10 M(RI ID IX."JW.WK&ULKM9KO.ZY^>2^8M) MTR.= "MCD5Y=\$G.H4ZK%K7I>+T%RYO&W2 ^<D=I^<F\$X)@1H10JH MJJ^?YXG?&)
[NN2B2I^E3^*069H7 VIMY>..JXMXS3J.7\$ Rj65RXXR^M6A M>+>+C6T5Z7^4A1P.#^I)IVEY.BGF4Z5.9\$S14#%LNH^<+4KZ2>.%W
M/=&?/*E^N^/IOOZS^Z8 &S%.K(KU562<R(N^N\$Y\$NOIYMV\$UXLHTAW*GIF M.%>^CZJ M?R@^KP.S2 NVX.E2R4JN9JH80ROV1+>IO.?>
[7U@UH^6BWE.E' IOFH>."C>M%DG56<509.DA T.V7\$20>ETIXI5OUPLT TI@.LIHRH?I(RF&JY+IX+O MD="ME9K^4I3IE.C27+J&I^D4%
<3U4.%SS+JF>BRP0S5=HP7.9Y\LCO 6 MH>=>TF3M/AOZDMU.IW^CROAVX.PB.I1=*^EV@G .56IGI?15D^2D^1GJ+ MG8^MOD5L(L\$IA
^EWX@B^U.14BIZ29Y\$JC0L7^D+M1+OQB H M1QW+JGX& V+ZE Y>ST T^<ZTV 9I%+ G1QI<C&88RNI>MB0V.VU0Q M%TSLF#?
=KMP&S4YA20F.5.5/L6E>KD^0EWA\^<^< RK.HX^2I85K39\$D#8 MB5DV#&H^NITL.)&Z^S9.%/I2 /MIS?Y.)#>LOYITN^J2X=3?G8ZIM=F
M1^4S^JIA>T0 E W.W) +LSF^Y&4C.IFU4S.JL=E^D#8 B5DVC&L(O.K#) M/F+XI^&L#>WBPI WN#*2KPIDKMG""&D/I9* ("5F6V@>^3^U2N*
(VI+9TP^C5^ M^I^ZO>9>ANM^<=>441K9XX8^F<4&JMG.&.. AGI4.BH0Q.K85!AIG)XRI MHCA&[<41 8NC^P@.#06&@.#R5+QZ+NEI=<43.2>
U&SO#&).&DS[+ O0QH=3L M.2#F#%(@.MWI^H)KHM^H?>O9?=> 7CLL (W8#XPO+XYINTI^V53^0TIT MT^GP&KQRI^I0U+Z#4A.F&+>8XE@4
*\$4K M.*2) I^TQ=BXI4+BLUH% SGS MYP...1N.RA1^YIECNBSL(T@.28X^D>J%DBH+PI69.87@37YC2I%PBH(A9 MJ4WL^AF2*1)^#CMB-
CDO!5IM87JH/MF/YEJ%.I>#7&176Q.^Q7<Z/OZDEK M MFTY3J.ZS.!)\$TK ML^0KXP =FY."9MW 9D@JMXU0J2>LJ^I!+MWPAGVW#
(&+@CKCAKEI.OZM37&^<5^V1Z>V<@=>7N2^W1=TI)#%22I^?K=1JF4Z72P?10I(8\$S<)<I)EXPR<IAG^ MUJFG/8K(TI49+X MQH&=D^IV5;
<I(X\$7AAWZW4>?>0V+>6H%OJDNW^&O^Y M^I M Y.K=83JO2.>Z7U3FJING+I KO>^=I&YKIJ (Z^YR004J>E&1P-5^D M^XIL@I^DF *3E1_7C^Z8T

W4I22.Y2? WZ?>#% U!+ P04 M< ^J @ Y9 + ,#XUL # !0%0 #0 ^AL+W T>6QE@ M2U5BW< ^IIO^U=6+;J12^TYLHKRG6? Q1Q< CEIWIY?;IA #G#I/D 1B#^J^S5@^LGA C MC ^J^I(D L-N+B4. %Z1L?W\$N=,^F08 3 M# 1(^IG^715E *121.X*2.30A^C8>E1-S3MF)< ^1-8^J^D&ISO.6UM3.*YJ M.D%UT+1+8#Q^O^LUGN=-KS% #N^;LOU>^9GHXP2?>7>BUION:FAI. 1AIB+3 MLN2+3YQ 1\$IMY/<...B1H9W+21FT &@5...0^7QOW5.IV^C=^DN2IL.U.*< MYAFENN7V FOIMGB=44\$GXNFA=^VYRRJ6^5>2I)YJFP+=EJL#PYO7>3%(8B M#T^D0=1DIQI\$)@<@LO J3I WGB S2I.B@/=@JMG.5VEI@A^F<^<^EU+^92.J^IL.*R<@T^=W04>L+^+1.*W.Y\$XAB^,C9,&WA@<2#2IW^K9>(^OK %O3716^S12O1&RF>^*X!<^< M^I+&O=18^;#&K^8COC@.UY2^)(EA53^NV@W\$D23 %M%=HW&.^9>^&CWM^ML%T214GB1@!S^X@B#(^=B^8.M^ (5%DWHL^IZ@^9X^5K^A^OX 4\$L#!0 M (^*J #EF7BKL

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how.js IDEA: XBRL DOCUMENT//Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by IDEANET employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null;Show.showAR=function(a,r,w) {if(Show.LastAR)Show.hideAR();var e=a;while(e&e.e.nodeName!=^TABLE^){e=e.nextSibling;if(!e||e.nodeName!=^TABLE^){var ref=((window)?w.document.document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(!e.style.display='block'){Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!=^DIV^){e=e.nextSibling;if(!e.style){}}else if(!e.style.display){}}else {var d_p;if(!e.style.display=='none'){d='block';p=''}else {d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else {a.innerHTMLText=p+a.innerHTMLText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT/* Updated 2009-11-04 *//* v2.2.0.24 *//* DefRef Styles */.report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }.report table.authRefData { display: block; font-weight: bold; }.report table.authRefData { margin-top: 0px; }.report table.authRefData { display: block; background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }.report table.authRefData { display: block; background-color: #2F4497; }.report table.authRefData { height: 150px; overflow: auto; width: 400px; }.report table.authRefData { font-size: 1em; }/* Report Styles */.pl a. pl a:visited { color: black; text-decoration: none; }/* table */.report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; }.report hr { border: 1px solid #acf; }/* Top labels */.report th { background-color: #acf; color: black; font-weight: bold; text-align: center; }.report th:empty { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; }.report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; }/* word-wrap: break-word; */.report td.pl a { cursor: pointer; display: block; width: 200px; overflow: hidden; }.report td.pl div a { width: 200px; }.report td.pl a:empty { background-color: #ffc; }/* Header rows... */.report tr.rh { background-color: #acf; color: black; font-weight: bold; }/* Calendars... */.report .re { background-color: #f0f0f0; }/* Even rows... */.report .re. report .re { background-color: #def; }.report .re { border-bottom: 1px solid black; }/* Odd rows... */.report .ro. report .rou { background-color: white; }.report .rou { border-bottom: 1px solid black; }.report .rou { border-bottom: 0px solid black; }/* styles for footnote marker */.report .fn { white-space: nowrap; }/* styles for numeric types */.report .num. report .num { text-align: right; white-space: nowrap; }.report .num { padding-left: 2em; }.report .num { padding: 0px 0.4em 0px 2em; }/* styles for text types */.report .text { text-align: left; white-space: normal; }.report .text .big { margin-bottom: 1em; width: 17em; }.report .text .more { display: none; }.report .text .note { font-style: italic; font-weight: bold; }.report .text .small { width: 10em; }.report sup { font-style: italic; }.report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 205 245 1 false 56 0 false 5 false false R1.htm 000 Document Document And Entity Information Sheet http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 Statement Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 Statement Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet Parentheticals Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 Statement Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 Statement Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) Sheet http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement Parentheticals Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 Statement Condensed Consolidated Statements of Stockholders'222 Equity (Unaudited) Sheet http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Stockholders'222 Equity (Unaudited) Statements 6 false false R7.htm 006 Statement Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 Disclosure Organization and Significant Accounting Policies Organization and Significant Accounting Policies Notes 8 false false R9.htm 008 Disclosure Accounts Receivable, Net Sheet http://www.chinapharmaholdings.com/role/AccountsReceivableNet Accounts Receivable, Net Notes 9 false false R10.htm 009 Disclosure Inventories Sheet http://www.chinapharmaholdings.com/role/Inventories Inventories Notes 10 false false R11.htm 010 Disclosure Property, Plant and Equipment Sheet http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment Property, Plant and Equipment Notes 11 false false R12.htm 011 Disclosure Intangible Assets Sheet http://www.chinapharmaholdings.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 012 Disclosure Other Payables Sheet http://www.chinapharmaholdings.com/role/OtherPayables Other Payables Notes 13 false false R14.htm 013 Disclosure Related Party Transactions Sheet http://www.chinapharmaholdings.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 014 Disclosure Lines of Credit Sheet http://www.chinapharmaholdings.com/role/LinesofCredit Lines of Credit Notes 15 false false R16.htm 015 Disclosure Convertible Note Payable Sheet http://www.chinapharmaholdings.com/role/ConvertibleNotePayable Convertible Note Payable Notes 16 false false R17.htm 016 Disclosure Leases Sheet http://www.chinapharmaholdings.com/role/Leases Leases Notes 17 false false R18.htm 017 Disclosure Income Taxes Sheet http://www.chinapharmaholdings.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 018 Disclosure Fair Value Measurements Sheet http://www.chinapharmaholdings.com/role/FairValueMeasurements Fair Value Measurements Notes 19 false false R20.htm 019 Disclosure Stockholders' Equity Sheet http://www.chinapharmaholdings.com/role/StockholdersEquity Stockholders' Equity Notes 20 false false R21.htm 020 Disclosure Commitments and Contingencies Sheet http://www.chinapharmaholdings.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 21 false false R22.htm 021 Disclosure Subsequent Events Sheet http://www.chinapharmaholdings.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 996000 Disclosure Accounting Policies, by Policy (Policies) Sheet http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies 23 false false R24.htm 996001 Disclosure Accounts Receivable, Net (Tables) Sheet http://www.chinapharmaholdings.com/role/AccountsReceivableNetTables Accounts

[Receivable, Net \(Tables\) Tables](#) [http://www.chinapharmaholdings.com/role/AccountsReceivableNetDetails](#) Accounts Receivable, Net (Details) Details [http://www.chinapharmaholdings.com/role/InventoriesTables](#) Inventories (Tables) Tables [http://www.chinapharmaholdings.com/role/Inventories](#) 25 false false R26.htm 996003 Disclosure Property, Plant and Equipment (Tables) Sheet [http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables](#) Property, Plant and Equipment (Tables) Tables [http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment](#) 26 false false R27.htm 996004 Disclosure Intangible Assets (Tables) Sheet [http://www.chinapharmaholdings.com/role/IntangibleAssetsTables](#) Intangible Assets (Tables) Tables [http://www.chinapharmaholdings.com/role/IntangibleAssets](#) 27 false false R28.htm 996005 Disclosure Other Payables (Tables) Sheet [http://www.chinapharmaholdings.com/role/OtherPayablesTables](#) Other Payables (Tables) Tables [http://www.chinapharmaholdings.com/role/OtherPayables](#) 28 false false R29.htm 996006 Disclosure Lines of Credit (Tables) Sheet [http://www.chinapharmaholdings.com/role/LinesofCreditTables](#) Lines of Credit (Tables) Tables [http://www.chinapharmaholdings.com/role/LinesofCredit](#) 29 false false R30.htm 996007 Disclosure Leases (Tables) Sheet [http://www.chinapharmaholdings.com/role/LeasesTables](#) Leases (Tables) Tables [http://www.chinapharmaholdings.com/role/Leases](#) 30 false false R31.htm 996008 Disclosure Fair Value Measurements (Tables) Sheet [http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables](#) Fair Value Measurements (Tables) Tables [http://www.chinapharmaholdings.com/role/FairValueMeasurements](#) 31 false false R32.htm 996009 Disclosure Organization and Significant Accounting Policies (Details) Sheet [http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails](#) Organization and Significant Accounting Policies (Details) Details 32 false false R33.htm 996010 Disclosure Accounts Receivable, Net (Details) Sheet [http://www.chinapharmaholdings.com/role/AccountsReceivableNetDetails](#) Accounts Receivable, Net (Details) Details [http://www.chinapharmaholdings.com/role/AccountsReceivableNetTables](#) 33 false false R34.htm 996011 Disclosure Accounts Receivable, Net (Details) Schedule of Accounts Receivable, Net Sheet [http://www.chinapharmaholdings.com/role/ScheduleofAccountsReceivableNetTable](#) Accounts Receivable, Net (Details) Schedule of Accounts Receivable, Net Details [http://www.chinapharmaholdings.com/role/AccountsReceivableNetTables](#) 34 false false R35.htm 996012 Disclosure Accounts Receivable, Net (Details) Schedule of Changes in the Allowances for Doubtful Accounts Sheet [http://www.chinapharmaholdings.com/role/ScheduleofChangesintheAllowancesforDoubtfulAccountsTable](#) Accounts Receivable, Net (Details) Schedule of Changes in the Allowances for Doubtful Accounts Details [http://www.chinapharmaholdings.com/role/AccountsReceivableNetTables](#) 35 false false R36.htm 996013 Disclosure Inventories (Details) Schedule of Inventories Sheet [http://www.chinapharmaholdings.com/role/ScheduleofInventoriesTable](#) Inventories (Details) Schedule of Inventories Details [http://www.chinapharmaholdings.com/role/InventoriesTables](#) 36 false false R37.htm 996014 Disclosure Property, Plant and Equipment (Details) Sheet [http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails](#) Property, Plant and Equipment (Details) Details [http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables](#) 37 false false R38.htm 996015 Disclosure Property, Plant and Equipment (Details) Schedule of Property, Plant and Equipment Sheet [http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable](#) Property, Plant and Equipment (Details) Schedule of Property, Plant and Equipment Details [http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables](#) 38 false false R39.htm 996016 Disclosure Property, Plant and Equipment (Details) Schedule of Estimated Useful Lives of the Assets Sheet [http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable](#) Property, Plant and Equipment (Details) Schedule of Estimated Useful Lives of the Assets Details [http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables](#) 39 false false R40.htm 996017 Disclosure Intangible Assets (Details) Sheet [http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails](#) Intangible Assets (Details) Details [http://www.chinapharmaholdings.com/role/IntangibleAssetsTables](#) 40 false false R41.htm 996018 Disclosure Intangible Assets (Details) Schedule of Intangible Assets Sheet [http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable](#) Intangible Assets (Details) Schedule of Intangible Assets Details [http://www.chinapharmaholdings.com/role/IntangibleAssetsTables](#) 41 false false R42.htm 996019 Disclosure Other Payables (Details) Schedule of Other Payables Sheet [http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable](#) Other Payables (Details) Schedule of Other Payables Details [http://www.chinapharmaholdings.com/role/OtherPayablesTables](#) 42 false false R43.htm 996020 Disclosure Related Party Transactions (Details) Sheet [http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails](#) Related Party Transactions (Details) Details [http://www.chinapharmaholdings.com/role/RelatedPartyTransactions](#) 43 false false R44.htm 996021 Disclosure Lines of Credit (Details) Sheet [http://www.chinapharmaholdings.com/role/LinesofCreditDetails](#) Lines of Credit (Details) Details [http://www.chinapharmaholdings.com/role/LinesofCreditTables](#) 44 false false R45.htm 996022 Disclosure Lines of Credit (Details) Schedule of Principal Payments Sheet [http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable](#) Lines of Credit (Details) Schedule of Principal Payments Details [http://www.chinapharmaholdings.com/role/LinesofCreditTables](#) 45 false false R46.htm 996023 Disclosure Convertible Note Payable (Details) Sheet [http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails](#) Convertible Note Payable (Details) Details [http://www.chinapharmaholdings.com/role/ConvertibleNotePayable](#) 46 false false R47.htm 996024 Disclosure Leases (Details) Sheet [http://www.chinapharmaholdings.com/role/LeasesDetails](#) Leases (Details) Details [http://www.chinapharmaholdings.com/role/LeasesTables](#) 47 false false R48.htm 996025 Disclosure Leases (Details) Schedule of Operating Lease Liabilities Sheet [http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable](#) Leases (Details) Schedule of Operating Lease Liabilities Details [http://www.chinapharmaholdings.com/role/LeasesTables](#) 48 false false R49.htm 996026 Disclosure Income Taxes (Details) Sheet [http://www.chinapharmaholdings.com/role/IncomeTaxesDetails](#) Income Taxes (Details) Details [http://www.chinapharmaholdings.com/role/IncomeTaxes](#) 49 false false R50.htm 996027 Disclosure Fair Value Measurements (Details) Schedule of Assets and Liabilities Recorded at Fair Value Sheet [http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable](#) Fair Value Measurements (Details) Schedule of Assets and Liabilities Recorded at Fair Value Details [http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables](#) 50 false false R51.htm 996028 Disclosure Stockholders' Equity (Details) Sheet [http://www.chinapharmaholdings.com/role/StockholdersEquityDetails](#) Stockholders' Equity (Details) Details [http://www.chinapharmaholdings.com/role/StockholdersEquity](#) 51 false false R52.htm 996029 Disclosure Commitments and Contingencies (Details) Sheet [http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails](#) Commitments and Contingencies (Details) Details [http://www.chinapharmaholdings.com/role/CommitmentsandContingencies](#) 52 false false All Reports Book All Reports ephi-20240630.xsd ephi-20240630-cal.xml ephi-20240630-def.xml ephi-20240630-lab.xml ephi-20240630-pre.xml ea0210807-10q chinaphar.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT f "version": "2.2", "instance": f "ea0210807-10q chinaphar.htm", "nsPrefix": "ephi", "nsuri": "http://www.chinapharmaholdings.com/20240630", "dts": f "schema": f "local": f "ephi-20240630.xsd", "remote": f "http://www.xbrl.org/2003/xbrl instance 2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl linkbase 2003-12-31.xsd", "http://www.xbrl.org/2003/xl 2003-12-31.xsd", "http://www.xbrl.org/2003/xlink 2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt 2005.xsd", "http://www.xbrl.org/2006/ref 2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated 2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net 2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference 2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" }, {"calculationLink": f "local": f "ephi-20240630-cal.xml" }, {"definitionLink": f "local": f "ephi-20240630-def.xml" }, {"labelLink": f "local": f "ephi-20240630-lab.xml" }, {"presentationLink": f "local": f "ephi-20240630-pre.xml" }, {"inline": f "local": f "ea0210807-10q chinaphar.htm" }, {"keyStandard": 216, "keyCustom": 29, "axisStandard": 23, "axisCustom": 0, "memberStandard": 30, "memberCustom": 26, "hidden": f "total": 71, "http://fasb.org/us-gaap/2024": 55, "http://www.chinapharmaholdings.com/20240630": 10, "http://xbrl.sec.gov/dei/2024": 6, "contextCount": 205, "entityCount": 1, "segmentCount": 56, "elementCount": 420, "unitCount": 5, "baseTaxonomies": f "http://fasb.org/us-gaap/2024": 636, "http://xbrl.sec.gov/dei/2024": 30, "report": f "R1", "role": "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation", "longName": "000 Document Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": f "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "p", "div", "body", "html" }, {"reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, {"uniqueAnchor": f "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": f "p", "div", "body", "html" }, {"reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, {"R2": f "role": "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet", "longName": "001 Statement Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2",

~~"us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:OtherReceivablesLessAllowanceForDoubtfulAccounts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "unique": true }, "R4": { "role": "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement", "longName": "003 Statement Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c6", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c6", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "R5": { "role": "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement-Parenteticals", "longName": "004 Statement Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenteticals)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenteticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parentetical", "menuCat": "Statements", "order": "5", "firstAnchor": null, "uniqueAnchor": null }, "R6": { "role": "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3", "longName": "005 Statement Condensed Consolidated Statements of Stockholders'2019 Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders'2019 Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c9", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c14", "name": "us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "unique": true }, "R7": { "role": "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow", "longName": "006 Statement Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "unique": true }, "R9": { "role": "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies", "longName": "007 Disclosure Organization and Significant Accounting Policies", "shortName": "Organization and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "R10": { "role": "http://www.chinapharmaholdings.com/role/Inventories", "longName": "009 Disclosure Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "R11": { "role": "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipment", "longName": "010 Disclosure Property, Plant and Equipment", "shortName": "Property, Plant and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "R12": { "role": "http://www.chinapharmaholdings.com/role/IntangibleAssets", "longName": "011 Disclosure Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "R13": { "role": "http://www.chinapharmaholdings.com/role/OtherPayables", "longName": "012 Disclosure Other Payables", "shortName": "Other Payables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "R14": { "role": "http://www.chinapharmaholdings.com/role/RelatedPartyTransactions", "longName": "013 Disclosure Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "R15": { "role": "http://www.chinapharmaholdings.com/role/LinesofCredit", "longName": "014 Disclosure Lines of Credit", "shortName": "Lines of Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "R16": { "role": "http://www.chinapharmaholdings.com/role/ConvertibleNotePayable", "longName": "015 Disclosure Convertible Note Payable", "shortName": "Convertible Note Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div", "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "R17": { "role": "http://www.chinapharmaholdings.com/role/Leases", "longName": "016 Disclosure Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div",~~

gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.chinapharmaholdings.com/role/FairValueMeasurements", "longName": "018 Disclosure Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.chinapharmaholdings.com/role/StockholdersEquity", "longName": "019 Disclosure Stockholders Equity", "shortName": "Stockholders Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.chinapharmaholdings.com/role/CommitmentsAndContingencies", "longName": "020 Disclosure Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.chinapharmaholdings.com/role/SubsequentEvents", "longName": "021 Disclosure Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy", "longName": "996000 Disclosure Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.chinapharmaholdings.com/role/AccountsReceivableNetTables", "longName": "996001 Disclosure Accounts Receivable, Net (Tables)", "shortName": "Accounts Receivable, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:AccountsAndNontradeReceivableTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:AccountsAndNontradeReceivableTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.chinapharmaholdings.com/role/InventoriesTables", "longName": "996002 Disclosure Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:InventoryDisclosureTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:InventoryDisclosureTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables", "longName": "996003 Disclosure Property, Plant and Equipment (Tables)", "shortName": "Property, Plant and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.chinapharmaholdings.com/role/IntangibleAssetsTables", "longName": "996004 Disclosure Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "ix:continuation", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "ix:continuation", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.chinapharmaholdings.com/role/OtherPayablesTables", "longName": "996005 Disclosure Other Payables (Tables)", "shortName": "Other Payables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.chinapharmaholdings.com/role/LinesOfCreditTables", "longName": "996006 Disclosure Lines of Credit (Tables)", "shortName": "Lines of Credit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:LongTermDebtTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:LongTermDebtTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea0210807-10q chinaphar.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.chinapharmaholdings.com/role/LeasesTables", "longName": "996007 Disclosure Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:LesseeOperatingLeasesTextBlock", "div": "body", "html" }, "reportCount": 1, "baseRef": "ea02108

"ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.chinapharmaholdings.com/role/OrganizationAndSignificantAccountingPoliciesDetails", "longName": "996009 - Disclosure - Organization and Significant Accounting Policies (Details)", "shortName": "Organization and Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:OtherCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": { "p": "ix:continuation", "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true }, "uniqueAnchor": { "contextRef": "c57", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": { "p": "ix:continuation", "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true }, "unique": true } }, "R33": { "role": "http://www.chinapharmaholdings.com/role/AccountsReceivableNetDetails", "longName": "996010 - Disclosure - Accounts Receivable, Net (Details)", "shortName": "Accounts Receivable, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.chinapharmaholdings.com/role/ScheduleofAccountsReceivableNetTable", "longName": "996011 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net", "shortName": "Accounts Receivable, Net (Details) - Schedule of Accounts Receivable, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:AccountsReceivableGrossCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.chinapharmaholdings.com/role/ScheduleofChangesintheAllowancesforDoubtfulAccountsTable", "longName": "996012 - Disclosure - Accounts Receivable, Net (Details) - Schedule of Changes in the Allowances for Doubtful Accounts", "shortName": "Accounts Receivable, Net (Details) - Schedule of Changes in the Allowances for Doubtful Accounts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c46", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c46", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:AccountsAndNontradeReceivableTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.chinapharmaholdings.com/role/ScheduleofInventoriesTable", "longName": "996013 - Disclosure - Inventories (Details) - Schedule of Inventories", "shortName": "Inventories (Details) - Schedule of Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails", "longName": "996014 - Disclosure - Property, Plant and Equipment (Details)", "shortName": "Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c6", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p": "ix:continuation", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c6", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p": "ix:continuation", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable", "longName": "996015 - Disclosure - Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment", "shortName": "Property, Plant and Equipment (Details) - Schedule of Property, Plant and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable", "longName": "996016 - Disclosure - Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of the Assets", "shortName": "Property, Plant and Equipment (Details) - Schedule of Estimated Useful Lives of the Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "td": "tr", "table", "ix:continuation", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "td": "tr", "table", "ix:continuation", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails", "longName": "996017 - Disclosure - Intangible Assets (Details)", "shortName": "Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "p": "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable", "longName": "996018 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets", "shortName": "Intangible Assets (Details) - Schedule of Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable", "longName": "996019 - Disclosure - Other Payables (Details) - Schedule of Other Payables", "shortName": "Other Payables (Details) - Schedule of Other Payables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "ix:continuation", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails", "longName": "996020 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c91", "name": "us-gaap:PaymentsForLoans", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c91", "name": "us-gaap:PaymentsForLoans", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" } }, "reportCount": 1, "baseRef": "ea0210807-10q_chinaphar.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.chinapharmaholdings.com/role/LinesofCreditDetails", "longName": "996021 - Disclosure - Lines of Credit (Details)", "shortName": "Lines

of Credit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c93", "name": "us-gaap:LineOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": { "p": "us-gaap:LongTermDebtTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c93", "name": "us-gaap:LineOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": { "p": "us-gaap:LongTermDebtTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable", "longName": "996022-Disclosure-Lines of Credit (Details)-Schedule of Principal Payments", "shortName": "Lines of Credit (Details)-Schedule of Principal Payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c112", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "ix:continuation", "us-gaap:LongTermDebtTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c112", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "ix:continuation", "us-gaap:LongTermDebtTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "longName": "996023-Disclosure-Convertible Note Payable (Details)", "shortName": "Convertible Note Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c113", "name": "us-gaap:DebtInstrumentFeeAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p": "us-gaap:ShortTermDebtTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c113", "name": "us-gaap:DebtInstrumentFeeAmount", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "p": "us-gaap:ShortTermDebtTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.chinapharmaholdings.com/role/LeasesDetails", "longName": "996024-Disclosure-Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c6", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c6", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable", "longName": "996025-Disclosure-Leases (Details)-Schedule of Operating Lease Liabilities", "shortName": "Leases (Details)-Schedule of Operating Lease Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c2", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "ix:continuation", "us-gaap:LesseeOperatingLeasesTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails", "longName": "996026-Disclosure-Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": { "p": "us-gaap:IncomeTaxDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": { "p": "us-gaap:IncomeTaxDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable", "longName": "996027-Disclosure-Fair Value Measurements (Details)-Schedule of Assets and Liabilities Recorded at Fair Value", "shortName": "Fair Value Measurements (Details)-Schedule of Assets and Liabilities Recorded at Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c2", "name": "ephi:BankersAcceptances", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "div", "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c165", "name": "ephi:BankersAcceptances", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "ix:continuation", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "unique": true } }, "R51": { "role": "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails", "longName": "996028-Disclosure-Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c2", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "div", "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ephi:AftertaxNetIncomePercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": { "p": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "unique": true } }, "R52": { "role": "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails", "longName": "996029-Disclosure-Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c187", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c187", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "p": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div": "body", "html": 1, "reportCount": 1, "baseRef": "ea0210807-10q-chinaphar.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.chinapharmaholdings.com/role/AccountsReceivableNet", "lang": { "en-us": { "role": { "terseLabel": "ACCOUNTS RECEIVABLE, NET", "label": "Accounts and Nontrade Receivable [Text Block]", "documentation": "The entire disclosure for accounts receivable, contract receivable, receivable held for sale, and nontrade receivable." } } }, "auth_ref": { "r222", "r257" } }, "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/OtherPayables": { "lang": { "en-us": { "role": { "terseLabel": "OTHER PAYABLES", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": { "r373" } }, "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": { "lang": { "en-us": { "role": { "totalLabel": "Total Other Payables", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": { "r50", "r51" } }, "us-gaap:AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable [Member]", "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": { "r50" } }, "us-gaap:AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Other payables", "label": "Accounts Payable, Other, Current", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r48" } }, "us-gaap:AccountsPayableOtherCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrentAndNoncurrent", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Other payables", "label":

"Accounts Payable, Other", "documentation": "Amount of obligations incurred and payable classified as other." } } }, "auth_ref": { "r106" } }, "us-gaap-AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Accounts Payable, Trade, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r12", "r48" } }, "us-gaap-AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/AccountsReceivableNetTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in the Allowances for Doubtful Accounts", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": { "r804" } }, "cphi-AccountsReceivableCollectedWithBankersAcceptances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "AccountsReceivableCollectedWithBankersAcceptances", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable collected with banker's acceptances", "label": "Accounts Receivable Collected With Bankers Acceptances" } } }, "auth_ref": { } }, "us-gaap-AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofAccountsReceivableNetTable": { "parentTag": "us-gaap-AccountsReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofAccountsReceivableNetTable": { "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": { "r146", "r224", "r695" } }, "us-gaap-AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Member]", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": { "r687" } }, "us-gaap-AccountsReceivableNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetAbstract", "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net [Abstract]" } } }, "auth_ref": { } }, "us-gaap-AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofAccountsReceivableNetTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "http://www.chinapharmaholdings.com/role/ScheduleofAccountsReceivableNetTable": { "lang": { "en-us": { "role": { "totalLabel": "Trade accounts receivable, net", "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts of \$13,706,077 and \$13,786,074, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": { "r797" } }, "cphi-AccountsReceivableNetDetailsScheduleofChangesintheAllowancesforDoubtfulAccountsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "AccountsReceivableNetDetailsScheduleofChangesintheAllowancesforDoubtfulAccountsLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofChangesintheAllowancesforDoubtfulAccountsTable": { "lang": { "en-us": { "role": { "label": "Schedule of Changes in the Allowances for Doubtful Accounts [Abstract]" } } }, "auth_ref": { } }, "cphi-AccountsReceivableNetDetailsScheduleofChangesintheAllowancesforDoubtfulAccountsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "AccountsReceivableNetDetailsScheduleofChangesintheAllowancesforDoubtfulAccountsTable", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofChangesintheAllowancesforDoubtfulAccountsTable": { "lang": { "en-us": { "role": { "label": "Accounts Receivable, Net (Details) - Schedule of Changes in the Allowances for Doubtful Accounts [Table]" } } }, "auth_ref": { } }, "us-gaap-AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r51" } }, "us-gaap-AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": { "parentTag": "us-gaap-AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": { "lang": { "en-us": { "role": { "terseLabel": "Compensation payable to officer", "label": "Accrued Salaries, Current", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r51", "r697" } }, "us-gaap-AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable": { "parentTag": "us-gaap-PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable": { "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": { "r32", "r140", "r558" } }, "us-gaap-AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": { "r14", "r15", "r73", "r147", "r553", "r584", "r588" } }, "us-gaap-AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r1", "r9", "r15", "r428", "r431", "r493", "r579", "r580", "r775", "r776", "r777", "r785", "r786", "r787", "r789" } }, "us-gaap-AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid in capital (APIC) for common and preferred stock." } } }, "auth_ref": { "r63", "r733", "r914" } }, "us-gaap-AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Additional Paid in Capital", "label": "Additional Paid in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r602", "r785", "r786", "r787", "r789", "r857", "r915" } }, "cphi-AdditionalSharesAvailableForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "AdditionalSharesAvailableForIssuance", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional shares available for

issuance", "documentation": "Number of additional shares available for issuance.", "label": "Additional Shares Available For Issuance" } } }, "auth_ref": [] }, "cphi_AdvanceToSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "AdvanceToSupplies", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Advances to suppliers", "documentation": "Advances to suppliers.", "label": "Advance To Supplies" } } } }, "auth_ref": [] }, "cphi_AftertaxNetIncomePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "AftertaxNetIncomePercentage", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "After tax income, percentage", "documentation": "After tax net income percentage.", "label": "Aftertax Net Income Percentage" } } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Compensation expense (in Dollars)", "label": "Share Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } } }, "auth_ref": { "r370", "r371" } }, "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofAccountsReceivableNetTable": { "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/AccountsReceivableNetDetails": { "http://www.chinapharmaholdings.com/role/ScheduleofAccountsReceivableNetTable": { "lang": { "en-us": { "role": { "negatedLabel": "Less: allowance for doubtful accounts", "terseLabel": "Allowance for doubtful account", "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables", "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet." } } } }, "auth_ref": { "r798" } }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals": { "http://www.chinapharmaholdings.com/role/ScheduleofChangesintheAllowancesforDoubtfulAccountsTable": { "lang": { "en-us": { "role": { "periodStartLabel": "Balance, Beginning of Period", "periodEndLabel": "Balance, End of Period", "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts (in Dollars)", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } } }, "auth_ref": { "r148", "r225", "r268" } }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amortization expense relating to intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } } }, "auth_ref": { "r6", "r285", "r291", "r707" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Potentially dilutive common shares (in Shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } } }, "auth_ref": { "r200" } }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } } }, "auth_ref": { "r24" } }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } } }, "auth_ref": { "r24" } }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } } }, "auth_ref": { "r104", "r117", "r142", "r170", "r203", "r207", "r215", "r216", "r256", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r419", "r421", "r458", "r547", "r636", "r703", "r704", "r733", "r752", "r821", "r822", "r873" } }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } } }, "auth_ref": { "r137", "r151", "r170", "r256", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r419", "r421", "r458", "r733", "r821", "r822", "r873" } }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Assets, Current [Abstract]" } } } }, "auth_ref": [] }, "cphi_BankOfChinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "BankOfChinaMember", "presentation": { "http://www.chinapharmaholdings.com/role/LinesofCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Bank of China [Member]", "label": "Bank Of China Member" } } } }, "auth_ref": [] }, "cphi_BankOfChinaCommunicationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "BankOfChinaCommunicationsMember", "presentation": { "http://www.chinapharmaholdings.com/role/LinesofCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Bank of Communications [Member]", "label": "Bank Of Communications Member" } } } }, "auth_ref": [] }, "cphi_BankersAcceptanceNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "BankersAcceptanceNotesMember", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable": { "lang": { "en-us": { "role": { "terseLabel": "Banker's Acceptance Notes [Member]", "label": "Bankers Acceptance Notes Member" } } } }, "auth_ref": [] }, "cphi_BankersAcceptances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "BankersAcceptances", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable": { "lang": { "en-us": { "role": { "terseLabel": "Banker's Acceptance Notes [Member]", "label": "Bankers Acceptance Notes Member" } } } }, "auth_ref": [] }, "cphi_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable": { "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable": { "lang": { "en-us": { "role": { "terseLabel": "Building [Member]", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } } }, "auth_ref": { "r91" } }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "periodStartLabel": "Cash and Cash Equivalents at

Beginning of Period", "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period", "terseLabel": "Cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth ref": { "r18", "r82", "r168" } } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "totalLabel": "Net Decrease in Cash, Cash Equivalents and Restricted Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, "auth ref": { "r0", "r82" } } }, "us-gaap-CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "terseLabel": "Supplemental Noncash Investing and Financing Activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "documentation": null } } } }, "auth ref": { } }, "cphi-ChinaPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ChinaPharmaMember", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails": { "lang": { "en-us": { "role": { "terseLabel": "China Pharma [Member]", "verboseLabel": "China Pharma 2019s [Member]", "label": "China Pharma Member", "documentation": null } } } }, "auth ref": { } }, "cphi-ChinaPharmasCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ChinaPharmasCommonStockMember", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "China Pharma 2019s Common Stock [Member]", "label": "China Pharmas Common Stock Member", "documentation": null } } } }, "auth ref": { } }, "doi-CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "CityAreaCode", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } } }, "auth ref": { } }, "us-gaap-ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } } }, "auth ref": { "r120", "r143", "r144", "r145", "r170", "r194", "r195", "r197", "r199", "r205", "r206", "r256", "r309", "r311", "r312", "r313", "r316", "r317", "r338", "r339", "r342", "r345", "r352", "r458", "r593", "r594", "r595", "r596", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r624", "r645", "r668", "r681", "r682", "r683", "r684", "r685", "r759", "r791", "r790" } } }, "us-gaap-CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (Note 14)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } } }, "auth ref": { "r58", "r108", "r550", "r623" } } }, "us-gaap-CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments And Contingencies [Abstract]", "documentation": null } } } }, "auth ref": { } }, "us-gaap-CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsAndContingencies": { "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } } }, "auth ref": { "r92", "r300", "r301", "r688", "r809", "r814" } } }, "cphi-CommitmentsandContingenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "CommitmentsandContingenciesDetailsTable", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]", "documentation": null } } } }, "auth ref": { } }, "us-gaap-CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock reserved shares", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } } }, "auth ref": { "r61" } } }, "us-gaap-CommonStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsShares", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock (in Shares)", "label": "Common Stock Dividends, Shares", "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits." } } } }, "auth ref": { "r10" } } }, "us-gaap-CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails": { "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } } }, "auth ref": { "r742", "r743", "r744", "r746", "r747", "r748", "r749", "r785", "r786", "r789", "r857", "r913", "r915" } } }, "us-gaap-CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet-Parenteticals": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } } }, "auth ref": { "r61" } } }, "us-gaap-CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet-Parenteticals": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } } }, "auth ref": { "r61", "r624" } } }, "us-gaap-CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet-Parenteticals": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock shares issued", "label": "Common Stock, Shares Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } } }, "auth ref": { "r61" } } }, "us-gaap-CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet-Parenteticals": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Common stock shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } } }, "auth ref": { "r10", "r61", "r624", "r642", "r915", "r916" } } }, "us-gaap-CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, \$0.001 par value, 500,000,000 shares authorized; 17,162,771 shares and 10,625,788 shares

issued and outstanding, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r61", "r552", "r733"] }, "us_gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r16", "r153", "r155", "r160", "r543", "r564", "r565"] }, "us_gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r26", "r27", "r44", "r45", "r219", "r590", "r687"] }, "us_gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r26", "r27", "r44", "r45", "r219", "r687", "r764"] }, "us_gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Concentration risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the [benchmark] (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r26", "r27", "r44", "r45", "r219"] }, "us_gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy": { "lang": { "en-us": { "role": { "terseLabel": "Consolidation and Basis of Presentation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r43", "r698"] }, "us_gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us_gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Advances from customers", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r354", "r355", "r356"] }, "cphi_ConversionOfRelatedPartyNoteAndInterestToCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ConversionOfRelatedPartyNoteAndInterestToCommonStock", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "terseLabel": "Conversions of Note Payable to common stock", "documentation": "Conversion of related party note and interest to common stock." } } }, "label": "Conversion Of Related Party Note And Interest To Common Stock" } } }, "auth_ref": [] }, "us_gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Converted share issued and outstanding", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. [Part noncash] refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r20", "r21", "r22"] }, "us_gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebtSecuritiesMember", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Convertible, Redeemable Note Payable [Member]", "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": ["r826"] }, "cphi_ConvertibleNotePayableDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ConvertibleNotePayableDetailsTable", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails": { "lang": { "en-us": { "role": { "label": "Convertible Note Payable (Details) [Table]", "documentation": "Convertible Notes Member", "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ConvertibleNotesMember", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails": { "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes [Member]", "label": "Convertible Notes Member" } } }, "auth_ref": [] }, "us_gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us_gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Convertible, redeemable note payable, net of issue discount", "label": "Convertible Notes Payable, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": ["r51"] }, "us_gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us_gaap_GrossProfit", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": ["r76", "r170", "r256", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r458", "r703", "r821"] }, "us_gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": { "http://www.chinapharmaholdings.com/role/LinesofCreditDetails": { "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable": { "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r308", "r819"] }, "us_gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": { "http://www.chinapharmaholdings.com/role/LinesofCreditDetails": { "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r308", "r819", "r820"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." } } }, "auth_ref": [] }, "us_gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk [Member]", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r87", "r219"] }, "cphi_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "CustomerOneMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Customer One [Member]", "documentation": "Customer one.", "label": "Customer One Member" } } }, "auth_ref": [] }, "cphi_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "CustomerThreeMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Customer Three [Member]", "label": "Customer Three Member" } } }, "auth_ref": [] }, "cphi_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "CustomerTwoMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Customer Two

[Member]": "documentation": "Customer two.", "label": "Customer Two Member" } } }, "auth_ref": [] }, "us_gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r11", "r50", "r51", "r105", "r107", "r174", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r709", "r710", "r711", "r712", "r713", "r731", "r782", "r810", "r811", "r812", "r868", "r869"] }, "us_gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Conversion price (in Dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": ["r94", "r320"] }, "us_gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Note converted into common stock", "label": "Debt Instrument, Convertible, Number of Equity Instruments", "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity." } } }, "auth_ref": ["r39", "r54", "r98", "r99", "r320"] }, "us_gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt extension fee (in Dollars)", "label": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": ["r55"] }, "us_gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": { "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r53", "r319"] }, "us_gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r11", "r174", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r709", "r710", "r711", "r712", "r713", "r731", "r782", "r810", "r811", "r812", "r868", "r869"] }, "us_gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt instrument redemption price percentage", "verboseLabel": "Lowest volume weighted average price", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": ["r113"] }, "us_gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt redemptions weighted average price", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "documentation": "Percentage of principal amount of debt redeemed." } } }, "auth_ref": [] }, "us_gaap_DebtInstrumentRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchaseAmount", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Debt redemption amount (in Dollars)", "verboseLabel": "Redemption amount (in Dollars)", "label": "Debt Instrument, Repurchase Amount", "documentation": "Fair value amount of debt instrument that was repurchased." } } }, "auth_ref": [] }, "us_gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet" }, "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r376", "r377", "r548"] }, "cphi_DeferredTaxAssetValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "DeferredTaxAssetValuationAllowance", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance on deferred tax assets", "documentation": "Deferred Tax Assets Valuation Allowance", "label": "Deferred Tax Asset Valuation Allowance" } } }, "auth_ref": [] }, "us_gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r6", "r31"] }, "us_gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r6", "r203", "r212", "r216", "r703", "r704"] }, "cphi_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "DocumentAndEntityInformationAbstract", "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 1-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": ["r756"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r757"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": {

"http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": [] }, "us-gaap-DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": ["http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Domestic Tax Jurisdiction [Member]", "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": ["r379"] }, "us-gaap-EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Loss per share.", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap-EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r161", "r183", "r184", "r185", "r186", "r187", "r188", "r193", "r194", "r197", "r198", "r199", "r202", "r409", "r418", "r445", "r446", "r544", "r566", "r700"] }, "us-gaap-EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement-Parententicals"], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r161", "r183", "r184", "r185", "r186", "r187", "r188", "r194", "r197", "r198", "r199", "r202", "r409", "r418", "r445", "r446", "r544", "r566", "r700"] }, "us-gaap-EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy"], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r24", "r25", "r201"] }, "us-gaap-EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": ["http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"], "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 }, "presentation": ["http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow"], "lang": { "en-us": { "role": { "terseLabel": "Effect of Exchange Rate Changes on Cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r867"] }, "us-gaap-EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "presentation": ["http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "U.S. federal corporate income tax rate", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": ["r380", "r721", "r784", "r853"] }, "us-gaap-EffectiveIncomeTaxRateReconciliationTaxCredits": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "presentation": ["http://www.chinapharmaholdings.com/role/IncomeTaxesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Enterprise income tax rate", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits." } } }, "auth_ref": ["r381", "r382", "r784", "r853"] }, "us-gaap-EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options [Member]", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "doi-EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "doi-EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "doi-EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "EntityAddressCountry", "presentation": ["http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166 1 alpha 2 country code." } } }, "auth_ref": [] }, "doi-EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "doi-EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r754"] }, "doi-EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "doi-EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "doi-EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r754"] }, "doi-EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri":

"http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": {
"http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": {
"lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label":
"Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence
number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] },
"dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory",
"presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Filer
Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer,
Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based
on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r754"] },
"dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityIncorporationStateCountryCode", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": { "lang": { "en-
us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation":
"Two character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": {
"xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": {
"http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data
Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every
Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files)." } } }, "auth_ref": ["r758"] }, "dei_EntityRegistrantName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": {
"http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name",
"label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by
forms filed with the SEC." } } }, "auth_ref": ["r754"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": {
"http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company",
"label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the
Exchange Act." } } }, "auth_ref": ["r754"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntitySmallBusiness", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": { "lang": { "en-us":
"role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting
Company (SRC)." } } }, "auth_ref": ["r754"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": {
"http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation": { "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification
Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer
Identification Number (EIN), is a unique 9 digit value assigned by the IRS." } } }, "auth_ref": ["r754"] }, "us-
gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityClassOfTreasuryStockLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us":
"role": { "label": "Stockholders Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts
are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain",
"presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails":
"http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": {
"lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance
including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r10", "r132", "r156", "r157", "r158",
"r175", "r176", "r177", "r180", "r187", "r189", "r191", "r204", "r261", "r267", "r298", "r353", "r392", "r393", "r405", "r406", "r407", "r410", "r417",
"r418", "r426", "r428", "r429", "r430", "r431", "r433", "r444", "r467", "r468", "r469", "r470", "r471", "r473", "r475", "r478", "r493", "r562", "r579",
"r580", "r581", "r602", "r668"] }, "cphi_ExtensionFee": { "xbrltype": "percentItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630",
"localname": "ExtensionFee", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails": { "lang": { "en-us": {
"role": { "terseLabel": "Extension fee", "documentation": "Percentage of extension fee.", "label": "Extension Fee" } } }, "auth_ref": [] }, "us-
gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable": { "lang": { "en-us": { "role": { "label": "Fair
Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per
share as practical expedient." } } }, "auth_ref": ["r326", "r358", "r359", "r360", "r361", "r362", "r447", "r448", "r449", "r450", "r451", "r452",
"r453", "r454", "r507", "r508", "r509", "r710", "r711", "r717", "r718", "r719", "r722", "r724"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable": { "lang": { "en-us": { "role": { "terseLabel":
"Level 1 [Member]", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities
that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r326", "r358", "r363", "r448", "r453", "r507", "r717", "r718", "r719",
"r722"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueInputsLevel2Member", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable": { "lang": { "en-us": { "role": { "terseLabel":
"Level 2 [Member]", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are
observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active
markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r326", "r358", "r363", "r448", "r449",
"r453", "r508", "r710", "r711", "r717", "r718", "r719", "r722"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable": { "lang": { "en-us": { "role": { "terseLabel":
"Level 3 [Member]", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption
about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r326", "r358", "r359", "r360", "r361", "r362", "r363", "r448",
"r449", "r450", "r451", "r453", "r509", "r710", "r711", "r717", "r718", "r719", "r722", "r724"] }, "us-
gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementInputsDisclosureTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/FairValueMeasurements": { "lang": {
"en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Measurement and Measurement Inputs, Recurring and
Nonrecurring [Text Block]", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial
instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } },
"auth_ref": ["r103"] }, "cphi_FairValueMeasurementsDetailsScheduleofAssetsandLiabilitiesRecordedatFairValueTable": { "xbrltype":
"stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname":
"FairValueMeasurementsDetailsScheduleofAssetsandLiabilitiesRecordedatFairValueTable", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable": { "lang": { "en-us": { "role": { "label": "Fair
Value Measurements (Details) - Schedule of Assets and Liabilities Recorded at Fair Value [Table]", "documentation": "Line items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": ["r459", "r460", "r461"] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FinancialInstrumentAxis", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable": { "lang": { "en-us": { "role": { "label":

"FinancialInstrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": { "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r334", "r350", "r434", "r455", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r563", "r706", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r734", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r799", "r800", "r801", "r802", "r858", "r861", "r862", "r863", "r864", "r865" } }, "us-gaap-FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "role": { "terseLabel": "Intangible asset useful life term", "label": "Finite Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in PnYnMnDnTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days." } } } } }, "auth_ref": { } }, "us-gaap-FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": "us-gaap-FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable": { "lang": { "en-us": { "role": { "negatedLabel": "Accumulated amortization", "label": "Finite Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } } } }, "auth_ref": { "r141", "r282", "r290", "r707" } }, "us-gaap-FiniteLivedIntangibleAssetsAmortizationMethod": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationMethod", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "role": { "terseLabel": "Amortization intangible by useful life, descriptions", "label": "Finite Lived Intangible Assets, Amortization Method", "documentation": "The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed." } } } } }, "auth_ref": { "r283", "r699" } }, "us-gaap-FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable": { "lang": { "en-us": { "role": { "label": "Finite Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } } } }, "auth_ref": { "r284", "r286", "r287", "r288", "r289", "r290", "r292", "r538", "r542", "r692" } }, "us-gaap-FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": "us-gaap-FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable": { "lang": { "en-us": { "role": { "role": { "terseLabel": "Gross carrying amount", "label": "Finite Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } } } }, "auth_ref": { "r282", "r290", "r542", "r707" } }, "us-gaap-FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "role": { "label": "Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } } }, "auth_ref": { "r284", "r290", "r292", "r293", "r295", "r538", "r692", "r707" } }, "us-gaap-FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable": { "lang": { "en-us": { "role": { "role": { "label": "Finite Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } } } }, "auth_ref": { "r284", "r286", "r287", "r288", "r289", "r290", "r292", "r293", "r692" } }, "us-gaap-FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable": { "lang": { "en-us": { "role": { "role": { "totalLabel": "Not carrying amount", "label": "Finite Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } } } }, "auth_ref": { "r538", "r807" } }, "us-gaap-ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } } } }, "auth_ref": { "r462", "r463", "r464", "r466", "r665" } }, "us-gaap-GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "role": { "terseLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } } } }, "auth_ref": { "r78", "r647" } }, "us-gaap-GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets [Abstract]" } } }, "auth_ref": { } }, "us-gaap-GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "role": { "totalLabel": "Gross (loss) profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } } } }, "auth_ref": { "r74", "r76", "r116", "r170", "r256", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r458", "r702", "r703", "r791", "r792", "r793", "r794", "r795", "r821" } }, "cphi-HainanHelsponMedicalBiotechnologyCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "HainanHelsponMedicalBiotechnologyCoLtdMember", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "role": { "terseLabel": "Hainan Helspon Medical & Biotechnology Co., Ltd [Member]", "label": "Hainan Helspon Medical Biotechnology Co Ltd Member" } } } } }, "auth_ref": { } }, "cphi-HelsponMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "HelsponMember", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "role": { "terseLabel": "Helspon [Member]", "label": "Helspon Member" } } } } }, "auth_ref": { } }, "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "role": { "totalLabel": "Loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } } } }, "auth_ref": { "r75", "r110", "r116", "r545", "r560", "r702", "r703", "r791", "r792", "r793", "r794", "r795" } }, "us-gaap-IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": { } }, "us-gaap-IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameAxis", "presentation": { "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails": { "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } } } }, "auth_ref": { "r386", "r856" } }, "us-gaap-IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityNameDomain", "presentation": { "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails": { "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } } } }, "auth_ref": { "r386", "r856" } }, "us-gaap-IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": { } }, "us-gaap-IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/IncomeTaxes": { "lang": { "en-us": { "role": {

"terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } },
"auth_ref": { "r171", "r375", "r379", "r383", "r384", "r385", "r387", "r388", "r397", "r399", "r400", "r401", "r598", "r721" } }, "us-
gaap_IncomeTaxExaminationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxExaminationLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": {
"label": "Income Taxes [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r386" } }, "us-
gaap_IncomeTaxExaminationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxExaminationTable", "presentation": { "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": {
"label": "Income Tax, Examination [Table]", "documentation": "Disclosure of information about income tax examination currently in progress or
completed during current period by tax authority. Includes, but is not limited to, description of examination, jurisdiction conducting examination, tax
year under examination, likelihood of unfavorable settlement, range of possible loss, liability recorded, increase (decrease) of liability from prior
period, and penalty and interest incurred or accrued." } } }, "auth_ref": { "r854" } }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } },
"presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "Income tax
expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense
(benefit) pertaining to continuing operations." } } }, "auth_ref": { "r118", "r127", "r190", "r191", "r203", "r213", "r216", "r379", "r398", "r567",
"r721" } }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxesPaidNet", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
"role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign
federal, state, and local jurisdictions as income tax." } } }, "auth_ref": { "r19", "r167", "r389", "r390" } }, "us-
gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
"negatedLabel": "Trade accounts and other receivables", "label": "Increase (Decrease) in Accounts and Other Receivables", "documentation": "The
increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts
receivable and other types of receivables." } } }, "auth_ref": { "r5" } }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
"terseLabel": "Trade accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations
of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." }
} }, "auth_ref": { "r5" } }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
"terseLabel": "Other payables and accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease)
during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": { "r5" } }, "us-
gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": {
"terseLabel": "Advances from customers", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase
(decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": { "r536",
"r780" } }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag":
"us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase
(Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the
reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": { "r5" } }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-
us": { "role": { "terseLabel": "Changes in assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": { } },
"us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label":
"Increase (Decrease) in Prepaid Expenses, Other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs
that provide economic benefits in future periods." } } }, "auth_ref": { "r5" } }, "us-gaap_IncreaseDecreaseInPrepaidSupplies": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidSupplies", "crdr": "credit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 9.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": {
"negatedLabel": "Advances to suppliers", "label": "Increase (Decrease) in Prepaid Supplies", "documentation": "Amount of increase (decrease) of
consideration paid in advance for supplies that provide economic benefits in future periods." } } }, "auth_ref": { "r5" } },
"cphi_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.chinapharmaholdings.com/20240630", "localname": "IntangibleAssetsDetailsScheduleofIntangibleAssetsTable", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable": { "lang": { "en-us": { "role": { "label": "Intangible Assets (Details)-
Schedule of Intangible Assets [Table]" } } }, "auth_ref": { } }, "cphi_IntangibleAssetsDetailsTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.chinapharmaholdings.com/20240630", "localname": "IntangibleAssetsDetailsTable", "presentation": {
"http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Table]" } } },
"auth_ref": { } }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IntangibleAssetsDisclosureTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssets": { "lang": { "en-us":
"role": { "terseLabel": "INTANGIBLE ASSETS", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or
part of the information related to intangible assets." } } }, "auth_ref": { "r283", "r294", "r691", "r692" } }, "us-
gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet"
}, "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of
the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment
charges." } } }, "auth_ref": { "r284", "r807", "r808" } }, "cphi_InterestAccruesOnNoteDescription": { "xbrltype": "stringItemType", "nsuri":
"http://www.chinapharmaholdings.com/20240630", "localname": "InterestAccruesOnNoteDescription", "presentation": {
"http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails": { "lang": { "en-us": { "role": { "terseLabel": "Description of interest
accrued", "documentation": "Description of interest accrues on Note.", "label": "Interest Accrues On Note Description" } } }, "auth_ref": { } }, "us-
gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr":
"debit", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails": { "lang": { "en-us": { "role": { "terseLabel":
"Interest expense (in Dollars)", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest
expense for debt." } } }, "auth_ref": { "r80", "r331", "r336", "r712", "r713" } }, "us-gaap_InterestExpenseNonoperating": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } },
"presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "negatedLabel": "Interest
expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": {
"r211", "r779" } }, "us-gaap_InterestExpenseOtherShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "InterestExpenseOtherShortTermBorrowings", "crdr": "debit", "presentation": {
"http://www.chinapharmaholdings.com/role/LinesofCreditDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Interest expenses", "label": "Interest Expense, Other Short Term Borrowings", "documentation": "Interest expense incurred during the reporting period on other short term borrowings." } } },
"auth_ref": { "r112" } },
"us-gaap-InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
"lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } },
"auth_ref": { "r163", "r165", "r166" } },
"cphi-InventionPatentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "InventionPatentMember", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable": {
"lang": { "en-us": { "role": { "terseLabel": "Invention Patents [Member]", "label": "Invention Patent Member" } } },
"auth_ref": { } },
"us-gaap-InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventories [Abstract]" } } },
"auth_ref": { } },
"us-gaap-InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": {
"http://www.chinapharmaholdings.com/role/Inventories": {
"lang": { "en-us": { "role": { "terseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } },
"auth_ref": { "r278" } },
"us-gaap-InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": {
"http://www.chinapharmaholdings.com/role/ScheduleofInventoriesTable": { "parentTag": "us-gaap-InventoryNet", "weight": 1.0, "order": 3.0 } },
"presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofInventoriesTable": {
"lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } },
"auth_ref": { "r772" } },
"us-gaap-InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 6.0 },
"http://www.chinapharmaholdings.com/role/ScheduleofInventoriesTable": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet":
"http://www.chinapharmaholdings.com/role/ScheduleofInventoriesTable": {
"lang": { "en-us": { "role": { "totalLabel": "Total Inventories", "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } },
"auth_ref": { "r149", "r694", "r733" } },
"cphi-InventoryPurchasedWithBankersAcceptanceNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "InventoryPurchasedWithBankersAcceptanceNote", "crdr": "credit", "presentation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
"lang": { "en-us": { "role": { "terseLabel": "Inventory purchased with banker's 2019s acceptances", "documentation": "The amount of inventory purchased with banker's 2019s acceptances.", "label": "Inventory Purchased With Bankers Acceptance Note" } } },
"auth_ref": { } },
"us-gaap-InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": {
"http://www.chinapharmaholdings.com/role/ScheduleofInventoriesTable": { "parentTag": "us-gaap-InventoryNet", "weight": 1.0, "order": 1.0 } },
"presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofInventoriesTable": {
"lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } },
"auth_ref": { "r774" } },
"us-gaap-InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": {
"http://www.chinapharmaholdings.com/role/ScheduleofInventoriesTable": { "parentTag": "us-gaap-InventoryNet", "weight": 1.0, "order": 2.0 } },
"presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofInventoriesTable": {
"lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } },
"auth_ref": { "r773" } },
"us-gaap-InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } },
"presentation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": {
"lang": { "en-us": { "role": { "terseLabel": "Inventory write off", "label": "Inventory Write down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } },
"auth_ref": { "r279" } },
"us-gaap-InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } },
"presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": {
"lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } },
"auth_ref": { "r203", "r210", "r216", "r703", "r779" } },
"cphi-IssuanceOfSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "IssuanceOfSecurities", "crdr": "debit", "presentation": {
"http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": {
"lang": { "en-us": { "role": { "terseLabel": "Issuance of securities (in Dollars)", "documentation": "Represents the amount of issuance of securities.", "label": "Issuance Of Securities" } } },
"auth_ref": { } },
"us-gaap-LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable":
"http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable": {
"lang": { "en-us": { "role": { "terseLabel": "Permit of land use [Member]", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } },
"auth_ref": { "r825" } },
"us-gaap-LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } },
"auth_ref": { } },
"us-gaap-LeasesOperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesOperatingAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Operating Lease Liabilities [Abstract]" } } },
"auth_ref": { } },
"us-gaap-LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": {
"http://www.chinapharmaholdings.com/role/LeasesTables": {
"lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } },
"auth_ref": { "r870" } },
"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": {
"http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": {
"lang": { "en-us": { "role": { "totalLabel": "Total undiscounted cash flows", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } },
"auth_ref": { "r486" } },
"us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": {
"http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": { "parentTag": "us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } },
"presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": {
"lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } },
"auth_ref": { "r486" } },
"us-gaap-LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": {
"lang": { "en-us": { "role": { "negatedLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } },
"auth_ref": { "r486" } },
"us-gaap-LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": {
"http://www.chinapharmaholdings.com/role/Leases": {
"lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not

limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": { "r477" } }, "us_gaap_Liabilities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0,
"order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "totalLabel":
"Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise
providing economic benefit to others." } } }, "auth_ref": { "r11", "r50", "r51", "r52", "r56", "r57", "r58", "r59", "r170", "r256", "r309", "r310", "r311",
"r312", "r313", "r314", "r315", "r316", "r317", "r420", "r421", "r422", "r458", "r622", "r701", "r752", "r821", "r873", "r874" } } }, "us-
gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND
STOCKHOLDERS'2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of
equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r68", "r109", "r556", "r733", "r783", "r803", "r866" } } }, "us-
gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit",
"calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0
} }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "totalLabel": "Total
Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be
paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r52", "r138", "r170", "r256", "r309", "r310",
"r311", "r312", "r313", "r314", "r315", "r316", "r317", "r420", "r421", "r422", "r458", "r733", "r821", "r873", "r874" } } }, "us-
gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract",
"presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Current
Liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": { } }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Non-current Liabilities:", "label":
"Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": { } }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/LinesOfCreditDetails": { "lang":
{ "en-us": { "role": { "terseLabel": "Line of credit facility amount", "label": "Long Term Line of Credit", "documentation": "The carrying value as of the
balance sheet date of the current and noncurrent portions of long term obligations drawn from a line of credit, which is a bank's commitment to make
loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby
letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional
on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be
classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a
long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation
on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except
for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement
is expected to be financially capable of honoring the agreement." } } }, "auth_ref": { "r11", "r107", "r883" } } }, "us-gaap_LineOfCreditFacilityAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAxis", "presentation": {
"http://www.chinapharmaholdings.com/role/LinesOfCreditDetails": { "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation":
"Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of
entities that participate in the line of credit." } } }, "auth_ref": { "r49", "r55", "r782", "r819", "r820" } } }, "us-gaap_LineOfCreditFacilityExpirationDate1":
{ "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityExpirationDate1", "presentation": {
"http://www.chinapharmaholdings.com/role/LinesOfCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Due date of line of credit", "label": "Line
of Credit Facility, Expiration Date", "documentation": "Date the credit facility terminates, in YYYY-MM-DD format." } } }, "auth_ref": { "r49", "r55" } } },
"us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityInterestRateDuringPeriod", "presentation": { "http://www.chinapharmaholdings.com/role/LinesOfCreditDetails": { "lang": { "en-us":
{ "role": { "terseLabel": "Interest rate of line of credit", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective
interest rate during the reporting period." } } }, "auth_ref": { "r49", "r55" } } }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityLineItems", "presentation": {
"http://www.chinapharmaholdings.com/role/LinesOfCreditDetails": { "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable": {
"lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit [Line Items]", "documentation": "Line items
represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined
in one or many axes to the table." } } }, "auth_ref": { "r308", "r782", "r819" } } }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr":
"credit", "presentation": { "http://www.chinapharmaholdings.com/role/LinesOfCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Line of credit
facility borrowing amount", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the
credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the
facility." } } }, "auth_ref": { "r49", "r55" } } }, "us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityPeriodicPaymentPrincipal", "crdr": "debit", "presentation": {
"http://www.chinapharmaholdings.com/role/LinesOfCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest paid", "label": "Line of Credit
Facility, Periodic Payment, Principal", "documentation": "Amount of the required periodic payment applied to principal." } } }, "auth_ref": { "r49", "r55"
} } }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityTable", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable": { "lang": { "en-us": {
"role": { "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual
arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of
credit, and revolving credit arrangement." } } }, "auth_ref": { "r49", "r55", "r308", "r782", "r819" } } }, "us-gaap_LineOfCreditMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable": { "lang": { "en-us": { "role": { "terseLabel": "Lines of Credit
[Member]", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to
a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the
particulars." } } }, "auth_ref": { } }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LinesOfCreditCurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": {
"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Current portion of lines of credit",
"label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations
drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the
application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be
made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on
the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a
long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that
clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met (1) the agreement does
not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the
BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } },
"auth_ref": { "r50", "r105" } } }, "cphi_LinesOfCreditDetailsTable": { "xbrltype": "stringItemType", "nsuri":
"http://www.chinapharmaholdings.com/20240630", "localname": "LinesOfCreditDetailsTable", "presentation": {
"http://www.chinapharmaholdings.com/role/LinesOfCreditDetails": { "lang": { "en-us": { "role": { "label": "Lines of Credit (Details) [Table]" } } },
"auth_ref": { } }, "cphi_LiquidityAndGoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.chinapharmaholdings.com/20240630", "localname": "LiquidityAndGoingConcernPolicyTextBlock", "presentation": {
"http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy": { "lang": { "en-us": { "role": { "terseLabel": "Liquidity and Going Concern",
"documentation": "Liquidity and Going Concern.", "label": "Liquidity And Going Concern Policy Text Block" } } }, "auth_ref": { } } },
"cphi_LoanPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname":
"LoanPayableMember", "presentation": { "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails": { "lang": { "en-us": { "role": {
"terseLabel": "Loan Payable [Member]", "label": "Loan Payable Member" } } }, "auth_ref": { } }, "us-gaap_LoansHeldForSaleTerm": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansHeldForSaleTerm", "presentation": {
"http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Term of loan agreement",

"label": "Loan, Held for Sale, Term", "documentation": "Period between issuance and maturity of loan held for sale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r861", "r862", "r863" } } },
"doi_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "LocalPhoneNumber",
"presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "terseLabel": "Local
Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } } }, "auth_ref": { } }, "us-gaap-LongTermDebt": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": {
"http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable": { "parentTag": null, "weight": null, "order": null, "root": true } },
"presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable" }, "lang": { "en-us": { "role": { "totalLabel": "Total",
"label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt.
Excludes lease obligation." } } } }, "auth_ref": { "r11", "r107", "r325", "r335", "r710", "r711", "r731", "r883" } } }, "us-
gaap-LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": {
"http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable": { "parentTag": "us-gaap-LongTermDebt", "weight": 1.0, "order": 1.0 }
}, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable" }, "lang": { "en-us": { "role": { "terseLabel":
"2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other
securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year.
Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } },
"auth_ref": { "r8", "r174", "r329" } } }, "us-gaap-LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": {
"http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable": { "parentTag": "us-gaap-LongTermDebt", "weight": 1.0, "order": 2.0 }
}, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofPrincipalPaymentsTable" }, "lang": { "en-us": { "role": { "terseLabel":
"2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other
securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year.
Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } } },
"auth_ref": { "r8", "r174", "r329" } } }, "us-gaap-LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LongTermDebtTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/LinesofCredit" }, "lang": { "en-us": { "role": {
"terseLabel": "LINES OF CREDIT", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } } },
"auth_ref": { "r93" } } }, "us-gaap-LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermLineOfCredit", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-
gaap-Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet" }, "lang": {
"en-us": { "role": { "terseLabel": "Lines of credit, net of current portion", "label": "Long-Term Line of Credit, Noncurrent", "documentation": "The
carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's
commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of
credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in
time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would
normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term
obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-
term obligation on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the
lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the
financing agreement is expected to be financially capable of honoring the agreement." } } } }, "auth_ref": { "r11", "r33", "r34" } } }, "us-
gaap-LongtermLineOfCreditCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongtermLineOfCreditCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "label": "Lines of Credit [Abstract]" } } } }, "auth_ref": { } }, "us-
gaap-LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LossContingenciesLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-
us": { "role": { "label": "Commitments and Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } },
"auth_ref": { "r302", "r303", "r304", "r307", "r372", "r708", "r815", "r816" } } }, "srt-MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": {
"http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } } },
"auth_ref": { "r219", "r716", "r736", "r739", "r824", "r884", "r885", "r886", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897",
"r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912" } } }, "srt-MaximumMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": {
"http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
"http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable",
"http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label":
"Maximum [Member]" } } } }, "auth_ref": { "r303", "r304", "r305", "r306", "r365", "r372", "r451", "r535", "r575", "r576", "r589", "r614", "r615", "r676",
"r677", "r678", "r679", "r680", "r689", "r690", "r705", "r714", "r720", "r724", "r725", "r729", "r730", "r737", "r823", "r875", "r876", "r877", "r879",
"r879", "r880" } } }, "srt-MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember",
"presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails",
"http://www.chinapharmaholdings.com/role/IncomeTaxesDetails",
"http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable",
"http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label":
"Minimum [Member]" } } } }, "auth_ref": { "r303", "r304", "r305", "r306", "r365", "r372", "r451", "r535", "r575", "r576", "r589", "r614", "r615", "r676",
"r677", "r678", "r679", "r680", "r689", "r690", "r705", "r714", "r720", "r724", "r725", "r729", "r730", "r737", "r823", "r875", "r876", "r877", "r879",
"r880" } } }, "us-gaap-MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MinorityInterestOwnershipPercentageByParent", "presentation": {
"http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel":
"Ownership percentage", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the
subsidiary, expressed as a percentage." } } } }, "auth_ref": { } }, "cphi-NMPAAApprovedMedicalFormulasMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "NMPAAApprovedMedicalFormulasMember", "presentation": {
"http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "NMPA approved medical
formulas [Member]", "label": "NMPAAApproved Medical Formulas Member" } } } }, "auth_ref": { } }, "srt-NameOfMajorCustomerDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": {
"http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } } },
"auth_ref": { "r219", "r716", "r736", "r739", "r824", "r884", "r885", "r886", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897",
"r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912" } } }, "us-gaap-NatureOfOperations": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": {
"http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Organization and Nature of
Operations", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products
or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination,
including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and
uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } } },
"auth_ref": { "r119", "r128" } } }, "us-gaap-NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {
"http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-
gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0,
"order": 3.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "totalLabel": "Net
Cash Provided By Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow
(outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and
providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and
obtaining and paying for other resources obtained from creditors on long-term credit." } } } }, "auth_ref": { "r164" } } }, "us-
gaap-NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" },
"lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities

[Abstract]" } } }, "auth_ref": [] }, "us_gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us_gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "totalLabel": "Net Cash (used in) provided by Investing Activity", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r164"] }, "us_gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Investing Activity", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us_gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us_gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow", "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used in Operating Activities", "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r82", "r83", "r84"] }, "us_gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "terseLabel": "Cash Flows from Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us_gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us_gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us_gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow", "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement", "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails", "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3" }, "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss for the period", "verboseLabel": "Net loss", "netLabel": "Net losses", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r77", "r84", "r111", "r136", "r152", "r154", "r158", "r170", "r179", "r183", "r184", "r185", "r186", "r187", "r190", "r191", "r196", "r256", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r409", "r418", "r446", "r458", "r561", "r644", "r666", "r667", "r750", "r821"] }, "cphi_NetProfitSalesRate": { "xbrltype": "percentItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "NetProfitSalesRate", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net profit sales rate", "documentation": "Net profit sales rate.", "label": "Net Profit Sales Rate" } } }, "auth_ref": [] }, "us_gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "label": "Organization and Significant Accounting Policies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r130", "r131", "r132", "r133", "r134", "r135", "r178", "r179", "r180", "r181", "r182", "r185", "r192", "r202", "r220", "r221", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r297", "r298", "r299", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359"] }, "us_gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle." } } }, "auth_ref": ["r23", "r130", "r131", "r132", "r133", "r134", "r135", "r178", "r179", "r180", "r181", "r182", "r185", "r192", "r202", "r220", "r221", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r297", "r298", "r299", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359"] }, "us_gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy" }, "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us_gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "totalLabel": "Net other expense", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r79"] }, "us_gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "cphi_NoteRedeemableIntoShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "NoteRedeemableIntoShares", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Note redeemable into shares (in Shares)", "documentation": "Number of shares redeemable by Notes.", "label": "Note Redeemable Into Shares" } } }, "auth_ref": [] }, "cphi_NumberOfTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "NumberOfTradingDays", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of trading days", "documentation": "Number of trading days.", "label": "Number Of Trading Days" } } }, "auth_ref": [] }, "us_gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficeEquipmentMember", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefullivesoftheAssetsTable", "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable" }, "lang": { "en-us": { "role": { "terseLabel": "Office equipment [Member]", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "cphi_OnnyInvestmentLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "OnnyInvestmentLimitedMember", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Onny Investment Limited [Member]", "label": "Onny Investment Limited Member" } } }, "auth_ref": [] }, "us_gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us_gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us_gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" }, "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us

gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": { "r116", "r702", "r791", "r792", "r793", "r794", "r795" } }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/LeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": { "r482", "r732" } }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.chinapharmaholdings.com/role/LeasesDetails": { "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": { "lang": { "en-us": { "role": { "totalLabel": "Total", "terseLabel": "Operating liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": { "r480" } }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": { "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "negatedLabel": "Less: Lease liabilities, current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": { "r480" } }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "http://www.chinapharmaholdings.com/role/ScheduleofOperatingLeaseLiabilitiesTable": { "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "verboseLabel": "Lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": { "r480" } }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/LeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease payments", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": { "r481", "r483" } }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "http://www.chinapharmaholdings.com/role/LeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Right of use assets", "verboseLabel": "Operating lease right of use assets", "label": "Operating Lease, Right of Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": { "r479" } }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.chinapharmaholdings.com/role/LeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": { "r485", "r732" } }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": { "http://www.chinapharmaholdings.com/role/LeasesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease weighted average lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r484", "r732" } }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": { "r391" } }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLimitationsOnUse", "presentation": { "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards limitations, descriptions", "label": "Operating Loss Carryforwards, Limitations on Use", "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income." } } }, "auth_ref": { } }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsValuationAllowance", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards available for future taxable income", "label": "Operating Loss Carryforwards, Valuation Allowance", "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": { "r855" } }, "us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "terseLabel": "ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": { "r47", "r85", "r86", "r102" } }, "us-gaap_OtherCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Other Cash Equivalents, at Carrying Value", "documentation": "Amount of short term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": { } }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss - foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r2", "r562" } }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofChangesintheAllowancesforDoubtfulAccountsTable": { "lang": { "en-us": { "role": { "terseLabel":

"Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r2": "r3", "r465", "r472" } }, "us-gaap-OtherEmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherEmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": { "lang": { "en-us": { "role": { "terseLabel": "Compensation and interest to related parties", "label": "Other Employee-related Liabilities, Current", "documentation": "Amount of obligations incurred for employer-related costs classified as other, payable within one year or the normal operating cycle, if longer." } } } }, "auth_ref": { "r51" } }, "cphi-OtherReceivablesLessAllowanceForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "OtherReceivablesLessAllowanceForDoubtfulAccounts", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals": { "lang": { "en-us": { "role": { "terseLabel": "Other receivables, allowance for doubtful accounts (in Dollars)", "label": "Other receivables, less allowance for doubtful accounts", "documentation": "Other Receivables Less Allowance For Doubtful Accounts" } } } }, "auth_ref": { } }, "us-gaap-OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Other receivables, less allowance for doubtful accounts of \$27,929 and \$27,017, respectively", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } } }, "auth_ref": { } }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } } }, "auth_ref": { } }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } } }, "auth_ref": { } }, "us-gaap-PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Other Payables [Abstract]" } } } }, "auth_ref": { } }, "us-gaap-PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForFees", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding balance of extension fee (in Dollars)", "label": "Payments for Other Fees", "documentation": "Amount of cash outflow for fees classified as other." } } } }, "auth_ref": { "r4" } }, "us-gaap-PaymentsForLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLoans", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Loan payment", "label": "Payments for Loans", "documentation": "Cash payments for and related to principal collection on loans related to operating activities." } } } }, "auth_ref": { "r4" } }, "us-gaap-PaymentsForProceedsFromProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromProductiveAssets", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments for (Proceeds from) Productive Assets", "documentation": "The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles." } } } }, "auth_ref": { } }, "cphi-PercentageOfBalanceNoteAndAccruedInterest": { "xbrltype": "percentItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "PercentageOfBalanceNoteAndAccruedInterest", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails": { "lang": { "en-us": { "role": { "terseLabel": "Note and accrued interest", "label": "Percentage of balance note and accrued interest", "documentation": "Percentage of balance note and accrued interest." } } } }, "auth_ref": { } }, "cphi-PercentageOfNetProfit": { "xbrltype": "percentItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "PercentageOfNetProfit", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of net profit", "label": "Percentage of net profit", "documentation": "Percentage of net profit." } } } }, "auth_ref": { } }, "us-gaap-PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } } }, "auth_ref": { "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852" } }, "us-gaap-PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } } }, "auth_ref": { "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848", "r849", "r850", "r851", "r852" } }, "us-gaap-PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } } }, "auth_ref": { "r60", "r338" } }, "us-gaap-PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } } }, "auth_ref": { "r60", "r624" } }, "us-gaap-PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } } }, "auth_ref": { "r60", "r338" } }, "us-gaap-PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet_Parentheticals": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } } }, "auth_ref": { "r60", "r624", "r642", "r915", "r916" } }, "us-gaap-PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, \$0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } }, "auth_ref": { "r60", "r551", "r733" } }, "us-gaap-PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } } }, "auth_ref": { "r150", "r280", "r281", "r696" } }, "us-gaap-ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "http://www.chinapharmaholdings.com/role/LinesofCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from lines of credit", "verboseLabel": "Line of credit received in advance", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } } }, "auth_ref": { "r17", "r782" } }, "us-gaap-ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": {

"http://www.chinapharmaholdings.com/role/LinesofCreditDetails"], "lang": { "en-us": { "role": { "terseLabel": "Received proceeds from loan", "label": "Proceeds from Long Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": { "r17" } }, "us_gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Borrowings and interest from related party", "verboseLabel": "Interest expense", "label": "Proceeds from Related Party Debt", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party, including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": { "r17" } }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk [Member]", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": { "r88" } }, "cphi_ProductFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ProductFiveMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product Five [Member]", "label": "Product Five Member" } } }, "auth_ref": { "cphi_ProductFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ProductFourMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product Four [Member]", "label": "Product Four Member" } } }, "auth_ref": { "cphi_ProductOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ProductOneMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product One [Member]", "label": "Product One Member" } } }, "auth_ref": { "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": { "r217", "r537", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r693", "r715", "r735", "r737", "r738", "r740", "r741", "r817", "r818", "r824", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912" } } }, "cphi_ProductThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ProductThreeMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product Three [Member]", "label": "Product Three Member" } } }, "auth_ref": { "cphi_ProductTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ProductTwoMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product Two [Member]", "label": "Product Two Member" } } }, "auth_ref": { "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": { "r217", "r537", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r693", "r715", "r735", "r737", "r738", "r740", "r741", "r817", "r818", "r824", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912" } } }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": { "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable": "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": { "r7", "r487" } }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY, PLANT AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": { "r90", "r122", "r125", "r126" } }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r91", "r139", "r559" } }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Schedule of Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r487" } }, "us-gaap_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentMember", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable"], "lang": { "en-us": { "role": { "terseLabel": "Plant, machinery and equipment [Member]", "label": "Property, Plant and Equipment [Member]", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "totalLabel": "Property, plant and equipment, net", "terseLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r7", "r487", "r546", "r559", "r733" } }, "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentOtherTypesMember", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "terseLabel": "Plant, machinery and equipment [Member]", "label": "Property, Plant and Equipment, Other Types [Member]", "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": { "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r7" } }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services

and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": { "r91", "r487" } }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable" }, "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives", "label": "Property. Plant and Equipment. Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": { } }, "cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesoftheAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesoftheAssetsLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable" }, "lang": { "en-us": { "role": { "label": "Schedule of Estimated Useful Lives of the Assets [Line Items]" } } }, "auth_ref": { } }, "cphi_PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesoftheAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "PropertyPlantandEquipmentDetailsScheduleofEstimatedUsefulLivesoftheAssetsTable", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable" }, "lang": { "en-us": { "role": { "label": "Property. Plant and Equipment (Details) – Schedule of Estimated Useful Lives of the Assets [Table]" } } }, "auth_ref": { } }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow", "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" }, "http://www.chinapharmaholdings.com/role/ScheduleofChangesintheAllowancesforDoubtfulAccountsTable": { "lang": { "en-us": { "role": { "terseLabel": "Bad debt expense (reversal of allowance for doubtful accounts)", "verboseLabel": "Bad debt expense (reversal of allowance for doubtful accounts)", "label": "Accounts Receivable. Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": { "r162", "r271" } }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails", "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": { "r303", "r304", "r305", "r306", "r357", "r365", "r367", "r368", "r369", "r372", "r451", "r510", "r519", "r535", "r575", "r576", "r589", "r614", "r615", "r676", "r677", "r678", "r679", "r680", "r689", "r690", "r705", "r714", "r720", "r724", "r725", "r729", "r730", "r737", "r744", "r813", "r823", "r862", "r876", "r877", "r878", "r879", "r880" } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": { "r303", "r304", "r305", "r306", "r357", "r365", "r367", "r368", "r369", "r372", "r451", "r510", "r519", "r535", "r575", "r576", "r589", "r614", "r615", "r676", "r677", "r678", "r679", "r680", "r689", "r690", "r705", "r714", "r720", "r724", "r725", "r729", "r730", "r737", "r744", "r813", "r823", "r862", "r876", "r877", "r878", "r879", "r880" } }, "cphi_RawMaterialPurchasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "RawMaterialPurchasesMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Raw Material Purchases [Member]", "label": "Raw Material Purchases Member" } } }, "auth_ref": { } }, "cphi_RedeemOfOutstandingNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "RedeemOfOutstandingNote", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Redeem of outstanding note (in Dollars)", "documentation": "Amount of redeem of outstanding note." }, "label": "Redeem Of Outstanding Note" } } }, "auth_ref": { } }, "cphi_RedemptionAmountForOutstandingBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "RedemptionAmountForOutstandingBalance", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Redemption amount (in Dollars)", "documentation": "The redemption amount for outstanding balance." }, "label": "Redemption Amount For Outstanding Balance" } } }, "auth_ref": { } }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet", "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": { "r223", "r364", "r497", "r498", "r549", "r557", "r617", "r618", "r619", "r620", "r621", "r641", "r643", "r675" } }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet", "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Related Party", "verboseLabel": "Chief Executive Officer and Interim Chief Financial Officer [Member]", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": { "r172", "r173", "r497", "r498", "r499", "r500", "r549", "r557", "r617", "r618", "r619", "r620", "r621", "r641", "r643", "r675" } }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails" }, "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": { "r497", "r498", "r872" } }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails" }, "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": { } }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" }, "lang": { "en-us": { "role": { "label": "Related Party Transactions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r223", "r648", "r649", "r652" } }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": { } }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet", "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": { "r223", "r364", "r497", "r498", "r549", "r557", "r617", "r618", "r619", "r620", "r621", "r641", "r643", "r675", "r872" } }, "cphi_RelatedPartyTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "RelatedPartyTransactionsDetailsTable", "presentation": { "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" }, "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "auth_ref": { } }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/RelatedPartyTransactions" }, "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": { "r494", "r495", "r496", "r498", "r501", "r599", "r600", "r601", "r650", "r651", "r652", "r672", "r674" } }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",

"weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow" }, "lang": { "en-us": { "role": { "negatedLabel": "Payments of line of credit", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": { "r81", "r782" } }, "us_gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/LinesOfCreditDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Repayments of line of credit (in Yuan Renminbi)", "label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": { "r81" } }, "us_gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": { "r374", "r692", "r703", "r881" } }, "cphi_ReserveAccountBalancesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ReserveAccountBalancesPercentage", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Reserve account balances, percentage", "label": "Reserve Account Balances Percentage" } } }, "auth_ref": { "us-gaap-RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r65", "r100", "r555", "r583", "r588", "r597", "r625", "r733" } }, "us-gaap-RetainedEarningsAppropriated": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAppropriated", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings, Appropriated", "documentation": "Amount of accumulated undistributed earnings (deficit) not available for dividend distribution. Includes, but is not limited to, retained earnings appropriated for specific business purpose." } } }, "auth_ref": { "r36", "r37", "r64", "r169", "r554" } }, "us-gaap-RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r132", "r175", "r176", "r177", "r180", "r187", "r189", "r191", "r261", "r267", "r298", "r392", "r393", "r405", "r406", "r407", "r410", "r417", "r418", "r426", "r429", "r430", "r433", "r444", "r475", "r478", "r579", "r581", "r602", "r915" } }, "us-gaap-Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap-GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": { "r114", "r115", "r159", "r170", "r203", "r208", "r209", "r214", "r216", "r217", "r218", "r219", "r256", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r458", "r545", "r703", "r821" } }, "cphi-ReverseStockSplitsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ReverseStockSplitsPolicyTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy": { "lang": { "en-us": { "role": { "terseLabel": "Reverse Stock Split", "label": "Reverse Stock Split", "documentation": "Disclosure of accounting policy reverse stock split." } } }, "auth_ref": { "us-gaap-RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": { "http://www.chinapharmaholdings.com/role/LinesOfCreditDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility [Member]", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": { "cphi-RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "RightofuseAssets", "crdr": "debit", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow": { "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities arising from obtaining right of use assets", "label": "Right of use assets", "documentation": "Right of use assets." } } }, "auth_ref": { "us-gaap-SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenue Benchmark [Member]", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": { "r219", "r762" } }, "us-gaap-SalesRevenueProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueProductLineMember", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Revenue, Product and Service Benchmark [Member]", "label": "Revenue, Product and Service Benchmark [Member]", "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": { "r763" } }, "srt-ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleOfChangesInTheAllowancesForDoubtfulAccountsTable": { "auth_ref": { "r192", "r366", "r760", "r788" } }, "us-gaap-ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/AccountsReceivableNetTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Receivable, Net", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": { "r62", "r69" } }, "us-gaap-ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/OtherPayablesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Payables", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": { "cphi-ScheduleOfAccountsReceivableNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ScheduleOfAccountsReceivableNetAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Accounts Receivable, Net [Abstract]" } } }, "auth_ref": { "cphi-ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ScheduleOfAssetsAndLiabilitiesRecordedAtFairValueAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Assets And Liabilities Recorded At Fair Value Abstract" } } }, "auth_ref": { "cphi-ScheduleOfChangesInTheAllowancesForDoubtfulAccountsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ScheduleOfChangesInTheAllowancesForDoubtfulAccountsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Changes In The Allowances For Doubtful Accounts Abstract" } } }, "auth_ref": { "cphi-ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ScheduleOfEstimatedUsefulLivesOfTheAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Estimated Useful Lives Of The Assets Abstract" } } }, "auth_ref": { "us-gaap-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/FairValueMeasurementsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Recorded at Fair Value", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value

measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."} } } , "auth_ref": { "r859", "r860" } } , "cphi_ScheduleOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ScheduleOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Assets Abstract" } } } , "auth_ref": { } } , "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssetsTables" } , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } } , "auth_ref": { "r805", "r806" } } , "cphi_ScheduleOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ScheduleOfIntangibleAssetsLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable" } , "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets [Line Items]" } } } , "auth_ref": { } } , "cphi_ScheduleOfInventoriesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ScheduleOfInventoriesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Inventories [Abstract]" } } } , "auth_ref": { } } , "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/InventoriesTables" } , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } } , "auth_ref": { "r13", "r70", "r71", "r72" } } , "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/LinesofCreditTables" } , "lang": { "en-us": { "role": { "terseLabel": "Schedule of Principal Payments", "label": "Schedule of Line of Credit Facilities [Table Text Block]", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } } , "auth_ref": { "r49", "r55" } } , "cphi_ScheduleOfOtherPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ScheduleOfOtherPayablesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Other Payables [Abstract]" } } } , "auth_ref": { } } , "cphi_ScheduleOfPrincipalPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ScheduleOfPrincipalPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Principal Payments [Abstract]" } } } , "auth_ref": { } } , "cphi_ScheduleOfPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property Plant And Equipment Abstract" } } } , "auth_ref": { } } , "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofPropertyPlantandEquipmentTable" } , "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } } , "auth_ref": { "r7", "r487" } } , "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" } , "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } } , "auth_ref": { "r35", "r38", "r39", "r40", "r41", "r42", "r95", "r97", "r99", "r100", "r143", "r144", "r145", "r205", "r338", "r339", "r340", "r342", "r345", "r350", "r352", "r593", "r594", "r595", "r596", "r714", "r759", "r781" } } , "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" } , "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } } , "auth_ref": { "r753" } } , "dei_SecurityExchangeName": { "xbrltype": "cdqarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" } , "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } } , "auth_ref": { "r755" } } , "us-gaap_SellingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingExpense", "crdr": "debit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" } , "lang": { "en-us": { "role": { "terseLabel": "Selling expenses", "label": "Selling Expense", "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services." } } } , "auth_ref": { "r78" } } } , "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails" } , "lang": { "en-us": { "role": { "label": "Supplier [Axis]", "documentation": "Information by supplier." } } } , "auth_ref": { } } , "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": { "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails" } , "lang": { "en-us": { "role": { "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } } , "auth_ref": { } } , "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": { "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Price per share (in Dollars per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } } , "auth_ref": { } } , "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": { "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3" } , "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } } , "auth_ref": { } } , "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } } , "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet" } , "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails", "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" } , "lang": { "en-us": { "role": { "terseLabel": "Borrowings from related parties", "verboseLabel": "Borrowing from related party", "label": "Short Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } } , "auth_ref": { "r48", "r105", "r733", "r882" } } , "us-gaap_ShortTermBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowingsAbstract", "lang": { "en-us": { "role": { "label": "Convertible Note Payable [Abstract]" } } } , "auth_ref": { } } , "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails" } , "lang": { "en-us": { "role": { "label": "Convertible Note Payable [line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { } } , "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayable" } , "lang": { "en-us": { "role": { "terseLabel": "CONVERTIBLE NOTE PAYABLE", "label": "Short Term Debt [Text Block]", "documentation": "The entire disclosure for short-term debt." } } } , "auth_ref": { "r93" } } , "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" } , "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } } , "auth_ref": { "r129", "r143", "r144", "r145", "r170", "r194", "r195", "r197", "r199", "r205", "r206", "r256", "r309", "r311", "r312", "r313", "r316", "r317", "r338", "r339", "r342", "r345", "r352", "r458", "r593", "r594", "r595", "r596", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r624", "r645", "r668", "r681", "r682", "r683", "r684", "r685", "r759", "r781", "r790" } } , "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" } }

"lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r10": "r61", "r66", "r67", "r132", "r156", "r157", "r158", "r175", "r176", "r177", "r180", "r187", "r189", "r191", "r204", "r261", "r267", "r298", "r353", "r392", "r393", "r405", "r406", "r407", "r410", "r417", "r418", "r426", "r428", "r429", "r430", "r431", "r433", "r444", "r467", "r468", "r469", "r470", "r471", "r473", "r475", "r478", "r493", "r562", "r579", "r580", "r581", "r602", "r668" } }, "us-gaap-StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet", "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3" } }, "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r175", "r176", "r177", "r204", "r478", "r537", "r592", "r613", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r641", "r643", "r646", "r647", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r668", "r745" } }, "us-gaap-StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "documentation": "Statement of Cash Flows", "auth_ref": { "r1", "us-gaap-StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "documentation": "Statement of Financial Position", "auth_ref": { "r1", "us-gaap-StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "documentation": "Statement of Stockholders' Equity", "auth_ref": { "r1", "srt-StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": { "http://www.chinapharmaholdings.com/role/ScheduleofChangesintheAllowancesforDoubtfulAccountsTable", "auth_ref": { "r192", "r366", "r760", "r761", "r788" } }, "us-gaap-StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet", "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3" } }, "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r175", "r176", "r177", "r204", "r223", "r478", "r537", "r592", "r613", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r637", "r638", "r639", "r640", "r641", "r643", "r646", "r647", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r668", "r745" } }, "us-gaap-StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "General and statutory capital reserves amount (in Dollars)", "label": "Statutory Accounting Practices, Statutory Capital and Surplus Required", "documentation": "Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices." } } }, "auth_ref": { "r46" } }, "us-gaap-StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow", "lang": { "en-us": { "role": { "label": "Issuances of stock for intangible assets", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": { "r20", "r21", "r22" } }, "us-gaap-StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": { "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Conversions of Note Payable to common stock (in Shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": { "r10", "r39", "r61", "r66", "r100", "r328" } }, "us-gaap-StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Common stock issued", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": { "r1", "us-gaap-StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": { "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Stock issued during period shares (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": { "r10", "r60", "r61", "r100", "r593", "r668", "r682" } }, "us-gaap-StockIssuedDuringPeriodSharesPurchaseOfAssets": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "presentation": { "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Issuance of common stock for intangible assets (in Shares)", "label": "Stock Issued During Period, Shares, Purchase of Assets", "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": { "r1", "us-gaap-StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Conversions of Note Payable to common stock", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": { "r10", "r61", "r66", "r67", "r100" } }, "us-gaap-StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": { "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Issuance of common stock for intangible assets", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": { "r10", "r60", "r61", "r100", "r602", "r668", "r682", "r751" } }, "us-gaap-StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet", "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet", "http://www.chinapharmaholdings.com/role/ShareholdersEquityType2or3", "lang": { "en-us": { "role": { "label": "Total Stockholders' 2019 Equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r61", "r66", "r67", "r89", "r626", "r642", "r669", "r670", "r733", "r752", "r783", "r803", "r866", "r915" } }, "us-gaap-StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedBalanceSheet", "lang": { "en-us": { "role": { "label": "Stockholders' 2019 Equity", "label": "Equity, Attributable to Parent [Abstract]", "auth_ref": { "r1", "us-gaap-StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity [Abstract]", "auth_ref": { "r1", "us-gaap-StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/StockholdersEquity", "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": { "r96", "r169", "r337", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r353", "r435", "r671", "r673", "r686" } }, "us-gaap-StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": { "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails", "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails", "lang": { "en-us": { "role": { "label": "Reverse stock split", "label": "Reverse stock split, description", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": { "r101" } }, "us-gaap-SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "auth_ref": { "r1", "us-gaap-SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": { "http://www.chinapharmaholdings.com/role/SubsequentEvents", "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": { "r502", "r503" } }, "us-gaap-SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://www.chinapharmaholdings.com/role/ConsolidatedCashFlow", "lang": { "en-us":

f "role": { *f* "terseLabel": "Supplemental Cash Flow Information", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap-SupplierConcentrationRiskMember": { *f* "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": { *f* "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Supplier Concentration Risk [Member]", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": ["r87"] }, "cphi-SuppliersOneMember": { *f* "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "SuppliersOneMember", "presentation": { *f* "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Suppliers One [Member]", "label": "Suppliers One Member" } } }, "auth_ref": [] }, "cphi-SuppliersThreeMember": { *f* "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "SuppliersThreeMember", "presentation": { *f* "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Suppliers Three [Member]", "label": "Suppliers Three Member" } } }, "auth_ref": [] }, "cphi-SuppliersTwoMember": { *f* "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "SuppliersTwoMember", "presentation": { *f* "http://www.chinapharmaholdings.com/role/CommitmentsandContingenciesDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Suppliers Two [Member]", "label": "Suppliers Two Member" } } }, "auth_ref": [] }, "us-gaap-TaxPeriodAxis": { *f* "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodAxis", "presentation": { *f* "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "label": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": ["r854"] }, "us-gaap-TaxPeriodDomain": { *f* "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodDomain", "presentation": { *f* "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": ["r854"] }, "us-gaap-TaxYear2023Member": { *f* "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxYear2023Member", "presentation": { *f* "http://www.chinapharmaholdings.com/role/IncomeTaxesDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Tax Year 2023 [Member]", "label": "Tax Year 2023 [Member]", "documentation": "Identified as tax year 2023." } } }, "auth_ref": ["r854"] }, "us-gaap-TaxesPayableCurrent": { *f* "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { *f* "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable": { *f* "parentTag": "us-gaap-AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { *f* "http://www.chinapharmaholdings.com/role/ScheduleofOtherPayablesTable" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Business taxes and other", "label": "Taxes Payable - Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r50", "r51"] }, "cphi-TechnologyFromBonierMember": { *f* "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "TechnologyFromBonierMember", "presentation": { *f* "http://www.chinapharmaholdings.com/role/ScheduleofIntangibleAssetsTable" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Technology from Bonier [Member]", "label": "Technology From Bonier Member" } } }, "auth_ref": [] }, "srt-TitleOfIndividualAxis": { *f* "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": { *f* "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "label": "Title and Position [Axis]" } } }, "auth_ref": ["r796", "r871"] }, "srt-TitleOfIndividualWithRelationshipToEntityDomain": { *f* "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": { *f* "http://www.chinapharmaholdings.com/role/RelatedPartyTransactionsDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "cphi-TotalOptionOutstanding": { *f* "xbrltype": "sharesItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "TotalOptionOutstanding", "presentation": { *f* "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Total option outstanding", "documentation": "Total option outstanding", "label": "Total Option Outstanding" } } }, "auth_ref": [] }, "dei-TradingSymbol": { *f* "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": { *f* "http://www.chinapharmaholdings.com/role/DocumentAndEntityInformation" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "cphi-TransferPrice": { *f* "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "TransferPrice", "crdr": "debit", "presentation": { *f* "http://www.chinapharmaholdings.com/role/IntangibleAssetsDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Transfer price", "documentation": "The amount of transfer price.", "label": "Transfer Price" } } }, "auth_ref": [] }, "us-gaap-TransfersAndServicingOffFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { *f* "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": { *f* "http://www.chinapharmaholdings.com/role/ScheduleofAssetsandLiabilitiesRecordedatFairValueTable" }, "lang": { *f* "en-us": { *f* "role": { *f* "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r334", "r350", "r434", "r455", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r563", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r734", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r799", "r800", "r801", "r802", "r858", "r861", "r862", "r863", "r864", "r865"] }, "cphi-TwoThousandTenIncentivePlanMember": { *f* "xbrltype": "domainItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "TwoThousandTenIncentivePlanMember", "presentation": { *f* "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "2010 Incentive Plan [Member]", "verboseLabel": "Two Thousand Ten Incentive Plan [Member]", "documentation": "Two thousand ten incentive plan.", "label": "Two Thousand Ten Incentive Plan Member" } } }, "auth_ref": [] }, "cphi-UnrecognizedCompensationExpense": { *f* "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "UnrecognizedCompensationExpense", "crdr": "debit", "presentation": { *f* "http://www.chinapharmaholdings.com/role/StockholdersEquityDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Unrecognized compensation expense (in Dollars)", "documentation": "Represents the amount of unrecognized compensation expense.", "label": "Unrecognized Compensation Expense" } } }, "auth_ref": [] }, "us-gaap-UseOfEstimates": { *f* "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": { *f* "http://www.chinapharmaholdings.com/role/AccountingPoliciesByPolicy" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Accounting Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r28", "r29", "r30", "r120", "r121", "r123", "r124"] }, "cphi-UsefulLiveOfAssetsTableTextBlock": { *f* "xbrltype": "textBlockItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "UsefulLiveOfAssetsTableTextBlock", "presentation": { *f* "http://www.chinapharmaholdings.com/role/PropertyPlantandEquipmentTables" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Schedule of Estimated Useful Lives of the Assets", "documentation": "Useful live of Assets table text block", "label": "Useful Live Of Assets Table Text Block" } } }, "auth_ref": [] }, "us-gaap-VehiclesMember": { *f* "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VehiclesMember", "presentation": { *f* "http://www.chinapharmaholdings.com/role/ScheduleofEstimatedUsefulLivesoftheAssetsTable" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Motor vehicles [Member]", "verboseLabel": "Motor vehicle [Member]", "label": "Vehicles [Member]", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "us-gaap-WeightedAverageNumberOfSharesOutstandingBasic": { *f* "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": { *f* "http://www.chinapharmaholdings.com/role/ConsolidatedIncomeStatement" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Weighted average shares outstanding (in Shares)", "label": "Weighted Average Number of Shares Outstanding - Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r193", "r199"] }, "cphi-WeightedAveragePrice": { *f* "xbrltype": "perShareItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "WeightedAveragePrice", "presentation": { *f* "http://www.chinapharmaholdings.com/role/ConvertibleNotePayableDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Weighted average price (in Dollars per share)", "documentation": "The weighted average price per share.", "label": "Weighted Average Price" } } }, "auth_ref": [] }, "cphi-WorkingCapitalDeficit": { *f* "xbrltype": "monetaryItemType", "nsuri": "http://www.chinapharmaholdings.com/20240630", "localname": "WorkingCapitalDeficit", "crdr": "credit", "presentation": { *f* "http://www.chinapharmaholdings.com/role/OrganizationandSignificantAccountingPoliciesDetails" }, "lang": { *f* "en-us": { *f* "role": { *f* "terseLabel": "Working capital deficit", "documentation": "Represent the amount of working capital deficit.", "label": "Working Capital Deficit" } } }, "auth_ref": [] } } } }, "std_ref": ["r0", { *f* "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1", { *f* "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2", { *f* "role": "http://fasb.org/us-

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"210","Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477439/946-210-55-1"},"r745":{"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic":
"310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477802/946-310-45-1"},"r746":{"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic":
"320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"},"r747":{"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-
12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"},"r748":{"role": "
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1(a)))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3"},"r749":{"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic":
"320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"},"r750":{"role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-10"},"r751":{"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic":
"830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-11"},"r752":{"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic":
"830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12"},"r753":{"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b", "r754":{"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b 2", "r755":{"role": "
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308",
"Subsection": "a", "r757":{"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240", "Section": "13", "Subsection": "a 1", "r758":{"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "
"Regulation S-K", "Number": "232", "Section": "405", "r759":{"role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483014/272-10-45-3"},"r760":{"role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic":
"450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483076/450-20-50-10"},"r761":{"role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic":
"855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483399/855-10-50-3"},"r762":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482861/275-10-50-18"},"r763":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"},"r764":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477351/944-825-50-1B"},"r765":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC", "r766":{"role": "
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b",
"Subparagraph": "(1)", "Publisher": "SEC", "r767":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
"Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC", "r768":{"role": "
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b",
"Subparagraph": "(3)", "Publisher": "SEC", "r769":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
"Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC", "r770":{"role": "
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c",
"Subparagraph": "(2)(ii)", "Publisher": "SEC", "r771":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
"Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC", "r772":{"role": "
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"},
"r773":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1"},"r774":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"},"r775":{"role": "
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"},"r776":{"role": "
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"},"r777":{"role": "
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"},"r778":{"role": "
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"},
"r779":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification",
"Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-
S99-2"},"r780":{"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-
45-28"},"r781":{"role": "http://www.x

[illegible]

[illegible]

[illegible]

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

1VK41^6L9+*VF.D.O% M18@3/=HF8L^0!P590!MPRT3U^"K.L.13PX.M*^XV^!GM*^SVJ#BJ6!UT7?JPOK47).%MO0^1>"4U^ANL<[U\$MOJ8*)GO&I3U
ML7PC+1@0>9GHVZ%V3"JEZH75PUU"Ri8=S.PW0P0?9G3B.VPMX:(77&+8#!.4!NCG3M1?^LBX#^!B5?/IC^>2!930F5\$Gv:@=HP*HTR?K
RL+P^!W36@*XCM.MIVJ@<@A*X4.^17#>=JEW3M/R2(FKJHCNCG@.20A=^YH^L6!Z4HORE^!28M
^2TK^L470=P^\$ZQ@4DH0W^TM166X.#.O+Z!D2?05K5?O4!VE22.D2V^MUHIG=6+^UN^=05!Q*8GP6N7@2RG^INL^!CV4&!)HFX(?
F!S^A+9AW^#.V5 M75N!68SA+0M! 8!9WHRH^! KQ2C3!8!*+&^\$8X.#Z! LU^A.R.DYBER^/6 M.FO B63!UVAH2^!X^U+^!
<Z>^&K9<^>^!9!O=DP<=>^!6^O=^VHLG^!<61JN!) MVXMH^!LC.:!98 F1MEQWV5!=\$KX7EQE^ZZR%U?29KEQF!V10&99W.PZWIS
M/"M^N<^"F45U7M!X8PZ!)RY3S!@MH8.R!L^!QSF^\$U.5V^"AT2K4/17EXPKL6Y M\$^!M.?^!A7\$BK^>^O*^X)G"!1.(UVH6R!)?S R G5 7@YT
M!S^("2..PF<^<U+^!ZOKH9C!+^*(3N2^>[SK]^>12S6^RN&4 P6JML1LNW9^COUH^V!DXH2.^N MB#L+HR!Z6!)W3%SJ.O!^?@B>=R>N.(O.V28
<^)*L!VEOO.P@H!S904A(J ML.PGAXN!D>RKPF8017.TDMO>%\$C2N&?KXX.^O!^!K<^!FU>|^=<5(T^!VH M!@W?7"!^GX.)
!(#@AT^!V8.C1!J!K5P+DY(MH!FZS!11"M+^!DEN=^BK=^OC!89.F.MT.VH2!^%.TDL=PN=^!X3!7H\$XK"1!&^!H405R^!1U^!N#@>2SY=^2^M? G=W>1/2
T!OO>^+^!MN&^/5?CQ^OH&W!>^OOWKX!TJ^!Y=NE!>^!^D M1^F\$^!^E^VW>?G!ZXE^GK?YV?OYW!>K!1.C!YX_72F!3.M!J!>OY!U!^?OHE
M37^OS=AZFLP OOB!3G!X>GZ!>?7 P.V.P>ER^>6=^!VR!U^2!O.GG.ZY^M/^?^!K!^!J5!)O@^!^W2^!2TWY%!A5WA!0Y!Y!WEZ_?^!<52?+H!BH
MGZ^T=O.FLM^OC\$!27!<^<0^#=#Y.H^!J!GLQD!OE!OTX?O!7!>75Z>^YZ^C9SKY!HGLZ WP=43N1!^?FW_X+^F7W_SK_M!
%)WG_K)N!^!O.:@VC4!192!W/X9.I3M6FLD@H#7/4.^RKWH!)UJO6N.^MKK!P_CKY3!F*^8#5\$D)&
M#=#R=^!N*^&17^9.2_PFD+4MRM.OB\$:@%W52B8!1&>*MH?+B 51^!^XODIN4+M_KU4.^LEBU(O&F!4!8OPFAY==^X!D6)(K>H!P!687G.OY!IKC^T
OVI4>G M6?U/G/CN.^Y^!YH!RW@LOZ^V)M0T9SJ!>^!ETX^!OWCZY.1)OKHLO1 MKBV^64!F!054ALM#(6XH!5P!U!^!PG)BST^X!D#%
<@+^Z^Y^M^M+^?M.H#6.^MNIU^=M!ZD92!\$MR2D!@^!DH6U^*^?O^!@MX!A52>^!U2NZ*^@O9+^3NER80!T!M!^!H
M%W^A^!Y?P^OCK#&^PWVGS^%I\$8BWA!^!1 D@^MHVB!>9O5*8F34>A 2+ST72!JAQU/^!J!>6>B+A PG% P@Z 7Q/F3R?4+9O&@%A MH/Q
^S@*4UP5RGTPK&=E&AG!6AE! 92MXY7ZX!^!UL.C=WY2H!28!Q!@1 M 5K^&T6H%\$AN.8G@9.(GHGVK.#Z.KM%."Z#13#&LJEVF@9!G!79ML4!
!MA M 5!@S9K!C(TB2!Z!A^!P9)9M>82.YON4D#T!T58Y!>W.&^?VN3+N.8? M=3C&O=L9X!X!5!ZY.^V^!W^!STO%=UVR2*GR3.ZCE%!?
5!&2DPY@.1Q>0+!1^?2WGS2!KF!+R/H!O>D^FX#00P^VBN!6TV6\$OC.A4!# (F&#^M\$+>.9^U!\$%^!T2!0=^!^=ASM16
MORK9C=S(ZL!D^X!7A\$!@K3RBD!SE>H@!V?)J!>^!8*+^A&#^B#&ZBTN.!50?%\$ MGC\$?WH+^%R!^!TJX!^!5!P>9X%MM!@0MU^EK0X6\$
^SOH^5Y)TE!M!>^AD!ROZG!T!S!\$A.^M! 84SBZP.P5!JF!@BLK!((6^M^..KY.A!+!M M6M5F.^!&KF?^T.^!J \$=^SPFY@P2@!9N 2=I9N!H3O!GASD52R!
(F!\$!QO!^!M1N!XOQ!>^ MIEUO!S2!\$>^*3.ESH!@L.S.^5?T9T!Q!D9^8!HUGM^ H58N!8!>^!^!H O?>M^!6%LEUE_4=U EXG.Q 5A!UQ\$E\$FK
O.5 0MP%IE29G.I^BG*^Y.MZ9PX^S!U@E.^H>OK%6OGA^E/A0=EAPP.99M=L!^!^!^!THSFYA.^/TAS!&6Z!
M+2!^KV^9A^3MG3^2HCWO^J8!+^/FS^W.CT2!21N^Y!TO89!F9F.U02^Y M.D!P9798R^4E24ZCN(X>F12&9C%/
H6+ABHK_2B6^!L6UBK2^!9U&5\$5E MVE&ZNB5+^KDP \$P6P8!)UY^!&A2?GPJ!4?XN^5=">X0HH99U@YO3<CX0 M!U!+U45*!&
(5=^="VZ!2^B_Z\$X@!A2A!1LKF\$>^0.BG!)C!X% 31(XLA M^X_BTRB!3Z=9L&H!\$!)YGIU^9D!^BJUO!H^?)R%7!W#O.^!P4.ZUBB!J! MB@H9!J!NE!YQ
81W4!/^!>C 4>XKDT79H#^J44!6FIZ!>324!*(B>MGM&%L M#&WS4!^!L/HV.^CYW!7>2"%O/9X.D^V^K?9OZ^A93S7!^!42^9?D\$HZ M^*
(%1%Q+^B#N!NTV^KVVH> ^>F7 3BX&T.2S>13FUO!3GWFX M0B_C9!@31?%A.PIY\$T@W@PU!6>W G!("%PD248!3K8!^OLTN^M0!&>0 DL"
MEF!>^VX^9B0.19<^!E H!FF!^Y&TT.2W.^>2^!KDM!2!>1!TJ DEN!K!VJ= M!S!GCW!Y>[2HW0D3%3J>KHEJ!M^K*
M!P!A5ABW4!S!H!N>O+^!&G_L&#^M.^!U@.^!>2@>^?>T5>J!D^Y!J0B M!&Z!U!4URJ2186^HHOS^30VF5KQDW<^M.M.5>^!B>KU8>^21.3F^B^1F^9
MH.RF1.8EC7!S.N4#8_EZY+2ZGC.%18N#D.YS! PTWMH6.C6T^&Y88!2W\$HB M^&V^!X<(!FL!XZ>_52Y#^!NGOA!^#<=^VTQ!T!&CN^4Y^OW_E
M5A6WFM#A M6 Q4#&=^/7L!^KU@>0.2C.^B8!6PX^)!5CU G!2@1?^"FGB8M(G^!\$3 MYX!\$S.EM%#XZ.^!6L=^3 19F!&O!90\$ESDOX%N^?K+O!4?
D8S>=9Z+N%!)OQTK! MX 8LG^H3!H!H0@G^C^!U!3UVZ^N=>^T!F59!4Y#K!XU70WX9!4M6!^Q!1R MC!&^ETOLN.F2!P0M2^K4548/=OATCMP
U0L#8^!U!U!^!H!K!J3B3VP7!J.M.Y&VN^5Z<4Z^*8H/K6Z.SE5P!TE!F!5\$ R991^!D OAG!F>?2W!^.#!>9<5A.T!)0!3@S85^UG2DYJN@77@A<
Y=J.D.2EM!H!E3!Q26+JAA M+!V.P@=&#%>JNG918 V9!H&@A%&=WF3O7>^_FV63@GSH+^!5WM0!&^20!H.M.W#5!EFPV^MWV<^&5^_V!4
%CXBI!HSZ2>^!TUEJ!COR\$?Y!P6E!Q.O^X^X!5>L1B3_8CZ8KE MNMRM^OU.^B:L9!V.H.TV@!^!YCG/3Y8TE5!M T\$W B21^MKIX^GDI T.WR0
ME.YM1^TE.^K@^9Z77DF=K!+ A!EB(RFO=TW!6XQDMQC92B&AT^!^!UY@V% MFD!>6^OYTO!>>U5^!UR_J7D2^23(C+^!W1FV0Z!A.VGIC"
!6!H!R^EC!)H.^M5Q2>38^N!TUO!^2%Z&.G8%TFV38EP7A7G!26!(\$>SEU.BZ>CL.O.K\$FW MO^!S!
<^!JK_GMXZ@^!8^R79Z\$O!Y!3!>=BVGLYC.^!J92%\$Q!F.O.YY2 MK9!&!)PZ!T!K0_>^VVL^B!6&0S<^&=0S%L^!H!H4OFJAV7C_YLFNB6\$!\$# MB.^M8
%K0@+^!X_@10 Z50^13RS4!P7=^OC!GC^!%BU85GB9FX 2Z0S!Q!4#Z M.^!>9Q39 42O@.8.%Q^>NS<^&7!0M!9PHJ#G.R0V0 M+H!B!U3^?>
VO\$^<3!<.^!X!KZ%70^<%!^?2.Z2VB?@/LY!X(WKX4!&JMT3E M!KCG>I7DC2ML935K 7)O\$0K5!BCL!2!70E/O07H!SD2%EGLSIOD^R.Y%K\$!
MWR>ZD?7\$M QS=^!O=ST6&U7GRBD+^Y#^!\$WQ^BQ.1?>=UNF!8<5!E%<M M\$TSHFF^V@CL!RXX!5ZFH.^B^%X15@0@2!O%.HFW?
4^!Y<@A8 MSA+FU=^!18X^!&K5G+V+M5 M?V9!H!MZ!887%0!T^T B?2!9S2Z=X\$@A5G^!TPNV0MC_R@6E5.6 F7VUO!L+^&M.6D1
ML@31=V\$<70R0944!PZ!..+!\$M95KGUA8T.DS!R!H4C5.H!NN!Q!&=5S.
ML.O^O\$^3TWB(!Q\$ZDK!O"5XEL<^!2ELRBF!CD+T4<0/A)"MLI.&\$DA&6!H M74?X1%\$E)24M;H5^LM5S.LNH@R<6^""33.X MT8D!O).^#%J\$!
<4T&Y2!L!GD.PZQY5>^!4TV\$X!0^9A!3%<5-O!P53K0 M8=EZZ<^!M.BC_X_KMC.HNPS5.0D*=M0^7Y!EAG9!N>^!ZEW2DH.9@M7!R M^J=B.
3H8Y2!5HZYVM^=.3@E4O+3@YM=.%!@E!\$!0!O<^!&89)M5^5AD0C7OL! MX^&6F9?DS@I4ELU&G^T!>@>.\$G^J!BX0!GB54Z^!2!L!7OC!JFWET6.S
C3SZR)"7 M3AXOGC?O.GCH%#C MUJ!N4@70AS\$K8!2!^!CU!N5N2<I2.U.M^*#OPUT+!&4HZ49T.BD3B M\$+>U!5!^7Z<1%2
MVS!Z\$!S:GH^Y9P21HTF5.8 %A!K>3844TU@\$/G1%61V^O!R.^2&HG %MX@!BCN:~&!)MT!6+^H!N\$&75HK@O.
3!JRAKH!P6T!5^ZSL^N44+JCN7<^!M.G!^5!6CORA=^+OR<O.1#^R@^4TSM4E+>^O^!6G(8SW^LS2+^9L^ON64 M!O2!LS!H8^S3!M^!Y!
%T&T!N28A!39E!7DF!C!H@ ORW!L.EBMZ05>^!H MLX@NM%^! NM^*O.ZC.S!U2A&HT!^!6@S@^GE>CD>UN4=^OP!81#3=W7S9 M^7+SZ PT&^6_
S.5XOLRY+^!23R=\$!>N0=37!\$K.77!<V?)ZU= PR9#L/HT M+G.DYCP^H=SC!44K6.!#O!
HH.1G0!K=^!H7UTWC^!SDA!P%A>2SC.8.OF!3<^!MB59!E!W7%2022\$!S2^2T0 H.M^!A@K=^!#OY@%HKCR.QCNE GLE+0M)6!H3_U!Z+
(2T.A=QV^!03 M34B!9!<9=[3]BQ!P!J5YLL0A!\$F.4RNLWF>^&W!Y<4>^!6!M5^!=\$T!M9_9L.LLSY+9!Y!<="OXF!^OD0!Z!9N<^!\$6S!Y!H6.^!R
_WY02 # S< M89=W4@!<1 L75K0%ARZ!>V+!O^8%@T!L!6W4A3T!9@!1ZB4!J!\$8&1L!L&1EZ
MA0&G2EDU!9!#53@DVL!M^MGL!8^7CO@VF^!4("L!+W&6^@8!FWC/64BV.^2TZ!%D%N^%.O!HE+^6H!(*+4#Q22L5E15!+MU(A@%
<^*%U!RCHGCC^K^YTZ!A+Y!U#V>V<^\$!DC!Q!K!M^!A!Y!BL3!HUA M42 \$VA+GZ+LD_XY:0D!W@!HRC!U!F5O+X.^!7@H!4RZ_X%)O23Y.B3H
MAFC3!M&M^YH@_JY^=15NT!H0%3!A!8 V5CN4M!&5!&4E2X06^%!"XR^4JFZ^"<1 65^!O@>^!MV63X!>!^?LR1& M^!&63H)A=N+L3QOR8?>
T.U4+!Q!N!N!9NYEW9P@<^V!)!4ES2.K^7T4 M!&Z.9!3U7D?>=^0(6)!N^V^2!9!H@^TUE2O>^&H.^!LOV!M!C2N^>
M3UPG^<X!5GHG3H!YB@^!H!1KK^!+L9\$..PS\$!2&JEBU!L!2%WT@!S LY MD!@3!<9.06240!VUS MO^%)@BTD=HGF\$%^!B?Q
SW#A318SICE1^="^*0Y8^!P8^*2K!9@>^Z&WY&M@<^!^!9P0Q^V!10T>AZ8ROG_S!PX!7&P^*C18\$F/^?808!F=R5
MB4!8D^!HDI!>32P!^E..E4!S!D!T!W!S=^!N2!3W!V!@^VT.T!15>^G@!180U!O!A7CH%>?@Q7UQ>^!6?7PXXM!\$6 !J)"PK
MHT7!DD!2! B7OP!2C!C#^#DA Y<2!0&N%6#NSV?T8N+TAKXOT^Y>YKO76\$+ M!Y!&C)CU=^!%\$>NUF"#6.QM""J8!3!SE^79%6J!
!>W_E!S_C!UF#^#@+H M004!U!6VHG!AY.Z<^!T^!WD#CB HY!^!4ZPHWU!DO!S+YF>3429W2\$0!B M2^
^!PE481.%!H!K!LEB!G_!8A!N!2PG!V_P!002P!%@_!JH_6.Y!M M^F M2=P(D@_WS_F0>^7ATCH?W!U!Z^3HH!>^!<^3!M!L!UT2!V!PF0= MO5OT>^!K!
KU!F\$3=22_55T!3!U>29\$SB<^C%.HGLWX@1!<@SZH!@L62Y!&^!M!O!U.5EWL!^!1U^CHV^!22 W!JZ_1A!4!C!X! C!K_!%CAQWLGP8C^29
M_JRV T^!P9O0!2^!H>OOZ!J&A9_O+!9_A%8_S3.SKZZ.W.MU_10Y9#\$Y!U MD^O!H_4 WE=N1N!>5Y89(ZH0L^!W!W^?WE5>0Z^*6D%!"\$0\$_O2!&O8)?
MO3HZ?O7Z7Z.OGO!LLHOM^2X!C_#0.Y2Y^!<^!2?TO!W2!O.CO.C%>LP\$! MXO@KF!H5B!^!+^!#6!CDZ%O8Y
_YKZ>@>OQ!AE#DA!M+^!DYO&YMED!X^!ZT M^V!%!ZT@T@^!"G^P!#!>@>.\$C^!+!F+20T7)SBT.^59V^ER&V^4 LHKB8 M2#?^!V?Y!
6#X^S^M4@2G^!G^SC&8=HE2D^@H9!LG>2>@!/^!>BZ!PD^% M;U!L.RAUV&MG7^F!^!@8!^Z&<^!^!&J!DC!^!C!Z_@!J!^?&1D%!"@^!KS!<
M22.7%2R!^C\$HF^GK^A^2VC^NXXB.E5BM!B7_%.<^!#B^SX@!4 MX8T3!R T.^!<^!62DY?Z7Q!^ MA<H!Q5W!96!L^K%0AXLC.ODPY!Q>NHI!
M.A!H!ODX0."U^_69.J&47G>EWP>I^H^K!H2>_5!H!<@!O!F^<_86Q@X!3!X!M@!H!C!T!2FV550?^!598.^!I?9!5!MO.K\$P2.5!A8^P1R!>^!ZP!J+HW ("R?>
430H!D!VE6O.MNJ_2^!<^!>^!%WEY^#J3_U@QGDW\$^!&K^G!B!>^!%T!>P!C\$OD!J!3^B%O!>^ M!^!T@UW.D!O+^!+HR2YB.U^!F!75_9M&E5
M^V!LC_W0\$^CP@_!%VM&1MD6#P8!Z%+!OTED4!T!4F77!^!SSH3&C!<79D!0%WM7E!H.R9EC@.N.0#BWW M^6040NKEV=PG?6MW06U(>^%
(2GY@.3!W0Y3^<^!<N!K!1^0XWK^B9R!W!F.O=^!M!\$@<^Y.Y.G!29M!4!H^!S!&7^!<^!P%N2!3SP^R8 !H!E9XKW&CM.)K\$^D^!<
MREPH!L9V!ZZL74!J!^!YJRA#74@.#Z>G3K^YB^!W!>R^MT!E0H7>^!\$H!P!2R!5!E?^V>7^!#XG!&4%6!1O!1DX9P.GDM@^" MG.R@S1=P
T0MN%8FR>K!P2!LVS3#P%JZ&6\$H M^R^V6!XPC8V0=8VXT^3^E@H7^W^ W9D>U!G!L!P!^!W!J!D&SN!F!G!>) WK
M#8^9%RR&3PP^!>ZWE!J!3_""(QOWT!K=M!^!%L\$!O3O!W!N7!2!Z!^!APGONH.M!G=^!@B\$ T!R1 2>^!H5 %D.8#.#K#K=4\$R!U<3K
X7S!E!Z!BF@O7C?0 M.2^P6^!>PGR!V0O9W2C5K#1R>^*#C.AX!S5BWC!R?T?Z?Y!U08!R^T!>L MK@/U#_K54!&S<^K58!)^VE9+GN(6 P.MDTK
X>O>EGTD!K^A #U 8@C!15L!Z!7R9!D!>A!DA6.^!K+^DEFJN8CVL!M^>M^!1!0^R?0^G8>O4 A4^!>6R !JL!H!M7B4&S.V#^26.R5@28_3XE^M M0?
1\$TT0@!\$!6+!O?>A!4\$X@<^!<CUP=O^K!L^SSAMH_1?OX>O#^!B^R0Y# MP!8+U.MK^Y>SA\$.11\$O8CBLYRDW?TFTB.H!X!JBB^*O4!4YO<^B!+^&F0
M!AT!>^!AG!_J.9HH!A8_Z@RE!5#O@17^!<1_#OT.^!TA=(5!HFZ D#Z8EG4!X ML>4!4!V!O!Y!P3W^2Y!N9G!A!E.QC9!>+K!&6Y^2<^Z^8P8_6^E3
M!>5<^!TV<^N>U^!MYZE&(4U_F.6^!2^9 8.^RP7\$!L.L8 W#>#>81P!^!F!4 M&@&83Z538&GS>3KU!84U+6!\$G8O6J#&^!J28^E\$PGD.8!8!EZGRX!Y3.Z.V!
(MADU!U@>ETD7HP=7 #C!<4!S!N!2M^\$P2=M2@A#28#^O_&9/!0SK4>O M^S M!WKT!9%\$VS.D+G_RLB+3!WGH!HK+C^!\$&+^FK!&68@>?
7EWWY!C!A#^!JGYCL M6=GRSHN.8.E!F5^M>BONA^GS30.B5C3BY^!M.N5!J@T7TU!Q!CD!&>>P ME%+?&1#^!A!+^!NG#E?
!\$MNA\$N!X^!>J!BDONV!K!5Z!W!S!O.O!H!T M>=YAZ!H!>DOHNL2!28P2!<^!>S>.%>A RD^3+^!#K!H!Z.KP=U!D?E!0 3E.DSS M@R KE#^!YB^G?WF8
B5ZP<>O.^2X O.^3+U^%ZH2F!+H^NB%_H!H!9W M>Z>3E^2.OZ!X.^!>25YV!H!G9!5 S2.^&8KY 9O5U^O7Q!>^!M^U+^O!>O! ME!F^1^VQ
O.C6!82S.S!9#^!>38!K!O+^+23V!A^F!M!9H.8!YV.JPW^6L.YCO\$K2^!M7?Q0!\$5.Z%W!F@W!N!O!H.5RUD\$7N3 M^YQ!H/^!\$@%^(173\$TAG>_9
^!NLU+!J5\$FB+96!2FH3G832!6!>1.T^B^&^YK M.25>4WB2%!(C5!F!T!EMOR%EQK_U7 2F.MU=^2 3K.8P!OT@!<^!A8.S^Z!1 MN!J!&W8<^!+^NW
ATVFB<^!>2.11E_V.O.C.Z.JM&#N&P\$W!LAZZ T M^IF>@<=^?QTP.3A4.^939P^V+^!H8J!>X!O^H4V_V8S=24!J6L6^!FS^P.^!^!R\$!NQP7F^!N^O!U!F7W
M^Y93_?0!2<^!CKAR+V!5&^!JL#BYH#94.&!)^OB=GDH&8^U_# 2MAL3H!M@F+H2P^AA!R!+SO#&7@6R=^!>+^!>B#<=^#3.89P^VSYO!K6FB^YL(^?>
C)@H!8DAG^9X@!C!5=^!JF=E7^&!)@N&J9JDDH M.^U^W^!C9G_YEY2(F@7B8^V6S_KE!#>^!L! 8!#^*(Z!N2?1.V^S2!+W9!+XG^4!07YC<@W5O>#

MJHIV5\$,"+IDD9,1C\$=T@BTJ4X\$!8E@H3KT^(<<>1J2Y\$<1SJ+FFOJ(P)\$ M.B:4XJL'ARV:@<=>COW0K2O.P\$+GA.O)7VY1-YO=>XWB0/06.WQ4M/2G
M-3NGPOJ.0JE F\$J!QX\$<"Y4RD \$Z\$>UJ- "#.Q&FUUYVF7 7-LU"U"WTTF(M)\$MROQB(8-"*N->D,1J2D%?+P.U13%0\$<6:\$Y6IP*20!Q2-GD3>&K/7
MMR>0H\$FTS*8)H#H9 3%,+(<%)\$Q^T=7HP="(F2,E).D3^5L[SI4?*.HD"W88 M!63AK6S:W!1!(Q8L@DU9W6.(M2)&%.4WY\$F.L!0O/(YQ*OJ
<^2\$^&D%F M6*M.T\$<2"DH1*Y2I8 Y.AM,/+ &FE+>0WF@NFN>3R/CIS/OT,=61D M13 3T,567D>"P9.27 7.KZ"D<3TJY:YH?G">4!0/F
IV"TRQ?YPF<4 MBQ.FFK&YI*9I3.B3.0+VE.8.02JPI" MFZWLOG!%H,/>B HAILH29W@Q W= M2"X/1.\$YDY.KY?^6DPI
QM+&.8T^W!>2-MX& PBO3H1W@J/!+U ORR!>6PHV.W\$3/!<=JCO /@BF5!P6#>-U K"N."1@UU%>2U1+5!*K&6K2G\$&G
M 45WT!MBIN<%LK*31"LU\$D'IC (%!ARK !\$=OJ^1O43D+9+/NWEV*.>UU M>.<# /O+D)#=H.VHSYS4D9GSHI?HA&"0HUUF.S.=6 09X\$#<-
BK*WL%P\$KNED0325M4!M.)Z).S83 4.9"H!QC)\$ + "H+IAY9^&.VR"J!UR0&1.Y^!V\$F&QQ."HT MJ\$MPA@E!J2Q
TW5(>HJB NN@!PC% U21A47GM)\$6Y9MO/N3(0B_1ZGOJKT1"87,4G-M.?D;K/(*.!)5HVA9(NG ^&Q/ TVRM.R49H 2\$Q(!+!
MBYQ+9+A=FY3#DL=P\$!0LSJ3UAYNH2K<6-.0CV CRK\$>IN?5GNPH\$FP^ M.D=-9.942LY6.YVTD0Q!#U
Q"2\$4\$C.BF..JS9IO0@9UY8*%7 ^C@?2.Y. "' MCX2H"O= =B@+!N:T!^%>.JL?7J(XIOH!Y49I6*M5B5=QA-# 6KA='>K?8Q?XCI:UWC5YG:16L6:<
M1J9U+148:04A)IQ@<1X2. \$0?0?5%K*G?>M+!U L OD .X@<2COIK^ W!MV^ WMX= /OPZ.T!62G987!+!%|N1BOE?
Z>19APEAF!O2I4\$>4E+V(XK< MKD?91"7!WGM1XJ+ X3JLBD3R! !\$U!60>#S\$R1<6U9TNWTMEJ\$7!O@<#NNM"/ M:XQU5U!>?K<+?
\$4.HSO+7!22#0#/JK261WEF\$%T &PV5+>44Q.X ME \$@DQ <7E=D&/4J6K !Q@YU(&?4PL #O XC3186\$|@< @D<4V6X)!U.#^!<
M\$&.*KJY!BSWA\$=PYUX!67!7&2.Z !819W@(!+!<..L&*^ET4>4!^(<H9H=?R M1+!%>+TR>^E#E+!%>%Z6+JT 5M%U6X
7EGUAX[V!O\$R<7%Y=KB!|H!B M^@S=K9:G? MQ>75V?GN7AIC^!<1 7Y1^L=MANB?C&SWV^E!H!F V<|F!U)!
M^QUA7!W!>+L8^PXP+#!ZUEFX!Q.SMB MV982YQ@SB.H 6BUI1H!<JXGL9UO5.1GBOD^L.VV(CXYE VW!1UO=0VT"D& M3KZ? 71SND 2.(OCLB/J
/"DM*5!\$T@%* DU# 7N?EDVAVL^S"VV4A(D1#Z M9M+=)HK3%8ZW)U\$<1T|^<#!V^S[6#L9CP@P@>(E(Y8!AF(<..9?>?\$<+8 M3DL4!O1
(B#KYT8. <5N2W"&EOK6* N!07CO"RVF1!5\$.DW@S^..H\$>)< MI(9>P2593>CZP(5S.<J&@Z!&W&B! P*!7 #Z
M^U\$XIPNW<7@T!&G"MW+!>G.2!B=(5F5M8".9VX9!\$%NG*) @!O!&#"/UPZ MW!E!V!>."S\$P5F <6E(#N(4+GZ@&6KAFDSF
8@VLR!#9HBX4G+29"PZF&! MA4DH!"L4.BF!"@3QJ DCYG!)3UL^!0*"/Y4K("1"EZ.&@XJ4 8R!A. M(02!W5DX*OBY&(&I&W?!2!&9R
G<TH*Y(DX%U\$#@'B'Z^!JA!S&A!>+79X!7S?7!2T9!>9+N9 M#H!)X.\$!Q4H>KO MBL *T^NRR4!9.V\$<J!U+
|P!+!F!F!LO\$CD\$A\$5PHH4>8JP/ZYN#P!#^AY*L M9IVS3S=1|/..@!10&6 10\$#@!IG1=9KVBFPN 56C\$FN84!>TO>./\$RIOU#
M!KZ#8YIO.Q)98^!H0WK6 T!52\$ML/!<D!D1HR83QB!U!LP7!<J!U!O MTMPGCHX*# H206RLYF<(<H!EYZRC"6>DY^E/YHL.D@VZR3R5\$<-
!.\$LM3!\$A<<2I5:M8>OR!)!TS!JED\$V M\$!GBE!CN0X=A48J?>\$4KD!G>?).JHT !^(<(*!0X)GYSW.!CMX<"UI?#F
M\$S^YU!#1X<^WQY< ^FN^!.#@+!L2.0W%)!EBZ.V1+1CFITJ!P*\$H\$U1V MM)*C(5+28"5G0!M7!5 EC7YV3*N.^V0>@6@G.^%#C1*HB:R
<O^EXH!M>+>^YE&.!E!C">+C!&OO8^HA0R^ZW? S)#!1SC.N^03PL^!WZDS@!>"3 M9<#0FSN CBZC? *VKNH 3G8^8\$P&XPHPUKY(N.6LXX?
8.W2P\$Y!+5QOW!W3YV4G>.V!HV>D*FQH *)5 M.A. \$S Q\$G2+1N^@SHIZYBEP^0Q@<5BMD!FEB!B \$&AXG B+ !QJLH@2S&
MY7KE/(<^MMWKN;J6L0!V%<0OHF4'W/HZR*<+V39F &6A59J@<|DT>+!< (C# M >@)<^6R-LJ.8G>F=#LS!E!\$WY!LJ8:J!<U&"1&0?
*W1W+ZVG;H!H!\$ M7.2!+E'8 !H!0A MHAOL+G.A!U+A4 46X^!CLVA &QA>#*RX!LQ>J!R^Z!E&W.2?# MH%9%6!+6Z^!DQC?UZZ<3.(T!K
CK"P.=+!<ZB<+Y>8=#(EC!OQ6WM8/M2!JN.B>1B1DNYE+!Y# PY&92!< W-V9J1<4!17694J\$&#?H#N%6>8P+!A MRY1+L R6!<O!T8A)!<JIE(HB
(K@<F!S!JOYU.OYM"!H8E.379&18%"2>O3H M)WX42EMLC9!<J!C3D(Z'R!N#T.OJ/M2E %GX/\$\$5%FOI&2M RRG6\$!9W45 M44Y"AOQW0#*@F
73AC# 4F^!TJ9BFXQFXO<>2A M!7>O"!&M M9G:=-M5!K3?U#!CY^!/@YVLYUVE^<G3NC3!FSQRY!PA/QE9 GB.F<M
<%!PN^4!<N^"S(\$\$R.C7!(@D0U? QV"KN!UCYNL9'##?Q+S^R8^!K M0<=-.64\$HURLG..3KT5!>+O8.(XL !U #U"H%O4?HK8\$.DW&HJ
#Z.PUK+ M!+O91%Z!2? H3JY JYGEFFB(!<@+32TGYT M (3V4C-") .H5?@2. >>9\$DIP6EU?K(*3>P6S14KELW@Q QO7ID*!K56!
M'9K(1>!N8JR.XT""!D&DEP^&+ !JTRGC5EW+!#2.1 PNOJFCV5JNW MY1(VB.2DCI^V=?@SAC!O# YO+!S@* WVWL<+!>=)PY3*)M^>UO(T.D%(\$?
86C60DRW"> =#M5>VJ VJ25K"4!2! @.33SON!ASC0!INS24R6)!%<V7LZ.Z M!G LUS7.LK?
MB(.TR^B8Z<1#8+2!2CU#76B!70!@!JW!30MFYM7!41!ICU^!M !^!HAB YTRB8!T..Q&GOO!>R5>@="HSY5OO# !|!<^)#CR!%)Q!5TN! 77#!\$DG!A8=
M&J2XB2!U1O2!3D.1=R\$BQ2K!W^DN4!0\$KZN?>7R ^!<O?2D R@4Y28C"6#S M.T- LGJO&S!T"#.GKS=7 X3A&R2!R 6"\$M&DW=#9VX(7V O
4<24.1G.2&3% M@J%L"3")YU@!<3!>G0 #L/>R3MJ7TR5C=-.2 O2W!J* MGJ5+5D\$70?24 R&NGB=52WQOU1.0EXA&.H>P?0!LUBI/K4!" + #G!<^!<78
M0J.3W^<G01Q9ODD!3X".2Y!<1\$XPDA 2!D+C.ZB=1L9 .T# "H!M# MBZ(SG^AWIOOR(C83!<@J.C.OM*#@QSL ^OQJ!>7%E82J!U U6W33M923Z.W
M\$IGZ\$2!<3^GN4CRTR" NO^WLOGZ^HBI2PY!= XXDC 5CZZ\$5H+V\$XN^!%8 M+!(<8HRH& 7%U!JT=384!>TO3MIH4!<DMES.A7H9!
G!1*Y#X>ETL>B MR!!K&K.T%M'D#G?JSGVY.ITD.;7%<1A6<7 !%N! A@!9"R"TI^ AOF!S'=2.9 MUHLL.#?)?+*)R^O0J G!|!T15U<(<W.WB
+TG!0\$AFSJ!18B.&K+!WJ8 M#+6) !A7\$T!6*HK5RA"+4U.DO.*=F(!<L389Q<9Y? NMGE!Z=@9ZZ=M/ M0BJ!\$|=+WTZAER!D)SA*O62"
(#YZ^4!E!<ZJ5OAE< "A*AH)9D!<OWA>Y M&O!<4ER@JOLER@QM@-.84?>O!K32\$YP!<K&7C!D+8 .!7*5S!|=Z\$3.P M53!\$@<C8SW34*KSP
6*5=X%!>U1C\$WL/Q!"B*\$FMDN12L6.PX+RM5KW M%M!Q\$S=.G+Z(X!H+7#C0DY!<O^NG^F=K0).Q
MU!JW.A7&|@2,200+19V\$0+&^<K+<0ON !7!""%!.KTO1&SZMX.P.OXLTCX56! MJ? 7A(BN.7^>7F.W7!<GUUZ97=+!<49@D\$(< SO>+!<@.S.T^26?
VQ!Q!9 M@<C!LQ! YB!K(R!<JQ OYLQ>=E!B! B+<#^<H!<0@A 4!T!H(KLR@<^PYA M!@A9.##M8WYG#<P!<J0\$.&RHNB*OP.ZV!<!)Q!<C!N^!L0
U=Z1!5W M.S@<JOOLDCHKOY\$%>=1>)>YWNP#(P@G+&^"V.AEN(!H:59\$8J!HD<JNYNN7 MJ!P^&*VO>FXW^4!J+6"!D1=C?RHGN09D#<-
B+*B\$Z2@!<@UGJQ5+6!U0!) M!1BBD4TD2A*6R\$G(NY)2!V6#2Y \$RY!12U8W!P^ MN+8 TS:(DOUD9@&@<V!<=AD*L8H!DZ=N!<8*?
D%LW:1326#4@<HU!8MVZ MJ\$4VZ^V!K8#LPI.H"#X!)# =.*\$XFD%&\$.#0#3\$DEJE 5F\$&#KP\$U"BZ("5+!4JE!8K2!PO#(!<W.GYJ)C?
0MFY+!U!M\$E14<1=29>C.#M\$W!U7!A=2!<N0 !\$3!<PDX!S05(KJ'WN P8PSKO8K6K!B*5JN="!E2*@LF^H!H!
M6'G=1'H'CHE"6JR=QE.2.S.)"0\$&#&5^18#EE C\$J!<A!W !18W^K 7#<^!1 M4Y12HXL^4JLL?B O^KA!COA\$!2 F/4!>V\$*H8Z(OOZK?
\$C+!9JTA\$#MT2F/M3 Z@+!1VNHDQ1+!@<G\$N!<V?F.ZC\$.SLP67!%T?<L<&3.&@<LY>F(!<Y8V% M 8COFFO7TX2 U?<+4HV1+!J \$DB\$+
!E\$K=*<C!+4A098920."DM.L!3\$S6A* M834WGC9C6.@#?2E A!T?R(M4!JTL" .!JYPSN6J!2SWAE S.V!M. M!)Y K!BK!9VF^!H!A!P(XTW!&*PN!<7.L?
AW-!<KE^!U48.>#JN!+!>J!E M@("*)!0*";.1<7TWXL(N CO7G@0L.3!V!RT2!F0> MD5WW0J^9M X\$=*Z9G! MKOH>0W>%T46GLX<?
*XN&IQ9R0>BFI9.(C"O"> .4RJ8> EXH!&A272YW3C M8TA.Q^X>="%.KM>^2 QVT/PT".O438FO!9W@G+K!G2 !2<73>\$.S!O@

(U!2:PH3+A8'ZG-0)W M!<O/BLR^VB?DPB-GK!<^%3@HD9=A7FIPDJ!O)?QE#4A.PX6#\$P.17/CPV.MHM-LWPLH;(<N2'+T!YGN<-&@&O
<OVT3&%W.3!R!<#0@<%VR W6=FV!DFQ!UO MU0T4%<(W19?Q@<O/QA/F!<)/HS") MJS!B+B-X3WD)*!K.?
Z.%GAY 0DZ"2#19QX^<UHF4!>259+U!MJB^<M. %ZG)YCL!79<C!NMWUY<7EJ!>)ZA1:G!L/UZO+ZW?H9GEU>7Y?F?;4+<E
MV(T6XS98!W!(<5%2?U!3BIX>K6^F!<E %36W\$FM1 XYU/V?<PAV!3!W0?UJ<M7)T?
H.OSE=7KOWX<AU&JK30:WWEK"W#Z#K3!X.9@<F5Y\$3!06G^!+Y!(! MS#^FU@>6!Q!8I7O'BZ^6#CFHZD6!)#<ER(OXBA)LE:# M8H
23:S!1!7#)!<REB5\$&9>+68R=*L ORU0UZ=I1=!\$U!U?M>+W3M^Z M^#4M'.OL2>VBI!\$<?00?2"RX^!<AWJD9L\$V?QA*CA^XY\$4^U
M!OQU8.563J7S45M9!>S&(<B!LGGIT GU:G?F18R-63.X!9XYV!>@6KE" M.J=<D(H^VNC^B J&C.O!Y*YOI<9FMB.E0
!J!P!YTK?<TWL\$SDV<8/R! M<18>YCMH.#@<I3PY3VA:C)F+SF!QB^FL.@B.T!TBCI" G!\$K.WY)!*YB8U^ M5B0.#(<8! 3V66C9M*UE,4F=N?
2#H!#C.\$+!<03HK+>19\$WF8@T!<5H@<U M> 9Z/@8!P""!CPA\$3&(*2!<130&YR=8.P^X< F!R^3?7KKN=?6QN.D?<#C MY7?
+F-!<U> ".*\$W!W>V\$SO ^X?+F!&X!9H^!FOOU8 O!Y!T!H0!N7L8% MO&C!6M3H!E=M9P?=\$\$K ?!E?!(V!T)94HCL^K-BLQ"-*!D!<OKH/\$GI
M+4UMRO9#L!H!D!O\$.P5!<G%M!\$J!0!M!\$Q<K!N9!H!<PX)YU4<@<7K-5%* MW#3Z3N
DSG^K'E6N!NF!%<@WT8T!1%<U.E\$U\$T^4V!P@+!+<+U!T!<729Y< MG!<F W=W^WZLYR&\$*9H.UZ0TKH!<J 52FSL!H0.W!LD/F
A=U4(3,='6!4 MBL27E?+!AZW!B'Q/8> %Y M02S!4" &8%!/1H6WG.)<D&YG/O8F XDCCO10
MR^7B^(<76 !Y".H7=V@<J+^L2!X3!P!SE0&HJ^3>8^<J^HE8U<J.K2TL6M MU.1!3R.19S/>1P4>(!*5C^>WZ*.Q2^0(6W7\$)A&GE@Y42-
2=,1LZP?T.L" M9LC0T.#?ZIU ?W@5K !J 44M:.*L7.&/(B#C+NB?A!F3"PN)W3N!>L5DN=6L M3BC?6CG#<[H!S!<M+!<V.ZIQP""UP!<GT-
K21KU5?5#K:KM@!L!JDL.#!U!Y2!BF2D4TB=QQ.3?< MZ..42?<V73E.A!OO^!<K\$Z/R!RNWTJ!2Z75S?+4!A.3M!<I.O!J6ZE0
M!EM!747APPK^VS-VYG?S=|#=#B2"06ODV/E?<D=6EZ@T!JOSL!N537M?R*"Z MR/#QTP!55L!%5!157\$!<OU.TNB7H;79-/5\$PX>?LH3#<C!
!<P6)3 M.?6&EB/A?3V+Z&44B>T4CU@<Q/!7.2K!BF5!<@F^<GZ(#J^E^!)OYW+! M!V6ZMN#62;
(9C+G!<1\$ZM>W(V<1^CS)9M9N)P00!3S0!G5W R>2"U9 M!F3U.MSM321R!H!O@<NWS" T#>|<^%Y2WZ.7^UX1R!)U.EA!MS>-5Y9SEU48?K
MC3S!W90G0=<=JEFFZ-9LH!P.OG>8BBE!13PB9XIA^UOH#<@E!HOPJQ!R! MXO16NK8!E*.8@H!R\$D1((H)80\$2>1.W:8?
BSBZ!<2H*7@<@H!<B!P.BA! M@5J?T2M !7V-7S2!0L.3^<7R!&|+!J.SF O NCLHN0^!Y !8O5&1?<C>\$ MM1=#AO6!FEU-@.3B-
!U1N!<B!Q=RH!+FY.:GL!QXW.OK^>6^FB"TS!3! MDA!H^>0X5Z!>ZWFR3UI& <K!78) VY-SJ!6.S8 M!2==*PT1M4\$EA?)B2-3!<IQ#-?
=5H? M6%GOX60R3.ML7DP^< <^!1KQW2&=S%V79K.3OX^X+!<R&V^O6G>J!<5!AF!LXO3866-YXSWTW\$C B05?
K5.85!O!ML8:69XXK<T!<UT73RO!<^V!5P=CL&AK M^P^L^!X5!HB>24AMM4! !2H!B?7\$2B2.J /XO>=<SOL>^<3/4(5W0M DF M!TJY.(QY
4NP5!P"G7VY7.W!S\$N7HE9!\$&B8/RO.F03OI+!S0FZ2S:&UA M&TE.Y>Z!\$J.XWOH!O. #B+!O\$!SH.&1#ECK!<A(\$RU= 76R!P!<@<DC&M
M.MQC.N!7!<8#9!P.MW.V.^!<9^<T!3D!ZA&MR K3=\$E6W!<T?<D9.IXV@7D M.NX&S \$!0N!TEZ.UX!Y3!KH!Y%.PAO?#282P=<BQ!53Y-
3C\$79XFH!R!Y M2!H!<2 G.C5.YGFEF!@8W76UTP!>+<74.R.HVG8^<1<^!)S!7%WP<9!3R&<M..%0M2%"
H!H@<J07>QYX0+&#<=16/2>+G6?X\$0="DR@3T4X6^<KPH>#>K9,AZ@<E.S:7Y/YQGR OT?7 M
T!N!<LD>D>D!G!7T""M(S <+>XG O<3R.IKXU)S^M92<|K!<EY/6!>=U/ M>E!K2P \$8Y9/(2^ROM!MGGVEIPZ22\$ESO?
\$C90%#<CKH!Y^<L.32 !B AMC8!53!8FXCN7QZ MX6ODFT!>OW+34YMZPF^<M%HY_0HN! BOL'G>?X%.0.4Y#(4!G +F&&4 MX!<Q6J!<+
&N.Y.F!OK=W@!%<?<Z\$X0G> .!K&THONFRQF!>A^# 7 M!J4XU/DH.AK!4^CR.DS2> 7XA-H\$!L8&AD2^#P%!)F @!D9:<O#D^KK"0Z2
MHP2S!V+D+O (<W>+<L9=10+!<X+K 84>CM&U!4V=88JHWA!0ZF !R!E?<..MS!|B80D>;AG5^8W/>4<
(HYV\$30#0&DONM5CTMK+3U!P!G;K!<Q/4^H3O M8@<Q\$&ODT^WC0!<X4!<2DG^+UAUV^OER^<=>L9.A&?T O^N)T3)T!X&3
M).LUK5@T@13Q!S\$399+!P2O!<V@!4.G(%!<F58L_Z4""%O=NS)(Z!Q(V326 M-NKOUG<6L.MR-(B-K%P&%QHIN&V\$<

#S6HJZ_HATGZ1S^<3*04-LF9G47-1 MYNIFO\^V\WM\ SH4K+9"(UP*X\I9#"-*.AMEL^7CR\$42*\$9-6&L#>|#S8A7N9-MR2H
416K53R)S#=-RU6(I-Z)JL/1C&:7H<#DTS#;+N+V(IOLYWD,D,M8RYK1)Y\N\,IFPHO3/(1)N^A,OI#"#N:CJ.^OO_9#Z_I=Y/9LRT^&OZ!
MG0=|HG+C3-#N\^E^C>+G32_9E5LE.G@:W*XKJXDT8Y\$TLH.ITZR4>+> MCTYJPBGITFE4S#C?WH\I"K">QTH.<#I%#2S\KW_7MED)3
M85\$S%T."LM[SD]^C^~9\JM39^~D3G&6\$;8H/YUT(>Z;1HV),#%C|S|<2\4^M=V3J),/>('>+MOY##+6/JFX_AEOI"&2F?
I@C|OKHAI"/CC;^TN>7=\$R5"OCLK0610\$3IQ4Q_W"l@6=E)&=-W\$N_+3+UG_MIP_4M5+PBEJ|Q&|RV16EEI0(4)Z%_TWJ&JFG+RU^
_ILPV(UHIF)DOZ;+*OMB~;M.M%K|Z9T3X.362=7L&|8T|S4Z.S#PBG(2<=C1D2B\H2@F8ZU=F_17A7<9&F
M9;M6>0+=;FN\$H_9_XU>CS%IX^YR<>"Z1*6/+>BK.A)7\$K;CZ-V%/\$K>.%=-MH^B^HBUO(9T=G>=>UVEL
1%Z;DK^A73;6|BL#D;+SU82.G;IT7S47Z_M\$.@2^IS(J|N1)"O\L8V0L^JP/M#M#JE>898.BKZ\YC_YEU*"|U_Y7E"W"@
M\$;F&XVQ%;&+1)8ZYA8U&=-PXN/6ZXRM2_0TICE9K0Q#V\=-56WM1^A582-EP4+X^DHIVN?
5N1B=3IH=WBM57486S/5ES9_V6W6W%Q29H&^K;T.JH_3V#|H85\$H.O-MO&H<@TXH1E6/^FEXMH_H|"K^#"A?#BW-IX|T@;-M0.FP7E80
M1DBA_7D.K+V.GW=-\A3OC.QV9\$ZVS0;+|D8/&R/88>6^G(D0=>F6;ZOHO_15@=Y3R:RT^3|V7DC(H&F|Q=S.LJ.GH%_M|N>>)VW-
SZX;UO^U2F=G-OR0JM|FU7E_>JV4E-G1_Z2OA@X=;E.S|(FMY\$7T^6X+^9WG(9VY(8R\$9=ST)*#>OR(F+L)9_R.\$)?RO>SH2^E4^UI8OA
M@A4NC.@^64|VB.W9UHW^C&VU;56@PZBZ;7-Q?#>_Q+@A;H_KIYS_@&|D;CT+ MW#5K;11"L(@)-&0P+6S@9_A5YR.MW.KKL1 M-
EC^4^K|3)AA).Z.7@%A.#C&C|A\$N(485RNEJ_G|H#B"XAC2|H)I; MUXGZPL_7G|KTU.X40H<.<6&J2C@37-LW&
M(H;M|C|420<@TYZ&GFDYX75@8YG)48W)A@|HJTL\$T^I^=UJE>*B&+K^4+
M.V@B21466ADM0DS!^G|FZ/6B#P.BCV;9(2BP<^XOO_1H#Q>K8V-(=MG/5^M\$G&MC.+|Y.C.|I)@C5RY1:7T;NM9%@F*
%C205<_8YAQDI#_32LVB3HO1_MO/?3*"1F6_K/(JC^2L54@V9ML>2\$@-6%#=-_*7>G)O-SWRY|/2SW+|UUA_MX)NZRK3202KG;I?|RE
I+>\$3-3W-9VAKPP9OV\|V/BSSQN00!^~;Q|(<0@>F&:4Y^5+|/0S@KYV3#^C2_ML_IXB(|SQ^W;"EK_-38I^D^I5*^*1N;G^MXM?
7C3(P^O)J3CB\$Y-YAW|3|+I(I%&F|N;=ISG+(E8A)EY.MF#29<&"8_X;(H8K+|9G^9|BAT|J;+&(MPU3=6?V|HD7U"ZL66F!->NA<
M(B^G)G^0NKB&^O+!^5=Z9A|F8YQ6@C\$HHH%M^M8.MK) 0C%\$S^>-6H_MG|S.^T|>(GK;"#6|PC#-HXB8F6|YFUD;+8C4|KUE
>HY6"OLMHH.%08E_M+%^3^ED/%+OJMR)O_\$.X^/-Z|EE5;CJ3^PR&^0;/J_C=-|6&E3&^F.J#Q
MNKWI|GX^G8T;AWL#VC(+C1^/-<6=5^9H_2|&H5&#V;J|@I0_H^E^*);2F
MT_>A8A8=#JB+LR2B360>7F&BC4ZC=F;G|+96W0ULJ(0N&+Q4AY(;"^F_D9UR%G6Z4|S1U&^UEBOR);85#C^3SB^TH^54TG
MM;EBRP6^Q50^#XL_PMN;L;H>V|O7_(@50404Z@?MUH^G=64EFPB^G^I2_M;"1U|UKMS\$|HX1VH89&>TW\$&O|V8FR0^Y4)9D^MVT
M)?E|O<8NM-"Y#-UHBUT?.RO|BP%9AA:I9|?9D_1OC|0>VYN.@^G^WB|&@(
MX_UB/X%+@U&@IW^MRJD&=1R^\$SEH\$|5U%#|Y13>=C=G9R+3X_M4&1JTHR|GU^*_-1C#S^L54@\$_JO_@;E^1701|!-1-PIY0L|A;@H2Z0=-
M0A21PIKQ_WIS2WZ^UOMT^U^F%_F@#@9B|N|&A|J(LX+<+|Y>5_16\$KQ>M4)@IKC.@FFZ>ZKF_FT9|(B|^I^C-M2D\$Y;O0|B\$&+6+BI^
(O|8_2^GW)5ICW^_0&X4|IR);6Y)KF<|5-|5)3^I^M^54A&K8=>9WB-8V+|DF5HQQ&9@<%S)U#80G\$BEP@CNB5_Y3C\$3D|R|2CPI?
MIW>>Z;0==Z523R*!-ZUJL"3L(;;YQFHDE+UV8(S^B^88?^@A_X;5=A|E4_M;#(=%6_|MU>5);5PR^#6?V.OX@|1YR6^|>=\$24_9D"YB_-/H&|
|NXP_Z#5ZB_MT#A@_N0X84N+!;6BR|S;P0#0@QPC|^TVY_O^0|P^5QD_SDNQ2_NW4V1\$C_M;"XMT^W@7|Y|_MO?CT6NK#
3&0^Q&#\$.+>#(7)H%|04BQ^?I^Z^HHS_M@4CFF^R|7^BRYX^=|JCGT9^=|OLV^#"KAN|T_M2^8|J)I&O/PEPZS;K;79|52&|^|@U_K^2R-
XA<_YUY;UU;C^SRX|<_LH_IUMO^R#H_-B\$.6?GVUT006|0@ZV_XM9>\$\$\$;CGTV_YVR;4.(%4D-
L_K5@56E_7**8L|TN@5JEQ%Y&M8TH|M|5VO_MDI^\$F6K8-6)#P>N|/H_1E+59YR|YET@;0_J=05|_4|Y87G^!>H0T704T4_M48?
L\$Y4725%9R&AE4A6(>)&5V?PF>>O|_N;QX9>7|/9_NG=F_CMF|=-_O#ZB4) MWCRZOQ|>TV_2N_P7W|_KCY%|E|H^|7%|=W?
OGI/CGIY?#1NXN=-S^M_M?_KQ^W_|V^2T_0?WRV>><^C^I^?S_C?OG^I_7A^U^|VER\$ WYZ_.9QKYW7
M=S_<=O+>_O^K|_X|>=SW/^""%ZNAW|_K|3XY^OWH_S4EV#R>KU_N_IRO_M?PH>G|XZN?_M|NRW^/^#W?YT?
_TW==O=K^<^W%W|>_OWYMYO^F_MOW@7?2?W6Q2|W|H|MW?20_MSU;3H|/PY^FSZ|>|L_7|T>|>|YX_N_NQIV_M;+|/7YS|?XK|0B?
KS/^IW>VK5UIZN6).;R02|Z_U%|=|Q@C|WQ6D_MCZ.*9&L8-0DDP^!NAGNSHJ)=HBO9_H4&59|+15Z#
(C+";@F(RQ_9U7A|&MB**8N2U|>K;@0#-1^C0Q|SP|Z6>|CFT^MQ8W79C;WYP5H_MR|0^5_ZU_(-S92Z0#_P&W^"|>_
|S|&87|ZH_S^MDI^M9OSQ|>GMD#+O?^ME^SBC&V|6)&#C61M|;3UWW|=XZ=Z3E\$4DG^ZF)8TR#;;5L9Z;V^>#>L)I)*_O
M|)BBFA|YKKE\$-G5^H%>1Z91^S|H_AN^+92B(DQ26|P|TL<@>O^T;@<--P_M7;8^%X0@_Q_U124ST_9K^<2_ZK>_M|SK|B1^EV-V\$41
|O)Q&5VD?4>FUH-F80!_0.+*4+8^R-5^""|JCL|W|@|H_K MH=|HRP-\$UK_O9SH+@6O-|TS|=^PXH85C=++++Z3L6?YNIDTV^3SBK%F8
M=8^JLM^("EKR<^5|H#S8EL^=SNZFS8HKH2UN1(C8C%G6T^|RQM_QI-O^C#<M5|U9H|8Y2)"480U/0(BHU|O_4@>JGX6-&
<9CEXMW>0=;+I+9/Z18U^U.HOX|_M?5F8_7_3B(G|H;K;S^+AF1G&X4@<;M2^6+1<4^&067-MX-65%A_W27^HQ
D+M>0);|B7U+G|P>G|9_Y|>PX>#PWF8_<(|S2E)&3^M_M-G^6E+@05L08|ONB^3W|H|TR_UW^H^D;+R|YU&XSN878@/N|6_P8
M|8|P&4Y+S^TX4,TC29G\$!1#O9?P^20@_SX|FX.R2:B8Q=(6%IP#)7;6^00Y_M\$71/DWK/6^%|SE).%_-Q\$V%/(!
TZL^X/OI%6(12K0A0U68_Z^B;C4-L_MSSZ<|PR\$20V^%P^4Z;+;6.TC>5E)EYF>Q_R6&UE_A3^8|_^|XZ_T/
M=H_P0RC=NT|AH;7SO_OVG(U)_ZDG.YN|Y>B=^C^IUG!_1C+1M|HDL9_M5#|IV1A|BL19M;5)ZKNG<&+;3V.NL?=>1060P5@^H&4_4?
^XGNS17_MS+&5N);HWD5%VW-Z\$U_26U@=>Z9S_C|_WF\$)8%(H|C^K);PID^>EV;7AU_M-K^&0X9_5E|I2M-M\$<^4)OA<+^E+^#?
+100:"O_A7_7X9(6)(SS^AT>'M|_R;8/P^F."5&F?B-B^JER?4)9_Z#_R;FR&OP3G_M;6_|EL>#1)P8G|H\$-6;#SSEC^N|;A|_X2FDL?-D0_E=9R1?
EAQT&F=0-7&_MMH|MV9^PYN8G<^>|7&CR-1&4_|2F@>|7223^?AS^>+RB^X^\$|^*XV/Z
MQ_30^QR+AI9:66_4S^1C3|^0%89E94+&;%=98S+Z<^H^>|PCJ9|^S"N&^@D)084,0RN7^9_N)
MH|H2V.V.WW(+P1^T^@>H.#8@4>8.OX^<^W0X+L;7|IR_XV7|?+^2K71>M|C@;SU4\$UO|E?8|D1S|L\$M|H^H+2F
M7344@|^I^O=|Y_C=|Y_B793VQ9.SLXXZR_7(@OR3_+|+|+V_"P?NA"(I<=&(KH_M6.O10CZ^F%+11%);(YS_MO?3%^AT\$H5DU4F.#08>
(_NE|E@_L_1CFPL^@=W_MCPL;=|S7&K4P.)BJAF7Z">7N/T#*>_R1W|@9|^P|^Z|-(2%_#=#8.C|M|S3|SZ^C^S;WZ?K25
LPSAW;;G|N;);F@UX|O_L_D=W0Y_E^7Z|7|@S_M^P|^T5^B_B^J|8-G|MD;ENNW3TH9%|485KT@IV+|+X|SLEOYOLS;A5;
MB@3/L|CRE2N51VW^O_ZD-CVC+3|T.W1PEQRW>8^%KP^BQ=A^XZ&^|>_M.*KP;EB|PH;FHPFR<^1AE^%Q;N+3;0^+
MYE#>AP03+(6YKT8L8%7>07\$Q&(U_M_ADR;6SG28LT=WQ|^+|G^<MIR%)8|75.ODTG^Z^%|(KH5@=>MFT4#|^I^O;@34;+BW<^I08
=7^<^E^|HG*.F9B7^K@*)@0_M#\$GCV_O&7|JLZUZ4^M(\$|T2LLV^|Y;;;FQGTDC95U=<1XCRD|M4|7^Q7N9#);+
(>DK1S/P=7MQ4R94H_FAH@)DS6.DT7H94|9_|AN;Z%|VN_MJP2789+&>|I^\$JXC\$_?)CGR1@7-8#K@F^#SG=ML_JK-F\$4JX13RU^C|S9Q
M|_KU@XPDX&8|H>@1.R|Y<M+Z;OPL+>XWHC2JR%5M&=NTW&N,V>(\$/C^=|AJA/A^+;Q1JW+1<0SV
M|;VYH+VXP_O_?Z5MSX3^Q^2PX=OV005NR^JYRR3EDUBDXG7J5S/Q&WA@3W_M|B6R-M%_WSMAZL_M_^|Q.WB|_7|H|O+!<7>SP?
U^P^E\$JGI^>TQ/P_Y_MT4|&F^=(#U|J1K@69&7/#_P|AUV|S\$E|F3W4|+MC;JL#|K>RXG;-^3_-^|?M_
UDI6^S(V4_M8A6^D)0TR/U9/H7\$LM_X.W6ADB1GM5.C3DB4HZR^2\$5_M4+|S&)A|;|7>.G|+>>^&W<122?HK9T;V_|13R|
^PB<^W^Y@6;"#MF=1&E04|(JBBC5U=MP_M;IO+|8R)H^?8S;X;A>G|_Y\$0_STK_TGK_O@/H_?V74AFK^|94>|FM_P\$
MR|H|A+X.H>4Y#15U|F|92MH;"AG2DGKTO2W\$22_9^#*DOE|A^&AE(S2_WAE9|F&4N^>^A|>R^XV4W5_2\$C0>_MV^HZAX|/COLFB;?
<=T<3QY|&7+Q^Y|_M=UNHL3GG8+&W6Y--A=NN0YMM_OY_MG_|M+I&G2S|QIW&I+W%
X+7);T_K|W&^Z)G_C2AFO4=R#;56U8E6J^*LAS@Y3&6^2I8S>1LB@Z2IP<|^#M5-FIX|^_EV|L5_|DV_#_P#E_V=1^Z^F.E69AM>NB|
MHH^%DRA?N?>YR)|M;D)0U^9E7L\$^*D\$^<^MNDT64T+K>O|O_KW_M|CU^B(SR|HG\$7N?K/(W^1|ORGX-E?
1RG_N_7V_DP5EC^V=E\$^<^|53S41P7\$698560^36"#C+O(GB=(7C+&4AUFIG\$V_&UL&J^T^Z^|J9>+M_IQKE|BHXY?
JZN^UNIFKVE;N_B=LXSRH;-9#^X4GCA0(#_M=T;A|O0C^8K+C8IT2^R)\$V61D@A\$0|H|OTC;N;2;1F2|U+|Q=VY@6HUFNH|+C_3A-Y83N
M|H;|LRX\$|(N85B_BWC@=_HOWG^SV_HFL#4J^@3M=DEDYK<;E7QM;THE_MDIJXEHN-
"JY_7C2|I7^Q&M)^\$S50L7IY^4^UI05J|K|F76_>8!P;|N2<0>H_MK3^0L6R@^W&_7G&9CKNDZYWUJ|V|TBNF|P|>ZPU2FBL|9LU>|8A\$PK6)
@_M^?>3E^P4Y&U9@_M\$ZM6^4#P10_@(#\$OOU^VZVESW|H;09.O\$^239=G9E|G6-NF^5_M\$V^7!|P=L154\$*704ZQ#NU_Z^<^R_BG^G?
+>9@_3E\$8HR7W|Y\$NK;=4=V|FD9V(W_M|@&E|)(ZQ7^J%_C+OYOL\$Q6)C_>|H%;0F8-"G"(N_C^E=|SYZ/3Y<^M_MQ_X_M;8|8|>+>
(**23Q0^12LA|T(9/R>7J?F^")N|D|J4^MX9L7_VORX|/S=S^T^ET^(*@D2^"1A|I.F&+RX_T+60WVT|^|LYY^|5AD(=W_M|_8^@|^ORT8|J6|
WP^IQ>R/G^M5)Y9S6J|^?GKU^LC|ID8+@P_MNK0T_9&^X36_8^Q^MB;43X^BEG1PV9=Q^>B9|XF965^&>C^<3_M90@?ZAE-W-BG|5WYWT
Y|(A=C0G6P?%)C|B4N0ZW#35/F.20(ES%+<MD^4W+O&X_X5AZS5L0@<+>@^V;|RA=^NV+^%H_|W?T_O#|=|>WC>L@UV
M^*M;P=F>+10A|1NWG)=%;E|2.6|P@_>\$5-EF+P+3LEOK048;BU>4/M%_FQ812^ESYO^U|XHV_\$&OE7>2^#534^X>TQN+|B|PD^X
_BNG4T;+H#R_M%6Q^/(I8=1C3BQHV|+B;H\$T=I|Y^P)|<7PF2D>^>D;S^H@;S^H=E^+=D\$7_M|
|Q>+B95TZ@&^&QA_6@E+DG(RR_A9)2Z>|R;GBPL^QBT30EH=|E@|H_O_M^).^009A^Y^L@C;HO23^UR%UY_KG^2E_M_W01O6?1_CY=
|X;B\$|L|C5VG=CV1^"R?|2T^M;B;X6L0?PTL+K|<70^R+<=M5N1S|QV|_S&Y^K\$^0I+D|QYF2=01BW4_!|(DJW)|Y1^780RY;E;M|+G
MG2Q<5=0A+|S|_>Z^6|7E@|6|BPB_D0PM+^S3|SL2E>KE\$ZCE3Y2VR!|=E_Y^M9A/OZ|J^O|H^EE&OZ+!B;5Z#
3A;&J/(R\$N4_PVR_%L510?B=_YADE_MQHO|(Q5^F&DEQMP0|-%_E2=L&C:0M6I84?GD|^+IS=^J^\$EK;I_MAR18_KBE|I
<+>M|_V^31>I_D%&YWP^>Q6M7Y&1R^%#>+9|Z;B|I&B9>&L_M7T6I\$V2-
VW|HJE^NPP&@4Y9<^U7B;+B@;@P|P(18B:UD)|&^V;0..10^C_CKW3+O#84+^GC_#P5G;"<(OZ^M_M|I?|Y8((9RO:4_425#O42^*
|3WT<@K?0-)>9YUC6;&"T|E|Y^&#FB^47^MSY3&5_R&=T^S30_XPR2^C;ED|E3^NLG&S<6-A;#N|6&|2S^264CT=-.B^3
M6V#-9@%DFOJ_A4N^#7R\$C5|@_1S%^&BQMGGY_P|PVO?Y<=2B76TF%/V2+(
MS59|7K;W<@5\$|_N*_CX6|4QBE^7^E6C@>GWE_5RP4E>MO9T|<\$.G\$V_M:E7M-BG^W1Z@?*;M3M;B0;JLZ4);LU4C;I5K|HHOG?</p></div>

@(H.Z.I3.U2R/2-P4B6.VN3JUE!7W"7&47>I74W2,*,9K4!4A)E%:Q96-M\AY:>MC_5I\MZVIKL\)/H\$.!=S86S84T.&H&&R%LAS
ZZ05XF.I7M%Q079XK.MONKZ!P6>H+>%X\HBX+H<(H.Z.I3.ROGS:@2+)(JFZW<|B"%V8-M"FLPG8V%Q;D3A|3;@:L2FHITQ==
[XH=R/YI\,%0X1W3"?>RQV&JAS4 WWP.ML3QRS5?GYS8XR=G%3.03&\$.>8SXV+\$(I<#=<@O6;E.%\$V"L^6;C7HQ&M8I|Z-9M@^X-
@H&BOPAADO5_VR=7Y|@B9QE-SJOHJKRSC|H?70MA@.6.:"M_4CLOS^NA51.5>ZHL2RF(E-,2HF*,Z!!PR>_BU(MX%VFZ6^|W(KTE|ER="MQ2(H7P55.AFU*4|)>_QERK)IOUBDY#G;:K MQ-#J4W|4HP4BT|T9##%"^U;:E,*%=#M840K%0|649D+50L5KJ\$_.RT V%
MHR"ZTA*+.%TG&|R&30A3O9^P<@6)_H1C%3@ZC M=G->O|I3&:LO(J|W8PZN1VU9N%#B\$/%@H|QR&^4+U#Z:5/+!+8K*W?5X
M\$T\$X0.44JP<.#P|6\$|0X&|H2S"LYO!P=WZ|_.#G|L\$?P>_.O|_@M43+&E MW;:|BL?>E|&HWMEL<@:RO?>9HOJ *6!>
A/(<#U\$^P_8OS4&\$&2|3X6PV M%4V7.D:&D:076_4.S@7/98O6|H8R.|7V"C:E2O4|<>NP A%F8U^VAKPR^K")9|>|HAE7SK|XM7YCF?
PL0) #|E|K8F.X L#P*;>A8B+KZM%P.MXQPQ3G4FJ5+|_TOK>.:>|Q<_HDFXL@>KH.UQ\$|B^H"R:E9GXY@/H(C%4&V%
M&9VB BK@R(PY|JR@OP7G2_4P"^^^|_OH>|IDYN.O#H+ M7_6Y|_1.ME628L^T=H.E+Y)G")RO:./_.0H*22_"=E@.IK2?>@.|^+^M%QJ+
(W|>WW^>C@B\$.SG|GM*5WMH\$Q@)EJ-G/2WTFZH"1B|D|C=(@80"MV10U)
'U|6|GS9W=#6(FOG2W752W&HF(P@M&6^AGP@==.W81^!AG?>^'G_ M%1M^2^K^0L=8-0Q4@8F|EU 6>H*RT EGI?_V4O=;EBG M>;
(E|_*K9_"K=(#NV_5VT.O&|Y|P2^|EMA^35D|J|SOI MO#89Y;_F-D.M"Y^+^Z|4L5D&FKYQ/J^0+91B6<\$:U>|---%\$|V+|!>FJF;4Z(5*V|+I
M#.#N#6>?>K"GEFYCBT M8UP.F.F|BUBK5IXLK6|BGLZ*GJ#_4U"WGU*HE MS*=
(@>@CH<B4L"LR|CZ7A5>5/4UUPB.1*T547^5&5P3(\$CAJ#_VE|&>X(M%0;X\$0?XL C3*%|N.F3^9AU@.@|=#R74C("K%B,D1+|H\$G/N?
C.%2HK;"F| M|6Y6A9C2_2_G")3P+0.BUR.O>2^8^45A0|K&|A|1_400+|J3R=B|>*"^<
M@KDT|H)4(17KW|%CQV&1^DD.YN.O\$^2/&5P|O1LPK+&XD\$F.I MD_R.O#FSG)K&+B=&.NPO/BZ&B M3?8?T^1^DF(
^="#XAJ9C^T9VKP^Y^+2O@>7(&W82NU<8|!#^|Q2#_RXQQSN M<4Q*RG^)|@S42BS@#6*|B|^J
W>ID^|32&2.7TXC_LN%_MHS"6,@=DH@F@>M_4\$2|@ODR^\$D^VM!:#%8*(.I_L|UE);JZ=HADKK6%5I^5M16IQ.KJHV+|=Z MG"?K|HM|
|FS#>6%E.DB\$&781F&+U41CRM_ZZ?8\$QM+_.75B1P2DD^0SBO MIN-/2#&W4DH.Y*5N|.BF*!_XE"S6NE^128SKZ3MG38C\$S|Y75Y6S?
@?3% M7_YM|=+0X*?V(PYV221Y^IX/FL^U("W|_DPL#;^6^4(A?RBZ@Y>\$)8WJ>E M)IWTBLY|^=4R6L0OY+MF<|OF4C60U)UM?
0ASRV\$R#++S>_!Y0|B^_4\$BKE MEZ|SGTXZCBKQ57\$%M|%M&%\$JA_<C_7+&3^CQOH_*+|KTM^LWF77QQ*?M;JW*8*^JRF"S>;
GQ(NI8>6\$|O6&R*M=T|@M\$1Y_<A|_!^1%O*^|*7M.O4MWOTGF+M0".E9(=R^0(4+1H24EN9_M3)3I63=DR0U7.SB;M|RE1.BK2;F
M\$S"D2+>D1\$;P_>=^1(XF|ET.O@:A|S^7Y|?51XY05."T82 M&XU|JZK|O1D|J9K^X^7+BATLVWQ#<3ZL8AN@|H|H4)ZY?
^V|SVX|J0R|=Q\$ MQ(|J<7@3|;|ITM *K(^RG(|(?5070/D*%NB|K.3BL:L@V7G\$^Y%='=7PSU+ M.O-%2KLA1ZST#Q?)?K*6IM9|O2C&)>
|6UP.XB2|3@_B2*^N1E^G=-B^S M3|:U6|Q3*?2_X\$@0T#>M:N80MF>BY#|E|TR;#J|08JY^0W^<0_8_P2% S MON%R)"T6B5W%_(E7G(F-
/Q;P|Z"ZY^V>%WF/V>0|MN^L_80WAO@&1S^1%Y/Z/FT4.N^3+P|_PLJ62OE&7V6_F);/R?&7V&^LJX6M|U&X|+)^+2?OUS:N
M2;L_#Q@>27)ENCRIY|_M=HSHC>*G&NB/O0O_1%YYQY^N^3<1S_Z^XDG<M|I9USZ\$Z>0_G1-Y*#7D+>@>|MO1#PE>|X.K?W-
BY.H|T60+^|!0>;A19_M6D>9.A8_AS?JG|_>7T_>?2POM+F.%NPW_=|Z^VU^9*^=09WK_9L M%O8^J%B3?CO9U^FVK.W4#CUB;
(_P72U@(%H_Z|23NO#^Q_>?VK9WSIGP(M?XN|34<_U20%|A\$5|1H|90^R68A.O5#|8L3^#|B#V|H|=|C*^90|&91OZ^M.C8S%^2%JM1-
9BMAXH|YU(A6_U|D)U M:6BVW|;8Y)=@0@O/ZH|H#|	O?|_!&00Q#^6#;2CH^<^J\$OYW7A)4? M/V^MF|_?
J9|WNWF|S|>_<S<+|J52D_HUJY|7HNN;("K^CZ|5H\$DTGGR_C|_M^"W?Z17|40F4>|J3GZ|2@SO|:PX?;E.G|Z0@XO>(U"ZA6^5-
D|)W_\$|K MWP5O.+/<?^"H@:H%;BNPW&^H|0WZ<_"QPM)32H|>>FP9\$A"A"B14P.3_ M7L-
Q76Z8|PK>"MR8%+2Z|9T+8N@3S9DT|6H+R|B|I4@%|99Y90|".96=^D MV^*F^D;(Z|:I0.K6/XG1(9T8KXT
35ZQ|J84U^JW^M^FSDX^RK.A#5UJWO^MGQ^H47F)M<4XZP|N|V@LP=6^N&61>16?+YM^8HT_V/_OW.W|F?1M|J^6;R
MB^LZL_M9;S)LI5O8.K MY^U5;O\$+^MH4|AH4|Z|R|8VHTPK|<\$UYCQ?_V6|AAU|FB +|:|/Q|?5
M9(Y+^<M;1_!_J|6K)VNL|_I|E^F:68V9^NC&SHS\$G(S|ZQ+EOHO%=T(N|K)Q).Q|9PPHXL&B_P|9_W6HUMXCQ=6\$6YRN1GO&0#T2I^Q5";
H|8| M<?^_YF9LOQR-);(1@CNI^MIP=5>+>_?H8VT|S@.OZ<@%9_\$IK45U>U%IGB ML|WD)OAY<_H^"U0M
MD|_5C_|U|H<C^H7C4S%+6Z=L^2D_XY)R@|F^3B3X7_0.64LK+TJ|V68/K0 MX6/2_7UD2|N.9CBAD|XSC)B+BU^|RH|&+5S.I9FLL+L)HR|Z>
(&|ZB0^B8S@8|K^|CVF8_<O(B3U@_YA_<R)_H&CK?H-CF@:9U?O6|JVUQ5^M.BJ6SW)^>Q_N;5|L2_H|Q33|IS4BNV_<3%
Q3|IPQ^<_!M6>YZLEFV^E\$+^|_J|.MIN@9;B|4AYYO_3UPE^P4Y|GIG3|L|RH|&HVP"@AF(3\$PQV^3\$AX=6K+|MT34|IZV|
Q>_2YMOY&VV3J(XC|ZR^RGRERP^H^#<%/25K.RK\$V.FV4=TY^>)D8|/HJ>07|RR|Q^A|HRR^CKS1O:P+^|AZ?
M)AO_/#%E8U9@<WBY)PE9;2^0W>S>*>ZD1PD2">9_P ML378_ L=0^Z?^\$0E@T
M1_&5O9S|ARB^LNA|MLK6C9HHTCY=4^7SXGWA|4ES^V^08_."Y|+Y(>1#|Y.X9P193*?G*_.K2I938T:#1M21WSR M<^
Z)W;BE46A|U%6B9J^415W4_-BG0A5!^")O(|GNM|B8J^D4^+B_45.7U_M_4HH9H^P1!<^<G|YU?+^XA8|+^ENJ6+O8HY-
H|)=|N;>5C7\$|L18|Y<2 M+0SS|I_R2OKPK|DWBYF;_-'P.EYE60C)&|YHP^0QIU5UD69RMN<&S|+Y M|TC4Q#N-
T^VYF00#M7M(QH|H.A|CV2O(8X.K?SL-U<^M%FE+|KM3&WWE|U|S&O8^HY_|&8B9YS;G<2#QO GC+L_4\$S^Y)U3CR4>125?LBZ|
B7T-Q=|1.C> M62F^B|4_&Y\$<^D1&1?U\$|_|=M H/Y|OYA|_<^<^G^L&F@U@8;|!>O M_+C5^|2+>0R6O|5|6^6#^=10MNXLV.?
&E^45HKK|WDGN^K_<5!6_PDS_ M%+^A85<.(NVU|0?SF_JLY5;_GDTY3Y<_KH|TB|0Q7XZBG7|7?)Q; M O^9/H9B;?
3FMG>_8K\$0@I50ME1^B3V;UVDR)G|F=Y\$LV%\$EPF3W*>W+0O: M=EB3;G0.FXC;)+(>1T(VN^2G-
3T+>UDX|JY2Y08QZ^B3|>^DL08_)#A1.F.MTYMH.6VHGHV|HK\$|L_1W?F_1EQL9|UF7WN|JOB%UWDH_*^|L0XFTD3EREAU|X M;_
|>BSZ(|46|)LI U2LR^N4Y>|D0DQO=|N N7^OG\$;%#5>4JB\$MFH>T M-JMDYIEST&%37HB|N?N;_?>A4|D%>UYKSPZR^2H^9GPI&_<
H#>@D#^<X4 MA(N@80YV^>@Y^C9_3U|_!&%(X|C)ON^Y|OHO@&S=TS^TW(E^EPI#KA32%+60 M)
|LB^*M38V&0%6>B#6E;_76QL^"AF%D">7^DLQ^R1(V\$|OVL)6U4^"IM<_PE6 MSIOH;1_ MT7#N\$2|@5IMA:9VJ|JUK(E0\$32?^KER|ZD)
(UJ^|T:4|VHOR.XGLQG)=7VH M9T9WU?5F|OE(^BN^OT#^<+|4_G2B=" GG^C0K;EQ^A.3*(5^N5E*^<@061I2Z2W605%_*NMK@N_""B(
M^FA9T^509|YAL|H|8H|8Q8D3^B0G|L(%).\$FF+X^<^0.FGX.J2=E3;NL9<^>)D M_@>\$^|K5I3.GW=^G^<S\$45J9;@X 5=|R5WSJ^
|0N1CT7YX.P^Q6H&_O|SFG^Q|&4^9Y^6N|>MO=1P^WX MEX>0LU^62X0TH&V;UPO4#_K3@J+CY_*T1R9W7N<OC#>+^2|654+4U7.H
M%|(L5;1^>V156ZY|HSF|48VB5:LOYAA6X+^|WT3^K|NTD|Y?Q2E K MU|VE"&@>B|A>S9HY-BL454BP_7P.K@95TH>D^G^F?
C|M7)^%|DLAAWD^4D24&_ MYO^=3 _O(D(L 6>A;+9Q^=9|>F|^+TL ?\$NIB;?R)YF_4/\$^QT&8145EH/904#AC.I7Z|J\$^L6+Q3(
M8^H^_9AC_79\$=3&IA0F^YV4P39<_KL^~BR|>)C5(1 FO S|64\$O\$&N|H%6& M 0UA<^&B|^EDM<|/3^<CB;K|CM|8D^=E9\$FRWY-2AA74^7J-
W908RL_NAK^MPL^|90A|8^%|H|W|TODP|A_4/#=%OP|V+6-7|1&TD.N6|/<_>9|S6(2."&|UEOY|J^|Z@^*1^5G3K ME|T9);RH^|91;.G_<KRU-
X>6E|HCK&DW#Y4D\$)S;AYD;|H|PTDF87S;4\$<^PJ M-S82+|Z+T#66=)5?QZV.58L_4^VN|HV@6|

T|H^028%?^L%H".M7P)FGM^*CEJFW0?9|OGABJ72;U(Y^A5%M_M^VKGKCPW=38;5.R/MIX|VP".I7=8.)E*OSG=^%SLW^BK5-|DRS|HP-1-
K|_ M_UXA?@|D@R|P|S.CK|29F^B^K)\$-L^S^"N")%QU AD| M?Z^O15|3D|PCPPL^A?X(|HP-WY(#B8|2QIS^AGWZTB-GT9;L&>1DUD)9|4
M2C^49_1(|?|_#ZBH->->Q-NMOR#G-Z<@X1^>F^OACAN "RKH^E8.KOMX/0 MVC_CU<.);3AJ5-
YCY#;9^0|OFE|O|+JN^8Q.I^D^Y8L9%&7JX"&INF&A;_ MKZ?#=&N|E=L*(58L5BB0H?Z8=^K_IX72KGB4Y|WBY6ON<_M&)QS.?
^X2WS|?^(|9N#|E=#N^OYLS_P.E|I50M<@EL;IR^Y|TL MQ^3+^F|_M3T2_@X7AD^<2WZ|L^3QGGSF M^QAIR_6WT|H\$|2?
QDU;MU;=6*^K|X^<V|I<4F|J8KD=HON)"BK;"C^M|H|3|OR?/283^>^HWD;&<_T|@>T+D|>OYTZ.S|U H+1W3|>7OB61^B6##
MCROF.YM|5_W%5_SY?^KYFBZ-B=|IQR&4X04IAM+7%V&O|H_ZOSS^M.F MS^9&?0XU4EGIM^X|TG^ESL_P\$W3%|FE\$&HW+|
^3Z);OAI8L^U5+LJF M4|<.(1B|T5)1S_&7X65SZXJF^Y0(TMUVKT@_M5DT|^*KF+X(@>J0&N3^(M48^L^S^HO9"
@^68&H5H9#2TFCQ(MLN-HC.MCZZYVHZ@F2VY4S@>_I\$8YQ^0JP^*\$&=^|HV+1_4^""39PA72&^W\$0T8;DB%4
M3.JR8^MFW90A^XV|BQ6*^H;KZZ_S|CH# T^DO+>=/\$4+^AMQ_M.B=7 MM;HULHO5XT"/EF^F?
81;_V2OT9A+|B|TNE|XAC+&^83^H@|C;P|=^& MN|HWR|JMUZ^A^CRKND@%HXY#140!<4LZ|L=QLZ^""(F5\$36% MX4C|O|U|T^B1<-
!Z4O-T|Q9\$"-T@48_OD_V6_84T^*3/E1@=E@GX.U@&X.M+W?F@#M?W_>EX?6X;7K(|A^6>G_?FFL/RCR1K^=Q^>VZ^B;H33DSGE)R|5
M(&6T|O|T^1/8O=QUA32P=V|A M^R|H|J9|4U|>%7^>ODH\$A^Y>VOQQ_V0&_#A1Y6^"L&OY0|_Z25*=\$(<^M7I2E8B4L#|H|X_*J|
^PQ>2DX2^&K1A-Z-HY|1#1N\$&K^N@K;GS.XER.^|XC.M5PKA2IG^A2LY8EY)+K1<0^<^V|W0")^T.75@OK|SA_1U^Z^5Y^V6K#|7R
M(^>5DC>7>_SCM@#6A60 W|W|G_5^>TW%UMDNH)O(8|1^?P3|R6^8&5M^Z_U MCR?(_ MOO|/|WZX9A|H/C1%PGF;?%9I M1^R
^9I4|.DSX50=M)TE^M_?_YD9;\$0WT<(^T^O-P4L6Q^B.W595U^NW0_M78S|)=LEC?
(L5@+).56;K&B|&2|L_YH^+Y|P^U^07FS.A\$EB&7MP|T\$%Q_M|A00G|JR.QSHR8|S|?OW!@J_Q-B@;F|Q+V/J^R8LB72|H(OF|D+8|A@G|
^IN#^\$1^DB.Y=W9|X?Z|C1C^A+J|W#<^R\$;+M;#_IS5BOL9^E_0%|V|7@X|Y\$+XK5(E2OR^X^DY-!+0B|T^#)=Q\$^HA"! M;D|93B
@Y^62R4AD|J|VOU6;6\$|C%88<=BU4Y|>D3E M<1^IEO6(CDD|H8L^1_Z_#XK&CO\$ M1Q_>Z^#|A2 J|4|2BAT|O^140&O#8;54BTRN-
M_%\$JNH/H|UG|>J M97&8UD(U%|(|BR4>G#UN<^B4@8=|BPFO1&^H|OX(Q*5) 1;>D%\$79BWF@_"@D3UCLE;|
|S|_IG|6AE|D^P4@VW2|6SC MC8#&|_9M|PZ_RYM=F EA48\$P^0>|G2Q_|Z|>_4;DUY>AMS;I7&R<.(I M7BH= S2K|IR5?
7MS.6|8MRCO^_F|S|_ QD BK^OQ;O5U|B-WELP8D|E5Y MOJWN_|C|OKKXC^XD|X+76PLH^6CGQ6;^Z@8P(2/W>W_4/5S5#|+J|1=>J
M2.JRO^INB^(|7D>^G^&DZ|H83.\$|_U+7/U0GKPW^9^OYRUW?>=IZSB8|RV M|CXO|JX66S| M4_!O7Z^X&(^J#P#3^R
OYQ6<=87|_7T758^RH|4_ZB|H(UV5P80)OY\$% M+LD&C|AU|K0A/283MBA|1^6BPWHXVEXUA%9^4=698-6CT^S|L6C|J|JU M^+>2GC-
H^>UF==EUH|=|Z#>7^BFH|>YFK_1Z|5YRDW7# AUIA4\$FN6G)>O.9HT^X5^IZ+L9|L1_|PW/NC20R40A.DQO M8;NS^_OQZ0^G?
XY|^I^H|Q_990W44UYTB^W^#T M^WZ|AT_M|M(4DUK\$U|Y<1F|Y_#01E^236600<^5_*WH\$ M#_>12-

/5S:X^0KSW6IEG<1>5X:GZUC:10Q@'= < HA&#WP@PL'P^JT&L5+PA MJ3>
(C;>NWJO*RH_KNNIONG9?1Q:G.T?D01H06F>;B1460?>XJLZB?N50A_MV>B*KG6R8J7K8.419IEO)B\;3-FFH(E)=%?A401QEM?
Z1WDIDSKH/!-L#IY7BAGF2BH\$=50GABL_A2/DE/2.TSN^A(DT1*GPRRY^B_+VUE@#0A5^4&+Q5WOB-(QDRSX=___^5%Q_M=IY\;
EG=#FGAO_..S5Q_44>2\YFM.H^WOX<|M6S[7A\~R)DZ/75S9+G:&~F M3^1YN1;0@/1KE+##%5I=I?6,"IQ8UK2Q2\^<:7&~R
M8N8R...)=T2UFML&W@V<.,>7)@'Q&2EKA_X_W_..QL2F6&0)=ABX03GY_ MYW#PQ_Z>F7M*3P3JWU2
550:JQO^S+S+0>.:1D^65A\;CNTIR**+4X:&A\93 MC)RG&?0V>+NJF7Q/IG@!<#A4.L2^A_+@#)C^-03/4KBNJ~.IU,^CB[D@G%:DHD=2SS+
MP80=+5#3N8JTDZT>4DH&0HD0_Z12)N\$N^2JA6% @T=#NWF:IOD<+9C/V\~M^H2IY?08WL^+>V?CQHS/ULI*?>2=L6-0A^K&ER|8|
\$T#>RW-1.%P5/LI(I M^/"Q.T.=9[XLOA<-7)+!R*!_K1E6(9I&@G?7=-/6U:2CQW;)L^OH;!E MR=(#)=I!\$F:76L0:NO37V/I= Q.?NPCH-
&+2MGRCT^X0M2EH\~M^7IZ^* M4.5)3D.E0:9R1&QI6 &=^XEGB+ @P1DP=8A+C=A4GH.7&~8@R5%/L9>B\$M
M(OH_DJF8XC/=)=5=%3ME&L_1+TS2^A#^F0XUM%VQ6^ADU(#3):\$N0?2%)(- /U U=7T.D#K\:"GF8\F8:Y14F8E)
MI@'EIE+0%.">78/\$U04@K_#\$\D43S/IM8I/G >LGSS/ID<~1%SS^4*~08
ME_IVNZV.8'(V\~!EAR\9"W5AC"&7D)WX\H8J+~KYNTV#QWCH/TX&_~*RH
M\$;%Y\$F />ZYXC\$^YY6JW7^9"P^N2NI8O#5H^O_..H2^~TE^WH?^VT%KHYL)ISUF:C40@_MO?IG@E)!!ANVMH>Z^3^9Z: IPBY+KF10YTY^
/!H3\$~MW+D)H<~36\H^C\$8%~JW6^*KG^>)TQ28ED(U705*BSJWW^6_2TCMYS2G7^VW5^~CMCN
MJC#1E5/Q^NTU2^3J>.:J9S\$C%~P\$R L-&7EGIR^HJO:IQ&=>_TUH143QWW? MU3_08H\I^TZA/QB;A7*
(Y94SFRJL\$@M4VZ+0_..)/H\>^<@')W\$?AV9 OPVKP~96(0W_5KS MRF~65X_7\$1R \|=K:C\$G6BIHD(Y+&QP>H>KTL:EH(G^~GAZ_:Y6F
T1<+R MVS_>_Z:(6-XV/EE%X1LF&6)OL:@KRE.KOH1GNY^CCFZ.\$R#~"3OPN*MT)RG MRT_8%L,Y1%;M\$1=LJY=I)@:J=7>L#?
X4^6+U4(6E9Q2Q040FOYGO_B01FQ#K0?="GO^H@((#M:L9L=U)O)FZS>I54) MOY^7^00^3DL=\$O_>/I_3W3IVH@_BM:>#"#25RW
W^CC^9:&.@4U^&T MAYZ20^PR(6U01<I_X6+O3<>(!\$VG7^IB^73B:U@;X;R8^EH8IU+,(A2)_M_4~8G79J^W6H@~^9Y0^3/IF5
EQ5^4^AT\$|NJ0QJ0+IAA|B/764^2^LNL MV@~R^-?G=3&~I2:FNI<~1+7=89N2+JG8^5D01E\$|0_>./+7YQ#%I2C MC^M)4/=^*~?
7^NH(973J)J=W L+P^"=4=37,1DG@OR2K=XC7W3\D%NN/&H@_M#U).I.%99%)^*^J>&+VQ^K%:4_7^T<7Y(AIDZH(A~KG%XI_~I93^IDHE~
M^\$F^W^&^0^<3^7P\^(-WYBT^P>X51UF=H+&CT#VY3I&X7.G(\$*X)8L/YU&_W M!AHV2.6<%&W<9>@NY;&.)G640;QM9:7EH&WC?<
PT\A:(/900A:X.O MO+!;~)=BBI545Q0&VECH>%4Y)U51~5VZ7I.E5:81NS99\$A\$Y^I8X.RD1X\~M5T7="02(G:U4!QAJ^VLVM^~)K:J^P^7L
IKW%FXG+0 M<8+!+<5)NMYUUFU_9\~1%?8T&O#@BZ15(2J>M2)TFU^<@SJ^7LP^7QA^VHXKE MWAF_F6_HLP-L5.E)AWA_CMH@U
D0:IR5O(RR)<^~VX7J(GXMW72&^TCM)76^MA)?~\$B09I F#QC\FN!:(T0?#4^"O+*\$U^OX**/*~?B4\^QOC*C_(-Q^MM
M55:5(^0@R5.V^6G14=9DN(7&^G 9M1X=/_W8D_!Y)RTM_ DESK:60:9VC MG(K=CL_R=FF#WMA7%_!#~(B\$Z8_#1~6IW
1%V/;/>C<\$^&QG&<^1TE\~MVSXB):TG87H+&45L|A:&1_~GMV;K@<BUOT@LHPH~M_KLA/AI~A13@.KW MKMV^VY9;C7^BI7W.T35
2A735)_Q<~1S7^GC^9C^#(<@JW_..0LBH;_M(GIGOR+~I6B2R GC.8Z61 W6GZ_H|=BR19_7A_M/CX^#>7 \$WL^A&*~1JY**_.KJF@
L08XC1^'Y=^~K_RQ^>Z^"J?_X^OOKMQI^?#C_~G7H\^D,"INWO;U>74W>! MELYK/XP3)W0I@MC_(8E=)|DXV4G7\$?G MV^N5\^WHZ
<(!^<6S0RRG|(-BOTTZ087ZX^2E#VNT6\$YG^JV= IGZRF1\$@IW#T7F\$!+<".MLT^+X20\$R_~
RHR>XMF@("HGT8,3^E|S^&B\$WM1"/TYD5Z8C%P7IV%~ MJ+DA^%T^J2B+~BH^5N
CF^1B RUH2C9W!#C2Y:E.CVYZ2E^|X_"T^>^OGI) (9Q3%~U%BY^P2GQ-B\$;_ M9T_U2&D3U;X AG.H:E%
S0JQVLO&4H_0<>E&5:&1^PH4U_Z(7%(Y13U\^P5_M1:Q_#1A\$8J^)-YY0W;G&^2KDI&~I68#_#M%+1+Q3%=D6^(\NHXS)PG1<_W
M^QJ2JG/CWYU@A1=D16G4>~3J_#^A@~)Z33|H>:~#Z/B^#6I@.Z+Y=)/LJ43 MNT^4FYIUY^*J=M:U08-S_H/&V9\$B1G:T71-T^2KWL_YULLH4I-
!^S_#~M~2=JHG4M0&S^#4X_#7Z5_!&^E@SHU<_!LIG95L&C&=S^Y^~2E<)SO@%4_~Q\$P^CZ_M+5N\$XP79Q^CV;1H%_3XD<Q_.\$3Z%*?
WR3P-2HKTUR^RLQZ|H^#K14U@FEA MN?U8T%|VBXV_~Y5F<~\$MZ1IV+\$1^ZL^F9H_JQ.IXT%J3\$)3VL4X^S55 MC_71#/~7_U^+= 8XP&M-
58=JH_6)OYSP^I\$@&SG^*~0ASTFV153_2F#^~J+D@FBGZ^+I97>
M=52P&+HJB^G%1R@/>^>9.JD=X(\$O.G6K:PZS3Q(/42KU8GN@<BIWK5KECK) M3#1P|H4=@U8GMOT>
I#53@ZFUHP^5MA^HUME:#2^0_DPC^"Q_*16I(9R\~Z_M:MH)5%M73I&~4@PC8M)_&1S\$=(K_R152^Y%5QY0^PB%)-_R7Y)+>7@D0^*M
^/7J.8\$)2@D^A\K\$<=P^FM_~"~^QR57P7_/0I^>I7&KQI<9_7I-H=D_M.CIGM^#6\$R^<8Q5ZE?^0?)Q\$Q574.4)C0G^6BC5WXOLL^ZN=TO9?
XR^"Y_ MDDPC&S04RF^Y10NIQG_!<#=(1KIF7)2HQ_T_E+L^M^H1I5=5)=R^WIG\~MV%#8>OY=I^2^JRSJZ^71YI
KOY^">FF9@GFRY_Z_&1?4F6.4<1.9_0<_YR MR;ZK^GGQH:4H@+JV|91G7HEY5FC(A)&TMJAA=+Q M0X_B+1#8WJ#RZLT3;FQ0H|OB
5C7D5ZA5-WJ/(H|P^|T^#B7^M=20MQ) M=-FPFP=16EB^K_R=OHI\$5M^XOX_~WHJ@SY4&P<6X)MBJCAU53%Q_~Q59H_MZJB^P&AZ+_T?
O3JMG0!ET2M^FN6N;_SUZ_HO^7P(+5H|6F_K2J^54~D~M2LRF&+BA^ (OR/71:NLE&5/I)Q_~SV^+=IY12P4I0M0^BNF7^P\VK^"V
MH3IEX8DQ3UX_M#7RLJVI(3NTZW<|NVVUY2+KUO^>_9I2^7YD^T^Y^>ZZ= M23I8478P^IG5_~ZCDF1&6.GMP@I@^5S^V^OT@/_=+1%>?
KA+C^0SKSB MY_JHW35P%_Y_0N7J_5Q|@%.ODM5H_F|<@NCP9=7&);K@%_JLBSFD6.9^@V MT(C)IOVM6X=9\$2HFQ|^>
Q1E&7(L:RX^71R>#HO_MN|^&~<|ILLXOL+^QTAL=#C_J\~G)8IS&^5ZBJ\$S.OH00A5#~#7E9^O&01N!
MY:T7L,1L,D|@1^7ZDV9#0F7\$;#%~OAG(B9#+(I4?Y7N)N)AL0S8H<78Q3B,V~M^#K0G#5J^N+>1H4BPY|RO?78SC4.W;I".PQ<
XB^="S+&YLOA)0XJ.1%Z9I_L M^&~BH^%XG_#%|H~R)DLENAN=1@7I;TE=.%A5!>V |DSBHSFSDW7@>^4@ MIX_<XQJY@E3P="^29B
1:~?ZLK_?<<3FLYP_~6I|5NMU1H83IS? ML;/RR<\$) 7#(P6+AY23)=7=BM_~FD+D1^Y9TX4TK>2D>NFRS2KD^6W&M| MO|+
(R0H11A^USJFNH+2TE2_E-EX2^0IC^XWR&^LECNDI=3(G5U^X5W1_M|+J5:DM+~5I4CL_RL?>YLK+TK^C64HB_%^UIZ
MB\$BVH)D_#U4DH?JHN^+U\$5P1^XT4^N^HIO9^FE_ZFU^M_<G(2_M980VLCOS#8JR.8M&XT1:1@WJ8@HESTE:T^8U|N0:A5;1%LC4:
M0J7;L_R>SJ(I3_U#8+>=^9NV62_~^J9I;"2_7(FQ_T^"M_~G^ERPE8G|<#8B)WK_3585IH#\$L<4VY&X MCQ&XYL(SI&3^J0:=
I8)&138X9&D S@57&~RUPTG8L_V6(^LO7+PFQM?_*M+!^FI\$|^FI^%?L7IVXU7R<3F6M0>#0<<5N1S_#H9?C7^" M:S\FG_M|P:
(I>@LNUJ2DEF6G6#1?&~DPI~L:CC5)R8S_JK&?EJOY^9.F MI%7I8_5PJKB25>I8=)JB.@_JQA16IOU6^VR.V9C^LZJZ)80^5EX^+D8I)
I+^"LX5Q_M^C>/#IE\$0_1^8^QF&I~2^M=VW\$9)H^"U<PQ#J_~^T/I/G^PRKW~"8W^M^D4_G M&~(YCEIEQ;9\$UDE(=H/G6B3)
<#3_@_T9R_XAI&C+4Y2><2034J+(V\$#8H|M);D8ENZK^>TJLH^U~1.8Z,8I\$^PG MAL_~"/R^+ME_!3F3O3_2W_T5^QIB_B|V^A3(K+;
(Q&C^TX;) MJD5_Z@FA5W0A8/2PBS+M MD3T~I~RGZ:H83_~^PH|C>_0A0Q.GJEW^PLMQ
MV+3/75K;)KF^0Y8;TGO^="84ID9KXNX_H.N4CHV?S|NY?R;D^8?;@U=1M22 M3(5H;6952E:M:UUF1M@DN6^XISZ09J^IY?SL SH7L-
E^&^IMD=DI%>_ALP M^C_OIAZW+3M^LY~ICZW1^I^>_1^#~CFV^IAR>K_97L;~^IW^&QO8BE5_MJ>=>I0M4_0+=^86U)RJNEM^(>(-
N9|HVD)G(GK;JOU|884V9L1D&(4+P_MYPH1^PK^CKI^ T#H~KTE5.Y4S+>=BD#IS.@?FUXSJ;2GY8:9>RLZQ4NBGI_742;_ M00F4PZ9^VG-
2F@Q@U1L^6G@K^V0I&8(Y2K02_ML45?M^457S^~Y01=5MQ>^ 42C^4J4LM4^<|JISA^>C_@6=N42)H=+6.8S^N3 M|:07H8)R^BT^85&I-
ZPZK^W6_7&(SQ7I0#1%E)A|6_Q^EMV%~MT_1H|M9O_2I_W8X1RPV>Y9WETT2GW9L3;JK:69XZ?D?20744ICGI<
G^<F@WD8HH7BI>UTY^<=VQ\$R_~M_5(3^+0S_.\$H\$9AJ6=2*2JH@|+>B803IQIF^&K8MIQX18I0.9Y88H.6 M)^!0;H6J>^YI|LIGOZ??
\$06^LVE;6_V_14D_T:1?>8_VIXB@A:U|827X_M4%\$~EKB^&_9K1^I%JL02IM^0AA)BW^6=ANHEZY^D0^<7B>D\$!<^VNRTRT(-M_GGS^?(3=
(H3H;7U>PJHAL5H^2KG&1_4WCK>1 M82WIG;A=F^6.1YT18T@TN>VNF2\$1&C)UC_HLZ+8I^D0?BC8G<5ZTLB1AD2M
M^M5&+3)-(/B:<|^Q/TX/UT^7AL|^A6WA3UHG N&^<_<5^_T995^*?#S/M0KXM;_1_ZI_5^"W^ZM5OG^C9G^J)DS)NH+(= ("7!
I2IN;A^+G\$+SEIX^"KWZ+RI_>1&Z04K3I4_I>(5C)_@8X71%1^~#YL9O/\$\$#>;H0_L)X=P((&MYT^>_?LID9I+34OY6N&?@L&5)F;QI8WWLF?
P^ZW;=HH8;4^_!AZ26A|Q_MH0|5TPPGIGT^G;2B=T91Z_D^/_+A|P^PH1E2^7K0^"V?&IN5H MDS.HNZS?(U1;HIOLOQ&W948C^\$0(C)T^2T\$R?
I0F^3OT^K4^QA^<GKA9^<M^O@W2W^_JA_<E/ (33GONN\$2>%^T^_~#>RD_KHVY08Q_@/?^&_A61(KWTBK^M^NV5^AX8-
Q6A3:~)CG|UHVO:E(NV>\$PR=|XPS49DCOY_LUPMV^5ILRW+ML M(9L#<4G5M^F7SUUEYE8=V^\$SM:4&DMB|0M+=M&TLBQ\$S
^79/<0H6@2;=L+H&(6ALFC6J_!E13FZ45E^TM(BI&9OL>JMM@_M8SHF=|9_A^>C_<W%IO_G)B&E>4/A^NZ+^*WR>^*~0I^*~&D;11N?7HS-
G#S_MFT@*M=6XJK#S|S)C3@|H_..^T^JBA^T^H_&8NPI^<D^01YUJF^T2G^X_M=9I4(_Z^Z_5I^0502-
X;9C=7AW2>927T17>5UGGRJG60&6#:=9_VI^" M4^<3^DS^SMY^JYEF3^RYUCE55N_R/O@>Z;O4D#^\$V78H!52%=>."\$LV0JFSU_M|:0R9
\$V|_E#8FC=J3WL0R_8/I;G_MK>2J+CKY942G^W2^KNDM81XKR03_MH^"IO_#\$65-6L5@6+!8&*8?N<5_F-
EITN@U+GX4UXS@HH5ZIG89&X?~SM5_M5?W^H=S<+NHCB>Y_0I^L)?_1MNTEM+@R.\$LJH\$QQ%^&28^H_N@63^J\$J
M\$J^<^>I8CFOOUMPI2DW;8~\$~>^*KJ?0JNE_K6IHJ^_VY32JCI&^*8\$SMC;@_MC>Z^+L\$@<C^&N)H^#Z^"Q.XR+QWK|=I0@ZMT6N;P:4-
BBF09_LLE^<O/I^F^U_M)=~.0FS=9&ZL|1P#>@>UHA5R^HM#H M 6&;7/O\$=>/(DD/K(Z:C-W^HHBC
M=9ICT^BU<~^PK&92B@F^T^U052Q_M6PHFYJASIPH|L^#8JFQJ|^9K=>\$S;UULY;7;R#6JHFEI3I7_MV GC:H_)X7I_109KZS\$EOP93E_M
M0^<3B_5Z^\$S@O=>@^CY1%MY;F8W^4OY+D;S+CTUJ3^RFITVRPF)W#^<1N_MIKR4P+H9 AC@|KOFBJ9#D?W
M>JRI4&U+RE5@W_R=|^5<~VT^<X&Y&G<+2(MU>^BO=3X/OFX6U)RXD3^WWY_MHA^TV0W_@~3_0MM0="IN7^YS_G_T6XF|
<#>=>13M10%|<^S^"=OX779_M^VBM(G_T^9045_NC;IUP^\$6>=>E6GGA<7J?S_@>V4EUL)/E|NF=KLU0^ MD~L9^KLAT1-
MOH=SYLJ>:0+~I2A+J>L_4CQY>^L_BNF3IRBOQ?>_MDE^2_1L^7CT_YUPD^>DZ^<I(N7W3H+POV%_QO(512_94W4^FCZ_D_Q5VZJ+0
MB7P|>O^*~;R<>5(I@^U.YOX<&U)W:0%>H>K0PLF^3.7?@C.X|BL_%XAU^_I MR#O%2^RO4=Z8D&D\$XJ1_Q^FRNOF7=#I> M^VFM3-
*R4^IFSX^QL1#;_MA32BC^M^<N_1Y\$J^13C1^PQ@^6;8W(K?_X1:X+D>|ST&<^&X>_32;D>8H MQSH;_3Z_TCZA^0^R^Q^B-
B_R:4(IYZ_ZU/981^DRJ^ZW&);3WCMI>3|@|=4_M?_EZPL|CWVB|H_~QJL/8%Y4|UKUFRP7_<=OUPE9^WZMQ|95JH%<0@<\$<8
M^G^F2;D<I&7&0AA55#;FXJN;CM^#F^K#&#U>5BO_JX0J^<=OAMUPZ)P^Q_M6N<^+M^O/TH|_3Q0^22M>@>@^"T^&
L;BMJH_4C_SHHP@_X878% M;125/G_@&G."6L\$L&\$S7\$1L1H^A>F_4GT;.PR52X^IY|O15+7PW_3D>I^# MW^W|_("KYJGTLG:?
^RI^DFY\$&P<~IR%&9H>U^G|Y7J^NAYE_4BJ^4C_MY<@_U15L?7K8J^="QON5^<M^H23T4I10>_Z&42)SP^6|MZHR6.\$0JKWO&

MMQCX/X8L@ZT1542RV83"P7?G I@X "MZ*?3@&XXYS%ZHH/B"W9@IW;M-?B*9PF->OZ8X&-U+;03N:\$JEB^%X4JNS.X3YJ-
)")9C9NBA@E I7\$S *M. Y(I A)=>?PJP^18@J>S4VD;K\$S6+HLX)F2 \$5_-@V;ADF3\$19:5 A4 1 M1 HI 5=^Z" 3I?A-N4-
8=7B6;A,@2Q9OK=>B. 1^1HCS1,OZ&KR9?UQ171 M^1)2WS(UE,H@&H^A>;,R1;>1@7UE;V=)*K2)HV17PF2(7V1+ M8[W179?
ZT*VJ*M*>..P>5%H66W22(&J^&Q(V3S97S;Xf@&1/!B(IAM>0)Z M^1JN:7X#1+FM:&8W7SM);,KLL=LMMB.5WCJH"L%FMGOI^?
74S&JU6\$2:X MKI#GNTYPEB;:KL&E7(L=#<4VSD+BA(18 1< >^/ GZ1=^?+KZ1=O_9? MW%7Z1#GVIH/W1;OUP^=-
>^;:/G1+OKPW2_O KB?>@>N/7H4WPS^0XF:~ M?OWN_9>GM^YE1N;?Y^?OIK/H^< 7YU5Y^?C^MM?WCOOIS _XZ^?OGFZK>OYUYI
M^HO&LPIOOHW>_R?@/EU^1.9R6=1.O%B5G7T;KNVDZ M3FN>O FM17GCS^O3NZ 09^BA1+K& 3D>^O3ILYY^FZ1OE=HDOYZ2Q=G;
MLZ1>^OKTYWMS?VW'X/OOYG^B8.KY31UKZ1-F^3F?KK1?)P1K?1EWJP 1?H9?7^IN?GW1>BGG IW:#R1 M?2?U:ULC-D+L(<8 ?
N=\$;4YPZ^-(0O1/K=Y;U=4^C9FV J9Y16^~#V.7(8 M@1>NL1OZ5;2FJ^<1@9TO84C6X M5D.B&+5DPUIMDY=-19PZ@4.
1ZO@C.4^HG;=1J1K81#)9;S A+D^1HB^@Z.1EMH<;1LOT2N.CP>6=L1#J1Z+P^G)5B^@M72;2D2M.2.6I2% MP&LI
X%M\$IRYJH8BS\$(XIE3=1.9R6=1.O%K M+Z^"C.6@7SV@>AJAU&VUM> " M3H67H6AYBNZ38BPU<5JNLTPF14K>A%>DV_-JHB";K"8:(
/TRT;+ \$Z#USD MR*VI@Q1+5_V1.C.C)OHHHAMZDI)@MWD#K*LF6S1=1 E6J#0A^R,%EO; M43M9H8C "AND4-497??6PVO64811%O;.
(OA_HJO<&BLP%0"/\$9M6FOJ(< MILCT;:P*AM6#M%WHM0VES&1S1^B=%M2HO5LKJH1T5%(%O_&U^"N1#SXRSF
MB+Q1)SK^8J2D_16GAG/HLX+DJO.POKIYH^LG131=0>V1@401^N<.,6>)< MSFEFS74# "A/OX^FD?G08JOEMH<JYQZ/8I^
J^H>OL#>?7N.M^>4. MA?>1.M?1)3U5RC4+P)>1@2 MR*NTU;1E1.N.R1+4=^D)3^A;1>M1Z)701=GP8.R413;^Z2D?)A9;YY(Y M;
1&7OIKFK;5WYVR&D^M&M7Z*HK7ODG-H,F@&0&A&NTB3.ZU MK1)6H#9E?@>GZSF-FQ\$ *D.A9MFWJ31+MG M#
EW1LK0H23IOC?)OG^&DGOH)S1N;LHHH\$?D^Z FA<L4Y?C.1L7R;4PFS, M2X96SD(S5FT4CV)IRPJ*PF^CKU^T)1KNTOV1>T/^
8Y^+2C7GYPH M%#Q51C^*VH1.BN7Z/"M (A^1-S<)DVB1H#W^1+17V01@ \$K&1V1CU: M>F;
J9"U/CV6157=FZ\$Z3CJGZ6@Y8@0X_E12NWK^+E%KNS9DQNDQ(10?D1C MO^1>0;WR?S,B4)JLVY0-"5&C/@B;
&QB8F*49T@2Q614Z2Y,B/2@U=-1 ML1:=W.M #YNV6Z^X 1 52R1QDQ#HG/E=N)#39>X?R\$60^YM-DI^S?#L9#Q77 M4=&*JIG#-'NE_Q.8\$0?
^AL>R^?D,+OVWU(J2CN"/(8&Q1%= 0_KJ^R+ M&P%8^"J_Q%5-2+\$CV=1@5D1@;FJV."^?JO@21AN:~*,EG_2H1#%G?G&"
M.VW?R#W61=KY87X9X<^/1^@E5.C6#6C2C\$Q1FV7>L87R8R\$1\$~*4)1*N\$ MY/AA^YV.%,+@ZA/3E1_P2NJO_M_1^3"QKQA,@I2^RA16%
1G.N%(DNX<=U&\$_R^VWQXS%OVQ;>9QH-YL@O-C M@?QM170C.JG^+L08SF11%#H=V@F1M.ZHT MV31,51^1C:PO;&@E,S1^1M)TH1#?
67^Z-5IEC30B@F1^1D4^QD5&O21^&9Y MEZWY;Y&R+7U/D1M7C.#&^&XC;YLV\$;EYJ2/@_ TH3QDB1F9RNO0<M.EK+H?>
8BIHQ@4VHHL\$U?*,*D/IL1N?AJ=UBH@.7-_\$^+1;+MW)6&15?=. MG36P1.S-[@C.Y%PT^@CQMZC^P2\$HPV4V_HA01M^#K>11GAH7@_158
&CNV M991@PS.S/XKQLE18FU *REB/G>X3!=(926^*#&1+D5^Y(11>6B73B^8.U+VP_ 49N;=,V%J^ S818F^=1+XK=E.H?
V1J)5Q1YZ;14NE>2A7?)P^SUXM2GCBYA M^V>A9?#A1^O\$EKL^FVG-KY1976HO?12&B1B."7N#U6Q1JD_+V7AV>@JK&% M<>HYMS!
1E+^DNQC-T^26GT+5PCE\$?>M&1MY&IS+=T^0F">601@AG1V#1.8C^1;PR%C.=17C8 M#
(7P.1%)SP_H8)=X1%X(\$&QLT%3POA.=W.KZ1B;6U(I(1P^5VPAMG015\$(BK? M_JN16KG(&--MK1T\$8#.S^AHV(N0H1)>1E-'N%^1ZL0-
MRA&46SMCIY=(@ MYL?+1)5T64L-4.G1\$>K1+U1+1^1.HK55\$1P9SA=G%/ 71>HKN1#N1-YF? M^A%RR5_\$XX7C\$S1>HFM6AWOZ\$-
AK+2,DC2IV>:;61#(<1HPS21?JFIT;E M=,15^24SUMX3R1&3YSBB3>TX1K@&4.15(36Y(5.4AUM1L@D #A=D61LV M<&7T^M^*^"##
JU^EN\$1W#EBOPS?P91H11QHCHN86-1%);2LE2\$RF.5 MS1?FPB1^>DQ6-6J-6PBZ@=M=1M0V7X54;+&K;Q3Y=DMUA2JZTJ;NOY.Y1
M#O.H1(R-O19&1#^*Y2P=*LR1R=+TQGH1)>7YWA9^X1^D\$4M^*9)@8C% M#-S.O.M+H%=Q6%A1%V2X7ZM??JHK/7?<;
ZJ11>9=EQ6+T2JN1= _E^M?J1^\$PU-BX#9=53TU;#AW;&FR1F1^ M22CRP>QWT#%.03WJ
MR+B;JU1LFDK.K^AK8LX_E@U1.N^T<4 ?H#H1LE9S1K1RHXREFF3WWO.P.MC?518C0HRV^<4C=1P.O5^VXK-AC M1=U5;1W?RC11-1-
H1AYVF+CL/E+Z3M^GM;#;IS^NL.M(O1K5A& 9_1R MGL\$@N.F%GI(5O/M(M2M1HG-D9DXE#XOM1KV<# ?
L:GP^78BEU)#U1.GH1UJ1;0F_DNE&M2;- MLF2\$+1(HX-M\$^NOT4YI27_6L#&- KZ11Y;K@&KRQ19VV5L7T)SA;- B98(KM7 MFORKY1G1-
E9ANZW) M<1L-6MWWV;5>JL106-G_1W/V)V?BS M\$ &#V9@JS+69R1BE_1Q+KT@Z(H3<;R?>=0X^_DZJ^PO.LK3G1CB2K^/?PX^G?5Y3U<
M/X1B11NY19IZ+CW9YY^Q^X;B1+1F70 M<1K#)^0_+1+DC<@12711?PE11.#=Q+9RRUY#1D^*U4^K4L;&
HJK&OZROBT44EMD5R^B4HQUO;(V1 M91-U2YW3R?PNJL6&A7=/BZHY(EC6 ML_Q9Z V 3J1^1DY^N1> M2^1OGR1EW1-
N1SQ^*27-KCM1D@2-MC^Z5F08L51@LBFTD141UC5D6NDJ1 MDV7\$KK6B.IACB^O+W<+DVC^UYSF(4Y1=TSO&R&9T01E'
>O1X3DP.&1C5+F MY14D1K\$17OD1#C<^Z5%CF+G)<^+=9.Y+OTX)MD7.H1E(P0@1ND&M^1^1) MCMS\$7Z;M@32^>8M<^
(6NL6BGO^VNM.OB3R0S1L1&QYV6@=%2<9JOANAKYQ M^1(^=K;9U1Z3)0^T.L M6%_@+^Z^G6^P^G#1+ V&=W8K2;1+4JM
1D;GZTL1^KU+1M BFH/Y;~&Y1B:@1LY1OEAZN4E1&9TP(1#W09^2N\$X)33R\$ 9AC67H0? M4(1^1SD_V9)S?371^'
>MSY ^<@5Y#DW7/301HAV9NN.T=1?2P.TF6 W51VVTWTK1MLU1D^6:L# M;."2XDJ? \$A%1(G1M//+;~>R\$W(R\$Y)#2"-W2XH1HJM0
M-O3;*1@E@JL^1BZ7EEA0><;5F3^ED#CVWG6M\$?- (+ (M R0^H\$&+\$># \$0 MV-YPG5L1P.8#-)*^STZXX1O+ #N1N4,";O)R^L1>"
K+;YYG1)&BAV+E.M.L Q+XE+1L^1LZF>9GU13+K^1A_197X1.91NP+ZVY&" 3OEZF21TL+ N9
M1G7XFU_H24R1H1>W7/G^<1JHK.AZ_49S1G/B/VK);19X17KYOB^=1VJAM982= M7.5;PK-HC49NUH>GF(<22PJH\$B@I-3-
\$KAD1=47L131Z:@D^9517E7/1R M^VIC9^4G3C^06D;K8(TOD6^Q^X^E)S* 4 TH 4.;&0^Y(>7>TY>C.LM M3U?
M1.8W6#EW.A1LR11JO1MH@2CG-A5X)O1V1B^E5XB7&K.01(O7P9&Z19 M=J\$K=3.ER%OH4N.M%/?WH2Q/9^&58&O=TDY^<9)&B-
1LH^F1/XA M178+D-> (W^V7+58 W^1Y@S.W1A-9#1&D@6.B2HZE@LKE4#U1VY^E0)AH M123S1@Q.UH#_O30<6R>&P
A1LM9>1%7:&9-&M^BYH1ITY<1)D4?+DE\$89XPL18^1VV2=ZH(FRM11S 4)=V&57/P0TL2> M3E%S-F.7C_9RTYVE&*J2TPVV>
(>ME^DLTE).?S&YYOZ71Z1P= M.11^>Z^E#16K\$1LYX51@-38;11^&2G.O)51&R81507)3.CW1@MGFW91>T3O 2
M10WBS+2_ZKP.1+K^W81B363L1%1.H99UC M+W63?J3:@XYW^W&@QSDW162^O4XEOD8O1-7?B-/16.UQ4^4KVM1 M?R1#
\$<*.8GRQMD8EV=QX%=1(5EN.X^+;95K=M^P^%FT<<^RVU)5E^10091QG&^M)H1 MG7(=K(K2%>4H11_21&^GT+NL8A^E+
(1BA.TWK.6>2\$;V1Q>)1@Q FF@7 MK\$?X)Q97>9#=- L0VE^JHUTC_-DQG+7?)#M1Z-3^1+1&P9?0HOEXF2.SVOG M1L1)AL43&Q/?
MW3(O=88GSU^V1B(OZG)1C(>Q_S=6-1^1(Q\$1.326P1^A) M5^P^Z#F."78PW@R2.0#=-A4E1)6NU#2PYS_1^NO#6T.N2<<6D1T&M.6J^5.
M^L9^F1G(HQKK1Y.K^*#KDSN_1@719Q&N8\$1F=9BWI(EK01(N1^C-A1ZS1Y8^R MK4 5^MF0.O1C.OA^Z6^V#L1_K932&
1LMV(58N1Y;.#1\$E:UE1YAXJ08^1O1S MAMZB1Y_R.9^%HJ4_3(16W@1)MTG):C8K #<9&53-1&;1W- 22AV2G5TL
M^XZ1U5M)5^G23\$1^0^QK1LC&-516 O65VPBV4RK&407=-1KA_1DYT^G1G M3H1G^RY06Y2GK&S X7+\$3<194.4>S*(GR1V7581H3+?<1
(?2-R+1+1A MS@-3V1U21,X= _96#Q<4-O-V<4RN^7K;=?T 9B^U1^PGN&O1+1;#GB MN11<6.);M.(1#1AD(P_T1F^M@(>QB1YHSXH
&13G?L1BLDM\$S \$<26JL; MUB&TOPOUO^ZITY)MXA#1+18M^*1J1^160QW>L.ZC M/5Z 1U7%L19\$D4/Q?Y&."9\$&J1#DAA^ACN\$N%
K750:SH/X=M,%"(X M*=7 #>-080\$1K 61^GCTK12)"*Q@D11&0\$ZC?9C#\$1^7(OH-XZ&DE^719AUV M<74
#J4(XG/%5O1V^1E7MWS2@&L8_ M@W7%44WCSO.CX/H1ML0U4;&QH YHQS&9 M>;5181XP(Z1VPA?4.M)VZ MIK#&Y;=1-
174ZDJ^J1B1F1&E&P=0T1Y2_G(F6^Y<>S&5^*K-?1>5EV#2410HZV?JAA#;JZ^1%\$#_ MV0^7F;1%SB\$N.V@ UD;S2M4
1\$+>#X1R1^1L1O1F9HD1.W@U^DTF ME^H1>90DG+VY^Z1%1JYVTS 01BM&>SH12.Q3#14@<T@<R@<W3J\$Z1#12 M1^F^1+OS-
*3.8R6WLR1.WO: M2+8H)U?4909/3MY7N'HAH DPWF(+OW/<#D.D1YTL_B1IH5\$2R^Y1>_ M:U5)0H^4E8V.S>=N@215;JL1HOG_)Q:Y
=U/=Q_8_TIGX/X31

--41O<'Y1_3_IUO1%^-!OF5VM35?6J0AV=RIDQG@Y%)AJYN>V^G91W M_O01:9")11^?OCPI/1T-HDKO)14L^9NRJX0>DT0@>=^Y22-
A^1AL1L3=_M))*)VCHGY4%?)>\$YD45;YY1,?%@D+M;V/P3/_5@>D_2>GCM;+*XD^UH M8MKZ;*14WWB6+A'=OT^?).H^6)XHT\$71_U1
<*TSCX1.TT^1+=G%TH>1N MO81=1+B1^1^+1#1SC+5319%41@171#?1W2M1-? MEFG3_UR?1XW\$^1^?
G11S_#FNX#WG&18D.4&Y(<?T#>KWT1(VYX&1MB M.199N/*+3O%KQ1TCX:7>^YB16/=>V17PH=+0)11C4==GZU?&^RQ>C^BP4N1
MFGVS=#DNSUA?K1101_GZ1NOV1MN?K1BC1VTIKR7>P.06%RY^18MKA5T1 M=3J=#&S;Z%(OZ31X13A?
1=#83.M4;:ROOS.OW;5X/GLXZGE*J&1T:P?H M1DW?HEWR^0/ 15;1^6^3D;15;.<.S3G_X^=B-C& WZY1S11;Z.^1^>.03\$ MU#-
_S_PAWY^<(SG1F# \$S1_1FB?ZNX3_?X1+57^1K2VMXYQH?#GSY\$QS6HV_"=V4?RQ=)?Q 95NTY
MEFE\$7SXXON1P^E/MZ1Z1_D33Q41^LM<516M^M=PDX1U@W=AJAMR.+G4_ M\$Y1OB8Q^C-# MSQ1>\$G1UX14+1L^WU1KR11^>_?)?
>_ZUU_UDIS?>P&1WU1AH.OU UAF1=1@5R^11<19P36VSQ1O.8V UUUV# WW3721+122 CV/Q)C8.OSFD2UO1Q MUUUXHO513V>_ZR1
(0&G^61R9:B_Q^+\$^-.WGC1L\$T%_TFF1&L(11=1.#: M11W1H>71S? (O>7=12W0W+W_71PO=DA@CBIA01WR(7TL=13U18V1Y1?
#Q)Y31&>*0S."AG@TC \$&QA+VY^1.M.G)=E^1&1C&11 4UXO);15.TH1A12WKS^E169T M9(Y-T 5.FYB^5QM-
F^POD^S1A;4O161Y+OAD_05W?1-4BW \$@11.151W1N^Y0^MION1^ M7ZXN1?
8O<*.T3M+1FXC#&H2SYL^&DD1YHYORH^>#4C5S6G1^1^F71BY^1+M.QO(2190^@O/H==^1SN61\$GDFKE22H_U1.+K>1=,?
N1%O\$;?/ A&\$B1D M@\$. T @0# 0+1^18WD07_7041Y;<"M<\$)&#BK?+DM101_H1F0FIK;%EO: MP
1_N(416N+&MR1R^4.^&E.2^N7_1ONFIYAC1C=11R@11+1/B^1^O@=# M:5JS6&?JOE_SP@_QXR>#P<51U&WS/^SO1^718YG:21Y>U1.5^=
1_XZ1;16B MK#=#D1<1PW^1Y1P4_1D#^2TNZ51/>81^81ODRG<5T\$M^\$DED+1^1+SWM&- M)+E^V>W)21O3ZMVNOF^U_1=0P.3>^E-
(Y_KK3MTGNREH138>VP 1V1UO3AC M+15V78^0S451/N) MB7(8 \$<0.\$1Q\$1L1+&1UW+&QZY =1L1MS^N_17
MMBRU/GEPEG45G\$1>FQ&ZL@##YMZ21%1B#>CM)=<=%NC\$2>1N^Y1^K<M<="A;_Z1Q>>4V;J12@9_LF1L;Y=0%.WPV=[TY01/1:7
%TP.E^=W#>Y0/ MZ(OKC?R/61;=%@N%)Z;85=A0YVO1\$@5^31S(B1ZC^J)F1D MZ91^1S+C#RM9;R=E).?MO?V5HA6/9.8SK-
1SZZ.*R>#Y^F#81FSWA1NOQ/3 MP1VD-5B13RY^BRBG^QW1<PS1)=HHMNA(%-8\$PR>1PKT1B7P^K/CZ1MDT55D)6V(#>;1U-H(&F5JH

I/40R R/>A2HEJ>HN6*#'+8|)W1|N|09F4 ME|2K#VB/DUY|Z8FOJ6EWWV|+G3)VXDF*SHN-ZI=F"#{Z0:J1?I2@|O5-9.>
M^ZG;">16|F|UVV^A|=B%|;1OH3;&8GCN:4#CO4|S4>|I0|'354*#&/+OI/=D MHGMD.%H@BG7+@B|Q:HD2^L^YB?|(9Q/((#2Z 9T8B.I:+\$
CJFP/T8?>f|& M6*(QX@O@DW|I>2\$65<4Y0BYFY|T|Q=XLV|AW=3|HWR8?3-G^@+65G|
MD|Z|2EPBOSG8PWN|Z+9|WLE|CPI|@.#U>&D-;L)5!-;|*|%'H'O MFNF>3SHB,?1G|RRK9^A|KPK-|X\$QB/JZ_YR9%X#S?=?
U%NEY('&BLDSX0_K M.T4|_!9|KJ(R5MDSAK0'9#B84). SN49@&3&\$UN^% M|N|G+|R|!?'%5F_)S/XDJ-O&4@6DRM|@G==8UMXAJ%|?
9\$4^~|RP|Z8'M|J9G&G^4>2QG6DZZWA\$9PY<)+8<~>N|SGZ8H@+!^P>?%::DWRZSM-;L MS'::@(|U8L&K*
%8&H%Q2A(5R|F+|103FY&XE?%#XAD#7;L BG"=;2Z/8S M2C=XH@&W-5C#132)W|2?GL&FZ;L|T-;HL4X3Y|G((N?BV0?2U|'B|;
MNR#X7@&O6%M>+5A ^~|7<&UX5+)|E+##TV;|PI0=|MR*++C4-73'6P2+P4#>./K.T07-R3%C\$;|JRZTC+BRXBX M17-L
A*V-^|SF2R98_C/G7L|12^2%2VGG/^F@6^9#%Q2:>0%.34#U;M2SP2H&0|E0
M&W%#"Z(FPUPC^M,3'I7Z1+|96@KQXS370S|H@|(ZS)@314\$)7U|H|/MN&(^%CC>2SB3ZD|<(Q-T_|OI>O^U3(*|FT83@L90
Q2??"#LB|BY\$;K|I+MO=NYS|@L|LPWS#84E."S<&9B-TV5+>|J|M|THM0=)DH;6H|@A7VR7|MSD MB\$=D'R;0/Y/!-%B7/T>8;!
|2P65%\$C^*#9((%H44PK^\$4RT|D+C*3-"F/^?4QO"M|GG):P.E|SOY5M>&|Y?GT/7N.A?>A6KL..%R^?QE<7USW|H+;Z)0_0*J
MA^ZPI^7F\$NL;SV_|PI^O^L|H(P>&'G9@V;M+C|T|Z(-_UHK 5Y2I6@WAW>G#T MR)0|PH|<@;3GADJR|02DTI6=|QMEP\$4.
H|W=V6|Q0|/^+C@%|IG8A\$0R6M MT=D|NTV0B=;W.VF6|U6|L^|J|T\$Q;@E0_-Z63BHA;X%-UW\$?T5=|W|C|DF M5|<N^?701M@;-C-
HS=D35|2|UQH\$NB2*#"M4L-6F"QVG(2B;6A;A9|=|B" ME%W5;CZ=PIJ+|XJ4=RYC|3|^?%?H."#NE8HD3|OKSSXA8R;RY|S|&OXFYX#
MOT<1'G)6Z8WFO2+|1P>K9N/7LF.Y\$6J#MW|P;QPVONJ3>W?|)|8SR|_|M<1^VTA5|B;5|U_H|O-A.%22&(^C "O|&|%f|T>K5W|
^Y5@/Q|HDW03 M^V;?G.EO^&=P|PU_|1_4|EV0BPQ?>ZXSH@.BZ(20+;K#3EUN&|)Z:2/5@G\$;HM?R\$WVKWKW|.3\$S/W\$ _RKDRTC5W<|?
(R?Z M8S3Z|Z(?\$59Q>_>_3P9<8"SH|A|L W>+W+C%&7/2H3P;QL#K^@X PESPR MX9T;L?L.RKV#PDV6|YD4V7ANB7|P
>"MQU>+|>Q7UX\$2?HH;%|4ODC1+)|E|V|JM^ MJ^CCK;ZRW?F" _5AS#D@&J^4QG6\$^(T)/9:6|D6W|.T&4PH|!-49W9H|"1 M=85"?
N^CBAK;J9(|%Q|MNZW;P.ZGO?I=&L.L.Q)HB;@OR3G|B;Hf5?2"^(+1K|LLV"\$@7D#+|W;6@OWSC>H|YVG"\$ G)O7 _\$F^
M|6J^2Y9\$LTy@1=%4\$ATD)SHZ?'T|>F02K@8 C|>H\$|C5S^_3?|YXB 2B"; M+*A03V|S.+|14Y+-N>Y-L%O2DU^# M-N<|9
-|D<^7A"O;N|+|DWS2|K8E%J_X7Y>1 6?-|P\$PIRM^UZDU^E| MV8O"4OA=QH?SNVSMGWM8Q|M ^R|B|0"Y<|MS?='#@2I?
>C>|_ODE&7R| MO#Q|/@RVZ8TSPH+>O)H^E|N-^&7S+|5VW|33K6|MS8H HERL|E2;QX|I-^M3|H|G/CX(LM(EO_)4-
K=R930^+|970Q(5<8=RU|D7.5NC>|@N.N4|L4 L%U2 M|JBZV2|D/HAB>4;YB#M3P=5VJU2S&X|O^T^R^@-|DPV|&WL@N\$*CK;F?7N
M%P1|T&V"|#R/^M|^XX%#|J383_ S005RUMQ56*5P^DT"A&.W>\$O|F#Q?KK%(R+
MQR^4>MM3+;KDM|UWON>N9H>Z2)JH|KKY(H7.5|Q|J=F+PG&3G|\$+>_EXO-
MWE|/TTX<O>K.O.\$'LRL1RF+EG+7^@.794CJ|HK36|F\$V@C4)8;GLM&8 M4*J".W>E0155H2VTBX.%E/|=|ZSN|Z+|K|V|PI(L4W
C|W|I_.RK023 M;1N|>_TXM#?CWPW7F^QBU18;0%6FX?|>B->7D|P8>OR8|J|U|M;4^A(M>8%5(9&VOE#LLL@ZLF1-#Y&E@\$Y
9"G"YV?/;>)|201|6LX|P=;/+<6 M-SAC|M|ER9M>^XKQ|T(WMP+7GP?+3|JF)4"IV@?T5HB9H@MM9%#|/GVW>3 M@V<7OIN6R?
3QM|VH;H1|)DX\$@B3;JWG(V-R\$=#6 -2G2A8826"K-%6AW|3? M"LLK#2@|F#>|H.C|@6@LE+ _ELW-67_U|P79&I-%;\$+E'@W..QC"V=(A2F<
M@|D2.IAQ@A^65MY.5+8345IGSJ^"G.W"+..)&N0*ILXZ?Y80;C-."#J MN|1;1.HF0VLT00>H_LH##.\$FODZ
SX+M^Q^K1MM|4&G|T.9.0 M%#@U.K|8Y3BD.K80^|7.YY=>9ZR+|_|3P#W|T|J#B|YU0|_&5-|7V"U
MP0P*"TB|A6;"VO|J^O&T.^=2V>Z;1#ZSGC=8D;./?E-Z|BDF^~^RX5I#U=UHR_)7727%T%|R2I?
19S.+;UOHX|UYG|RYX%K/8L'K;8'S&>8-M"|2F_I^RK|'C=|BMGFU\$=%PQ@W|CZP?LX@/^MG|LOQN|>Y3MZW;W-;F\$5">@N0
MW@(|XO|GCD|H;=2;M5|F3%5ER48K^KV=?O|Q|I?D^6Q;KK^JR>1"1"<\$U M\$ECNY<|@KN^OCF;F9;5B|J8Z|XJ^T|F|JW|^5D^|?
E(BL&>QWE@.9!);+ M?FEKN7S|F!>WLA?AK?#W@U9SA@+^+%VN|H56J|P|P0DQ%=-A-Z|J\$B|V|MOU_Z M%SC+K)
|2E(A1MTGFF"|JG4\$62S|Y7DHY;."MGBE%G-D^+K>O;GN?F^N|Y> M7PYXZY A|?G_O1K\$R M|U-7@|J^QZ^@H+K09B*N|)#)-
J3^8%INVO+TB MY83*"DW-3HO<M0"L@_W|?H^GU;D<#741^26|W|2LT3G%4;W#3L(0MP2TCK?44R@F=H|Z+AB H|G->Q/65!-
>8N|JH"9W;6SPD MN6#"TAGEMBOHG=T^K.I^BC|Y=>PZ4S^>_XT0?
C>I3L5D^|;WTY|^S|N1BP98(FE|ST)K3BO^+@D^HB2+H4+>0%|Q;F2|1^5Q7><|K@P.D\$LM MUJ=LIKO^~^<
J_O3P&BN|ZONM|e|E^A^Y|L@|2^0JMU6;G#S1|^#E8|>=?>|E9;T.0WEQ48-.Q4EF31DE^US C= MC3.@&A 9PP^QPYFLK4;
|U|^T&=W\$|/F=|R(+V)O) G)^LB^D31(^NU.P- M-8H151\$06L?K;=J8|@;M%|V|-80 D|^#Z92U#;0=GX9&.|NTP4/#QDX3P_28 M0?>ZLS?
R&40(=70G|H0CHH<^E05)>L4=?C8;Z1N=OL=KQ.6& M>#0|;FJ8|Q|3TP^X?23|9V..Z&T+VP\$XPQ.9N|AGEP|)VR M^F=42H7?2\$+>K-
T\$*=U\$ETQ=60JMP8=-B4P8C>K1*=\$/AEG|J+7JW8X@ M2J|K03?J_C|7^?=>KZ?@|^Q|ZNE|@B 2MZAgy%|ZONR|J4PE99/#-)
MXKZ45HRI6|>U5>P-2H^=>XGM0\$QZ0|LU9N@57L8(%#+%VE;SMM;B?&G= MZ?ZMRP9Y&FP&X1U|Q|=I9OX.GSOX??>\$H-O9Y\$U+
|<3KTKGHEBDL*PVD1Y MIKOD|H|H\$RFO.5ULAVP|7F_N3QS7_U|G\$>VOB=9++4A6P\$+E+?#C2AN"H^M M IX @>C1>P
|4&FVQA^_V7HZ;9KVOFN|62X%N;AMA_-0DWX\$6Z1Q#|H_|(R*B;|F|BN|XC)2VW/A+^@71970L40G_PUQ7%362Z|^1>^5|52
MG#^VO7VYJEIFD/NU6&|/Q|E46U M;F3A58K#;6@=3|&TE W@F73;PP.#FM|;F F_M_Y=J.V!+D9.EJCRN@.#^9HAA.#CQ?
QOX\$DGO0?I2>V_0%_YF^<6.1C20H M<^PI^8_|3R>TEHS%(|)L^DV10;472YZM|HD%=-N|4BQ^#08K(GKCH;5TF5K-
J2\$G|+%=DG8NHBZ|S|V1MB;@*#N@^5 MPDUL@JY%|V^N^D9ATLTZIG&?L2JBKGZ&GV;|U7H1?A8QO|
M(9|N|LPSY|Y94PUT|8|""^6Y8;(H|<@W|LAA^XT|H(6;C4U;MT?|5Z-HKDQ|&1_)G?X(HV)_M_YQ3>T3AD^XBS|T+^""1G
7;ZC|UE@X_-YB248Z6FWFAL MDO^U=O+2AP|_M(|6(R+Q)>|HW4G;GR>P8Y|+AS8T2?2AV|;(-=W\$ AR_8/X5T/C;"#"; M
7@40V|O@;@W@/G3&(QO>K)2P6_H|38SRZ|M>@UH^F^B|Q)E|G;XU_M_EW\$%6D7?>C4D_ZYX?N^>2K2H_W=2^L15".N^|;|^+=X?
#^9| ^>6M MY+9 <=D?7%X0^&UP>W-|T|M>HGX#|Y=|H<#O| M|MO=>576.3U|R)S>W@T(MX|SWDLN_+>?
FZF22#>9B68&\$9\$(7_9F^BC|_M_|/IX&NK;ESSPXV^%OG|B3;?@3?KX2SV5IE|L|C^X7L|T|60-#-;5Y_MJVL1%)XF^*D&@@?V93M/KC|J?
Z^R+YR7_*E0P6+|7D&|PT|@>E+G(MKY" M-D)Q50/S9YX5IS76#H3NC2Z=E.#;+G|!"Y^|R|F|H|&E";O_H3Q6K?^BA+
M+AL|LBBK%26J=K|TS3;8JL00;2.HZM"J|WMBMNZ|JY0ZKQA06P<^JL|Z M"9:0CM%3M|Q@U4\$%A5UJ^HPJ|HJEL+_M
8;74%4%M@6162|8#Q=5WMB+ MTV-|HQD?O^Z8H3VQ?7Z78<4P|F^M9+|\$UHY|BULH|_R_|J|C8E1595
MH2F_DKFAAT)3#H&6^4UM9+^;_*I2BH\$|S05(R"SHZG#I^2L">WV^&C^D3HM MZU?7|3SRSH| WY.9ZXS-X^|D03WI.
(>H9<"Z8T#^E%W<%)E|(|34&L|T|2SLU M;U_Y9C^6W|WQ42;U|T)FE9@|(M9KQU_<LWGEA;4\$5L^F|I7=..|U-E"=P-MB-J^RPI
NU5^TES/4U5/RWF;939:VPWHWZ748S>TMM4Z+9W4|R|1^5+|MBE-OR=IR| (MG)=Y%T^I88(051L MP;|W%)T-T3C|N10|G=
U@MU=|4|<P-RD0|'3S?2K;8J9|HBZ13>FIFUZ M|NH|@BQ<|Y@|9SW;Z^WM^PL_X_K26BWCLY|Y&5Y|V^?9D(=YRC&#Z0 M_-#3QJWV<:
WG\$.#L CF"@>MBF4Q&|@|f^O MGS??4H|H|FC#>?~?U?)F M6&|)T|(PYW|<@^&QJRS815>AA@U2CG/H4JZD|HRP4T
_5(26FG|FM#*=66)G>&|H|B|_2H@8-WF^5"N|VJW M.R;Z93E|J8-D8|1(^ GENL6G5N^Z|QDH;7+G;G|.#YXYX;@7=1Z=I2
MD218PVU|;148OGT+|XYA#^1X%N;C^4;5%;C|L^M&9N;6;L^Z&Q4.T^TE+L>M^|AJM.B;=&7NO@J(-D;E5F0J^Q|BO>R-
/RXMP3XWOM%#V|014P;""5VCZ MXK|XPFP^P9+>8*5|U2;1^4|OW05@+>_BF(K3;5IE|QES<6>3XMY|HC M0|R2E=Y|>G-;X^|>0/+
|3=K66|Y)A:PD_9J MD99#&|>\$_.OZJ&A^ZQ3'.XA+@AK|7JWK0F|>C|HAQ#-|2&M@Q^Z^N;SV^YKV^|T&R5) M?6&Y=<
<N7WU7|_9KVKK|?W3|0?L#|2C;JQ+1Y*+R?OZ|I_G^K@35+V M?>J2US\$Y^95_0|6?/P8ZINU6&JH\$ EPND(N^763|1P4\$|H-9>5D\$Y|J M5
0|?;.(UA%<9|Y^H61U9^8NK5.#KB@U@;ATUS)^B6D B^X2_K_O|LPU M|D&J|C6<8X_J8 M|098_Y|H|WUC6KZ;4#6?)Z>0Z
6|4FX|LM9KU7Y3B|9>2^B_V|P3 M62H&2|3P|XYZ1|>=\$S_YVW;6N M|0|@_T30|M?W&X_00@C-0|T83+Q|A-
O&PB6A^18X|FUASKRU)E5_/8 MVD16|^V\$0H7B_|A|6HOCO^6*_-|6DL06R>_T^J+&L8>|U|84K?CLLB.S
M^M8K9\$78X=P_|(WR&847CU1^2J^CWM)A^M|C|M(A|2|8)TP=OVE_(EN_>WX7MOQ?1|L;GOFB\$|;VY3XUT|+CY.A+ M2JZ&B1YQD
M_|J=GSCFC^A@4ZW/#1&T%2_|W^7V&PN)ZOCQV+1U>V3^C4_K|L5PHW<6 MV|+GM;7%JZ^X3NSC|CZX^0).04D-
KKJ|O^Z|@&U9U0#(^DCLX^Y|O_ M3VB^TGS\$ FG;LWA-XDT&L|C\$?P6V.F B+|JG|>>7=&GZV^*)?2|~8|X=;WT\$@*%/H|W.?@."/M
+4@TOU/Q|HFN|C4|Y^+Y8+6&Q_-X&*&47|_VVOA*<0<+))9+HNP?G??"M>|BQ|L4^?|"
H9|TSP=|Z_7_1ZY^H|_H8C7V|O+|HOPX\$7%P1^&|S>7%_TAO#^8 @_OEWVAP-R>P5_W9|_7USFY?W@KW|H MRU+K4^WR|^O^A_|Z|&K??
0|9WOMRWKR94|@L@|585B-3F;#%O|V9|@K_7E8B M|HYEZ3;#D_XVR?9|K^!^%2=13&<0;S.\$8FU+;16^Y|NRF7-AKR>=
M^IRD6B;TE\$^!#=#H|^4 B^%0?K>J M0@&^W^Q+S|N|X;MCTWCR|B;H_IEN5G2/F;X^%E@T<3?OH^M4.R.CX@1E|
2N.>O|K13V|Y4YSL^W^V>Z|S 3EX/5N^(*.S9^YACH031^MX070| ^N>D_Y;WY;B200692550"\$7I?M@_UHJ02AZ^6U|_9-|4=>8/5^U%|L
(&HWBS@TY; MD%|H|^KV|T<?_*E|+P0B&.%3|4*|L.MZ|F_.W %P|1|^|3^AB^X6VT)\$U MH9-
B|LY1@|A|Z|BDE0?7CG|454|Q>53|H|E|F">T>NM|D+3&P;J0L^YR4<=3
MA_R|3%3M|H|D|V\$^L^W&GW@4%|!-@BN3N=EE|H>TJDYXX+&_P_2|O MOJ3O^3W%|74MW)=ARK.7%|7ES;ES;7=C_75-Q^";
MSF+ MVV^NV "W@=T|?D|052ZC|R|CAV)"M^N^2D|Q(^S+X|H|ORGF36DPP\$U;J_79V&BOXBM^UE&QE6|EZ|Q|H.43
MM%+O;DU1\$;7\$S=+;NZ1Q#W\$=-E.\$H|_0K%Z%P|8;CTTJD^7.4_4YFZX55_Y MYJ.T+|3R^5;D2W36;_DJZ^MM|D)?
>|Q61:5QO|H9;35R_1+O&EMPL-?% M6E;NC#MY;I7;Z03XYK_6|WL^U%_3|;P@;YY EA5DV@EDJ;R;|67FQL& M_H|_-
DH^N/N%C|O11L^0FQ^2@L.CN?<#B0HE(T^ELEX|<S5_|J|R|HXF M1D)GK^W^&H^N)R.TN|=6|J0_5B06C-;+4%M57&\$PG;
3|RK|@LO_QJM;G8E7|300 M^#XP5A0&M;1U|4|6^Z3<7|9;K^B565_QD|D(G10^<2|Z<^D>?)E>_Q|HGE
M^D>)%>W51(G1|JN6SSWURMN56WE|C;O^IV<@&K9X^A^_|2#OT2;*)5+&-EA MW;U(D%AI5WF68&I<5RZ5H7IC(UM^IP|4GV+|IOAQ5:-
WRFE6=6;0G6959P;9 M*1;A|4S^?%#Q3AFHBJ?IH=45D|H^HU0;@&|>#D|H_|N|^GIN4Z\$(R;77Q5(\$ M8#LSR9-/OV=

<6I50")G<5H6.G'W0P)JL\I\T5.5(5CFL7=;?2(8.GJ.@M@J8\$3\$E1:8*4(Q#W)E"TT7=0H>5%I\I35YNWA9\K&?;\$.164<ID68IFDI+MQ-
B<8WE\$A-56BE\>B.T44'3_E06YB\H1E09-WE\OO@;\$.0.G/M/O MI9?N3UXH\%3.%NN4O_H\$R6<<D'?^D\G/489?##*G/M_%4<%KZ@=
=7-72(VH)M721M'U'W2F(Z&H\19\19\162F7fj=&T\HPZ=&T?>5_NHUBE97.5#%1M%*MGDJH?
6\6\K"IK<%%KMM\#-.!>0\W/8=D(00P7PYJU)R@S>IECO*DU\;LO-M5W+V+ZX*B'=\$*_6)^T?O6MB?
6Y'D#NBH\$B\JOZU'W2O:R9\$HORM2D+M8C;G=*M'RMM\?'(*.5N"P'L CLNL+J\OIX\J+KSTKM@JXJ6*""^P6+;..MLX*^!!75H\Z;
;@/4\05KF\;E.K=U6U+;3%RC8:29WLOKF7-57OKF56O4)M6LV;4E0J06-JRRON%XVP0^\\$RNNX?&:EP:8-EOLC HWHGD=JY6)%"ZUI^;N
M:.*H\;13YM;Z3;8'<@711&Z&HNS@J>D3^R=->L\$8#Q(%)8DC#.14/1M(H*MBR94&8UKA5;D&^J7I6_20C0;
(4J<\$)L"%9>GOA@/J'5:S23=N65Z^BQ MPZN:HVVY_V8)FESO=H-H=V19+?
#E+I A6CZP2AX&G@/72@&X/K1E&R6A\<YFK\00Q34D07816C/4WRZ9\8AA7"JM"6-*&=8J\U)=TW\Z_9 MU5HAT(X38
?/T\0W\H\$Q\$ZL>G5-;+2X7;S7MQ)+HHR*HFR-N-P\10JF M:.*EMF^*5\$GGBE2(*JNZP?
2M0#MXMEH+;+FV(=D04J1K\;.=HC2;%2JYB MU6<KA2U*73YD85.%U53K%?1R\1PK:.*J=8M53L9=P2M-P<(N5H&K5?2I
M5UZ\Y+IM\I)U7\$)=*SP\^<###DXAXP.^E^IE)*9=>>724798>"2.FZA\P9L ME:8@*?N\;V0%+HA)\=Z#EX MSD);9B%XX2.*+6EW3/1-
H&B'7E1:FL1.N=G&D?2H+5505%VQX'>1%2%Y\%;M%+55EEZ@X(22%#TFWL11VCY#YN
8:K^&.&.;JEB*#H0JUF\1X(21G0.*IGHZM;H\NZ/G'-7I^/OJU^>Z5/I
M=X@JLL=818+JBOF8\&O=B\$&T'9RGZ^+RSV);6HK2^M^PU^=<9?<35W^H^MF\$H#J\>NOZ\ VHTR)5)+>.CN=;?X1_ZHS);H1Z\I
(BRD\;@C49P'SN7 M_-8PR+&8DE;EMYMX;7\6X#N7U\68DC_\$3"P0&*Y).K^TIG;&ONBBHN4N^6>M\W3\OU\W>^3N
M:.^<6X\H\O:VYN\I_A#(=?<#N=#N67MY+;_L5E?W\Y0>"WP>W\J45O""M_AO#CVV5_""W5^2_*K^FN?Q\<>'7OOH<;
{GT\Y;Y&F&YZ1>JHQ.UF^MYV007+;A<@X\X&%E5C2P;#2\H+1\7((M\9UF^&O9PP02^GRN>Q-R93E^AFIS\3HLCYK1_ID5;
M8YFU\5404Y0\$E EVNQ>X^+XB\JV^C%M\;C=)FV4HM11^;U6V.5=(M^R(=8J:4*+?G8ZF82HYT&@/3\)_3G#)T^Y)U+;9%9M\^F1K=
8+;B)C3 MB_Y?SRWF\LOO>B\AY3A0=Z\SP1<3;Z+H\J8\I\#AA\H^E3U\$ MIA\3X\A\H>PY&;>(M4""CB6X_4H^8=M#PEFE3
MEJD_F%8*8RT_-G=?>\$ ZVVD\YSVL\%#2@M;\$AM_>+6:3\1CP;1)27P>"PI0S?J^NZV^UN#>?S2P3%.%7;\$DF_E#C;5^1P(CM^1N>VO5N
M2^H(4HHH*P0&R_XD;@=0\X.*J\<(^JENUJQEO+O*BF^U%HOJZIK#M9CDH M;5&L=INR)\3\$?68SE>T^>@\$.E;GH(2B_+@&"UICY.O0_XL
(SP73\$)\APBP_-MB#NG1NA^+M^<X\Y.N^E^QY90-J1B9QT5^2\YD\T^CDIY6DE.1S\$YA=)S)F;X;+119_EFY7P;@8Q\U5'4;PE MF^ZIZ+=\$ET-
V2&@&14H;-J5%Q9;K\I'=.7\;V^/E;QY^M^Q^Q^25Z3X^2\$[TX7WX^19)2\]*5>IE.0#A^C6 M7WGF.L\%>?FJ\%_SLW9JFCS59I\$O=;?
68WDE>".OY1:GA70/_PNS%'PJ=;_M1NRNL%)K?EMB^VBU^HCAASI>6X94?<3@J2=C955\33\$O8JYO5B_YW7KY MNSE7S^C)V^:"7EX3I
&1T^7A\1(O#N\=O)\HFF\ZH(2&C;A3JL)73JKY M;OF5IS\$0X;O\>"TS%X3HWH^V@RFV9-F;=DY%+#+=,O>>^EB;U\;@OV=#N^
M@1W\CW.VH50.3JUWU8XLM+1I4G&JTDR\N7E^Z\$LRB5U\2TZ0@0\6022I'

_W8@YO\NXYO.X08\T(1T184FR(K3\$=CD*FVM%64&'M?B^4M=EX3;&9O;?>.%\A-8>^?%#I=8FI^YES.149\ M?N=ZXF5
7&^Y42IRAC\Y@)\PF\G'G=R)<_U\=\$_M\KKYJLG7^BC;=MH98;<H8B2T\$G163#^E-B\9;j>IPI\M9C2;3_6D8;-9=\$M\$F7V
MD&N:45C0T^F5Iz+9%DMG.^D7^V^3E;J&B;U:3-7;FOOYS=^"HLCPZ;>*.DGKJ
M\N496GAH8\IW+5^D)2.4#%K;E5;>S>%R\X#^FU0\>IG\HJ^1)T4Q)*_MQ65&C2+6NZ"
I^>U2AN">%+ZG4".*4/CZCCU" _KFHIT^C_93077DML-X>X?%M>O:R45Z4.5F>3^1+I+H_Y?_J(&^O)PX9;=;S/D+IP6^<C1Y@(\UF\$-C MN-
=%DI\$G<*29X^8+VZ?76^<PQ%1%>+ZD)4C2H1-R<1-Q#VE3(ARQWILL"6IS MMY/Z<-IDO _+^A(+NE80%>A>_L-
IM_VPI^H9E7W\IZFPB9N%^UJNG^&LV3G+!!_ATS^&.2=?>C%MO\$IBB(8F4^O)1R#G8/O#Z;CR8>S\$YXLA.O*L=PC-.14:&+3WA2M66G"
M3^LO:QY?Q5V\>_9QU(N&7YC?6L.SQ\WS?2IEUWKF^E?%USOJ\ROV\06HKNF MA82T\TIR^GS@Q\RO&@-EPQDWY\MZ"Q\$5W:H@3H3><
/K:9 M2_GI2U2U6H<@1O^9/*>R>3@8+^%J8*M%M\AM+6&\$5?6/N18\$;/1^<8*7.9\\$_M ME3M6/MJ3UY_W7XT&N3^I97P\$;?"1?@+P_CFG(
8_DM8G\^D=FB-#(8U&H050WUY6X@&D;PIW_8D.GV>PXYX+M?/TB23A?+(!IT\$0C^TX?P+@8>1&T\$F\$V>G^J^D?C@0)3@>?&3CB\42
M%HL C8_F1OGU;^<KQ1WL\$|BN23*_M\$9EQK^&F^KX<?J\ZD_WSO_?ZW6_M1^Z^JNZ_14M_C:XO;F^Z WACRM8/_JNG=#\D\X\ME?
S@X\U\J+OMWYA\Y\+6>\$>_M_KU_B5/D^4Y\JW^>ZBBD?^>IWO\G\>PZO<15AB\=S=CA>%6FIN\IG\$IBU_M L^J2+^/?<=<S_8/_9L^>B
5F^(<+0FEPL^<1.^!<SBV_GPI9U>XF.NB4 MY^MC80P0EG\MC\X\$HL/B?NB&#H\R9PY_#GF\$SY%3^Q.PNID^TF?W@O\$>8(W.M;55GP72^Z-
R)HOSFVD\KND_AIZ^VR>_NM\J\$G_U1\HDI^*4OSW>@C\H^&A#_MCJFLP#>DKZ+);LYN@O#^;V'7:0P^&_LPIT^""#WBYWKM2^P-;_D^<_
MB#AR\5F^R\;I(\$2+@|NS\WG)\$XX.Z0\^X7LU;_I@_MF8:INV.@W\MT3\$T75N;9_1097+V4+^8*YQOYAB>\$4P=V^/O5+A>P.CVB
M%113>98W\Z2F>[SIHS_G@)I^V^W%6H5>DX22N_Y%\$X\B^0^<J^AV=?>MB_Q\$G4B\$Q^<^5.@T)^V\I%&Q(S>OUG;G1UVP^
(I\U\$)9SR-2L?/J-Z?_MP-<.%G^M\O\I^T#A.XS@K;JCX\I)P/D\$Y^K/L^GZ\I>KS MV^EF)25HBL^I?
X_%"P&OG\VL+3SF/>^"SP<>C\0@V\$#;_F/28V>#9Z/2\I_M_=V2;P5HHW/K_-3WJU=C>KL""JIGUR^COJH^>X^OS5\P20W\^6U\I
M^%OR_/>P;9\^@LPA06%6+^I_A8_HQ\U^Z\$DV652^3H M^VHYK\$F54C.W5=\$5-V>>P-P?P?U@W^R&>@;(SIG;E%LYXJ^<3U&1L.YW\$KF
MO/P4_F;3+J\I@G3R_QDVQ\XRL1G#1P_08SJ\$MJ^IX_HZSKD9YEX>_1FIRH;H4B^A^=LZ2^Q?4H\CL\I7
MFV9_4WVY^T^;_JPV\AGM1^;1Y&T\$G0_@9^I^P\BV\X3BTK3_#;A\010\$ M_W5HSES\A^WX\I^M=;LX\0#B_*IP^;C06\$W@6NK/
)H\$577^F.M7_S=AI^M^(5-1=P:T&^AP=@>F-7^&L/6@>V8PVPV@.=_%4)J\WO)X9JW2<6X>8 MA4UA(0001W&W+JCA^"
I8#I^P\$|@<^WV)ZPBUS^+NPM7TC^EHFYX^?K\$QY^*_M\X7^8AX^5_OEQ+N^<@RWTPIT_UH8^LJN2\ZO+GK0<4.H\J.S@R0:=PH+P
M\$OC^T\BZ/>OQ^I^<1B2_6+ E?W6_1.\$<5^79B;D4\$XK;B5AG5&Y5E^T^&(8\MBP2K^NTAJHP^V^H\$^YVO_Y^9^Q8<<HKXS
M;1KZAH2X\$@V1^A06^B.OHHK\$O\OWO\H5TC68F_9^UJHNKJYIKKHJN^M_.XG15#;^%\$10=**9^NIF&H4;C&B^<1^H\I\WSAGX&!
<9@<N5NHYB=(X; MEJ\+3J/Z68@K7\$%5WMK^%7<5;BM&5_#;OE\$;ZZFCNHHJ\%\$&D/I^U&P9\$ M@BIYN\#UT^)\AP3C3;XH\Y^/_C-
1#;C@L\$<5W4\7L\<2680\U^PHI@R8R_M9_-C30\$S\$CA=;O=B^2S\$^QOQ4OV;5/#?PLFPH;M;AMEZ\$^TE#.;>JHX\^M?<
F+BT/3C0;2X_R@FME\X;K8^4H^"V(YT\LPN;7^>@F+J\$Z\H&PEZB<=Q MQ6GUO)Q/=.%7I(+Z\N4&P014=S\I\);5!=CT-8;V5G
7L\I@6G@<XD+G M@S\OET^P6H^M^SP^RPI3;7<^1_3\$3^E)WNFA;B^K+(T\$S\$D5A59K0\LE56
M)02Z7^9#N2)U\460^G@+5/I#Z8O@H7(ORUL\$J\TU\$5K^Y M88^V\XCL7;);9.YOR1T1\;F/I9 M9MOXCAHS9ACDAS(B_';K8T&-
_PAU\I(=7B;^U^"K<6F\WDU_FCP3\I2X M\4#E@T\ZOX_L@>@P#R^H\KD+*OQU38^I3&+F+;VGC<1G^U;X(>L^W^Y M&@M>@#|_?<
O3Z8\$KJ7870QD>F6(VX?L\$;_I20(AH@3;@/I_P M^ZCY^Y\1;3L\I;KQW&5(ILB^80R_V@R^02)^<
M@-9P^QMD\I\JXG6PXQ^G<1@KZ06P\GFR&9K1>3ERV_M5\HXN_H3 M^%<T2DC&80\K M-35BH_Y^H>E^"X\I^0^I\A@<2EO;Q+O"
;\$(*TRO^UIP^K\=19+2I4?J-%R6&TE.CCNIN\^MF_SIA^PXD^G1^(5%Q)4_*&[AI^|=PON#N4>1OZ@/_W\G^>#1\H\;S11?_6 M^==X8Z.O<6.2I
2S#I\2^5V\J\$^=+;+FS<85FT^NR#HRYKCI7^T\$#<M^&C\JN_DX+SHIC^SL2018'(=1?^K\$B0\$;DN+5BA49BYM2RT)@_HPQVSKRD
MH)28Z\VL&QZ V7;@.@F;|=I\N&^*Y1.ZCD_YQJ9PWR_71#1JYID<82@0#I@M IE;^I_7%Q?I\$S6E04H>#FA?DB(6;2K&?WU\NK;
<<5TO^3\G\>8I=@M4;VXXW1T73Y;(F\$)2>7EE@/G_PYBTG\$W^L^C^M^0^10%IHL>EABGW#^TTI(^D\B\H)T^SK\#^HH\$&#F(W_I92
152N(M)KDV\^f>L1SF^I^C"Q#8^FL\+^%G^I7^GH^<JHW29Q;1#5%>@>WB2\TA MOI3RQ=WOAE_D4^F.FMR4(PX3XN^LHB(&=*JIGU8
M(5PSTC^28SM\S_VIQ_@XM(*)A^='6D\^IG\0R@L^+XV\JM\$98\$C^CI\$ M>J1GPT\;>B_<%H\A;BE;1_P-O\G\745CAW?5H
I4C3>J<9\SI^Z4C<_2#6 M=;PSIC^XF^M@_8M>/Z^P^@<#O\^P^9 R>GIG;_MQUMUS=<#N5\$UOZZ5SG^M^M^?H4C3^O2#8\^S(N;X\A\I
(B;1+10%V\$17_06&?E_2\$%ID&4C>@<C_ M9KU)DIY^<?ZO2L;XP;&%^OW JFI+^SGW6P2Y0S^9+GA6#L;\$H&+Y M
*MJS1W^N\$=ED\I0W^&#Y\$>1+D&L4H^<8Y^C\TV@<M^2\$+1^T^EM5_XK\$Z1Y\0)^^_XWISC\=YYP)X;EA+FTJ>L3;ED5W-;
MZ=46K;"E8?HH;L\U\#>(+OQ@4^(T7G3M^I&+K92O\;YQOQSERS4\$>J1;M+^F;C;E&4;_<+<18.@_MLD_TDH8\K^P##?
L6AT3HM0^XY&8N;8/_X;_MT2198\^\$S^V\IS^CFJ9(+?W60LVD<3Y2&^PZ;5CC4P6KM_O_ELOD_I9_-I^?DUU\IO+DJ;9=%&-(I_8NY?
<=6GV@Y^=;5H\H8\I^H\^M1C(E@)=>DB\$B\@<?3%#N(\$9W;92%4\PO\=Z#E\96^PH^%N\U^S.BSRN\;
MH98YA>7&P#J\$TYU^PA2G=;PEB#M^EDT2\I3RCG80^O^B=S;_&+A4X\^I^MM^9\4#>@WFEF^#\+PXJ
3/6V/ZLUENH=;M=%I;>%COR^5%Z1^<4^OGP@(#J>R\I\$>07T\$+ M8KI6D^S 5;@>V7CARO:W1.7Y^0MY2Y3;OC;9\%"X= +0PE06WE
X5&PQ\9==MX-A)8_7\$JW\FUFH&N\Y(I9@G;PY^6>\$TOG#&B#\$SM>^@+;87T^F1+Q\I\$ M\#V?
N=%0N43G/+G="7;V;MJJR#<X\$8UE^"BP69>7+1<-I2^N;2SN=U8)+_M3#O0ZQ>A^2^0V>8?RT+P^U)TPMCYLK;#2\0-
ZIH56^<4>=7#>E9G;XXA5 MFP3\H\48CGH9^R+DM>#X5X+3I^<_WA^0IE#%IK7G@/ANVV^HXE&D9^TT@2 M%)X+D<&Y
R6H\$=1K_#LXPFNO(MPRUPW=OSYM-9+\$.Y\TA6J_VD3H?UGR^"VT\$4+6;\$XM4<X^87K+I1G\I M60IX9A(LA.@-28L^I^I)O60\$S>
G5DH3^Q@O_R9<%B(O_/TXQK70^P6^J\6XR\7Q>JBYSTP_K^>@M;_R^4;G)TEIC=BO:.*@W;\$YB;
(\1)Q_&1NR\I^?2F;O&HG3Q5\I\XUM MOG\TIF^VVD+C\$>J705R9(34G^LL\J@f0\74GAZ6^8^)\^I.;>5;V&PQ M^;
"\$P#^&I^VFJ\11\DSNAS&3\$H>9PT19W\H\$Y^YLD^NNY^F\$;8L_V6F6Y_M22U+ WLD3^@S=^TFOA^70.5_3@Q.PI4\;(SHXZL\$M-
XA\$G0;&Z M&4L#;HS)P007H>_P^H7 MV_X?@'WO^Y\$5O7FN_';=YH^I+O-M ME\>@Q^JO^MB(5(#O_-F\$^03&?&=!
(U^@<^U\&7+L^C\>L^E+E3JRY^#YGIR(0:Z^N\>T^22\$H\A)7\AXU2%17X;IV+Z.YI^QOL^<^FR+N4VHV MA8Z64.\$%AWBYM(5;J_9
H76XIP=)^O^F8\$;70VQ>U(UZ<->2>SLLM1O_M9P1^2VE^8TY_I^R^6NI^A^8MO=51+9C^#24\I(9\H8A&1^2VVPMMH4\#(O_M+
(6.R3+^+&L=2I^E\$W(3^<TF69\4);K5BR;6DS+6)EU_L+J^A^KHHRUJ_OO_WLMTV49^8YISA>109?
0J7M<6YR@VH:E%I^HVT>@^*R+P8)QV^Z;MW_JL;4;BT\$2#^>EH-W^%Q^Z^IHH7ZZHWP;20C2-^86>UAHV5^ET6>O
MT\$6/O@O+&OKE/GE=J8BOJ3_-A^*K^CZ^FXM)IZ\$Q\Q?O\;J9@H>0\XR_XIBI^7_6KER>IAB^ M8N/8;<_4)N;3^H+^#HLOD
B>EPK^13JRHQ>YU61G/^7JTKQ^A_O3\O MYGS\VKEPLA\&2F_AIEI^*HOFIF\T\TXO\HR@(\H_U\I\K5;>CO\I^F8EUR M^O/)F

<1UYH^3I>J2WN /L*VL^<6T3MHF+C*EHNSUAFB7J3/H MMUP6DT4?L2HEGL9@W;2?^VH)UQ\$)8L(HGAGQ)5;)^@=I%:R3-*MW
MN419NZKWP&P@V(1/7D);/Z%'9U38<=:84?K5-A1%;^7:V^N<^C*GDD0LJ MR(SLV48?BQ)U@RIF/2;_VH1-
N:B8:P<-8P/L(R/WE^>7U/WZP?BX%TK<-MDD(PW)Y^<4L-8M79S^4&-NT=MQ^WTK7HWV-P\$1-U\$U 1%H3XY7
M+.&ZQ0"6.#U60=-;T!_"BU+3OPXV7X'G?N3070G'E(G#1'6W&\$AW/ M8"ZU MK&!'-'O.VXM>J%OAWYFW^0A|UOMFAJZ+|= /8&88 @2?
(OY23S4K; /L*6Q M7 %YSIESTV\$).*+|=?>=&2.@5AOXK E1%RKK4M/;LN/B\$UD= MO>>1 MG42;/H1-A07%.HHH=-.3U#H;X9<9.14"N?
*B(%)C/S*O\$H/V6=-.L9S*SJ J1C*5G+8S=- 24DFV)P7\$ZTZT OL"ILIQ M+P*PA11UYI*1.9^B6L;.. "H+%5'49S%"B>Y)6J^V-HDCPY.7F8>?
OKG.3;9-;C/R3/M<6U67#FYBLJB2<#YIU3D MMND9;Y?UV.TY@I;12U9NJDP^IN70LI"ILY4WDE+Q*P6J^M41J^J7>VX82I
M:KL<5*U.)5Z/T%74S13;UG&PR.7XV\6>(1QI L.S1X?^FH"@.SMH("BR?7 M1&GV;.*#1+^TSB.1+
(H7EVS7FUA|9U16BFFL/("=&@=EH+L#V^S\$IAM-J M%F6=NA F?N\$81.9>T%.F0#+BVU+7JM851+&ZT18("6AJ%TUJLQ
M_N5BN:97@U_CZR)9US5RJ6^Z^73MC+9.VCFM@EH@ M#SLSNA0+127*#F.3WC%;11@B/I6CGMW MH0UF.MHO *MU>P(G8IR5H)M

JOU0@/%.3>A@:6ASW=H2BH% ^43)&- M5X(HJ5(H+)^#T%(Z0K/H^1\$6@4/2L>R7>H ZMN17"E1E"+220%N19D9U#
MYK#1G@=I^P?7J5^KU;MM06ULI&Z;_O_C6^P*N5>^J@ICN/@Y51%R.7@*Y M=>N=S5IE79%5H<O#_SDZ=Z2%W;
IYNEJGW@5H1U;ZEL0#PJ.Z2M>H MHVC45145685M%^Y2DD.L_K<|;QR|&5P?_0J@.UR MA=!=JC_S\$1Z+1%. MKRPHG=V).*>.H?
Q2ZN^HE4=4#0P;=>CAB?%BF.#XY?&?+TE<1?>P=ON(C;1P)IMJ^HO13=7T@.<#KIN;KR41^1^2&9."DE|KE^JB;ZFY
MDG^KEHJW(PJE4(B=|M(#>P/L57^0=R9@H|Z+7L^O_E MC-VB:NRO;9S%;C/BVT)2=76:F(X<^+RGHEJRR JO_SLC^O;^H^1:1J5YH
M;MK>1?01>_WRYI>WSEDP^IOB;NQ%U%0#4^T^KX R0-A12^NP_4^M| MFXE|K|@*GIP*X\$|).<>5E+^A^Y>?
XHZH^V5WU8Q^Y^W8OX-6S26ICG5&H= M%E (4D<51.W-9- DR#O8&|MK.80VFT^D*4" 5UL>L%OCOL'8;-!SW19+1 MVR(
YIGVK|CFTE%)P-M 1%W%UC6.6(=Q%TG1UF^BCCAV^&- MCG1U3I^H886E#B;
(=2N1^90G"9B=-.F%Z)C+2&+*X#\$+ @4(C)7NNA11 M41^FZSD|DY6KVK""U%#H22;|Y/=VZ)3=VW;|K MZK*
1\$=2D&?^TYSM+M V>;5S^_3=6&-1;FF=3EF>6;<3XP&1H% ^8C7R\$|= MWIY=W@_)9|FUY RK=7OIC^4=1N|1-9ICG6
O#H&|WN)VJH-X@#(.#_A M^TAW^NUI ^YS&5YP)7AFIO.E|O^C;FY^|Q\$5|B5|?K|14 \$C3D?H7.5%|O85-MN(KOV
@9X^6|MZ5T.3U#6U.8<4^NAOF DW*Q19RJ=L0T7BZ06H%_%+4^M^5200;T7A9^\$|).556@K>80Q^NLLA|&N93 QY-
3)NZS|M^HOB-%H95Z< MRJ \$M 110OKIXRP4U/^56.8%H.(+*504HA3P19^OSFX*^X^W1BCA9MXU|\$ M0 DJ\$O-B2
41+&KHP3Q.^LXQH.P.Z#41>@H(S%<2^P=CIT1>?HKS|BU;17 M1V7>-|W=8\$13D%"K.A+<<^@+0UD*TM866FKV|HO%"Y.#@4>;
U_#M(C;M;PERIO)\$?^JHZ+@>U^#O=-A|%;134%LYVT\$41^1%TPZ&8WFTIG%QI<=;="8"
M1%E@X.@Y.GDC3A88N@!#^ZW^*N&M8W>=&=F X=10FX4M1=1Q2|B11;8* MU;G^S)=#Y9A1<#KT2JM."TE\$%;8|ZK#(KH=-Q-D1
#U/^EDBG|^E?71\$ M&=OKM^66H^0TF\$|H5^&SL%01=2|+4\$214=(WTF;|6W.*3|_(G.QSB)^.M66:Z2^H|O:4/?
V.;C|WOEEHYGN|YGN>9(3.Z1B;|<^+^1;\$. *W6@V.7_ M|M^OW+HQ?^#T;<^C?L.L?B0C|L>LB0|57."H^O@;?5\$XL(C=J5O>
M14Y>DIFOV.8+1%M1N-Y^8=<0 LR5W(E^V5=952AM>F<06;LPQC?)RGZGN>B|4 M#-^8+Y76S1>QXBT."40Z=D-
CXX^&G.7IYU:OPX@O@.N.85FO;MP38=G-8+L MUD4H2U^SU_5^5OD+^3^C=J.6# F9Q|XJ99VJ+;0#"=O+BI8B9*F1KI<\$5
MN_SNA^M666N2L%*P-84GY%L2U2P.2M#?B-J6M22X<=<4F CK5.2;1)
MIVJF;+F.)S2M.DC|2&@6TP*Z.84BWO|H;|G|5|7H\$|34R+3<0D#K9K70K; MX1-) (DCQV.Z'8Z6
M^MC^PM+IP|@>O8/E6.F1H)=YK6VY5JTIM.3U6^Y\$E15PV^H^5L11EK;KIGGS^PGQMX>7U
M+TP8%;M_G>NUI>OVHVC57IE3(4=Y.XI+1^C2&J\$=5^LB\$1:1-6\$O\$8;_ MZ_67FT02&PPNAT4V1CS|)-
H^ON8A0XK%)^Q>^ITXCA3F7|E\$E-#K<JF@ MSV;N|P|H+^&K_&3%|&=W|_ =103VFP648UF4CWR?10*>Z".06B|<_@X|M+(N?
OCBV^=*G|PCL#849^UCZ|)Z.76=*SB?4?C3FA%J5^|970X9T+1%|\$WM M;D\$)|OA3+1^1GJ#KDQYWQ>^X9I
M.BOWW)B3N0|_J@V3HCNXO|U;S0^Z|KD=;X=\$;Z#@.LQT=% SL"B^KFV\$1P MXG9UXP?>
3@U2WES4&PX17:NLT\$6G;T_V>Y@4|A08HJ1FZSD_")P^WJ-WP=3^(C?^@.B.)^|/3|2G|
MSOQ^9ZL;4<(-2^K|J)=HLS1U;M@O_C;|YG."|12+D @_U8&1Z;#31 M844Q9<::;\$_.W("ICD9S-WR"#6N#|;M3H%|XB5;-F;
Z|HJH&:6YK"&E|MD|=IL T^HC.W ZJ MT)^72|O*56\$+6#MZ YJ^I^7H>9ETVM*4UP+V*+J9T'4\$A3W4I79 M.;?&
MCL^*TWK^HLD8>YSW02|HB6.379*YQ0-|=# A(8 MKL^OK^_#3%8 PAD|B* M6X3QF8N^_#P#F.SGA.^|S#3&_#?F+L5A23
UE3Q)5GNFF\$&K\$&@2*^K^DQ.0^P4@SV<Y.VVF MAT<@;_R4|C/G2D(G8\$=O1%*LK T+T+|F+|B-X^L81+^4!1%|; M
15^3PUH?1>?R0&|PN/ ZOTNUG5)BWHWDI7S<=EJ-1 FP^UP;1\$C1DW&7 M2.9)2^A&UK;JU;OFB=J0MXWWR2(^+NPC06GM-"
P^L+V^R5V.R/ QZ|>&% M_-2Y_9HPGT^S&9C&|>6.8^WK^1".70^V_A6IK/+^QZ2|TBT|_8:P=P+QI6\$=T(HR|3.YNXRM-KQ6%|T#^X):
<=F=(X/#C_O M4U#&_HWHIE?N^_YZA1|PO-F2.1%8@|4QVBN@J04 C=1G.7%|<@;OL=-M%M?S_J_9)O4O_#H1>YQO4|_G3^LQ?
5\$MKE;55M7)MY|+|^E^IE>NO MW^Q7 F#<6EK%DI2I6;-2^I8DA6+>)1(2^XO|14C%0X0A;+2^15;|L MX@.E39^ GP&LQGKA.X
MRC^1FTT@=UHAXX SZ>_!|=813;U1| M2.#?NGIA(9HEA)H7|)=|O|VDKXW284Q-ZY)CKB7)75LR4V-3\$Y.Z3|>U-H MY8J8K)77-
FKE(1?%.*IC8X5)-"YKAXDCD=-QP< MOSS1H1|/7C.663VD+G9 M=102^JF7PN4F@U^TRLP^X#D
M0+MB^4.V\$Z^!>#S59;R5JCK5|O#P MZ|Q^BIHBOYCG9G93;76#6E#F\$|3+C%=)E3^C E6-(0D.A2WA>\$FJS-"&N
MOC+O= QF%U^<GJS;|S+|^6M+C|82|O%<|I=;_*%@C|+4 M%|J;=S?^I2Y3UY @M;+X_TL_#X&|8X|FN5!^O&IWB)\$L^2L&YX#\$_-
MNC|A)=EA*^ZA;.*X^"Q^C^M^?D@O13U<L|ZAY|DO?H_?HL4_);.j6=H^O: MEGI^M^U<P;_A9:BB.TF|N^Y^D|MVCNDJABS0QB4
MN^A)=LHKF9^P9DP< M^?D@|H24H_ZF\$K2>+L+3.NT=3G48E0%&7HS2G3-2Q.GFM^B3=P^8=-BX MA|PY1SD0M;3|O^E.G-
)OSWY@8@%+3KW;%B05%(-6WM%)%1%KL5;O2^5F M1|B2YMH^TP>P^>(UC&M)21>Q?+FJ2T%;RCZT_#3FH#|XE/G:5^0U-TC
M(OYS2 U2^BS@P\$O|N^E+R1#1>FZX.22EG^N^GX\$RXX M;DSI<-W)L70U^UFN.8^6B0IG?-(2%(-);G5%^?DA;U4H=?KV|)W>|2_6^
MW%P>H)D2K"!1\$NFOVB^JO(I9VUA;M|P^S^R|@06% MX;@>_3S/@4.ZYJS|B3;CM;6UT.(=;M*)U5S=8 ML2|FOC&-R;_N|6IP;
#(2J5GLL^).3\$IKB;C/V^%<^88E|@MDC0%958H% MD16C+>_ M%&F-6UZY>|U &%(G#+D &G%;\$P_YE|FE\$2(C^X^D J+8HYC|XS619Q^"^^<
D.D M^IW@?&JE^A%#@E^" _B^*=^3U0UL3I+\$.66(+4+)=)(7)03WG?L;7&;V!47 M;=,SD=%T%UBRSI(9MABB^RN9357|CN_KZ|R:
<^%&X;TPIR6Q.T3GB?>RK^D1F7MZW0.UF Z;7|>^AR\$ M.T84**B E>U2.T4N|?O+&U9#?M>|_Z+.#.H_4^O?^A|VW|ELPKBY983W<#2
MOQ^F_XB17)M|NC1W-G_4^FCNL/J3O|XK@N|XVG210|F8=F05)H=5;U-2|)7NY.B|N>^<
M6;ZOI^A^61S0^UOG\$PIJ2TC=6 3<^"= #R^7-2CIGR04GWE>^>P^2T3.RGY20UF39.M|J>UD>YN|VT%G9;IYEZ80AZ8.W60N=+C4T|<(-R
MZ>T.7=+*US^P;O_/_ G74YNHZ>#EVM1SX3+1\$^1K2M65HM@!E9TI2NS2D;M|> ME_MG\$2) BME|ESH|^26HO;H5AJBOU#(
:=B;\$IG\$TM) ZCEPS+IWTEK3TO^2 MO3=M;MO;TH6_XU>@?)_NNUZOC@S2;M^EN5\$W;EEIQS^KY?3H\$D*.(8!@_ MDIE??J>P-
H!@^0X2Q3KUCT=B^0>UUIS@I8^H5V9?^E;|H609>OYIO D6 ^I M7_."JN2Y9 D5H% (7#G^L8_#869;MF=0Q^S|?+UX*^3WEND0D8(?
T.0K M-JW;2>|V^GLO5?^15C01HJ3#_L>^Y.YV45BTW6WJKN;B/|ML_#7|C59CZS;H4.\$B86R576;THB2.2OP.WT+;
M14^H#>P^\$+^46H+L.K&RE@!3 V^_RH7|B)-CACXM\$&A^D^YMY7W^N7M^|_ M146Q|HVKB%O=2&-1^9MW6TVJMZ^LHV>(7O?
I03?EX/O_ZLG+Z70HGO."C MP L|^+&N|QAI^L^/J@&E7H_>|T=N_JZR3>O|_77X%2;CHEW=7<K^X?)3 MN0346;7%D%=>S
9Z&|D0O;A|TY\$&BK9D;+1%CYA|PGZ8|B+WOW|_9|A+^3? M2UD&4=J GFO&W4^W;L>9O|2|;PH7="|H819.9=ZZ1?AZ;&1 MJK?
4^LEZ M^>=<<4N2T;_5JG774_7VR^H1_17IF&3_EKK%E7^M-IOSNN5 MO^OJ9X&S;GG46@|f|6>1/5C|X?2+D>XLCWIS9=;
<68H6UHYH|+S|H@0|BF) MIO@N1-P=K/CHK\$#<2RP|fL5G|(+ =*(DK08K^E9M9Y4F2%U7^%?0B+6R^<=
MMNUKL.62X6K+&#&=F1^2|VGEFV|7|>;6|SYUJ%NOFW2S>W7^F<=X>8.9U|HDGG-J^"8>RZ^I%L2N?(3:W&5A3 M=)|JB-
<^HHQ(+16L3)AU.6=&YE+@.EY^DDC&I9^O9VAV ^L(&I0L)FK M^Q_ NS1A^" S;H;1&%;%#5F/7E"
(H1BXYH&ZAI^A^FK8Y9O+K1DP M;F-V-76H%53HRIOR4XV<9NX|;3T2(K.9)_1 7EB&J7-AV*)5-1+4EA|V7;Z;PC|^#
M4Y6^VJR>@G?^DIH3BE3>Q^GG9;TYOE05&H^ELR>WT;TIB;|YUSP5 M%NE/R J+EB;HF-4^1#17=0IU;L3 Y04QUE=R^VL?
\$73J8CHOE@P=9PRY4L+ M^Y6C.1EKJH;|S\$H^A>|H8ECL1XUES4WED|XRVKE9;Z?TK-H1P|QO5^* M09Y#DM2C+5/0:4?
|X2B@NJ603^0BK=4=#WS&(5 F75W<^=R%\$F>^|G2LIW| M;/_@MS/^B^1DVB H78^^^XBA?
TXD4J701#_ |N;16=V6V1=V=YI+60#;SB^M9_ THG>X_#86.04.2OYU^D3B6&*#8|^M-W='D#%\$9X|? WO;14OZ^P?^DTZ%S=+&@SJR^
M3M<3WQ="29QSW5^|H.H|0F6 TD|H|MZ|H^O^XJPTLEO46YA<^<_X=MV?
85AYWY^W&G4 F_+^S(42U1ME9)^B+^R;YR1.8Z0;W@_ SZV:8^SMQ M6W|A^HN^%1-6"19S03Y
9U;M\$X^R|JPM3(HCA)|E3Z8WT/(NOV)E.9>N. M.1PW_#68501E(A)16SX2>|CR3D|B-TGCD|H>4."|LZ@<>BZ^YK3HD8|)
M^<^WITSMM^M@^Z6W9E&MYL^M2|KMC^K&@_MMKX^DRJ%V15YG^AE|J3J@|S M_Z?UL^#Z?
HJK>@5V1K6S=<=CZ5D#%|LVI7BNP^#;+WGSY=N^%2T%5X2> M3NO#&E|SV MOL^*XLI
M_X2>B^-(HKDYV>V<8^*S3(K6/JA.L9Z.4)^#CJH@ML.P|S|YEU^*)QX5Z<|BQ MB-9PY<#);@Y3GB(D>W1^U
&9^OT657;CZ.PLMA^Y5KK\$25<|O.1P@?-(6PIC MME??BD_-JZ)0KTM+<9+XU^#1\$D^G2D:8>IM.GAR0)Q2*=64< U#E%9M1ZV
MOXPE|Q|).IGH0-1^H|Z<9WDFTS_RYNO_|BZ^N^W;1X2.5 M1A|)%U.^>L726;"6WP1HFT^NH&^VG3^(@C^V/L!@Y@|_R
2<8TY>B+T0 M9|S+M^R5YD&_H|OO=^YAR \$N=ZRO|(9DQ^U^G18W2B6^C2K3|S JK(HQ^M8#KW\$2P0-O?
HN#^H35Q(FP_ GS96;L_ %1.3YW=8J2A|H^>.)^UNWBR;D MZ;&@YQ4Q;A|IB2;1?
(FAUYP#|SF^&M)H&XF#J%ZBXF@>J9MW0B%\$MN^KX M+DP^R^+^&MR8.1R1MRJ^)^V\$A_J#.#B:@0^X3;1^H_7?
I07%7ZRIW&C MHE^\$2;Z@=;D#=#UADIHX5)6;C-GP^<^YA;J^AKJUH%5L VL^H^IV9L+<^UN;J1OX^"&#&(TW#^K-

!MGP=-\$'K60Q&0\$P5U.IHP MP".BWK_M/JDWRDS_32PWFFK C<~*HCON3JLK:SHLW!_U:R&F%_(2:D\$1/_M\$V+~"BG1_PC
X/@R#<1/K&1R=-1>R/BGLL<(CO<&-B-:(UA=@&M;3 7U&U
M&K Z%Y6L1F9&=&JQ>CY5%T!+JF0!0.51C#J4+6DAA98E#03?NX@?M8!_2D&R2SITU)&?
5_FP=J9:~IK-.X!3\$2A,%7#4044AC?A?65<#7GGS,P>J3_M!_U\$76VMKJZ2TG4EIP9#LZ3>V0"C+*JVOBNKL!P5=YG,K/4B0.\$T:F66MB;
M!JF@!0P=8E((6R!!JBZ!7S,AV\$(4=MFA!+8!3!77LZF:(!@D.13*LR1T7N
MVR2B!3\$1!20!EQW8&K6W1"&I<~)S:3,IN8>67.D,G37G%#C_9I9M MH+FB6!O XC\@~C!M4H!RYFO!PLA!)AM;L Y41W;
!SY,7K5G<_T2(YA MLRR1766310-NA>~(M;~ QW<~7&.98<C~30K1;<P!/>G-8_?AA)-W570G+ =0!ML@0WH>A12JE
MK\$@>M0VR/W=\$B:6+~#87DL=J-UH:C=OFB1_%EHN?IS8=,DKIW5KWIKOOSM-M737U?&C7"V
T^=2HUE%Y!R!<CY<<.80COXK\$EU\$&#CJ\$-QY>_4<H<_Z0,9 MLZR_.92?%W(0+M&7Z&RCYL!\$>@A3/<8CGV
V#~@AF\$0RHJ8!OLGL_M)9L<IX>/QTX4<41#<5ZZUM_V4@!H<9UT!SZC(S5_D:3%\$ +=FV16%"LS4KD MKS0JR9MB^<S)
<5T98(3C%\$UHD0G4)M(6\$WTFJP<~)ZS:AS&&359!_6!/_MA#HCCMFC<6~H-D15!9U;P_E>=6B6M3_0=FK<~@061H%EH5%?
J63%&\$!P_O M1180GAIN%KJ#AVHJ=S<_IF51Y:8WL!0-%257BGBPD(%?YEB4W#:#W#-%.B% M882I3XW=T/YX_NM_0-
&GP@P!H!Q@2!H8_*!>^<~!P-?..\$#QUI>H=Q#XDN M:(N_@:R TXB9EG.F<CM!:_@ M!_Q!<1G<4X"OS40.C@B!9<LOY8AS6,@Q<2K@?
Q!HC5<5R_QY2<_64L_M7T_-96P=J3VQ"NWQS5_Q!7F.G;@V7AS/A<_ADQC@!T\$SW!HQB"!W8?P8J!M!QB!8~MI"QU?
T!0P<_007%HU&BZM!D)R!)@2FNNAJ#?HDX>6C/170(0Y?WYZD!)Z<_G_M9*_M3#K"EZ<~?V29"\$PO_UYLNN!4N=1JZ+M6ZW6X?
G\$3H51UC&YY7020DM M<~>#K<@JF7JLA!&JMVBAJ!\$H5D0\$?B3*_M9R%+!T!&TF@V!<NXXBO<@IN%HL#JFHE:C02Z!<ZU%O.
!LB!_9RZ:N_M_OFTY?>_Z6FL!2G:N!&5U!YYPV73ENED^7;EN;MG0AG/9KJRNKX=F_H5#1NH!>A!_M%&U%55&KKUS2KKBK?&-
@P4!_H!K!%0!>H!SW3A7_R!P.PAN9_M8R_)FCY"B-N!2%?8F_B!_WRVK%&XJ6!MC+!>~*G7#RA>ZHWG)EY@!2A>VK7-M_QMV5?
&FO(!_6Y8O>U66Z;K>P!R!&2NE6Y4NC@?~*E8YBM>9BM!_B7_MVC!R!P!.(WF MKB2.MESB-
&K/3N*P~34K>4AMA2!LR00WG@NR2F-IN90QM6\$36,%7UECVZMR MIF>KOP!_Q^5^95BQ!T!+FPV2+!H!>J!@LS7-FM\$HB!VM*FR8*S-
(4*_R)(!5_MBKPD\$C!%C@;=/7=7.TS4,*G-9S\$SA-SE5HMXLJ0DL+G/8S\$3C-^MX%3G,%_M@=!!L\$./?KL#!:H-JM\$NZ(<^SGL_QNT7/0
MC(#FSC(2LB;YAHY<~#N6_Y014&L68ON5E3=-!IG(F_G)+N2!T5Y\$UWR_*F MM=UD@!1!T#>_!+!_D+~+9F%<~!-
9UY!+RAIBRX!\$SMWUOD^55H54_M:YP@U?0:K43L_KZ0_.G0+43H-I&/(Y8:L<16UGR!0<7!OF/HQ!J760M*56
MSM*RRNCXSRX!M!T5!636S0DD0H_E<K)S=R!3C=J3C+R2C+IN.RKM=V.K.9V M,K+V!_OX)G>KHY!%&FFT36WD/
KN">R5^B@N^N.8X4:452=#\$ZSJN)Y1_M2<_!F1#&BO?P&=%8BCI3UIM8?+F-KB>BWXE93!J>?+ZZN+!~)BM=
(5#J\$<~7SBZ#E>)3DV447EJ!W3~_8D:J=N!2!C\$<~L!JUA2#7LU#9(WHV8_M@S0+O61XU3B1:&TFRM)Q^4/G!_Z>.Q15!MB_Z&6P!_B3
J!(<8\$1X0R:) MEL=UP(0124)K^Z?VFWA#!>?0.PP"YL!\$3N_1>G!<~&MV&+>(2FT>C=D/#_M"T@V6HF!GX:.(S!J-
-1VG8!<~4~2_0^AW&+&6REQLX_&O(R!<~!>@:~M!_MVL_0!_93ZC!26~_4!J!_P-(QBH6"-89OI!)GSBD4!9M0.7#X"9BCAP@H
MCX!H\$>~<~R\$<~"7"9I7.5+~\$5J_YP.D6UX17R:5 KE,1/HCY_*22%~A_M:T;H2LXL#_J44VZ0?
YMELM<~\$Y!%+!3SR5B6US9ND!ZZWIK;V#^!_70:_M^35GZQ315@B.A7!F\$X_1!/HT!IS@2H=-WE2)JAI+!4&V_~7X61FV<@
MKUJ!H8Z.LNNJO(Z!O!Z5U@UFHMDQVHVBF"~F)6!W?_!\$3D_O-VM9DB_MUS5?I099C6N^@~!67QFM
@R/LM>X0:ORS34W~_W51"3W~KUM?Q>NO=FM7MO1!U-S%U!_@69\$3L_!76C<8_O6NT2PLA!J6BEG"Y!4M!)&CEG3*K"QO8M=
MK#PL!5=L\$>GLT=SGXS_#_T+W#J4D?4!K;J=2!<~IX\$GW^<~!N6SF5~_E^<~(HRI:_J=:_N!D976W\$&-R\$3F6N3?RKZT_M0K
B=3FN~(0F!%SGT\$!_HE1(HEJ!0RZ!92OP!2%J^N)3F<~^N9-3TX?H_M5#8SOX#3=K5+G\$4X3Q!7^3_T>1V!7*~>
H/DK0Y&J>S84!<~RA6<0>+!\$!M4AG"4@SBC/Q7T5^E>3!B*_DTV!HT!;U8UG99;-DZ,QU_M@&V2?M4S-C2">3*K+&ZJW2J5L<36?
~X6Y?5%HE@!&2IC@!@16!;QQ!D5=M?_M!@+(*V-
6.W006\$Q*PPQ+O9.9S_1LV!82;7%4W"B=GBOT\$IZI_OOFARW!Q32=SL_Y!N>_ZK=T2G0_~81H=2;A;V5YCL
M&SW@+V24EI+P8#UUJH99X/-8!<~!KQ?3D)Y@LN/S%L0+5"P-D#Q0R32U!\$M/8L76_R!9W+!H2ZV6?HBMW5MZW
224DX+~#BEEK.MX*3_6!H!>CR)U!CS_M!_YWP5O*TLJ(PD*6!P!_!TDOCS%L8L!UYJ?XSP2K/CPAHMH!_!0_BV9CWO-!6)*9+K!2--4I
M35_?0+!<A/Y9Y-KY6041K*~A*O\$C)044R9G\$XVSD#8V?7_HD0+NT_MJS?1&~"NI=7Q"?>DQ54D(+&H\$N0D#M#/=.@7OLZX
000XUB~626HZ_6~M!>WWV@W(D7 MSU&K!AR\$&N<34#<~K!U\$<4Z?<~7B!>V>W45@5P\$E>R>=5!T!6\$&Y!
M:_T0^/(TAXB0L>L3_B^Z!MIC;/P33/6!_X1!86H!39H9L!>Y*PP=I2!\$5AJY_MJH_S.VSX73_B)CZB^Q#_!8MSK2=*\$N%
(F2^W>~*3NAQO<~(V77+WOQ^<~2U MI_M(D@<~!J!C_Z!HOU9N!4G_W%~9E!_PLONPFC31SRTS:B6&~(NNTU_D9M*~M)!AL%T!_
H&S824E!&XAE(R^V=Q?<~O_K MNH&)_C~R!TEA6_2_#_G62>LP&^Q4O2N?13J0G?G?NL(TQ9BC2%<~?+X%!_M.DH!?
7&T!WN6!#~6(Z!R!3QF>3?5!PRTT0H!_WT+=O^<~!_!PVN>F!<~S^+1>_M!2BY90CLB&~4FM!&J9M!<~!<~!V?S*~9NG!B-4H0VT
MOZ"%TR_YOMPOTL!H17*P6!C92395H!S"905R+&_M=(&Y!B!LM2VZF_~FY6"~GMR5VCJ%+R;PC=C_ZV!):"Y/SJN7W!#GM!7KC
M_1EE!<~N0G!)H!96:51%>Z!F!9L!2OHR2FJC_Z+IM!#E&>TJ!44G!J0XUV_MJESJFN4!(HF6^CD_H!&RWA6OWY)"7%SYB"7@WS
9!3;#T!HTLD8HN!2PQ7QH_M=KRA_6RQOPPDHGX9?P6>0B1!_MB)MXY!HJP&!SMZ\$#Z>_0T&!)9-XC!FLO8K!+J((S^8ZIG^D2W.59?
~!_H_M!7V!<~CLUNPG3GSA#3HP~^2HDEG0!<~\$57X_18WB_ZN0T^Q!VU0!<~F>=I_M/L_0#QV=JKU@_PIRD!FKM!96A0^MO:OS#?H!J
!@/8QBXXQ!!H!C%)X!+&C_M7&A@BP+2\$%ZB!R#4LX1_B00!3(\$#L!:(QO=P!>B^!%E7!L!<~P&IGHQH"-
M!NY2%V@<~#V^<~JE+>DX!T+!HN:\$CX_W7!4XPE!R!K#L7>=O\$!F^&U/C_M(1K^0PRUG!>~\$IRD^9#
IGCB>~\$Z&!H!>S!JYCE<~BWHYHCPA^8^@&+E3Z_MLHJ^<~Z14XH!H^/43%OR_M=I7:O(PI3\$>_4HU_F544R-4/9M_Q(44AV&6H?<~
YDYZHSJAEQ&3W!V7HJ!&M80T!U4*~THU!ZOCNQ9SG#~M_\$@~"LS!UG?>~!<~FE=TX?F~_#Q0S!E=O/5+
M:37XHTW7!F,@<~DS>U%2!2XXT!&D\$UZ(7GBE&J\$*GZZ-D6\$P4>5_9@04PC_MA<@S5&E4ZP&@/6&@C21F_1ESN2W>J<~<~RKUFB
M#3W=-@!H!HNM&=56@V-O@8Z4M!E;DC:SZ>+Z3O_Q><~_K_005Q?W?IYE!<~!77_Q;H_M)~V#!\$+!1/EK?U#Y^>P_R!2CH!V!V(9!8;_<~0!<~R!<~Q!T!<~P8)8!3@:_M>J!DP0860FG_~#%0!Y+!E(3!<~(03)H9!C0_BU!<~X!WJ<~>O!<~!<~C#_M9^IT7(24
H!H3Z4P06W+<~C!Y07F@!<~KQO<~JL^O/S%>~!5+~EW_4A!D)M&9H!V@0H8?R=6AAP.KB2:L%_3V7!\$3T.O&~#FN#W-
~K!H@<~\$OMTY!82H!U!M%KWQ#AZ%<~J!C&1GH0QUKK?>P!<~VTN!J!<~WT!<~L^E!4N^0!KCP8@NJ3_Z<~6X4;HC_M#7=%<~DGY^1-
)35RF&R_~E2~_8_L8_N3H&TMDL\$A3BF\$F9XBP0U+RDZ_4_M!7!5@Z8OZR9W~!<~27^#N.)~*A^MV!<~L!<~P*9XQ29?
6B<~3\$8F>17F5NL@X^<~S)T!<~XU!<~Z^TYPYV2F^<~P@_M#M.T.O*B_~.@%8>~!<~@_<~FG^!G)OT5XQ!<~N)XLEV!VLP^<~&V!<~LP+<~+&#<~((<~*
MW260A!<~C!J88;9E6Q1A!<~38MYM?LC!6NE&AZWPF~(M)YP#QB4PF3Y!<~GRIOW^Q_+<~+&~(TN8L8!2XR(!6;~!MC2_3RJT_M!<~LYI?
EPML6>~CY#0KYK7^4%~H2M!J!XCA5BS3R)V5CPBDU!H8@W;H!B(R_MPN2TK*_R19_A#<~OZ_M!<~V!<~6E!<~<~<~8C3BC.RBNWDC~<~/GD?
EI<0(\$J95T_M:JBN>~76TMI4MAYH8&E4K!<~S_~"+<~KA2N7?1)2POA2EY37<~\$!8_UHF;+M;T)!_1AA?)49!<~PP#U
M!_MC49!<~S!<~UERTT!V9H_M!Y!<~BGLUIGZ_P!<~1%KSZ9BGH_GH!<~M!T!<~9!<~20!<~G!VQ.)<~3!<~MVZL0!<~N!M%KIES9!
MNK75GM>+N9R2+P>~!<~17\$~#C6DUHL_M;H^K(Q!<~(==<~A+PF(90!>3E8!W/L)QW_MH_VAO!4VLF!>O^<~GCRHS!F#^<~C1R(OLGR*
(<~!<~J5)K!<~5=VJA9-LZ!)2_M!<~HFVME!>?D\$<~+<~0C!<~Y!6_Z_ET7JOYN=<~X7B>?>~!<~R_M!<~VVTM9HE2!E=9X<~!YJ&EWSY-C!6.O5!Y-0^<~\$?
~A-SX!O0?_ML9X%(*KOV(GFGIU(WL#=#W2_R!5POVSNEVH_3@<~!<~S>5_<~!5?W=T+MY^<~M!3!_7G_!OR!>~!1M^W!<~F2!<~ED?<~7\$T!<~@-
~FHH^<~8YRNT^<~URM;H!U@<~IN!)X&I#S#>~!7!<~#PYKQ!J58-L!<~LFEBOE!Q!S7=W2K81*_MV^2B!<~TVYUZ3GE!3!<~ZVAYO*
!<~FLKEV6:RR^<~T=JFM@E/=8!5R/3>~!H#<~&HC_M6!0#9U&3@H&E_42FXI_3!<~AA!2LGEXO^Y#0X+JH^<~&O8R4N^>0^<~70";X65
MODH_2B=_%#3FU!)XP??>@98X*MRAR/_#_C%<~!N_B_~YH7!E0!<~0!<~%QAR\$M#CBQ!<~!<~?#<~B+HJ(#Z:6Z>C)9>
=2K^<~!<~I@<~FHK2&4*E^FEN2N""L_7_MBJ@+3!<~IUB^VRR2!<~0^2VR?GRU(X:~\$WV300\$NA3=GFH0@6H_WQV6!3B#_Y1_0_M2_!<~H
F%<~E^M631@56GXXK3&1*\$<~X(B!<~I#<~>~<~V!54F>E>X_L!LX+GO*~F!<~E8T9\$T_G^<~!<~R!8><~M4J<~_!<~#4.G@8-
X&KZXEL^<~E!XQ!<~L!<~Q!<~P*~D!P!<~!<~H%\$R^W!O(*\$X^M!)_!<~O?AW?6H^Y1*~BD!<~\$8)80LA<~4F!<~<~AXN6D!<~M!<~0K_2+<~(5_*Z8:\$CA
MB5!H!HWN^<~A8R-D(*P4LC&UPI!<~60>LPX&4W!H!>X>NSB;IB_M9J\$<~4&L!50X!X_4+!00U5!<~P!<~JZ2T_B9!HWC"
O(V(MX!<~H!<~D!<~4=MU4@<~PV!<~IPR7V@<~@<~#H_M!R1!<~("2B_S%_<~CL!D@<~Y!WTHG9K!<~0>~>TBP!<~E+CP=I3!<~BVU!<~\$@J36(*#
MY_3MY!<~A!<~B8^E^Z^<~<~9@<~@4!<~P!<~C_HZ!<~P_MJ/_4)N6C+RY!<~JYOK^<~=6L(%<~MKJTF@<~B80W74W9!<~9!<~E)=YWJO(740LKP@RF_MEBY!<~4VE?<~
!<~+F&~<~O^<~H@<~ETR><~@<~C!<~%<~!<~*~<~8EH8!<~<~("SSL>V!<~AHBT^6^<~7!<~M>~9S!<~U0_U+~<~U9!<~K#?<~04!<~>~!<~HT!<~N!<~(B9!<~L!<~UX?<~B!<~!<~NQ.G2!<~#<~@B
M&85>~<~<~!<~BS>~<~)~<~KW0D+P_<~P^<~3A#<~O!<~BX8SV^<~VXRJ!<~FH>@<~2!<~6G!<~G!<~#1)ME+<~TL9K0.6:H39MWL@<~!<~IMD3QBJS!<~LBR.6^<~#<~@<~M-
G&FR5%<~\$H&M&SKDT=X_~M6>8WS+D!<~6+W!<~BW5L!<~+ET@<~!<~HC^T!<~0!<~89C!<~=A3XEF52A!<~M!<~%<~A!<~EC.D\$!<~
MOV/B3S1NVBCN"S@V6"Z\$#>4C&~&W<~T7!<~!<~AQ.25&H:"S:*(A76NO+ED)YHFL_MU5196!<~?<~C_/_Z%<~(GAU:V&/_<~
(GR!R6=TSVS#_0Z#<~!<~97!<~MB_!<~\$M!(GL@!<~H2047!<~G!<~H!<~=<~*E!<~!R!<~66WCFY/NCUZLA8R#<~<~V56SB@VWN_MQM/_RP(M_2NR8*!<~5J!<~!<~5<~
~<~<~!<~@?<~!<~#7!<~9!<~8_WY+!<~+!<~\$YBCZF6C4A!<~M2>~<~!<~<~8V4>~!<~%UTG^<~AW!<~H2POD!<~@DB^<~C.L+X:O_9G^H2_!<~\$80Z^06WA\$<~G=G
M.D)!<~P!<~A!<~L4Z!<~XKP4M^<~L9+<~&~&QML75BWY_<~AM7!<~0!<~6%<~YNYZ!<~%FMB5&R>K>1
M=O_HFIT@P<~77ND^OX=EKE>1\$<~UK5@5!<~KO3GOU_H=^!<~PP?62!<~!<~8?<~?1=FT!<~EX_M"84<~!<~
(E\$<~EYPTK3CX7&E!<~T)ND^<~PQ!<~^DKRZF_X!<~!<~0&~<~RTIN\$9?<~O=?<~C^<~ME:9_S*H0_F_<~D!<~C8+!<~IMNOSD^<~R!<~G!<~43!<~<~(Z!<~A56>~<~X/X<~!<~J+<~NC?<~
V_MP.F>Q,\$+A_<~(P.CQP7M^<~V_~"G!<~(TU2R^<~!G2V/3_K:~\$8_C_Y:BOXW_M!<~2!<~@65?
!2=^<~2Q^1%35@<~K/11<~<~0YMP9_"R!<~>~J!<~H!<~U6F<~ARE.A!)<~J3!<~N!<~84!<~M^T?<~
T\$<~C80=1!<~LGL!<~VO7HF:~\$<~SFHJ9>~!<~HJ3>>~<~FZBI4T!<~&O5W0\$<~Y54=+<~M)H<~>~Z^<~14U!<~5%3WXFH@25L5=347YZH6>
&V^NH@8=PWJ6C6%8G_Z96%34)M4VXJH8//<~(75C+LHU_W:M4!<~5!<~U0!<~ZH^<~FJEB_<~R!<~N_HZ@<~\$.1#<~U+<~.DFL_MG/R?<~(E8HVQ@<~9YO/V

RM71L-^!@:-%H:HW2:-@LZA349#JHYT:!!-^GM M&@V=O1L-!6A09NC6:N=HV&HLS&AIK0:100&AHF&@T=RSU=B>T5 SCIE!
M=0&/S-50009S@-^VKJ62!N1@!(8<*2-W\$VECIZ)!&D<-#K2J.U*^FC+I4^C MjMRD3Z..TJ?6K>6!-IY+TNV57F@J?1F"MX!
T(GL8@?9&@:(CE>96!<L M?C<2/%JQX&W+!@6L:N5!<-K)J.0KM>H?23Y8H&M5SV(I%D#-W-HJ>Y
ML12P\$K*G67UNLJ=):.6&U9KV!(>S)=%K!<4O:-SPC:E>SIKBI\NKN1!<O-")M= MY0N0/BI/E"AEAS-QEBK>UFB,VNB6(G@T<^*5L5
M/8A.VZ2:1M?<0C"RX-!)GM<^!YK5:,*6!67C=:@?MZZ%Q'L\$>[M]2?DH8#@H MGF56,-2=K3G6K(\$-0?Y3I(V^0I+?XA?Q&
!7JK-^D-SUV)F2YTOO M7J9<6*RPHL&Z;-J1GZ*!<+&=HJ?E2Z.3H?S3TX !/0-"/> *O!%&2!>_#* M= /R;(\$!@)-"X,U>39C) T;U#
<,%\$P\$UTO#>V?K!N, LND,K!O:F+!15?3E?&I-6BZ?P8E,"@-!O4-3B8P811Z"-!>ZU> 4H--498-"191
M*;U^8(^P!6:Q+!Q^ARB"*6>ZZ#I0'!F\$C+@B-)K 9G:PW+<-?VOODZ"B5-MN)\$B5FK@ !,?/*3W\$3:D=;N#SV=D-.0I18H091RB
#LRI#E/L&:D7!HR!C5Z@^+G=D)H/L/MVLTW9\$A%G*CV!Q*,7/\$N:6,\$N>BY#+W&YG@XR7G=UN=|N/M/+A*>M;K)=
M74;"Y9YG9SMXPMO=&^C_M3E!HR>9@QTK>%GR-69\$FV9*,6\$7KZTF/6W@B!C9 MF=?
FG_E+!+1)L+!H9QH:GTA"@=+!S/B.A6*1V(9F5U:YBKB?_ \$"!+7-2 MG!Q+!A%*X@+!-
THIE/D+2("P3:9^&2)88CC0D6#Q!^Z9L\$#Q_X#%ZOI3&[!_ M:9 *%0!&&(W@KEA.@+N18\$GT:@LSJN!_ =LQ(%5?J!/_?D.^AM^_!X&Q-
D3 M&.%W%LB?>"8:JK2&-X"X&J!K/X7D:K.I5URWG@A2%L8D+(I2U+\$KF_E!J/Z#_ M!<E#)!"*UER6.QGSB6&0!XR\$Q7E,&-M-
@B4I8)Z5.9CZL!V@<-K-95 X6UW: MZE@X;0S!-(QV&?C2C&*)G?H#?(E=^P@5H.2EL,F*.P(W3+U9Q**VA"9&C MC7JTW=#ZUC@CT-
7-NE&?I5<6&R?L77%\$ETJZ65,#.G0^\$1(6N1HJ0!) MKJ0ZB!)! /7F_/EN.C. !_*L*_!HJ2UXTZF6*YBP)6(^8KI8BM5
MDID"R8R?/3G!VP!605:="NP6<^!_ \$:O_T&VPO!@JY^X",_>=2 MD<9=H!H19!_!_!QNWGD*PXTKQ7_PJ">2/
R&KJM6Y=&<>NND&E;,>_E@6W5!M MSDA_ ^M+SVW-F^I4BV!JL,>6X!&>G\$ZB%5Z@3%R@;B*JZNT'.5N9U?&P4D8' MVG-
!SP>W5Q!S2T!S?&SPX"-HN0-H!_ #2\$S=0ZV);DAU" &WZEKF!P-O: MY9)=+UMYZJQT+>R>=8T74E#9TPB<9Y1-7F+?2IH\$M
M#/TPOJ0N+L&B,EBRI^Y!PZLM%OY.L?EZB+!G=ZD'7W:|UYN!2M-UV:78;|UTZAO.K14?><? MMA?;_#OL\$F!LUTTF/WJ"
!PM\$)FI!8!#?6,TE#T9E6E@?IR5W-(Y4^!H"5 MY0+ @Y(DE@.4!G&CU;|AUQ!%W,+S"+A65H(\$1QZU);C,+U+U9!L!#UK
M")^#JGQ=5/FZ&|W<0=4V\$('G9J=2W)I36Z0^#%#-8PO:0ZUZ4/VOVR IO";? MJ%4JOQUFT!1^2STDHL !-
!6:136WOQ!U7>NFWB>|E\$SK+OOE8H;790UN M3D0>5(;F!\$S=RT+ 7.6YC9A!L+Q.ZXH0:QBEZRYUTHOV"JTR ^?^ST09+M=+?
H.R!LW0!HW\$Q4B!UM+>B-9D!2C!Y*4KA6&|H?>=:BQM6B1E+T M=;P!Q.? FWWJ8J>BR#;,&*6>0#HQ9)+%ZNNW1H\$-%
!MA+!H2-L!+0 MOV0OF)E:=>S<4*O0>Y!#1HJ@!H(77X\$G!H^+!HJ041#<^=S;|QJ!\$ M!JCE#S
!K(KSOV:/FEL7B6B5V+!RH21/7.O"HR:S)TOE0 M?7G6D*2G\$E#Y T!;9Z@6^)!HJ+@!_VQ'(YI3X"+K!XTL+DRC M"X/P.6+?
+K8&UJ!/G?H5C?E^CW8SMCJ!WYRG1@!Q/PH!D%#-G/G>Z2QW \$ M\$W7<_H#&T_/!+O/EF2EL&TN-/N+B:RA5*,F^CJ\$=E;81"M
ML4.XB2(UDR)/=-?KB_!L_K!Y^TZ_@H:9V(6H5N2;@-Q?2V!7C:CFX M<7"/UE?"S6J_/!1*!PS2&Z?
+)"Y@L+!)GD5ROKU0@)!<@E M206MI\$!WB M?
G3:5U^N+WDD23,^%0":8!#L9)5K#<=7V2X^WID93+ZNI>;OGQ&7_N4T55!9OASRHQ(F%J.)H4?!.G7Q^B MG(Z.O<L.TL4<"-1!N&T5-
_5?2\$X=+!?"OBV<^!JED!1.YB!8.D!H-+!H99LPYE!H J MOS1%Y!<^>Y3YI8"2W!4=\$T\$XS=CA!S="E
M.69PJF+DX\$48TJ!T@ZFA179_1"1(GKC^W9ZJA5^XY8.-4=N^GZD;<>^!X5 M;C!H;0.^!V%GLH/Y3-+BMH-!X|C2K^V
00MHXY"-DFA!5B0!C\$^36+>695Q)+P+EP#&25B\$8 MJHJ!>B"!8L@!<^VIR20?>403D"O=%C9H!<65@A*^?5,@/H(X^R\$
M6\$5\$*#M.?X:LGJD960L0DN9U!W: 12>(F#! M:PXG)"\$D-P MI/(612MENGE-C"@H5ADPZ?Z:Q^+!\$B!-
'G&...W4D!X!H+!E\$X0J8!:'9RYC'-PK!HZA\$(Y)E-B7-1_TDB!X:#%3
M?P+J!_!DFT@.N1^!0/%M^&CU!9+E#NE "\$>FW7(&XCHPA:9@ "KK1S*+E M"TO?2)UK2B"AQO'Y\$<2HER0W=(U6LA^V+!|"
(^2@3I.S: \$Y@8Z?1C MJ9"!<J"/#3!7CO!;DT:PF8-"/L!+1R!+!2!H3X2>4S=R=VD!V2%GX M)W BGY+KR.ROMMTDWX/*
(!3CF@PYT@QV^=OZ-1C^!H\$5HJ\$=A:N5 MY^&K\$6C\$5RJZ!H\$,"?FLA:5B6H?-,DP7\$(!?R#+OW\$U3M"/QV"\$S(E-MX<3B)6=-
>KUR'3P&?D08T.(!,9HHTGW>;MQ.XEE4GI>N):3YQW+3VA1!L MP&IX("7LS2/*2QCM/ZSOY%>P-
#.U# "L.G^A"YLVV!9&YO)7\$% 6&B.Z' 8!@3XE 8%\$A3PP9K!^XZ?*"134"XJ MAOXY&B0:3J!^<9UP!B=8&QD4
>QVD!6MT!1Y_#>!/D+R3HH:2 ^H4!< M6QJ=&@(^E_C_G..H8=Y?IO\$!4W8&?PJW%*"08T0!5!>H20\$B E)345N
M#^0\$ @BOF!G@.15Q*2P=FH\$A6%HG7# 4)76;2CCG(DF!H!8!G- M*^?2DBU5(5&HL,B>0!H.C^=A=6K21#
!P5GH3V/@5!;GSSLA.L00XR@!WY42 MOP\$1VBY^_K2JZ!HU7%R+^4U;|JD(AVL MS:QG "F!)-V1MI \$#SOMB
M.J!_T76V+!PGVB7LU0@ST+7!&D^27ABK&BN"60)!<^U!Y@#G!TBW&(O09&!-M:\$!8%IX!Z>P@H:HF190HY;N.J+
5C"3BA^!GZ_/KE/DJ("M!BU3\$ "MGWR?2^\$-!O"\$S!D3Y^<GCQ#C>^;V4"(P_LL>^Q00FORAHBQ"1A"#"H-W!MTT!<(&^*)A
M)!&@+R?2- XWMJC!MA;I!&@G_X3!3PD.AO_XTC!2!9DG&K9L1"<^=^!J!6=AT%&-047=-B=M \$!K!B^Y!T0URP"NM?U"+2=
6DU\$UN("50?QZSK\$)7)3T!C0/V;J1?2N3! MW@+6E!H-2YI89(4+ MJCK#6S!3ICY3SA-6:%OXXB_B!XQC8E;NOI COI6^58
_@#1.88!4WF.8(&:R9!K4!@.3TF9%?2R9?"Y2W4^OX/1^8\$!D MOT\$-1EG=@PRNO\14DO:&K"HD2-!B9AK^!6G3&HXQR!H=3?2FHV=*F
%0@ML)/M#/_O\$W&!)Y"/ LP#3UT'99A\$P<^RV!HNEC4V+ M'!\$Z\$T@5..P^Z6MPP1XL7@;)L!B"i5-B823X)0
MXJ2Z260ZR^Z0@.1.2%5#_!"<_""60+!-OP@Z2KE!CT70!T!HGM"57!P
MZ=G1DRTT!J\$&6/T^&O\$!L@LCU'TO:WDCBJA^VX2OX)9P.+KROP:>&_D&.M1 M:6!^+W1!F"(E3RMH^A.D-Q?
O42:JR:/F8Q:9>*2!P3Y%_ H!0%9!2V5&4>F7A M2Z3EW:CEW6TJG&X.1-9S!T-T-M<8=JH0V3@ DP-S*<1.CU@!8ULRXU&|;\$L
M"F6""V"9K*5!>2H9GM^TJX3/TRCA9*9!E05 0@8@^K\$6M"7J/>-!B)Y\$) ME4S!-%5/6+V4)XJM O1\$>3GP3!P1&
<@&B7-"ERIMKEJU7!4!H\$ZWOY*!60*MDAT?>+!* =HC8!H!&+&C2WP1B<LQR1#18FRBV>6J.WD8D1M"/0S!R4!
AK(3IB./@?B:HPZ:9CH@!19^"73!\$ M-4*8>DT!_&FCH7^<2E4T&*&Q!0<5/7PLX?!"0=GT=+2*
BKDE(3T+P=E@\$Y!L<_9A#X<_S!E4-HP8/E M.7!:(L?^*U!>VS0L4^R1Z)=Z/(5.?@3B(N&^R*Q*Z9KQ5Y_!O!ZGL!_O MZ1A02?
CP+!J(5_3&8"8J!@&JZ\$0U2YX!06>4Z70P ME+!/3!-DA:5(=VAA;J)?_!R=R%&0EJUA1\$S'+!P"D&B33@APB^CWCA MES?
_NXYG963?4(425/PY6WT?24CA,%<B4\$?DE+^>?O!H)UBZ>*3B&S3 MV3DIY"=<6H2Z\$A-
X&KD#E<3JD0B?2!X-CH!LQ0\$Y.FV7X-CH!Z8ZBK3.9 MI&>2.HHF B1VK4H&7*^K!+!&C&E_2!T3U718L"08.CIZ\$K^<...@P#A!4?
_W MUUVY3_C !AB^XLT!POV 8N1@ M;-3)4!|/6Y6;!--L!)Y%EMBJ-G_&A_%2M=\$&7 M895KB""?
&=HH1N.Q0HZN":S!_6163'64'(45E><+W4U:8@_1HRD!)T"G!+ M<^JDC2FT=1L_7!#K)W8-(Z!P0R\$!L'H>6=L)!\$!&*M#0
FD"HG.6Y4!L.TC#M!FOF8^!1.#SGN58,L!&|W:E<5!D)RAL)!XB)TE*4!+4EC87ZVS_O!XK2VJ.3(@T
M!O!#Y239/H@!"=HH7H/A!&_PXGE+1% UYY2+<+OV =UY!\$B!&Z^!20:8- MHA&40WY#2HN?XL"3YUS@,%1ZZ>0:%OA(M>@RC@?
X(U274UFB&J006(L+5^*9A-T:&M M=E4KG.7=)XJ:EMN*\$W-MYY=?!_5+!H!09)T=HFN?)F_8<5!M\$C.WLZ4MK_!<=
<>2+JW2T^6FZ/!-4 MABL!4G=F!)8!&+!Z!VGI*+!F%GTSS=+%!)U.MG4ZFZ&1.VSB6GU?EFJ5Y M8FD^>(\$P&?HP@
N^UZ^%XJ9+!J@3IVZ!UOGOC!V\$*;;736^/7*DS^W>:X
M^C^OMF!^GMWF6_N&L6U:2K>C!X!U.8!V5GE3H@!%W0U08N/U4&*U8KXB M+G.&VZV_HNVV<^K;H@YAS8#<8D7M#A
HX1:0\$#^<5R6?@!\$!57!&J>M=>G MY!D^!9X"-;01L<1?/B.C^_U+Q>&7!+@H!>0EFF TPFA0@CF",I>16*\$58
M!\$9AHBC)1,+9X)U.X.%24Q!^@GUDR1H#;_Q_%N0Z3^+M3RGA40G(Q:%# M:RR=>F6/K5Q!P^!Y!E.6.S/2E>^9.C.U)8/V-
M03TIFW+9/9RDC*NI/P>;8#W)J4-DH?SZ((3LLD)R!E=)KY"NMUE52*17S MI00!O-9!H)*\$ISL5Q<@JF6O6E!TU?IP(FL?
C0HH&QJ>B36DL2B!HCN"K M(X#5Z!H.4QU4AO@ZJ>ZJ#>G9D?4^!GVOT96G/O#A-\$!!%XYH>1A07V2M^P MD.?2-
ZLY#U:072D.4S%8O+K"LI%ZNU&:D8N13"MH"5DL5F.9Y(EG!T\$>4# M/EM4HLJZDK!H<0312(9AT!E")_8L)33:L_!3D8&D(\$O_T?
3VK5E@/V M!RXVDP? 4THPXRJR.1L!2MD\$@CB MI+ZSE(53;X'+L3FOB'%!_QM8HKV+) N4!DB*2!6T2.PP&BEA>482&^!1.6PS'
!&@&09YR2!8<^G*Q M5_!H3I7P 5%6)&@!#R!T.B!93F CXKJ- 32;6HNJ#?JU*1/8%LXCA) M*L4,"?
3!3:MW3%1HU^!-3%J!LP>|UFK!8!0X_K=1R=66YB^OZHXJQ""S MJK8X+!#RZPE!T8M.X9!UK<^C^&+!@N9)?
M""XJC3O25+!5PE^Q%2!XMQ*NE.F:9WS@#6B5C>^B!+^!G6!H9-LH=B5PV M!Q)!PHF8M!Y;W?9TF8?JS*4\$VH1**P!=!F F22;
@%@-D!Y#)?C;+ M8@=@@+0.9.L7K^X ""PC#%WPMTG*L?5VHO<^Q2#..)\$A'(%GM>L.CF:(3P!@H M)O!%ALD2;R1W:1;75#
M!6K2)HH^CQ!<\$!XJPEX&>5HD:MEB7P?&#)E)B"J%*>[28 SW0*""HH M-!<^*8&49L.O"TR.62W5(P!CO&^YKB)"1@%J91_Y>?
Q=HB-0.3P%P!ZW M-3WA!^48K.PO)#0EWVB!UJ^T94!>=8;R?1S!N5KK2U*NP!8E43&I96V3M/V4O#Z!HJ822
F.V!&C@>=K4Y7#?T!M#N2\$D^5%&S3G332A-8*M%G;H54 M.W:DF7ZW=H.D!H#-!F\$-7LDT@!|
(1N_Q%DU<=XI:5D.D4U(O86E5AGO!!# M#_+T-9S8*J.E=NEF=;^69Y0);J53GNGS(VOBWQ!L%)">|V1^A-/0M9 M82_AU:5-
Y8"/!N4!#0VCYF@OJ@ X6A9Y14E=E-N0>6@N7H?2Q?V\$S MVY=&U*G!F!+TX:8R:#69G:H^L^A2 U%=\$)!\$-
N2@SX!&+6RPT0B^8H!MTE MK&G&9!J;3&\$<^HF&LU%#-:(Q=OPHR31H2&Z-U-Q4Z?Z7!@<^<&?T.=H#7 M+!)9/Z(4"?&6ZV-
_#B@! G&PX.G;DL^>H!D6C2N!H2^W@QFR4K\$EYP3) MVY#H8-D48B8-1H@ESGNZCG8CC.F9,BG-BT_N"/(="2"WH
M(D33YD:RL^EBV!/?@_!EGVPH;FOAQ<%OIMV3.!N:-P.@ 6EN^CF*B MD2!N+5UKYK:Q30:=0G;+A53# MO!P01^:\$HB=-E\$4\$8T!D2D7
T!O2*"" M!H/W9!2J<24E!248G0/7Q>Y-6QZ!TP"0RU+>;B!6LG5PAUVX KB#W^F.O M\$ 4ES!BVX3H!P\$PS468-
'H0W_N4V;=&5S/DT!C5^K!H.D 3=Z8(5D!H">Y MNTGKCL7/J!NA@RTFC2V)6JAE!N!^P_M4O20#O<2!KI+2_?(IVF#0XRO*
M3 =&2^2D T+@TQ!""# N(DO&OUU!EH!S)060Y5 5VR8!B.M.PB-PB4!H\$A>A28:IZ@L\$& F&Y?&Q!N4)Q!<N!NK*A67!U
G4#3L6N&+DK"7!MX%:7V-(Z8O!ULDY G 7%#J-9"V>)"!@CH+!+!Z!H7AP8:9MO<0C:B11^*"" M2Z2_->A0904M4A
"TL<66QY..9R^)/D;B1SP/R?E(U^2(N*/5 M(Y+ B@!@!/*!7S,M2,0SUS#_0Q7Z5LG?B9:3EHR1G<^>V-6:DO0!L9@H&ZEHIYWM4%*>

```

VHZ=7UB:151#YUUV?M%H$OWZ*X.9D(PO"WJH"^(6=1JW4Z.4Y7/L51'X'H,R2!4+GUS./YS-1*3M',GZ&#OKT:CT=..R81&O:OYAZ
MJ>R_8N^L5K9!2!^TN(LMFV^^(H&ID?<IVY$MEGGCTFV MCV2G:J3S:CKS!O#32Z3:/>6LVK^JPV=-_K):9:;O MALI?JNI<
BIQ.4Q<.&#TDO?ELN?&=&ZMF>7-MJM#JY1*SEPVXH5TC/HC
MIT=UH+6T6GHKUV#E4.=2SPG2;5DVEA5LS0+!JV)S!^RVCXD.P.=#5FW>C4 M2H1HK*8AM'.0P0=:"U=H15>D:HLF8_!
!>"88IGW@$4V.K"S2!WONZ!AGA M3Z+3:J=[N$;8QW^)<XTL0N.V+M@S3.08PF6U8UNJVTI|*S8!OK$^CS(H.& MF)%UHU%?
VJKB,^@;K2K+:/7OI_C_H.DW0:PC.Y8X@SDAU",+HF+A9(F,M.4M)W!F).CKGVW4Q#0BMT6(K.43K9^):GU_1.08!"RW/AP_0@?
WH MP+A8C5*0!$IX^E)G^GY+Q|/"%FP+WLO941/9LW!(40LU!&C&NE#)02* G! M!A=B6 WDSUB R1!9Z0QOG7=8BQ7:>B!N=;0=?
I85*MA!65KB@!%!.!X^L!YIOQ<!O^!>.M:4+!_PZS.3:3!2!WS=ZE%3$5D#Z"PE3^Q&:R7BZ+>.H!&ZP!ST&+6O.SOSA$+<|
MX9(H!>C64++RR!<^!>+8L>!/5^&*%6!^@HRU=H!|'2N3$0B#X19$E?7- MV!<1/38:GH*GJ6BR/6!+BXB%KPEHL+9!M=
8Q/(+8DY5?).PL9!/"$A7!JWQ8!"L5JMH_TR_(NO"TX(9I7Q%*7G!5Y?>M<8^0./
!/@SM709!O"+Q%8MJKLAAQ72VL5DWP02VVHFX5^&WX|BCX!2O)# M'-6-
~04!@##J45#40V!..7J!>9HBC)>Q_<@OP$SG:SN'1"/R@."0f9 M@HU.(51Q,R4F,A!L8J%9TL+RL M+(6"4TYU!2
0C^Q0L*CR5M1VJFK&W5!EIS!HHH@6MLJ9>QAK9.CLK=!"I$!5 M.X<H$Y%.*IT$V#RQ.#V#*#252(RMCJ_2-
M!)L!/*V:0U(UVLVMTN|DP MX&$2&59=?LOH-IOP_W-U*GO!>"!A0H1CNAS?.SR=F6FVL&??7Q!@8=D6 MR%.;OB54T?
Y4CP+!"QD12.$?)$SAG+>MFE'OKM^FL-W+X%.00$;VF48-D1 M;.(T"AWJB90-6Z^2-
B#+S!^<;BIA:QG28.1V#H!EF+4FJ6M".K*.8B MW$KJFETX2S>)>S_8U0%<#S4HATL:9!<S(/.^UR!009H+^!>.T
M#G8M#K!<69G(AMQR?)D.DN YDF=^SVT).2;H MB>#$U<5FH0 3^!U^E/N6Z>4/UZN:0^9Q:F96"J
M4AP1|BMJN73HH1Z'!# 6B?<9YMH&.+N18RX!H&K6%RN-MH=;i&M|L 1*3 M^O17@>PXCZZ<1)TB2;E#*="PNTN&/FV|*
ISZMHGBJVT1A!9 76FMCL#37Q M6J6N2ABMB#*6='GH5D)=!5:.$9=H V-2%60BJAN(N 9GE2.B#O2)D^0HS
M$C^H@XWM=/'2:1@>92)>@C@<^!G!OQ@<)>L9>3ZEJMP2WLH.KP)F/X4GM@< ML2^H$6^6H0HTT'K"
!HOJ.VKC.8ZYVORR.M2<2.Y$1G7KH.EC=VY3!$8W@HES.B4LH92HAPU307=R.B/_<^23V:/1!^FGA*K;R258.NA!<7@<@-*>*!+7X!R
MULCL*$LX_-VM8"Z7@KD!RQ2*4S+(.JO!)24#L=>?M.WL9L)B -N2SW?(<M:.%5>*L5R.#+/K !!"Z>R($E!3CZ M'.Y!M+.X!FFY-
U4*^U3R).8Y MEVTA?>..%SMD _!H_5K.R@.*3$!O_/C"#Z)2!W:.(H!%17W09D< MFV!_ZOT?Y^!/<3SDPIYVBQSI-6UW:3+28</_
V4^YT+!"M6/3H@.KBU MTN5M!O+T+!)X!@3HS'E@!HTA !W0M^@<KO9D0O2!>3 M;@88D EDYU2.?
&+P^<.0M>JOO!HOH!U.N!YCO>7F4:45YB$XXAR M2?!"NSC0!N8V6BK !Y/..* V>2!GNX$BO=+.6@% MR$!UH4YIOV_BVL57%H
L!JFS:92WMMNVF#>9E!X.A- DPS2ND&T$SRJWDDH9F65.6)H6KYR:M-M=K.(M+1Y+68-
:6)Z8*T&.>A@+^X+;W^Z&.Y(=+'T9+^!.OGHS5,^>CX?O7!^* M1W1V9%TD&1>XP37%#3Y/"U-9?J?VVS8;>PRHG"=WJUI.JR!H3>(KVY*?
I5*KF MR)#.3HU<.</_R2NF.8)OH0D/OPZ=L8.OHNJ5WE=M69^72LN:P.A M5U.623PI7+B0|_#Y6L>3*5C.7WH *+I2%:(f7U!+JFU^~
JK..=;<7 M'MHE=3_ EN59A$X.1Z.I8$4!JRG&34H!LMBK+!>.G)F(V#B%54%$S_*$S; MK52+?E40*I3.3IN%M&"8<7_BH(U
P%7P!09NG2"DMM&WE$;S8S1@Q^M _*M6G0^2^*C8(HPB+M+>2=TK_#HD'KPZ%JX8E<25'3@<)>1#ACK=)!+^EWP.$ M9!@-
_*$3Z6!16>.=.17^<^Q<:Y!@?&.!U@PRW^*U%)BZ60P|T #30A01
368T8$19EXFM>M)90E-NG!K5N$78" MXL'4=3FAC.(N2JH.47/DS^D>&_OR3P$S= 0 2DBOH=ASTH.C#D3_%.S!BI M9?M
5#;+!%/@#;09V>6C1R_U-W4KK9ZF*9V265DY4I^1"8M9^<R.M:8% MF*#0J40WK7EA"7)/IF9Q!8G.%L3%W
M:=<1UQ(K(DV3!+=& Q)1HU.UQ?29VZU!)O6*="LFGV3C.&7;#!#R%KA:H6T% MV$0^BS!0_9MT-
K#Y0#V&@>_JC#ZOYE1GUIP5:#?2Q$JU=>>NB!Q>S9E5 MP!%M:Q!VU!>'A.QM@KYB*U"!-J!1%=(0@VD#7
M008$S!69(ZN6VOL6)/%*6UY(+E.>)E#?2^AK=3KQ:K=2 M5C;
SSF"9G*M'E!+!>=>L9MUC.N1.X)=!92JU*6L@FDI#/*VFT53;S5#9X MFI8UY&(N 1!7YF|=DOV1#^UYO(KUXZ.E^RG2Q?
%CI&ZVOB8.18 MGIWZ<=#'D'CU6W0!)P$H!TX&1@R:OCY!L<="*6$%#Z=ES:0#JUG>=!U M;)Y&.@WH&O#;BGY?
LU(=/A1"G!3:FO&"+D/3D1?H9-S!6U$;Z$-Q>124 MV!2H^/6!OPZ?>Q.HH-36!H>)3M$(UTYF9F5=!A&X1%|M!7TXPIDI-/WP M$-
@/!UC#1XYN$!@S.YO+H1=(+LUSUVFV6TS#E>GF*5M1HP"/8Z# P.J- M!OQ>HLD3:;=4)-B1-$42K!FI3.3JX@MWJ*0=;_NF>3*LU*
(S%#)#"YS.P?+&FE&#<.-N3S!B&2+UXF=^P3WR2K$!8D2L3 ""D>J/V!V06GFPZ:ZJ.EUW_HSN+T! MW^&%"(K?
AAE9&R!TM!+!J$TK/3U&EK#H!EAH9H.RH3N#PK MINIEDC.B*8$Y5AQ>6@MP!9.9A0$9(+98.A"S".D6 E<*(CDYPGMKZ0!<
M3@E_Z!N!5!&2HR31!>*<2TE!P5NRA?0?#|L=4VW""Z@2P!)&5R^T@X1@% M TJ%)S_X3H!+5#X!A:<9"B/T@DU.L-
DK4^R!>5!^_0!A3!/3M!<K!4L@> M52 0JK!9!9!@>.@G@90.0Y!H&Q!#10!|%)MX(#"Y0!2?>T.4^!D0C$&C;
M702Z.S)O...8=+7W/N8#PUSPU3A.ZTK!4@J0^@<5!#8M#N8>S:9VA+!+%0S M=+>2:8U;4H6HOP(Q)6!>'6FOH!X>I^R?Y*8!
(9Z<8@<D#>DIV_#>@Z M!KO9M,4BE2H!EY40K!>!.?+! M"06N(?!H!F=ZCB*ZOZM8#&|!$T2U+G MXW50=7X7EK236/15#J-!%G)
(4BG7.NEK>1QG84-BNM3IGXUYV+ Z(6C4.MVFA6.FR>E!K.SNDD4SH C@>V IY*!<1FUYMPX2U!+IACM!PK/7_S M6?
K(*GX15>C,E)76*^VDJDXK,5$VDYKXN;LB"E&FF8U0! M+6;+5.8N3R-EB^63!&=>.*MJ-!>R>V&H!^*!S2+J2OQSH?G_>6MDI-|
M^9$U!<1/B>K!>GAJHF&H!SZQC:;H8!>9J.R_YH($4H46!BB.3%1_U9_?B<4!>W>4G""164*0*FR#1S050G%
(5V3.93!2>IP(C+!6QV<0B&+!5*59KJ M!#2%GT8YU.1K.D<^<=>#-2;_BB OY&(2=>+CT$2!|B!J#^Z"SQ7WJ!$8 M8;)/@4>
AT3&8A(IVQ!)MCH= BZRM!H?@A^C.EI&29#;PBDEXM O+<^ M2^FV!8.Q0!<^G<%N""K%Q!S0!P!>W3OF<_!&Q%$9"M5@-
X>W#:/> M;AKUH!K'YZ6S-JG.Y1K5?S2#DZ1!3A">L<1E_T0621Z-6!O_?(&8S? MJL<61%9<_FXU9$H=#1>Y("5+2A:Q$SJV(1G$H
M$IX-W"R?7P
```

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~)3+UN?I<=6*;KD4/MOYV=^*K>?W5OZWZ;U>?KGI53;5DSI:G^A5I0/B_%L6JX^%PBET6T=7*R MO_UHJEI/ZU_7.L;IUX7X5WUOFW+J^VQ19LO.IJ--7K_~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

1)@X0#NE223Z12B8KTCF1^B6N6AQ:A#1:9D6=@.V7W.1C1/XSDH8JPP
MSP=^S8^NR^8B@AR2ZE5N818DX<!)OL>AP;P*4Y1UTY1^%U^>?MOX?N@JO4 M9E**B@@"^&^Y^*";?
IY+9LVI<^JHIVUP5WNUM06 FB(M&Z<= *)OF6QS):N^E^%2D (#251600V<^=AXC# ZBLFTKGYR M^>D+/:XB1=M;E.0&I(-
VT"/4)L%1:N>+X/X)8W^D4!DB=FYFW*Q5D.VD M%O/"MOK.#B\$K^N^FY(-0V2E0WH Y^>I3W>|HJ)^2%^2|W5^ LFWX3^QI|7&W
MGQ.HNDFEYV+& YD1LJ^K^XNF3.S3>>FC^#@%\$2:JCLY8H|@9|A|F%.\$B&HIQW- M)AHJB|Y\$!%9!T<@#?H3!^3H3Y-P4?
Z02L5L>H^("S@^:%W_ZUM7.@PD-ML2R!5SITH/+3PJ@*Y.5ZQWD4O 'T@E.JUJH.9UM3JCS@|%=H#5/9WTW7NZ. M?7.D8>ZCH1'K-
QD:7W<^MIKFW).D1Q.AC56!V(-QF-#^NI(MNKJ)OXP6BT\$B8"(3^TF3.XOW6&Z^"=*MKP0>+V2:J6F^Q0?JS.B9O-13/KOEYJ-IO
&4WC)VND4LWJ:ZJL<=9XIV(ML6.AOXCW3_GPU=T6H^V%:A:|C|QM%|):C^"_%O%O@ST>>17LA>#&)=((44Y M>%MIK\$/*?>1NE;
<>Y#UTPN\$:(/P(W6W#V*4G9G')!T\$:(H69JF|<FK7W M>EW/&7&#;/1U.6^S|P):!07!5XU>2G-OJ='!;14\$!#H0 (*J#EGB=DD?^00
15 M: 96\$P.C\$P.#W.#%E>#R+3%?8VAL;F\$N:1M15CK3^&\$A>*?_# M*%412'D^USL2(IG\$*G2))<8J?3:OE|V|
W2:MK(|H9 T(A@^!E4>OZO\$F MV/|<7NL&="D:7TFV^C|H|OG8UP%#:0W|W6:GWSJYQ^17>+1P.5T).EGY^K(36(LK?
E5UV^*==4IF<=V@MG?#H>6LYX-H7Y M^6)Y:DT=<=&W' QMG.JA /FLCELPM(>IHYUI@_17_3)6L|UF@V=^S1IQ^D M(C0?
YNI@=@K.F0U+;W^B3>UE8_10+X^<@82K?=<KZ.HR^_V7L+<1\$>90 M:@.GH)PCTJ^|ZD' 95TM<\$82*0SHXQO@Q)<\$A.7Z4YU0A0.
T9JL^<IFVAV M26^F^PQ@/'^3%Z+;IY3ADGW&4DW/(WY X@>7E 9\$3@3(0>XVNT-.9N\$W8U M>K3ST_MNMT|BB@F?),^=7H=6P
\$@P13F0L%75^FHK(9FZF@F+(1G03^*) M6..ID@EA&O08LMD^F18,D)I9K1K7LX6M: *|S8?@>9VHH^82YW9V%N>P^GX@
M|D(ZSX=88PC:B*2)M+M%8Q-FFB.V0I/#&0^809RL3*Y+Y>K2^="A\$>UG1 M1H28D2#JH=B_K85HD:/L-
PT2N).RP(V(J4Z.JP\$L|>);0>+Y"D=X?N| (MK&2-(87.059;1\$FRZ^1^<IO-EK^9P160N(EV7!%&))849P2|OJZ7#^<OK M^0:OD#>
<&2^GQ17NUJ5<=U\$<|R%Q|T.G>8@N^A\$R#ZOC_19B/>|*#="P 5' M^UJH?|>+\$0\$3EB=3|1(9);W4>P-1 Z-
MOEUAUBN4Q+1HY+2AWCW#7/) ML4=8WYDWQ#P_2|S=S+&LF(>F#>8 P+BT:I:TWE@QK/<9BIUNC(C.ZIQ2K M;13U?
Q3_1E@!<13H1E@;QT=Y 1^ BW^J|NU^45HM7LWQCF+BN2+&A>3I M*==76_V8^A8| QMUS.G-
O&\$&7\$KQ&;HTWNY3Z)5IT/D\$|0\$NGG^WCJTH>12^<^1^&-3#XG1<^L1T.J6>0OR+5Y(ALQH>"I.&.;2B-LUE4#GJU
M@A\$LF0H1F1%\$D3>6X1^9%2G/5A%BD|KAAE=F>4G^XWOL^P^<GD3 4W^DJQ M-1M %\$H8DJA1G/2V X^Z.?
O@)C#X91W^OWF:C@2^6=R+<A|SLR^DYD/J M7U1+<04 Q0 (<J^#EEH)Q.MQ_..S 1^ 0 M^1C<A+AI+3(P.C0P-C.P+GAS9%1+<04 Q0 (<
0^#EDA^2>W00T^&F M5^>80 1C^<A1+3(P.C0P-C.P7V A^;YX;G002P\$%M%_4 "J@ Y9V2FZ8ITZ #TF_#%0 @'6@ 8W^H M;2TR.#
(T.#8S.%ID968N>&UL4\$!L^A0#% @ JH_6;Y1 \$F<-.F; "2\$. @!E83 R;3 X;##R+3%?8VAL;F\$N:1M4\$!%|@ 0) D:P(09 @ \$! end XML
72 ea0210807-10q chinaphar.htm.xml IDEA: XBRL DOCUMENT 0001106644 2024-01-01 2024-06-30 0001106644 2024-08-12
0001106644 2024-06-30 0001106644 2023-12-31 0001106644 us-gaap:RelatedPartyMember 2024-06-30 0001106644 us-
gaap:RelatedPartyMember 2023-12-31 0001106644 2024-04-01 2024-06-30 0001106644 2023-04-01 2023-06-30 0001106644 2023-
01-01 2023-06-30 0001106644 us-gaap:CommonStockMember 2022-12-31 0001106644 us-gaap:AdditionalPaidInCapitalMember
2022-12-31 0001106644 us-gaap:RetainedEarningsMember 2022-12-31 0001106644 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001106644 2022-12-31 0001106644 us-
gaap:CommonStockMember 2023-01-01 2023-03-31 0001106644 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31
0001106644 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001106644 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001106644 2023-01-01 2023-03-31 0001106644 us-
gaap:CommonStockMember 2023-03-31 0001106644 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001106644 us-
gaap:RetainedEarningsMember 2023-03-31 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31
0001106644 2023-03-31 0001106644 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001106644 us-
gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001106644 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-
30 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001106644 us-
gaap:CommonStockMember 2023-06-30 0001106644 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001106644 us-
gaap:RetainedEarningsMember 2023-06-30 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30
0001106644 2023-06-30 0001106644 us-gaap:CommonStockMember 2023-12-31 0001106644 us-
gaap:AdditionalPaidInCapitalMember 2023-12-31 0001106644 us-gaap:RetainedEarningsMember 2023-12-31 0001106644 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001106644 us-gaap:CommonStockMember 2024-01-01 2024-
03-31 0001106644 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001106644 us-gaap:RetainedEarningsMember
2024-01-01 2024-03-31 0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001106644
2024-01-01 2024-03-31 0001106644 us-gaap:CommonStockMember 2024-03-31 0001106644 us-
gaap:AdditionalPaidInCapitalMember 2024-03-31 0001106644 us-gaap:RetainedEarningsMember 2024-03-31 0001106644 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001106644 2024-03-31 0001106644 us-
gaap:CommonStockMember 2024-04-01 2024-06-30 0001106644 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30
0001106644 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001106644 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001106644 us-gaap:CommonStockMember 2024-
06-30 0001106644 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001106644 us-gaap:RetainedEarningsMember 2024-06-30
0001106644 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001106644
cphi:OnnyInvestmentLimitedMember 2024-06-30 0001106644 cphi:HainanHelpsonMedicalBiotechnologyCoLtdMember 2024-06-30
0001106644 cphi:HainanHelpsonMedicalBiotechnologyCoLtdMember 2005-05-25 0001106644 us-
gaap:ConvertibleDebtSecuritiesMember 2024-01-01 2024-06-30 0001106644 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01
2023-12-31 0001106644 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001106644 us-
gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001106644 us-gaap:LandMember 2024-06-30 0001106644 us-
gaap:LandMember 2023-12-31 0001106644 us-gaap:BuildingMember 2024-06-30 0001106644 us-gaap:BuildingMember 2023-12-31
0001106644 us-gaap:PropertyPlantAndEquipmentOtherTypesMember 2024-06-30 0001106644 us-
gaap:PropertyPlantAndEquipmentOtherTypesMember 2023-12-31 0001106644 us-gaap:VehiclesMember 2024-06-30 0001106644
us-gaap:VehiclesMember 2023-12-31 0001106644 us-gaap:OfficeEquipmentMember 2024-06-30 0001106644 us-
gaap:OfficeEquipmentMember 2023-12-31 0001106644 srt:MinimumMember us-gaap:LandMember 2024-06-30 0001106644
srt:MaximumMember us-gaap:LandMember 2024-06-30 0001106644 srt:MinimumMember us-gaap:BuildingMember 2024-06-30
0001106644 srt:MaximumMember us-gaap:BuildingMember 2024-06-30 0001106644 srt:MinimumMember us-
gaap:PropertyPlantAndEquipmentMember 2024-06-30 0001106644 srt:MaximumMember us-
gaap:PropertyPlantAndEquipmentMember 2024-06-30 0001106644 srt:MinimumMember us-gaap:VehiclesMember 2024-06-30
0001106644 srt:MaximumMember us-gaap:VehiclesMember 2024-06-30 0001106644 srt:MinimumMember us-
gaap:OfficeEquipmentMember 2024-06-30 0001106644 srt:MaximumMember us-gaap:OfficeEquipmentMember 2024-06-30
0001106644 cphi:HelpsonMember 2024-01-01 2024-06-30 0001106644 cphi:NMPAApprovedMedicalFormulasMember 2024-06-30
0001106644 cphi:NMPAApprovedMedicalFormulasMember 2023-12-31 0001106644 cphi:TechnologyFromBonierMember 2024-06-
30 0001106644 cphi:TechnologyFromBonierMember 2023-12-31 0001106644 cphi:InventionPatentMember 2024-06-30 0001106644
cphi:InventionPatentMember 2023-12-31 0001106644 srt:BoardOfDirectorsChairmanMember 2024-06-30 0001106644
srt:BoardOfDirectorsChairmanMember 2023-12-31 0001106644 2019-07-08 2019-07-08 0001106644 cphi:LoanPayableMember
2019-07-08 0001106644 cphi:BankOfCommunicationsMember 2022-12-21 0001106644 cphi:BankOfCommunicationsMember 2022-
12-21 2022-12-21 0001106644 cphi:BankOfCommunicationsMember 2022-12-30 2022-12-30 0001106644
cphi:BankOfCommunicationsMember 2023-02-24 2023-02-24 0001106644 cphi:BankOfCommunicationsMember 2023-12-20 2023-
12-20 0001106644 cphi:BankOfCommunicationsMember 2024-04-01 2024-06-30 0001106644 cphi:BankOfCommunicationsMember
2023-04-01 2023-06-30 0001106644 cphi:BankOfCommunicationsMember 2024-01-01 2024-06-30 0001106644
cphi:BankOfCommunicationsMember 2023-01-01 2023-06-30 0001106644 cphi:BankOfCommunicationsMember 2024-02-02 2024-
02-02 0001106644 cphi:BankOfCommunicationsMember 2024-02-22 2024-02-22 0001106644 cphi:BankOfChinaMember 2022-09-30
0001106644 cphi:BankOfChinaMember 2022-09-30 0001106644 us-gaap:RevolvingCreditFacilityMember
cphi:BankOfChinaMember 2022-09-25 2022-09-25 0001106644 cphi:BankOfChinaMember 2022-09-25 2022-09-25 0001106644
cphi:BankOfChinaMember 2024-04-01 2024-06-30 0001106644 cphi:BankOfChinaMember 2023-04-01 2023-06-30 0001106644
cphi:BankOfChinaMember 2024-01-01 2024-06-30 0001106644 cphi:BankOfChinaMember 2023-01-01 2023-06-30 0001106644 us-
gaap:LineOfCreditMember 2024-06-30 0001106644 2023-04-13 0001106644 srt:MinimumMember 2023-04-13 2023-04-13
0001106644 srt:MaximumMember 2023-04-13 2023-04-13 0001106644 2024-05-23 2024-05-23 0001106644 srt:MinimumMember
2024-05-23 2024-05-23 0001106644 srt:MaximumMember 2024-05-23 2024-05-23 0001106644 cphi:ConvertibleNotesMember 2022-

04-19-2022-04-19-0001106644 cphi:ConvertibleNotesMember cphi:ChinaPharmaMember us-gaap:CommonStockMember 2022-04-19-0001106644 cphi:ConvertibleNotesMember cphi:ChinaPharmaMember 2024-01-01-2024-06-30-0001106644
cphi:ConvertibleNotesMember 2024-06-30-0001106644 cphi:ConvertibleNotesMember 2024-01-01-2024-06-30-0001106644
cphi:ConvertibleNotesMember 2021-11-19-2021-11-19-0001106644 cphi:ConvertibleNotesMember 2021-11-19-0001106644
cphi:ConvertibleNotesMember 2024-04-01-2024-06-30-0001106644 cphi:ConvertibleNotesMember 2023-04-01-2023-06-30-0001106644 cphi:ConvertibleNotesMember 2023-01-01-2023-06-30-0001106644 cphi:ConvertibleNotesMember 2024-01-11-2024-01-11-0001106644 2024-01-11-0001106644 2024-01-16-2024-01-16-0001106644 2024-02-01-0001106644 cphi:ConvertibleNotesMember 2024-02-01-0001106644 2024-02-01-2024-02-01-0001106644 2024-02-05-2024-02-05-0001106644 2024-02-16-0001106644 cphi:ConvertibleNotesMember 2024-02-16-0001106644 2024-02-16-2024-02-16-0001106644 2024-02-21-2024-02-21-0001106644 2024-04-02-0001106644 cphi:ConvertibleNotesMember 2024-04-02-0001106644 2024-04-02-2024-04-02-0001106644 2024-04-03-2024-04-03-0001106644 2024-04-17-0001106644 cphi:ConvertibleNotesMember 2024-04-17-0001106644 2024-04-17-2024-04-17-0001106644 2024-04-19-2024-04-19-0001106644 2024-05-20-0001106644 cphi:ConvertibleNotesMember 2024-05-20-0001106644 2024-05-20-2024-05-20-0001106644 2024-05-21-2024-05-21-0001106644 2024-06-17-0001106644 cphi:ConvertibleNotesMember 2024-06-17-0001106644 2024-06-17-2024-06-17-0001106644 us-gaap:TaxYear2023Member 2024-06-30-0001106644 us-gaap:DomesticCountryMember 2024-06-30-0001106644
srt:MaximumMember 2017-12-31-2017-12-31-0001106644 srt:MinimumMember 2017-12-31-2017-12-31-0001106644
cphi:BankersAcceptanceNotesMember 2024-06-30-0001106644 us-gaap:FairValueInputsLevel1Member
cphi:BankersAcceptanceNotesMember 2024-06-30-0001106644 us-gaap:FairValueInputsLevel2Member
cphi:BankersAcceptanceNotesMember 2024-06-30-0001106644 us-gaap:FairValueInputsLevel3Member
cphi:BankersAcceptanceNotesMember 2024-06-30-0001106644 us-gaap:FairValueInputsLevel1Member 2024-06-30-0001106644 us-gaap:FairValueInputsLevel2Member 2024-06-30-0001106644 us-gaap:FairValueInputsLevel3Member 2024-06-30-0001106644
cphi:BankersAcceptanceNotesMember 2023-12-31-0001106644 us-gaap:FairValueInputsLevel1Member
cphi:BankersAcceptanceNotesMember 2023-12-31-0001106644 us-gaap:FairValueInputsLevel2Member
cphi:BankersAcceptanceNotesMember 2023-12-31-0001106644 us-gaap:FairValueInputsLevel3Member
cphi:BankersAcceptanceNotesMember 2023-12-31-0001106644 us-gaap:FairValueInputsLevel1Member 2023-12-31-0001106644 us-gaap:FairValueInputsLevel2Member 2023-12-31-0001106644 us-gaap:FairValueInputsLevel3Member 2023-12-31-0001106644 us-gaap:CommonStockMember 2024-01-01-2024-06-30-0001106644 cphi:ChinaPharmasCommonStockMember 2024-06-30-0001106644
cphi:ConvertibleNotesMember cphi:ChinaPharmasCommonStockMember 2024-06-30-0001106644 2021-12-27-0001106644
srt:MinimumMember 2021-12-27-0001106644 srt:MaximumMember 2021-12-27-0001106644 2022-12-27-0001106644
srt:MinimumMember 2022-12-27-0001106644 srt:MaximumMember 2022-12-27-0001106644 srt:MinimumMember 2023-12-17-0001106644 srt:MaximumMember 2023-12-17-0001106644 cphi:TwoThousandTenIncentivePlanMember 2024-01-01-2024-06-30-0001106644 cphi:TwoThousandTenIncentivePlanMember 2024-06-30-0001106644 cphi:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01-2024-06-30-0001106644
cphi:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01-2024-06-30-0001106644 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember cphi:SuppliersOneMember 2024-01-01-2024-06-30-0001106644 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember
cphi:SuppliersTwoMember 2024-01-01-2024-06-30-0001106644 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember cphi:SuppliersThreeMember 2024-01-01-2024-06-30-0001106644 cphi:ProductOneMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01-2024-06-30-0001106644
cphi:ProductTwoMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01-2024-06-30-0001106644 cphi:ProductThreeMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2024-01-01-2024-06-30-0001106644 cphi:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01-2023-06-30-0001106644 cphi:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01-2023-06-30-0001106644
cphi:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01-2023-06-30-0001106644 cphi:RawMaterialPurchasesMember us-gaap:SupplierConcentrationRiskMember cphi:SuppliersOneMember 2023-01-01-2023-06-30-0001106644 cphi:RawMaterialPurchasesMember us-gaap:SupplierConcentrationRiskMember
cphi:SuppliersTwoMember 2023-01-01-2023-06-30-0001106644 cphi:ProductOneMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2023-01-01-2023-06-30-0001106644 cphi:ProductTwoMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01-2023-06-30-0001106644
cphi:ProductThreeMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2023-01-01-2023-06-30-0001106644 cphi:ProductFourMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2023-01-01-2023-06-30-0001106644 cphi:ProductFiveMember us-gaap:SalesRevenueProductLineMember us-gaap:ProductConcentrationRiskMember 2023-01-01-2023-06-30-0001106644 shares iso4217:USD iso4217:USD shares pure iso4217:CN¥ 10-Q true 2024-06-30 2024 false 001-34471 CHINA PHARMA HOLDINGS, INC. NV 75-1564807 Second Floor, No. 17, Jinpan Road Haikou Hainan Province CN 570216 Common Stock CPHI NYSE Yes Yes Non-accelerated Filer true false false 17162771 739337 1423838 15435 65915 13706077 13786074 254850 504448 27929 27017 28660 157944 161 2013 2818925 3732517 115610 110258 3972978 5996933 5817379 7100425 77259 116610 4393617 3255232 14261233 14649200 141036 966420 208831 298829 1606991 2282692 101056 90507 1140775 1133809 78628 77727 1024303 1030680 410415 940000 4712035 6820664 1403154 1411891 737522 742114 39910 6852711 9014579 0.001 0.001 5000000 5000000 0.001 0.001 500000000 500000000 17162771 17162771 10625788 10625788 17162 10625 37690719 35282256 -41684336 -39290314 11384977 11452054 7408522 7454621 14261233 16469200 924943 1097862 2294782 3058152 1940329 1244523 3600192 3026889 -1015386 -146661 -1305410 31263 11455 169820 219642 314252 91870 112033 580326 530032 164334 23747 195785 46755 8476 4047 6410 -5989 376135 309647 1002163 885050 -1391521 -456308 -2307573 -853787 1531 942 3846 1890 48140 137663 90295 217108 -46609 -136721 -86449 -215218 -1438130 -593029 -2394022 -1069005 -1438130 -593029 -2394022 -1069005 -45502 -523687 -67077 -318365 -1483632 -116716 -2461099 -1387370 -0.09 -0.35 -0.16 -0.65 16124241 1689985 14727410 1653076 1498179 1498 28926931 -36211496 11573065 4289998 191806 595 799405 650000 -475976 -475976 205322 205322 1689985 1690 29576739 -36687472 11778387 4669344 594941 595 799405 800000 -593029 -593029 -45502 -45502 2284927 2285 30376144 -36280501 11254700 4352628 10625788 10625 35282256 -39290314 11452054 7454621 1191077 1191 448809 450000 3000000 3000 1362000 1365000 -955892 -955892 -21575 -21575 14816865 14816 37093065 -40246206 11430479 8292154 2345906 2346 597654 600000 -1438130 -1438130 -45502 -45502 17162771 17162 37690719 -41684336 11384977 7408522 -2394022 -1069005 1473050 1374724 6410 -5989 411431 24259 -182533 344449 -1845 -294625 -719121 791042 -821907 -238684 -241434 -425153 11142 -458999 6053 44936 -657884 -1684649 28086 -60465 -28086 60465 492761 492761 505114 13708 14057 13708 519171 -12239 -23048 -684501 -1128061 1423838 2029971 739337 901910 43217 39681 187111 421458 237336 351463 1050000 800000 1365000 158926 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">NOTE 1 -- ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">Organization and Nature of Operations</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">China Pharma Holdings, Inc., a Nevada corporation ("China Pharma"), owns 100% of Onny Investment Limited ("Onny"), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd ("Helpson"), a company organized under the laws of the People's Republic of China (the "PRC"). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson's three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise ("WFOE") status on June 21, 2005.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the

PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the "NMPA", formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.

Liquidity and Going Concern

As of June 30, 2024, the Company had cash and cash equivalents of \$0.7 million, an accumulated deficit of \$41.7 million and the Company's current liabilities exceeded current assets by \$0.7 million. In addition, the Company had incurred net losses of \$2.4 million and had negative cash flows from operating activities of \$0.7 million for the six months ended June 30, 2024. The Company's Chairperson, Chief Executive Officer and Interim Chief Financial Officer had advanced an aggregate of \$1,140,775 as of June 30, 2024 to provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company's existing property, plant and equipment can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern.

Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, "Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern" management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued.

Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company's current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company's control. Accordingly, substantial doubt is deemed to exist about the Company's ability to continue as a going concern within one year after the date these financial statements are issued.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Reverse Stock Split

Effective March 6, 2024, China Pharma implemented a 1-for-5 reverse stock split as more fully discussed in Note 13. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split.

Consolidation and Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and are expressed in United States dollars. The accompanying unaudited interim condensed consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.

Helpson's functional currency is the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.

In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessarily be indicative of annual results. Such financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the "SEC") on April 1, 2024 ("2023 Annual Report").

Accounting Estimates

The methodology used to prepare the Company's financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.

Loss Per Share

The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.

Basic loss per share is calculated by dividing loss available to common stockholders by the weighted-average number of shares of common stock outstanding, excluding unvested stock. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common shares, including unvested stock, had been issued and if the additional common shares were dilutive.

The potentially dilutive common shares related to the convertible, redeemable note payable of 2,003,001 and 2,155,964 at June 30, 2024 and December 31, 2023 as discussed in Note 9, respectively, and the option to purchase 13,300 shares of common stock at June 30, 2024 and December 31, 2023 are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.

Recent Accounting Pronouncements

In December 2023, the FASB issued guidance to enhance transparency of income tax disclosures. On an annual basis, the new guidance requires a public entity to disclose: (1) specific categories in the rate reconciliation, (2) additional information for reconciling items that are equal to or greater than 5% of the amount computed by multiplying income (or loss) from continuing operations before income tax expense (or benefit) by the applicable statutory income tax rate, (3) income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes, with foreign taxes disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5% of total income taxes paid, (4) income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and (5) income tax expense (or benefit) from continuing operations disaggregated between federal (national), state and foreign. The guidance is effective for fiscal year 2025 annual reporting, with early adoption permitted, to be applied on a prospective basis, with retrospective application permitted. We do not expect the adoption of this accounting standard to have an impact on our Consolidated Financial Statements but will require certain additional disclosures.

From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Organization and Nature of Operations—China Pharma Holdings, Inc., a Nevada corporation (“China Pharma”), owns 100% of Onny Investment Limited (“Onny”), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (“Helpson”), a company organized under the laws of the People’s Republic of China (the “PRC”). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company. Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.

Liquidity and Going Concern—As of June 30, 2024, the Company had cash and cash equivalents of \$0.7 million, an accumulated deficit of \$41.7 million and the Company’s current liabilities exceeded current assets by \$0.7 million. In addition, the Company had incurred net losses of \$2.4 million and had negative cash flows from operating activities of \$0.7 million for the six months ended June 30, 2024. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer had advanced an aggregate of \$1,140,775 as of June 30, 2024 to provide working capital and enabled the Company to make the required payments related to its former construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing property, plant and equipment can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern.

Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, **Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern**, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued.

Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued.

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Reverse Stock Split—Effective March 6, 2024, China Pharma implemented a 1-for-5 reverse stock split as more fully discussed in Note 13. All share and per share disclosures have been retroactively restated to reflect the impact of the reverse stock split.

Consolidation and Basis of Presentation—The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are expressed in United States dollars. The accompanying unaudited interim condensed consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.

Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.

In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Company’s audited consolidated

financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (the "SEC") on April 1, 2024 ("2023 Annual Report").

Accounting Estimates

The methodology used to prepare the Company's financial statements is in conformity with U.S. GAAP, which requires the management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.

The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.

Loss Per Share

Basic loss per share is calculated by dividing loss available to common stockholders by the weighted-average number of shares of common stock outstanding, excluding unvested stock. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential common shares, including unvested stock, had been issued and if the additional common shares were dilutive.

The potentially dilutive common shares related to the convertible, redeemable note payable of 2,003,001 and 2,155,964 at June 30, 2024 and December 31, 2023 as discussed in Note 9, respectively, and the option to purchase 13,300 shares of common stock at June 30, 2024 and December 31, 2023 are excluded from the computation of diluted net loss per share for all periods presented because the effect is anti-dilutive due to net losses of the Company.

2003001 2155964 13300

Recent Accounting Pronouncements

In December 2023, the FASB issued guidance to enhance transparency of income tax disclosures. On an annual basis, the new guidance requires a public entity to disclose: (1) specific categories in the rate reconciliation, (2) additional information for reconciling items that are equal to or greater than 5% of the amount computed by multiplying income (or loss) from continuing operations before income tax expense (or benefit) by the applicable statutory income tax rate, (3) income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes, with foreign taxes disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than 5% of total income taxes paid, (4) income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and (5) income tax expense (or benefit) from continuing operations disaggregated between federal (national), state and foreign. The guidance is effective for fiscal year 2025 annual reporting, with early adoption permitted, to be applied on a prospective basis, with retrospective application permitted. We do not expect the adoption of this accounting standard to have an impact on our Consolidated Financial Statements but will require certain additional disclosures.

From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

NOTE 2 – ACCOUNTS RECEIVABLE, NET

	June 30,	December 31,
Accounts receivable, net, consist of the following:		
Trade accounts receivable	13,960,927	14,290,522
Less: allowance for doubtful accounts	(13,706,077)	(13,786,074)
Trade accounts receivable, net	\$254,850	\$504,448

We recognize bad debt expenses per actual write-offs as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is lower than that of the previous period, we recognize a bad debt credit for the difference. The allowance for doubtful account balances were \$13.71 million and \$13.79 million as of June 30, 2024 and December 31, 2023, respectively. The changes in the allowances for doubtful accounts during the three and six months ended June 30, 2024 and 2023 were as follows:

	June 30,	June 30,
Balance, Beginning of Period	13,759,993	16,955,959
Provision for doubtful accounts	1,521,000	1,521,000
Write-offs	(1,521,000)	(1,521,000)
Balance, Ending of Period	\$13,759,993	\$16,955,959

13,786,074 16,739,527 Bad debt expense (reversal of allowance for doubtful accounts) 8,476 4,047 6,410 (5,989) Foreign currency translation adjustment (62,392) (834,751) (86,407) (608,283) Balance, End of Period 13,706,077 16,125,255 2024 2023 Trade accounts receivable, net 13,960,927 14,290,522 Less: allowance for doubtful accounts 13,706,077 16,125,255 2024 2023

	June 30, 2024	June 30, 2023
Trade accounts receivable, net	13,960,927	14,290,522
Less: allowance for doubtful accounts	(13,706,077)	(16,125,255)
	254,850	504,448

The changes in the allowances for doubtful accounts during the three and six months ended June 30, 2024 and 2023 were as follows:

	June 30, 2024	June 30, 2023
Balance, Beginning of Period	13,759,993	13,786,074
Bad debt expense (reversal of allowance for doubtful accounts)	8,476	4,047
	16,739,527	16,739,527
Balance, End of Period	13,706,077	16,125,255

>16,125,255</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 4pt"></td>
<td style="border-bottom: Black 4pt double; text-align: left"></td><td style="border-bottom: Black 4pt double; text-align:
right">13,706,077</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 4pt"></td><td
style="border-bottom: Black 4pt double; text-align: left"></td><td style="border-bottom: Black 4pt double; text-align:
right">16,125,255</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr></table> 13759993 16955959 13786074
16739527 8476 4047 6410 -5989 -62392 -834751 -86407 -608283 13706077 16125255 13706077 16125255 <p style="font: 10pt
Times New Roman, Times, Serif; margin: 0pt 0">NOTE 3 – INVENTORIES</p><p style="font: 10pt Times New Roman,
Times, Serif; margin: 0pt 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventories consisted of
the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><table
cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr
style="vertical-align: bottom"><td></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-
align: center">June 30,</td><td style="font-weight: bold"></td><td style="font-weight: bold"></td><td colspan="2" style="font-
weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"></td></tr><tr style="vertical-align: bottom">
<td></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid;
font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight:
bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align:
center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom; background-
color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%"></td><td
style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">1,194,063</td><td style="width: 1%; text-align:
left"></td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align:
right">1,849,213</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align:
left">Work in process</td><td></td><td style="text-align: left"></td><td style="text-align: right">87,308</td><td style="text-
align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">413,597</td><td style="text-align:
left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-
bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-
align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,537,554</td><td style="padding-bottom: 1.5pt;
text-align: left"></td><td style="padding-bottom: 1.5pt"></td><td style="border-bottom: Black 1.5pt solid; text-align:
left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,469,707</td><td style="padding-bottom: 1.5pt; text-
align: left"></td></tr><tr style="vertical-align: bottom;"><td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-
indent: 10.05pt">Total Inventories</td><td style="padding-bottom: 4pt"></td><td style="border-bottom: Black 4pt double; text-
align: left">\$</td><td style="border-bottom: Black 4pt double; text-align: right">2,818,925</td><td style="padding-bottom: 2.5pt;
text-align: left"></td><td style="padding-bottom: 4pt"></td><td style="border-bottom: Black 4pt double; text-align:
left">\$</td><td style="border-bottom: Black 4pt double; text-align: right">3,732,517</td><td style="padding-bottom: 2.5pt; text-
align: left"></td></tr></table> Inventories consisted of the following:<table cellpadding="0" cellspacing="0" style="font: 10pt
Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td></td><td
style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-
weight: bold"></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">December
31,</td><td style="font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold;
padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align:
center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom:
1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td
style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom; background-color:
rgb(204,238,255)"><td style="width: 76%; text-align: left">Raw materials</td><td style="width: 1%"></td><td style="width: 1%;
text-align: left"></td><td style="width: 9%; text-align: right">1,194,063</td><td style="width: 1%; text-align: left"></td><td
style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">1,849,213</td><td
style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4pt; text-
indent: 10.05pt">Total Inventories</td><td style="padding-bottom: 4pt"></td><td style="border-bottom: Black 4pt double; text-
align: left">\$</td><td style="border-bottom: Black 4pt double; text-align: right">2,818,925</td><td style="padding-bottom: 2.5pt;
text-align: left"></td><td style="padding-bottom: 4pt"></td><td style="border-bottom: Black 4pt double; text-align:
left">\$</td><td style="border-bottom: Black 4pt double; text-align: right">3,732,517</td><td style="padding-bottom: 2.5pt; text-
align: left"></td></tr></table> 1194063 1849213 87308 413597 1537554 1469707 2818925 3732517 <p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0">NOTE 4 - PROPERTY, PLANT AND EQUIPMENT</p><p style="font: 10pt Times
New Roman, Times, Serif; margin: 0pt 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property,
plant and equipment consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"></td><td style="font-weight: bold"></td><td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 76%; text-align: left">Permit of land use</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">395,223</td><td style="width: 1%; text-align: left"></td><td style="width: 1%; text-align: left">\$</td><td style="width: 9%; text-align: right">397,684</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1.5pt">Building</td><td></td><td style="text-align: left"></td><td style="text-align: right">9,177,692</td><td style="text-align: left"></td><td></td><td style="text-align: left"></td><td style="text-align: right">9,234,836</td><td style="text-align: left"></td><

Less: accumulated depreciation

37,495,080	31,473,685	30,394,655	7,100,425
Property, plant and equipment, net	5,817,379	5,817,379	7,100,425

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

Asset	Life - years
Permit of land use	40 - 70
Building	20 - 49
Plant, machinery and equipment	5 - 10
Motor vehicle	5 - 10
Office equipment	3 - 5

Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was \$636,721 and \$640,979 for the three months ended June 30, 2024 and 2023, respectively and \$1,270,981 and \$1,265,700 for the six months ended June 30, 2024, respectively.

Property, plant and equipment consisted of the following:

June 30, 2024	December 31, 2023
Permit of land use	395,223
Building	397,684
Plant, machinery and equipment	301,818
Motor vehicle	303,697
Office equipment	386,334
Total	37,291,064
Less: accumulated depreciation	37,495,080
Property, plant and equipment, net	5,817,379

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

Asset	Life - years
Permit of land use	40 - 70
Building	20 - 49
Plant, machinery and equipment	5 - 10
Motor vehicle	5 - 10
Office equipment	3 - 5

Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was \$636,721 and \$640,979 for the three months ended June 30, 2024 and 2023, respectively and \$1,270,981 and \$1,265,700 for the six months ended June 30, 2024, respectively.

Intangible assets represent the cost of medical formulas approved for production by the NMPA, the intellectual property acquired ("Bonier Agreement") from Chengdu Bonier Medical Technology Development Co., Ltd. ("Bonier"), the Technology Transfer Agreement with Tao Liu, and the Technology Transfer Agreement with Lihua Li, both are discussed below. No costs were reclassified from advances to intangible assets during the six months ended June 30, 2024 and 2023, respectively.

Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen

It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was \$104,922 and \$55,161 for the three months ended June 30, 2024 and \$202,069 and \$109,024 for the six months ended June 30, 2024 and 2023, respectively, which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.

On February 2, 2024, Helpson entered into a Technology Transfer Agreement (the "Lihua Li Agreement") with Lihua Li ("Transferor Li"). Transferor Li owns an invention patent of a pharmaceutical composition for treatment of psoriasis (the "Li Invention Patent"). Pursuant to the Lihua Li Agreement, Transferor Li will transfer the ownership of the Li Invention Patent to Helpson. Transferor Li or his designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application.

The aggregate transfer price as contemplated by the Agreement is \$1.365 million which was paid to the Transferor and his two designees upon the issuance of 3,000,000 shares of common stock of the Company at \$0.455 per share based on the closing market price of the Company's common stock as of the closing date. The Company recorded the amount as intangible assets on the accompanying balance sheet as of the closing date. The value of the intangible asset will be amortized over its remaining useful life of approximately 20 years. During the ten years after the product launches to the market, if and only if the product generates profit, Helpson shall pay 10% of the net profit of the sales in cash on an annual basis to Transferor Li.

On December 15, 2023, the Company entered into a Technology Transfer Agreement (the "Tao Liu Agreement") with Tao Liu ("Transferor Liu"). Transferor Liu owns an invention patent of a drug combination for the treatment of chronic obstructive pulmonary disease (the "Liu Invention Patent"). Pursuant to the Tao Liu Agreement, Transferor Liu will transfer the ownership of the Liu Invention Patent to Helpson. Transferor Liu or his designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services.

During the ten years after the product launches to the market, if and only if the product generates profit, Helpson shall pay 15% of the net profit of the sales in cash on an annual basis to Transferor Liu.

On November 28, 2022, the Company entered into a Technology Transfer Contract with Bonier. Bonier owns the know-how of a technical invention and creation of an ophthalmic oxygen-enriched atomization therapeutic instrument, which has obtained a utility model patent (the "Utility Model Patent") and applied for an invention patent (the "Bonier Invention Patent") at the same time. Pursuant to the Bonier Agreement, Bonier will transfer the ownership of the Utility Model Patent of the technical invention and the Bonier Invention Patent application right of the invention to Helpson. Bonier or its designated third party shall provide relevant technical services in Haikou, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services, with a term of ten years.

The Company will pay a service fee of 15% of the net profit of the corresponding product sales revenue, which will be paid in cash annually after it launches to the market, contingent on the successful authorization of the above mentioned Bonier Invention Patent.

There were no service fees or profit payments paid related to the above three agreements for the three and six months ended June 30, 2024 and 2023, respectively.

The Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement. The Company's evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data for the related drug and the Company's estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the three and six months ended June 30, 2024 and 2023.

Intangible assets consisted of NMPA approved medical formulas, a Utility Model Patent and two Invention Patents as follows:

	June 30, 2024	December 31, 2023
NMPA approved medical formulas	4,736,859	4,736,859
Utility Model Patent	1,715,813	1,715,813
Invention Patents	3,002,782	1,653,028
	9,455,454	8,145,878
Accumulated amortization	(5,061,837)	(4,890,646)
Net carrying amount	\$4,393,617	\$3,255,232

Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. 104922 55161 202069 109024 1365000 3000000 0.455 P20Y 0.10 0.15 0.15

Intangible assets consisted of NMPA approved medical formulas, a Utility Model Patent and two Invention Patents as follows:

June 30,		December 31,													
2024		2023													
Technology from Bonier Invention Patents Accumulated amortization Net carrying amount Compensation payable to officer 1,251,506 1,243,506 20,000 12,000 Business taxes and other 335,485 1,027,186 Total Other Payables 1,606,991 2,282,692 Other Payables consisted of the following: <table border="1"> <tr> <td colspan="2">June 30,</td> <td colspan="2">December 31,</td> </tr> <tr> <td colspan="2">2024</td> <td colspan="2">2023</td> </tr> <tr> <td colspan="4"> Compensation payable to officer 1,251,506 1,243,506 20,000 12,000 Business taxes and other 335,485 1,027,186 Total Other Payables 1,606,991 2,282,692 </td> </tr> </table>				June 30,		December 31,		2024		2023		Compensation payable to officer 1,251,506 1,243,506 20,000 12,000 Business taxes and other 335,485 1,027,186 Total Other Payables 1,606,991 2,282,692			
June 30,		December 31,													
2024		2023													
Compensation payable to officer 1,251,506 1,243,506 20,000 12,000 Business taxes and other 335,485 1,027,186 Total Other Payables 1,606,991 2,282,692															

NOTE 7 - RELATED PARTY TRANSACTIONS

Other Payables consisted of the following:

June 30,		December 31,	
2024		2023	
Compensation payable to officer 1,251,506 1,243,506 20,000 12,000 Business taxes and other 335,485 1,027,186 Total Other Payables 1,606,991 2,282,692			

Times, Serif; margin: 0pt 0; text-align: justify">The Company had previously received advances from its Chairperson Li. Total amounts owed were \$1,140,775 and \$1,133,809 and are recorded as "Borrowings from related parties" on the accompanying condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively. On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB 4,770,000 (\$738,379) with its Chairperson Li. The loan bears interest at a rate of 4.35% and was payable within one year of the loan agreement. The due date of the loan agreement has been extended annually on identical terms, and is due July 9, 2024. Total interest expense related to the loan for the three months ended June 30, 2024 and 2023 was \$6,852 and \$6,945, respectively and \$13,708 and \$14,057 for the six months ended June 30, 2024 and 2023, respectively. Compensation payable to the Chairperson Li is included in "Other payables" in the accompanying condensed consolidated balance sheet totaling \$1,251,506 and \$1,243,506 as of June 30, 2024 and December 31, 2023, respectively. </p><table border="1"><tr><td>1140775 1133809 4770000 738379 0.0435 P1Y 6852 6945 13708 14057 1251506 1243506</td></tr></table><div style="text-align: center; font-weight: bold; font-size: 10pt; font-family: Times, Serif; margin: 0pt 0; text-align: justify">NOTE 8 – LINES OF CREDIT</div><div style="font-family: Times, Serif; margin: 0pt 0; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 21, 2022 the Company entered into a new line of credit for an aggregate amount of RMB 7,300,000 (approximately \$1.0 million) with interest payable monthly at a rate of 3.9% with Bank of Communications. The Company received an advance on the line of credit in the amount of RMB 3,800,000 (approximately \$0.56 million) on December 30, 2022. On February 24, 2023 the Company received an advance on the line in the amount of RMB 3,500,000 (approximately \$0.51 million). The Company has no further availability on this line of credit. The line of credit was paid in full on December 15, 2023, five days before the due date of December 20, 2023. On December 20, 2023, the Company received a new line of credit in the amount of RMB 3,800,000 and an interest rate of 3.9% and is due December 15, 2024. In addition, the Company's Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest expense under this facility for the three months ended June 30, 2024 and 2023 was \$10,237 and \$5,465, respectively and \$19,302 and \$10,568. On February 2, 2024 the Company repaid RMB 3,500,000 under this line of credit. On February 22, 2024 the Company entered into a new agreement on identical terms and received an advance on the line in the amount of RMB 3,500,000 which is due of February 20, 2025 </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 30, 2022 the Company received a line of credit for RMB 10,000,000 (approximately \$1.54 million) with Bank of China. The loan bears interest at the rate of 3.45% and was due September 28, 2023. On September 22, 2023 the Company repaid this note in full. On September 25, 2023 the Company entered into a three-year revolving loan and received proceeds of RMB 10,000,000 (approximately \$1.4 million). The interest rate for the loan is 3.35% for the first twelve months of the loan and adjusts based on the latest one-year loan market quotation rate less 10 basis points as published by the China National Interbank Funding Center on the working day prior to each twelve month anniversary of the loan. The loan is due on September 24, 2026. The loan is collateralized by the Company's new production facility and the included production line equipment and machinery. In addition, the Company's Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. Total interest paid on this loan was \$11,993 and \$12,724 for the three months ended June 30, 2024 and 2023, respectively and \$23,915 and \$25,320 for the six months ended June 30, 2024 and 2023, respectively. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Principal payments required for the remaining terms of the loan facility and lines of credit as of June 30, 2024 are as follows: </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Lines of Credit</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: left">2025</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">1,024,303</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt">2026</td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,403,154</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 4pt"></td><td style="border-bottom: Black 4pt double; text-align: left">\$</td><td style="border-bottom: Black 4pt double; text-align: right">2,427,457</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Fair Value of Lines of Credit</i> – Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the lines of credit outstanding as of June 30, 2024 and December 31, 2023 approximated their fair values because the underlying instruments bear an interest rate that approximates current market rates. </p> 7300000 1000000 0.039 3800000 560000 3500000 510000 3800000 0.039 2024-12-15 10237 5465 19302 10568 3500000 3500000 2025-02-20 10000000 1540000 0.0345 2023-09-28 10000000 1400000 0.0335 2026-09-24 11993 12724 23915 25320 Principal payments required for the remaining terms of the loan facility and lines of credit as of June 30, 2024 are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt"></td><td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Lines of Credit</td><td style="padding-bottom: 1.5pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 88%; text-align: left">2025</td><td style="width: 1%"></td><td style="width: 1%; text-align: left"></td><td style="width: 9%; text-align: right">1,024,303</td><td style="width: 1%; text-align: left"></td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt">2026</td><td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,403,154</td><td style="padding-bottom: 1.5pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 4pt"></td><td style="border-bottom: Black 4pt double; text-align: left">\$</td><td style="border-bottom: Black 4pt double; text-align: right">2,427,457</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr></table> 1024303 1403154 2427457 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOTE 9 – CONVERTIBLE NOTE PAYABLE</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 17, 2021, China Pharma entered into a Securities Purchase Agreement (the "Agreement") pursuant to which the Company issued an unsecured convertible promissory note (the "Note") to an institutional accredited investor Streeterville Capital, LLC (the "Investor"). The transaction contemplated under the Agreement was closed on November 19, 2021. The Note matured on February 17, 2023. On April 13, 2023 China Pharma entered into an Amendment (the "Amendment") with the Investor which extended the maturity date of the Convertible Note Payable to May 19, 2024. As consideration for the extension, China Pharma agreed to an extension fee of \$65,639, representing 2.0% of the balance of the Note and accrued interest on the date of the Amendment. The amount was satisfied by increasing the Note balance by the amount of the extension fee. The Company recorded this as additional interest expense during the second quarter of 2023. In addition, China Pharma decreased the price at which the Investor can convert the balance from 85% to 82% of the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, and assumed an additional obligation to redeem a portion of the outstanding balance of the Note monthly or be subject to additional penalty fees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">On May 23, 2024, the Company entered into an Amendment No. 2 (the "Second Amendment"), to the Note by which the parties have agreed to extend the maturity date of the Note to August 19, 2025. In consideration of the extension, the Company has agreed to pay to the Investor an extension fee equal to two percent (2%) of the outstanding balance of the Note ("Extension Fee") totaling \$10,934, and lower the minimum monthly redemption amount from the outstanding balance of the Note that the Company is obligated to redeem from \$150,000 to

\$37,182.33. The Second Amendment also includes customary representations and warranties by the Company. The Company recognized the Extension Fee as interest expense for the year ending December 31, 2024.

The Note was originally convertible into 70,000 shares of China Pharma's common stock at a price of \$75.00 per share through April 19, 2022. Thereafter, the Note was convertible into 35,000 shares at a price of \$150.00 per share. As of June 30, 2024 the Note is convertible into 2,736 shares of common stock.

Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default.

Pursuant to the terms of the Agreement and the Note, the Company must obtain Investor's consent for certain fundamental transactions such as consolidation, merger with or into another entity (except for a reincorporation merger), disposition of substantial assets, change of control, reorganization or recapitalization. Any occurrence of a fundamental transaction without Investor's prior written consent will be deemed an Event of Default.

Investor may redeem all or any part the outstanding balance of the Note, subject to \$500,000 per calendar month, at any time after one hundred twenty-one (121) days from the Purchase Price Date, as defined in the Note, upon three trading days' notice, in cash or converting into shares of China Pharma's common stock, at a price equal to 82% multiplied by the lowest daily volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company may prepay the outstanding balance of the Note with the Investor's consent. At inception, the Note was redeemable into 176,229 shares based on the lowest volume weighted average price of \$29.79085 on the inception date of November 19, 2021. As of June 30, 2024, the Note was redeemable into 2,003,001 shares of common stock based on 82% of the lowest volume weighted average price of \$0.2049 on that date.

Total interest expense for the three months ended June 30, 2024 and 2023 was \$19,058 and \$105,545, respectively, and \$33,370 and \$151,563 for the six months ended June 30, 2024 and 2023, respectively.

On January 11, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3945, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 380,228 shares of common stock to the Investor on January 16, 2024.

On February 1, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3725, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 402,685 shares of common stock to the Investor on February 5, 2024.

On February 16, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3675, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 408,164 shares of common stock to the Investor on February 21, 2024.

On April 2, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2927, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 512,470 shares of common stock to the Investor on April 3, 2024.

On April 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2774, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 540,735 shares of common stock to the Investor on April 19, 2024.

On May 20, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2539, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 590,783 shares of common stock to the Investor on May 21, 2024.

On June 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2137, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 701,918 shares of common stock to the Investor on June 17, 2024.

65639 0.02 0.85 0.82 P10D 0.02 10934 150000 37182.33 70000 75 35000 150 2736 Interest accrues on the outstanding balance of the Note at 5% per annum compounded daily. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending on the nature of the Event of Default.

500000 0.82 P10D 176229 29.79085 2003001 0.82 0.2049 19058 105545 33370 151563 150000 0.3945 0.82 P10D 380228 150000 0.3725 0.82 P10D 402685 150000 0.3675 0.82 P10D 408164 150000 0.2927 0.82 P10D 512470 150000 0.2774 0.82 P10D 540735 150000 0.2539 0.82 P10D 590783 150000 0.2137 0.82 P10D 701918

NOTE 10 - LEASES

The Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right of use assets when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company's incremental borrowing rate at the initial measurement date.

For the three months ended June 30, 2024 and 2023, operating lease cost was \$19,228 and \$17,848, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was \$19,947 and \$18,744, respectively. For the six months ended June 30, 2024 and 2023, operating lease cost was \$38,629 and \$37,635, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was \$40,074 and \$39,525, respectively.

As of June 30, 2024 and December 31, 2023, the Company reported right of use assets of \$77,259 and \$116,610, respectively and lease liabilities of \$78,628 and \$117,637, respectively. As of June 30, 2024, its operating leases had a weighted average remaining lease term of 1.0 years and a weighted average discount rate of 3.55%.

Minimum lease payments for the Company's operating lease liabilities were as follows for the twelve month period ended June 30:

--	--

		2025			2025
		80,148			80,148
		Total undiscounted cash flows			80,148
		Less: Imputed interest			(1,520)
		Less: Lease liabilities, current portion			(78,628)
		Lease liabilities, net of current portion			(1,520)
		Total undiscounted cash flows			80,148
		Less: Imputed interest			(1,520)
		Less: Lease liabilities, current portion			(78,628)
		Lease liabilities, net of current portion			(1,520)

The Company has leases with terms less than one year for certain provincial sales offices that are not material.

19228 17848 19947 18744 38629 37635 40074 39525 77259 116610 78628 117637 P1Y 0.0355 Minimum lease payments for the Company's operating lease liabilities were as follows for the twelve month period ended June 30:

		2025			2025
		80,148			80,148
		Total undiscounted cash flows			80,148
		Less: Imputed interest			(1,520)
		Less: Lease liabilities, current portion			(78,628)
		Lease liabilities, net of current portion			(1,520)

NOTE 11 - INCOME TAXES

Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the "more-likely-than-not" threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2023, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2019 through December 31, 2023 and the Chinese income tax return for the year ended December 31, 2023 are open for possible examination.

Under the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%.

There was no provision for income taxes for the three and six months ended June 30, 2024 and 2023, respectively due to continued net losses of the Company.

As of June 30, 2024, Helpson had net operating loss carryforwards for PRC tax purposes of approximately \$22.6 million which are available to offset any future taxable income through 2029. Approximately \$2.7 million of these carryforwards will expire in December 2024. The Company also has net operating losses for United States federal income tax purposes of approximately \$10.3 million of which \$5.1 million is available to offset future taxable income, if any, through 2040, and \$5.2 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year.

U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the "U.S. Tax Reform"), was signed into law on December 22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of June 30, 2024 and December 31, 2023. Therefore, the Company provided for a valuation allowance against its deferred tax assets of \$21,992,061 and \$21,531,017 as of June 30, 2024 and December 31, 2023, respectively.

The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

0.25 22600000 2700000 10300000 5100000 through 2040, and \$5.2 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year 0.35 0.21 21992061 21531017

NOTE 12 - FAIR VALUE MEASUREMENTS

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 - Quoted prices in active markets for identical assets or

Liabilities; Level 2 - Observable inputs other than Level 1 including quoted prices for similar assets or liabilities; quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data; and Level 3 - Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

The Company uses fair value to measure the value of the banker's acceptance notes it holds at June 30, 2024 and December 31, 2023. The banker's acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value:

Fair Value Measurements at	Description
June 30, 2024	Level 1
June 30, 2024	Level 2
June 30, 2024	Level 3
Banker's acceptance notes	
65,915	
December 31, 2023	Level 1
December 31, 2023	Level 2
December 31, 2023	Level 3
Banker's acceptance notes	
65,915	

The Company uses fair value to measure the value of the banker's acceptance notes it holds at June 30, 2024 and December 31, 2023. The banker's acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value:

Fair Value Measurements at	Description
June 30, 2024	Level 1
June 30, 2024	Level 2
June 30, 2024	Level 3
Banker's acceptance notes	
65,915	
December 31, 2023	Level 1
December 31, 2023	Level 2
December 31, 2023	Level 3
Banker's acceptance notes	
65,915	

[illegible]

Board of Directors through unanimous written consent and

the fiscal year ended on December 31, 2021, which was held on December 27, 2022. Upon the effectiveness of the reverse stock split, every 10 shares of China Pharma's issued and outstanding common stock were automatically converted into one share of issued and outstanding common stock. No fractional shares were issued as a result of the reverse stock split. Instead, any fractional shares that resulted from the split were rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and does not alter any stockholder's percentage interest in China Pharma's outstanding common stock, except for adjustments that may result from the treatment of fractional shares. All share and per share amounts have been retroactively restated for all periods presented in the accompanying unaudited condensed consolidated financial statements.

2024 Share Issuances

On January 11, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3945, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 380,228 shares of common stock to the Investor on January 16, 2024.

On February 1, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3725, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 402,685 shares of common stock to the Investor on February 5, 2024.

On February 16, 2024 the Investor delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.3675, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 408,164 shares of common stock to the Investor on February 21, 2024.

On April 2, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2927, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 512,470 shares of common stock to the Investor on April 3, 2024.

On April 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2774, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 540,735 shares of common stock to the Investor on April 19, 2024.

On May 20, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2539, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 590,783 shares of common stock to the Investor on May 21, 2024.

On June 17, 2024 the Investor discussed in Note 9 delivered its notice of redemption for \$150,000 of the Note and related interest at the conversion price of \$0.2137, which was 82% of the lowest volume weighted average price during the ten trading days immediately preceding the applicable redemption conversion. Accordingly, the Company issued a total of 701,918 shares of common stock to the Investor on June 17, 2024.

<i>2010 Incentive Plan</i>

The Board adopted the Company's 2010 Incentive Plan (the "Plan"), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the "Amendment"), pursuant to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the stockholders on December 19, 2019. On October 25, 2021, the Board of Directors approved, and on December 27, 2021 our stockholders adopted the Amendment No.2 to the Plan to increase the number of shares of the Common Stock, that are reserved thereunder by 100,000 shares from 80,000 shares to 180,000 shares. On October 27, 2022 the Board of Directors approved and on December 27, 2022, the stockholders adopted the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares of common stock that are reserved thereunder by an additional 100,000 shares from 180,000 to 280,000. On December 17, 2023 the stockholders approved Amendment No. 1 to the Amended and Restated Long Term 2010 Incentive Plan to increase the number of shares from 280,000 to 580,000. The Plan gives the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 580,000 shares of common stock. Through June 30, 2024, there were 84,700 shares of stock and stock options granted and outstanding under the Plan. A total of 13,300 options were outstanding as of June 30, 2024 under the Plan. As such, there are 482,000 additional units available for issuance under the Plan.

There were no issuances of securities from the Plan for the six months ended June 30, 2024 and as such, no compensation expense was recognized for the period.

As of June 30, 2024, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.

	Prior Period	Current Period	Total Compensation Expense Recognized
Stock Options	\$0.001	\$0.001	\$0.002
Restricted Stock Grants	\$0.10	\$0.50	\$0.60
Total	\$0.10	\$0.50	\$0.60

For the six months ended June 30, 2024, no customer accounted for greater than 10.0% of sales and two customers accounted for 63.6% and 13.7% of accounts receivable. Three suppliers accounted for 23.5%, 23.4% and 17.6% of raw material purchases, and three different products accounted for 35.2%, 22.7% and 10.2% of revenue.

NOTE 14 - COMMITMENTS AND CONTINGENCIES

Current vulnerability due to certain concentrations

For the six months ended June 30, 2024, no customer accounted for greater than 10.0% of sales and two customers accounted for 63.6% and 13.7% of accounts receivable. Two suppliers accounted for 19.5% and 18.0% of raw material purchases, and five different products accounted for 22.4%, 19.8%, 11.8%, 10.9% and 10.0% of revenue.

Nature of Operations

Economic environment – Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in

~~the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company's operations.~~

~~In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.~~

~~0.636 0.137 0.235 0.234 0.176 0.352 0.227 0.102 0.534 0.115 0.105 0.195 0.18 0.224 0.198 0.118 0.109 0.10~~

~~NOTE 15 - SUBSEQUENT EVENTS~~

~~The Company evaluated all events and transactions that occurred after June 30, 2024 up through the date the Company filed these unaudited condensed consolidated financial statements. No events require adjustment to or disclosure in the unaudited condensed consolidated financial statements.~~

~~+86 898-6681-1730-0.09-0.16-0.35-0.65 false--12-31Q20001106644~~